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Abstract 
Invariant natural killer T (iNKT) cells constitute an important regulatory arm of the immune 
system. Defects in the number and activities of iNKT cells have been linked to the 
development of autoimmune diseases. The glycoprotein CD1d plays an integral part in the 
recognition and presentation of lipid antigens such as α-galactosylceramide  
(α-GalCer) to iNKT cells, producing a variety of anti-inflammatory (TH2) cytokines, such as 
interleukin-4 (IL-4), and pro-inflammatory (TH1) cytokines, such as interferon-γ  
(IFN-γ). A decreased number of iNKT cells and defects in their capacity to produce TH2 
cytokines is associated with autoimmune diseases, such as type 1 diabetes (T1D). α-GalCer 
stimulates both TH1 and TH2 responses. Some analogues of α-GalCer preferentially induce 
the production of TH2 cytokines, highlighting the possibility that such compounds could have 
therapeutic potential with regards to TH1 cell-mediated autoimmune diseases, such as T1D 
and SLE.  
 
A library of α-GalCer analogues was synthesised and their ability to modulate immune 
responses analysed. Altering the length of the phytosphingosine chain in α-GalCer analogues 
was shown to drastically affect the TH1:TH2 response, with truncated phytosphingosine 
chains of 9 carbons skewing the response towards a predominantly TH2 response. 
Substituting the galactose sugar head for glucose (α-GlcCer) or L-fucose (α-L-FucCer) also 
elicited differences in the immunological profile of α-GalCer analogues, with lymphocytic 
proliferation being greatest in the galactose analogue, followed by L-fucose, followed by a 
glucose analogue. These differences in activity were also mirrored in the cytokine responses 
of the analogues, suggesting the C4’ hydroxyl group plays a key part in antigen recognition 
and activity. Analogues incorporating 2 double bonds in the N-acyl chain exhibited TH2 
cytokine profiles on a par with α-GalCer, yet dramatically decreased TH1 responses were 
observed. They also considerably delayed the clinical presentation of glucosuria in NOD 
mice. These results have provided important insights into the nature of antigen binding with 
CD1d, recognition of the antigen by iNKT cell receptors, and how such factors play a role in 
skewing the immune response, thus highlighting areas where structural diversity could be 
introduced in order to exploit immunomodulating potential, and find a possible prophylactic 
therapy for the prevention and treatment of autoimmune diseases, such as T1D. 
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1. General Introduction 
1.1 Cluster of Differentiation (CD1) 
CD1 proteins are members of a group of molecules designated Cluster of Differentiation 1 
(CD1) from their ability to stain leukocytes and the immunofluorescence of their monoclonal 
antibodies [1]. The CD1 family are transmembrane glycoproteins that can be divided into 
two sub-categories (group 1 and group 2 CD1), according to their predicted primary amino 
acid sequences, expression and functional diversities. The CD1 genes identified as 
members of group 1 are CD1A, CD1B, and CD1C encoding the three proteins CD1a, CD1b 
and CD1c, respectively. The CD1D gene corresponds to the CD1d protein which falls into 
the second group of the CD1 family [2]. The fifth CD1 gene, CD1E, has been transcribed, 
and the protein product is an intracellular protein that is thought to facilitate lipid presentation 
by other CD1 molecules [3]. CD1e is believed to be an intermediate isotype [4]. 
 
CD1 genes have been identified in the human [4-7], rodent [8-10], sheep [11], cow [12], 
rabbit [13, 14], guinea pig [15] and rhesus macaque [16], suggesting evolutionary 
preservation of the gene family [17]. The human CD1 isoforms are expressed as single 
examples (CD1A, B, C, D, and E), whilst in other species they are expanded or deleted; 
cattle lack intact CD1D genes, and rabbits express amongst others, two CD1A genes [12, 
14]. In humans, the CD1 isoforms are differentially expressed with restricted tissue 
distribution. The proteins are expressed on a variety of professional antigen presenting cells 
(APCs) such as dendritic cells (DCs) located on both lymphoid and non-lymphoid tissues. 
Group 1 CD1 proteins are, for example, expressed on Langerhans cells, lymphoid follicles, 
B lymphocytes, and a subpopulation of circulating B cells in peripheral blood. CD1d can be 
found on gastrointestinal epithelia, haematopoietic cells, thymocytes, circulating T and B 
lymphocytes, and resting monocytes [2, 14, 18].  
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Group 1 CD1 proteins are expressed on derivatives of haemocytoblasts, and are especially 
induced on DCs of the myeloid lineage [19]. They are expressed on cortical thymocytes and 
the human CD1c protein can also be found on a specialised subset of B-cells, especially 
circulating B-cells of newborns and infants [20], B-cells of the tonsil and lymph nodes, and 
the marginal zone B-cells of the spleen [21]. Group 1 CD1 proteins are, however, not 
present on most other bone-marrow-derived cells [22].  
 
1.2 Group 1 CD1 proteins and associated antigens 
Diverse antigens are presented by the different isoforms. Despite their apparent diversity, 
there are structural similarities between the antigens presented by the CD1 proteins. Most 
notable is the fact that these antigenic compounds generally consist of a hydrophilic head 
group with two long hydrocarbon tails (Figure 1.1), supporting the notion that CD1 molecules 
successfully present lipid antigens. The interaction between CD1 proteins and lipids results 
in the antigen adopting an orientation that exposes the polar head at the protein surface for 
T cell receptor (TCR) recognition. The finely tuned differences observed in the structural 
organisation of the five CD1 isoforms can account for their varied antigen-binding 
preferences and capabilities [23-25].  
 
The first antigens identified as being successfully presented to T cells by CD1 molecules 
were lipids [26]. The Group 1 CD1 proteins are involved in antimicrobial immunity and have 
to date been shown to present a number of foreign lipid antigens including a range of 
diverse microbial lipid antigens [26].  CD1a-restricted T cells have been recently shown to 
recognise the lipopeptide didehydroxymycobactin (DDM) [27] which is closely related to the 
mycobacterial lipopeptide mycobactin – an iron-scavenger derived from Mycobacterium 
tuberculosis (M. tb.) [28]. Contrary to the more classical CD1 antigens, DDM is composed of  
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Figure 1.1 Examples of Group 1 CD1 ligands. CD1a ligands: (A) DDM; (B) Mycobactin; (C) Nocobactin; 
CD1b ligands: (D) Glucose mycolates; (i) Methoxy mycolate (ii) α-Mycolate from Nocardia 
farcinica; (iii) ketomycolate (glucose monomycolate; GMM);  (E) Mycobacterial sulphoglycolipid 
(Ac2GL); CD1c ligands: (F) Mannosyl-β-1-phosphopolyketide (MPI); (G) Mannosyl-β-1-
phosphoisodolichol (MPD). 
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a complex head group of amino and organic acids linked to a single alkyl chain (Figure 1.1). 
CD1a proteins are established as binding with mycobactin in addition to the related structure 
nocobactin, which is produced by a number of Nocardia species, such as Nocardia 
asteroides that are most commonly associated with immunocompromised patients [29]. The 
latter compound differs structurally from a mycobactin in the positioning of the hydrocarbon 
chain (Figure 1.1B, Figure 1.1C). CD1a proteins also successfully present natural sulfatides 
(3-sulfated β-galactopyranosyl ceramides) with various N-acyl chains [30]. 
 
The diverse collection of antigens presented by CD1b include lipids derived from the 
mycobacterial cell wall, such as various mycolates (Figure 1.1D) (α-branched β-hydroxy 
long chain fatty acids) of which methoxy-mycolates and keto-mycolates are two 
examples [26]. Other CD1b lipids include GMM (a mycolic acid esterified to a single glucose 
sugar) [31], as well as the relatively recently defined M. tb. derived sulfoglycolipids (A2SGL) 
(Figure 1.1). This particular sulfoglycolipid is found in the cell envelope of M. tb strains and 
has been shown to exert a number of immunological effects, such as antitumor activity  
[32, 33]. 
 
Phosphatidylinositol mannosides (PIMs) and lipoarabinomannan (LAM) (a non-peptide 
mycobacterial cell-wall constituent) (Figure 1.2) are also recognised and presented by CD1b 
proteins [34]. Both PIM and LAM are made up of a phosphatidylinositol core linked to 
additional glycans [34].  
 
A group of compounds, based on isoprenoids, are found in a number of pathogenic 
mycobacterial species and are recognised by the Group 1 CD1c molecule [35, 36]. These 
antigens differ from what is deemed as the more conventional structure of CD1 antigens; in 
the fact it only contains a single short lipid tail linked to a mannose-phospholipid. 
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Figure 1.2: Lipoarabinomannan (LAM): Diagram showing the various mycobacterial 
glycophosphatidylinositols incorporated in the structure of LAM, highlighting the 
shared phosphatidyl inositol core of the constituent molecules, lipomannan (LM), and 
two different phosphatidyl inositol mannosides, PIM1 and PIM4. Adapted from [37]. 
 
It is structurally analogous to other isoprenoid-based compounds, such as MPD (Figure 1.1), 
which is an established carbohydrate donor in glycosylation pathways [38]. CD1c proteins 
also react with specific MPDs typical of eukaryotic cells [35]. 
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1.3 CD1d microbial and self-lipid antigens 
CD1d is a non-polymorphic, antigen-presenting molecule expressed on APCs, largely 
populated by DCs, which play a fundamental part in tolerisation to self-peptides and in the 
induction of immunity against foreign antigens [39]. DCs mediate interactions between 
lymphocyte populations, relaying and integrating a variety of signals through interactions 
with T, B, natural killer (NK) and natural killer T (NKT) cells [40]. Creusot et al. [41] stated 
that lymphocytes within a DC cluster both directly and indirectly instruct other lymphocytes 
by local cytokine secretion or by making a slight alteration in the DC function, respectively. 
 
The presentation of microbial lipids by CD1 had until recently only been confirmed for CD1a, 
b, and c. However, there is evidence linking the group 2 protein CD1d with microbial 
immunity; CD1d-deficient mice have increased susceptibility to bacterial, fungal and 
parasitic infections [42]. A number of groups investigating CD1d microbial immunity have 
reported that murine CD1d-restricted invariant Natural Killer T (iNKT) cells recognise 
glycosylphosphatidylinositol (GPI)-anchored glycoproteins from Plasmodium or 
Trypanosoma species in vitro and in vivo [43-45].  
 
Fischer et al. [46] discovered that the mycobacterial lipid PIM4 (Figure 1.2) successfully 
binds CD1d and in doing so, activates iNKT cells. This was the only Group 1 mycobacterial 
antigens tested that proved to be antigenic towards murine iNKT cells via CD1d, further 
extending the role of CD1d in autoimmunity with respect to antimicrobial host defence.  
 
Recently Kinjo et al. [47] have revealed that iNKT cells also recognise α-galactosyl 
diacylglycerols from the causative agent of Lyme disease, Borrelia burgdorferi (Figure 1.3).  
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Figure 1.3: The structure of Borrelia burgdorferi glycolipid II (BbGL-II). This is a monogalactosyl 
diacylglycerol which represents 23% of the total bacterial glycolipid and consists of fatty acids 
ranging from C16:0 to C18:2 in both R1 and R2. 
 
This has widened the scope for possible active antigens of iNKT cells, and could also aid in 
the understanding of the biology behind these lymphocytes, and their evolutionary 
specificity. Diacylglycerols, such as the one derived from B. burgdorferi, have also been 
found in mammalian cells, suggesting previously unknown self-antigens of iNKT cells.  
 
Self-lipids that are naturally present in mammalian tissues have been observed to stimulate 
iNKT cells in the absence of foreign antigens [48, 49]. They are known to include 
phospholipids, such as phosphatidylinositol (PI), phosphatidylethanolamine (PE) and 
phosphatidylglycerol (PG) [50] (Figure 1.4). PI is a key membrane constituent and 
participates in essential metabolic processes in all plants, animals, and some bacteria. As 
shown in Figure 1.4, this form of phospholipid has one axial hydroxyl group at position 2, 
with the remaining hydroxyls remaining equatorial. In animals, stearic and arachidonic acid 
are found in high concentrations of PIs present, with the former acid linked to the sn-1 
position, and the latter at sn-2 [51].  
 
PE is frequently the main lipid component of microbial membranes, such as in Escherichia 
coli.  Also when found in animal tissues, PE tends to have a higher proportion of arachidonic 
and docosahexaenoic acid. As with PI, the unsaturated fatty acids are concentrated at the  
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Figure 1.4: CD1d self-lipid antigens: (A) PI. R = generally fully saturated hydrocarbon chain, 
R1 = generally unsaturated hydrocarbon chain. In animals, there is a high concentration of 
R=stearic acid, and R1=arachidonic acid; (B) PE. R, R1 = varying hydrocarbon chains. [51];  
(C) PG. R, R1 = varying hydrocarbon chains; (D) iGb3. 
 
sn-1 position of the molecule [51]. PG is a ubiquitous lipid and is present in almost all types 
of bacteria. It can also be found in plant and animal cell membranes. Interestingly, in animal 
tissues the saturated and mono-unsaturated fatty acids are linked at the sn-1 position, which 
is in contrast to animal forms of PI and PE [51]. The fact that both PI and PG have been 
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isolated from CD1d proteins, suggests phospholipids may be naturally antigenic for CD1d  
[52, 53].  
 
An endogenous ligand that has recently been identified as successfully binding to CD1d and 
stimulating iNKT cells, although showing similarities to α-GalCer, is in fact a β-linked 
ceramide. The compound in question is isoglobotrihexosylceramide (iGb3) [54].  It consists 
of a ceramide group with a sphingosine base and N-acylated hexacosanoic acid, β-linked 
with a Galα1-3Galβ1-4Glc saccharide unit (Figure 1.4). It is a natural product of the  
Hexb-dependant enzymes (β-hexosaminidase A and B) [55]. These enzymes remove  
β-linked GalNAc residues found in GSLs of the ganglio-, globo-, and isoglobo- series [56]. 
CD1d proteins also present self-lipid antigens such as glycosphingolipids (GSLs) and 
diacylglycerols, as well as a non-self lipid; α-galactosylceramide (α-GalCer) [18, 57]. 
 
iGb3 has been shown to be one of the only GSL products of the aforementioned ganglio-, 
globo-, and isoglobo- series that is able to stimulate iNKT cells, expanding the cell 
populations of IFN-γ and IL-4, respectively [58]. Interestingly, it has also been theorised that 
lysosomal iGb3 expression is dysregulated by iNKT cells in autoimmune disease, such as 
type 1 diabetes [54]. 
 
The fact that a naturally occurring ligand, successfully stimulating iNKT cells in a CD1d-
dependent manner, has a β-anomeric link between the ceramide and sugar ‘head’ is 
unexpected with regards to the results gained from experiments carried out with β-versions 
of the parent glycolipid and the fact that it is un-stimulatory [59].  
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1.4 CD1d and α-GalCer 
GSLs make up a variety of significant membrane lipids that exert important signalling 
functions. They range from cerebrosides with single sugar residues, to compounds 
incorporating complex carbohydrate patterns of which gangliosides and 
oligoglycosylceramides are two such examples [60]. The differential distribution and specific 
pattern of more complex GSLs in tissues, ardently suggests that they play important and 
specific functions in these tissues. The organisation of GSLs in the membrane provides 
specificity in the sorting of proteins destined for both the plasma membrane and for the 
melanosomes in pigmented cells [61]. GSLs contain chemical groups located between the 
sugar head and hydrophobic backbone that can function as both hydrogen bond acceptors 
and hydrogen bond donors. It is because of this that they may be able to form lateral 
hydrogen bonds and contribute to an increase in stability and decrease in permeability of the 
membrane layers [62].  
 
GSLs are comprised of a ceramide backbone and a sugar head group. The former itself is 
made up of a sphingoid base and fatty acid. The ceramide portion is normally inserted in to 
the cellular membrane, whereas the polar head faces the non-cytosolic space [61].  
 
The importance of GSLs in organism development and physiology has been exemplified by 
knockout studies in mice, where the deletion of an enzyme responsible for the synthesis of 
glucose-based GSLs proved to be embryonically lethal [61]. Other research has shown that 
GSL deficiency results in serious pathological conditions [63]. 
 
A group of relatively simple GSLs termed cerebrosides incorporate phytosphingosine in 
conjunction with either glucose or galactose, and are present in plant and animal tissues,  
Chapter 1   General Introduction 
    
12 
 
 
Figure 1.5: Structures of galactosyl ceramides. (A) 2-Hydroxy-hexacosanoic acid [2,3-dihydroxy-1-
(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-amide. The 
GSL isolated from the marine sponge Agelas mauritianus, around which the parent glycolipid 
antigen α-GalCer is based. (B) α-Galactosylceramide (α-GalCer). 
 
particularly human and bovine kidney, and the digestive tract of mammals [60]. α-GalCer 
(Figure 1.5) is a member of the GSL family and it is sometimes referred to as KRN7000 [64]. 
The structure of α-GalCer and other synthetic analogues is based around a naturally 
occurring GSL originally isolated from the marine sponge Agelas mauritianus [64]. α-GalCer 
is made up of a galactose sugar head, and linked ceramide tail composed of a 
phytosphingosine base chain and amine linked acyl chain (Figure 1.5), and like other GSLs 
exerts an effect on the immune system [60, 61]. 
 
1.5 CD1 crystal structure 
CD1 molecules are structurally homologous to major histocompatibility complex (MHC) class 
I molecules. CD1 genes encode type 1 integral membrane proteins consisting of α1, α2 and 
α3 domains, much like MHC class I molecules, with the α3 domains being the most 
homologous across the five members of the CD1 family [18].  
 
They also associate with β2-microglobulin (β2m) like the MHC class I molecules  
(Figure 1.6). CD1 molecules are expressed as heterodimers consisting of a heavy chain 
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Figure 1.6: The CD1d protein (A) CD1 heterodimer consisting of an α1 and α2 domain forming the ligand 
binding groove, an α3 domain and associated β2-microglobulin (β2m). (B) Three different 
classes of antigen presenting cells and the distinct subsets of T cells they interact with, via 
peptide and lipid antigen recognition with the TCR. Adapted from [65, 66]. 
 
non-covalently linked with the β2m, which seems necessary for cell-surface expression of 
CD1. The human CD1 group is encoded by five nonpolymorphic genes that are closely 
linked and located on chromosome 1. MHC is encoded by genes located outside of 
chromosome 1 (namely on chromosome 6) and although MHC shows structural similarities 
to the CD1 family, it is genetically unrelated. These similarities could however be indicative 
of a common evolutionary origin [2, 17, 58, 67, 68]. 
 
CD1 polypeptides have predicted molecular masses nearing 33,000. However, the presence 
of at least three N-linked glycan components increases this value so that it falls between 
41,000 and 55,000. Crystallographic studies have demonstrated that the groove structure of 
the CD1 protein is comprised of two large deep pockets, A’ and F’, that open between the 
two α-helixes: α1 and α2 (Figure 1.7). The pockets are lined almost exclusively by non-polar 
amino acids; the groove has only 10 amino acid residues that are capable of hydrogen 
bonding to bound antigenic ligands (Figure 1.8). Consequently, widespread hydrogen 
bonding at the termini of peptides as in class I MHC complexes, and bonding along the  
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Figure 1.7: CD1d crystal structure. (A) Top view of ribbon diagram showing α1 and α2 domains, with the 
ligand binding groove. S (in blue) refers to a β strand and H (in pink) refers to an α helix. (B) 
Side view of ribbon diagram showing the α1, α2, α3 and β2m domains, with α helices in pink 
and β strands in blue. Figures adapted from [69, 70]. (C) Cartoon illustrating how the CD1 
domains (green) from a binding groove to accommodate a lipid antigen (yellow) that is 
presented by a TCR (blue). 
 
 
 
 
Figure 1.8: Hydrogen bonding between residues of CD1d and the glycolipid antigen α-GalCer. The 
CD1d residue is blue; α-GalCer is orange. The hydrogen atom of the hydroxyl (OH) group at 
the 2’ position of the galactose ring bonds with the Cδ2 atom of the aspartic acid residue 
(Asp151). The anomeric oxygen atom at position 1’ of the sugar forms a bond with the Cγ1 
atom of threonine (Thr154), and the 3-OH of the sphingosine chain bonds with aspartic acid 
(Asp80) Cδ2. Figure adapted from [71]. 
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sides of the longitudinal axis of the groove as in class II MHC complexes is not evident in 
CD1 proteins [2, 69-72].  
 
Both Group 1 and Group 2 CD1 isoforms present antigens specific to them by securing the 
alkyl chain or chains of the ligand within their hydrophobic binding grooves. This allows the 
exposure of the polar head group or hydrophilic cap at the protein surface, together with 
surface sections of the CD1 heavy chain, enabling it to be recognised by the TCR (Figure 
1.9) [57, 71].  Unlike the MHC class I and II molecules, the binding groove of the CD1 
proteins, although considerably narrower (9-17 Å as opposed to measurements of over 
22 Å), is significantly larger because of greater depth and the presence of only two pockets.  
 
Figure 1.9: Crystal structure of α-GalCer loaded human CD1d. (A) Top view of CD1d loaded with α-
GalCer (B) Front view of α-GalCer loaded CD1d. α-GalCer presented as Van der Waals 
spheres, white and red; α1 domain, light blue; α2 domain, dark blue; α3 domain, green; β2m 
domain, yellow-red. Figure adapted from [71]. 
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This is opposed to the several smaller pockets that are characteristic of MHC molecules. 
The fact that CD1 proteins fold in a different manner to MHC class I and class II molecules, 
suggests that they may have a different mode of antigen-presentation and T cell interaction 
[73]. 
 
The CD1d groove is larger than that of the CD1a protein, but does not accommodate as 
large molecules as the CD1b protein groove [18, 69, 74, 75]. The human CD1b (hCD1b) 
molecule has a binding groove volume of 2,200Å versus 1,400Å for hCD1d protein [18]. This 
significant difference allows antigens with maximal acyl chains of 80 carbon (C80) atoms 
(such as mycolates from M. tuberculosis) to be bound in the CD1b pocket, whereas the 
CD1d channel can only bind antigens with shorter (C18- C26) lipid chains. Unlike the CD1b 
protein, the CD1d groove is closed at both ends and is only accessible from the top face of 
the protein molecule through a narrow opening extending from the centre of the groove to a 
point over the centre of the F’ pocket [18, 71]. Also, the F’ pocket of CD1a is shallower and 
wider than CD1d and can thus accommodate, for example, the N-aryl branch of the 
antigenic compound DDM (Figure 1.1). 
 
Coupling the recently discovered knowledge of the intracellular trafficking of CD1 proteins 
with their crystallographic structures, has led to a greater understanding of the intricate 
workings of the immune system. This explains to why multiple CD1 isoforms have evolved to 
offer, amongst other things, immunoregulation with relevance to tumour immunity and 
autoimmunity. Sugita et al. [76] presented the hypothesis that the immune system has 
evolved diverse trafficking patterns to accomplish antigen sampling by CD1 isoforms and 
effective activation of the immunoregulatory T-cell populations that they stimulate.  
 
Chapter 1   General Introduction 
    
17 
1.6 CD1 assembly 
The five human CD1 isoforms take different routes through the cell before being presented 
at the cell-surface of APCs, where they interact with specific TCRs [77]. CD1 heavy chains 
undergo translocation into the endoplasmic reticulum (ER) membrane positioning the α1, α2 
and α3 domains in the ER lumen. A short while after translation into the ER the CD1 heavy 
chains associate with two protein-folding chaperones, calnexin (CNX) and calreticulin 
(CRN). This complex in turn engages a thiol oxidoreductase enzyme (Erp57) that promotes 
the formation of disulfide bonds in the heavy chain. This results in the proteins folding in 
such a way that the hydrophobic amino acids of the heavy chains are brought into close 
proximity, and the predominantly hydrophobic inner surface of the antigen-binding groove is 
formed. The oxidised protein then disassociates with the protein-folding complex, and forms 
a complex with β2m. The five human CD1 isoforms bind to β2m with varying degrees of 
affinity [57].  
 
It has been suggested that in a similar manner to MHC class I and class II molecules, the 
CD1 isoforms undertake a similar pathway culminating in antigen presentation, and that the 
CD1 molecules require occupation of their antigen-binding pockets before exiting the ER 
[78]. Self-lipids, such as PI have been nominated as candidates that load into the CD1 
groove during assembly in the ER.  Following this assembly, the CD1 molecules are 
transported to the plasma membrane, where the protein is re-internalised, and traffics 
through the endocytic system exchanging and acquiring either self- or non-self-lipids, or 
microbial lipids. Lipid transfer proteins (LTPs), such as Saposins (Saps) and the GM2 
activator (GM2A) facilitate the exchange of the ER-loaded lipid for antigenic glycolipids that 
activate iNKT cells [79, 80] (Figure 1.10). Although re-internalising and endocytic trafficking 
is a necessity for the successful presentation of CD1d glycolipid antigens to invariant murine 
CD1d- restricted T cells, it is a dispensable commodity for human CD1d-restricted T cells, 
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thus indicating that CD1d can present a variety of glycolipid antigens acquired from both the 
endocytic system and from the plasma membrane. [2, 18, 57, 68, 73, 78, 79, 81, 82]. 
 
 
Figure 1.10: Schematic representation of CD1 assembly and trafficking. In the ER the CD1 heavy 
chain (HC) forms a complex with CNX and CRN in order to recruit the enzyme Erp57.  The 
complex undergoes oxidation and dissociation, leaving the CD1 HC free to bind with β2m, and 
associate with lipids. The CD1 complex traffics to the plasma membrane, via the Golgi 
apparatus, where it is recognised by CD1-restricted T cells. It is then re-internalised and LTPs 
such as Saps facilitate exchange of the ER-loaded lipid for other antigenic glycolipids. 
 
1.7 Invariant natural killer T (iNKT) cells 
The immune system is a complex organisation of protective mechanisms that ensure the 
body is defended against microbes and other so-called ‘foreign-bodies’. It is an extremely 
intricate system which, if fails, can give rise to immunodeficiency. If it over-reacts against 
microbes, it can result in tissue damage [83].  
 
There are two arms of the immune system; the innate and adaptive immune system. The 
former is the front-line in terms of microbial defence. It rapidly gives rise to the acute 
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inflammatory response, and although has some specificity in terms of the microbes it 
attacks, it has no so-called ‘memory’; it fails to remember microbes it has previously 
encountered [83]. Distinct from this is the adaptive immune system, which although taking 
longer to develop and respond, is extremely specific and does show memory. The two 
systems work through direct immune cell contact and through a number of chemical 
mediations and cytokine interactions. Immune cells (lymphocytes) are specific for individual 
foreign antigens and proliferate and differentiate when bound to a particular antigen. The 
cells or their products then neutralise or eliminate the antigenic substance. It is the large 
number of antigen-specific immune cells present in the late immune response that are 
accountable for the memory of the adaptive immune system [84].  
 
The two major immune cell types are T and B cells. The predominant maturation of the latter 
is governed by the bone marrow and gives rise to immunity involving the synthesis of 
immunoglobulins [83]. T cells mature under the influence of the thymus and induce cellular 
immunity upon stimulation by an antigen [83]. T cells express a number of complexes on the 
cell surface of which the cell-membrane bound antigen receptor is one. It consists of two 
polypeptide chains. More commonly these polypeptides are composed of an αβ dimer, yet 
some T cells have TCRs made up of γδ chains. The signalling complex, CD3 is also 
observed [85]. Once T cells have matured, specific subsets are formed after  interactions 
with antigen-presenting molecules, and express the complexes CD4 and CD8 depending on 
the cell type [86]. CD4 is presented on T helper (TH) cells, which provide help for B cell 
growth and differentiation, and CD8 expresses on cytotoxic T (Tc) cells involved in the 
recognition and destruction of virally infected cells. CD4 expressing cells recognise peptide 
antigens in MHC class II molecules, whereas CD8+ T cells recognise peptides in MHC class 
I molecules [83].  
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Natural killer (NK) cells are large granular lymphocytes produced in the bone marrow and kill 
virus-infected self cells, in addition to some tumour cells. They function in an identical way to 
Tc cells, although they do not have true antigen specificity and memory like B and T cells 
[83]. Invariant natural killer T (iNKT) cells are an unusual subset of immune cells and their 
identification came about from the contributions of three experiments carried out in the late 
1980s  [87-89]. The cells express receptors typically present on both the T cell and NK cell 
lineage. They have been defined as immune cells with a semi-invariant TCR and are 
reactive to the non-self glycolipid antigen α-GalCer when it is presented by the CD1d 
protein. CD1d is an essential component with regards to ligand presentation and recognition 
by the iNKT cell TCRs [90].  
 
Unlike conventional T cells, iNKT cell recognition of CD1d does not require co-receptors, 
such as CD4 or CD8, which are essential in successful TCR signalling of other T cells, 
although some iNKT cells do express CD4 markers. Park et al. [91] demonstrated that 
murine mCD1d is exclusively found in the lipid raft microdomains of the plasma membrane 
of eukaryotic APCs, and it is this specific localisation that is crucial in concentrating and 
transducing signals between CD1d and iNKT cell during immune responses [91]. 
 
In a manner similar to most other T cells, the TCR for CD1d-bound antigens located on the 
iNKT cell membrane is comprised of an αβ polypeptide dimer, plus a polypeptide-signalling 
complex. The invariant TCR α-chain of iNKT cells consists of a canonical Vα14-Jα18 chain 
in mice and a homologous Vα24-Jα18 chain in humans, coupled with a restricted β chain: 
Vβ8, Vβ2 or Vβ7 in mice and Vβ11 chain in humans [65, 92]. The iNKT cell can therefore 
also be referred to as the CD1d-restricted T cell or Vα14 NKT cell. Here, the term iNKT cells 
will be adopted.  
 
Chapter 1   General Introduction 
    
21 
T cell activation is mediated by the αβ TCRs. The fact that iNKT cells recognise and are 
subsequently activated by a diverse range of glycolipids is somewhat unconventional. The 
semi-invariant character of the TCR, with a fixed α-chain and restricted β-chain would 
suggest that only limited antigenic structures would effectively bind with the iNKT cell. 
However, glycolipids ranging from α-GalCer, PE [52], PIM4 [37], α-glucuronyl ceramides 
[25], sulfated ceramides [93], gangliosides [25, 94], and isoglobotrihexosylceramide (iGb3) 
[54] are all presented by APCs to the TCR of iNKT cells. A β-galactosylceramide (β-GalCer) 
antigen complexed with CD1d, however, does not activate iNKT cells [95, 96], despite 
successfully binding with the CD1 protein itself [97]. This evidence suggests that the 
glycosyl head group of the glycolipid is a critical determinant in the recognition by and 
activation of iNKT cells; a conclusion reached by a number of research groups [92, 98, 99]. 
A possible explanation for this diverse antigen recognition is that the glycolipid head group 
binds with the TCR through a small cavity at the ligand-binding interface. This cavity 
envelopes the polar head group of the antigen positioning the α-chain of the complimentarity 
determining region (CDR3α) over the sugar ring. The walls of this cavity are comprised of 
unique amino acids present in the Vα domain and CDR3α region of the invariant TCR α-
chain. In addition, CDR1β and CDR3β residues contribute to the structure [92].  
 
The critical part played by the iNKT cell receptor α-chain is highlighted by the almost 
identical CDR3α sequences expressed in murine and human TCRs, both of which 
specifically bind the CD1d-αGalCer complex [100]. A specific α or β chain is not needed to 
recognise CD1d protein alone in human and murine iNKT cells, and this suggests the 
invariant CDR3α loop is intrinsic in antigenic recognition [100]. Figure 1.11 illustrates how 
the TCR of a human iNKT cell interacts with a CD1d-αGalCer complex with regards to the 
CDR loops. A specific α or β chain is not needed to recognise CD1d protein alone in human 
and murine iNKT cells, and this suggests the invariant CDR3α loop is intrinsic in antigenic 
recognition [100]. 
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Figure 1.11: TCR - CD1d interaction (A) Ribbon structure model of the iNKT TCR-CD1d complex when 
bound with α-GalCer. The light blue area is representative of CD1d; the orange-yellow 
structure represents the iNKT TCR. The glycolipid α-GalCer is shown in red. (B) Expanded 
view of boxed region in (A), showing the CDR loops. Colours as in (A).  The image has been 
rotated around the y axis 180°. (C) TCR structure showing the ligand binding interface.  
α-Chains are represented in grey and the β chains in pink. The CDR3 loops are coloured 
according to their genetic origin: Green, V-region; yellow, Dβ+N; blue, J-region. Adapted from 
[92, 100]. 
 
The efficacious accommodation of different sugar heads can be rationalised by a degree of 
plasticity within the CDR3 loops, particularly the CDR3β loop. The presence of CDRβ 
residues in the cavity wall provides a possible mechanism by which the CDR3β loop 
modulates antigen specificity. Variations in the CDR3β loop and the inherent ability of other 
CDR loops present at the binding surface of the TCR of different iNKT clones, results in 
preserved antigen recognition. This contributes to the idea that the CDR3 loops exhibit a 
conserved degree of flexibility across iNKT cell TCRs. This adjustability is usually typical of 
αβ TCR-MHC I interactions [101]. 
A B
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It is established that human and murine NKT cells expressing an invariant TCR α-chain are 
specific for CD1d molecules, such as α-GalCer [102], but the binding mechanism remains 
something of a mystery. Kang et al. [80] established that lysosomal binding of α-GalCer to 
CD1d molecules, and the subsequent presentation of the antigen-protein complex to T cells, 
is dependent on the expression of Saps. This is in contrast to cell-surface binding and the 
autoreactive recognition of CD1d by iNKT cells, which does not require Saps [78, 80]. More 
recently, Hava et. al. [57] demonstrated that the formation of stimulatory CD1-antigen 
complexes necessary for iNKT cell activation requires a spatial encounter between the CD1 
protein and antigen. The group stated that candidate accessory molecules, such as 
microsomal triglyceride transfer protein (MTP) and Saps manipulate the antigen 
presentation and hypothesised that they act as lipid transfer proteins involved in CD1 
loading [57].  
 
Given the important role CD1d-lipid complexes hold in the activation of iNKT cells, CD1d 
tetramer/multimer studies have been employed in attempts to track the response of the iNKT 
cell receptor to glycolipid antigens [103-107]. Tetramer technology allows the direct 
exposure of a variety of T cell groups, which can be visualised, enumerated and 
characterised from unfractionated lymphocyte populations. It does not require in vitro 
culturing for amplification, and thus, is a very useful and powerful tool in the exploration of 
mechanisms in, for example, autoimmune diseases [104]. It was shown that the Vα region of 
the iNKT cell is not a key contributor in the recognition of α-GalCer when coupled with 
mCD1, but it has been hypothesised that, in humans, identification is more reliant on the  
β-chain [98]. Stanic et al. [108] discovered that the Vα repertoire of iNKT cells does in fact 
impact both recognition and antigen avidity. They went on to demonstrate that the Vα14-
Jα18 iNKT cell receptor co-operatively engages with α-GalCer and analogue loaded 
multimers. Kjer-Neilsen et al. [92] concurred with this concept and although a number of 
studies state that the CDR3β loops do not take part in iNKT cell antigen recognition, the 
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Kjer-Neilsen group recently showed that CDR3β loops that do not recognise CD1d-glycolipid 
complexes are likely to result from either steric hindrance from obstructing CDR3β loops at 
the cavity surface or interference from the CDR3α loop conformation [92]. 
 
iNKT cells present as either double negative (DN) or CD4+ T lymphocytes that co-express 
an intermediate level of the αβTCR along with a number of other receptor characteristics 
from the NK cell lineage. That is, approximately 60% of all NKT cells express the CD4 
marker (CD4+), and the majority of the remaining cells lack both CD4 and CD8 expression; 
they are defined as DN cells [65, 109, 110]. The iNKT cell developmental pathway is initially 
the same as that of conventional CD4+ and CD8+ T cells. A number of genes identified as 
affecting iNKT cell development have also been identified as regulating NK and T cell 
function and development, further substantiating the hypothesis that the iNKT cell 
maturation lineage diverges from the conventional T cell pathway [111]. 
 
DN thymocyte progenitor cells that do not express an antigen receptor enter the thymus and 
proliferate, before beginning gene rearrangement. This results in the cells having a pre-TCR 
and CD4+CD8+ co-receptor; the cells are now double positive (DP) [112]. As the cells 
mature, the α-chain genes rearrange and undergo positive or negative selection [112]. 
Positive selection is the process by which DP thymocytes are salvaged from apoptosis by 
TCR engagement with a ligand. In the case of conventional T cells, thymocytes whose 
receptors can interact with self-peptide:self-MHC complexes are positively selected allowing 
them to mature into conventional CD4+ or CD8+ T cells. Thymocytes whose TCRs recognise 
self-ligand complexes too well are induced to undergo programmed cell death, thus 
removing potentially self-reactive cells before they reach maturation [83].  
 
Chapter 1   General Introduction 
    
25 
It has been suggested that the unique iNKT cell lineage occurs on or after the DP stage of T 
cell development through the mechanism of α-chain gene rearrangement and positive 
selection by specific self-ligands, analogous of the MHC class I-restricted CD8+ and MHC 
class II-restricted CD4+ T lymphocyte lineages [86]. The self-ligands of iNKT cells are CD1d-
expressing thymocytes originating from bone marrow [86]. Based on the expression of DX5 
(a cell surface marker), iNKT cell development has been separated into four stages [111] 
(Figure 1.12). In the most immature stage the iNKT cells are highly CD4+ and lack both the 
DX5 and NK1.1 cell markers. iNKT cells are also highly CD4+ in the second of the first two 
immature stages, but at this point do express the cell surface marker DX5 (DX5+/ NK1.1-). 
Mature iNKT cells are then equally divided into DX5+/NK1.1+ cells and DX5-/NK1.1+ cells. It 
is thus following the random TCR α-chain rearrangement that the iNKT cell lineage gains its 
distinctive signalling features [86, 90, 111, 113].  
 
Figure 1.12: Schematic of iNKT cell development. Double negative (DN) T cells go through gene 
rearrangement expressing CD4+CD8+ – they are now double positive (DP) T cells. In 
conventional T cell development, the cells become sensitive to peptide:MHC complexes and 
undergo positive and negative selection, the former resulting in the production of CD8+ and 
CD4+ T cells. Positive selection by CD1d-expressing thymocytes, on or after the DP stage 
(indicated by    ), together with TCR Vα14 and Jα18 gene rearrangement leads to the 
development of iNKT cells, by the expression of various cell surface markers, namely DX5 and 
NK1.1. 
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iNKT cells exercise a key influence on an array of immune responses and pathologic 
conditions and upon TCR cross-linking rapidly secrete an assortment of cytokines such as 
interferon-γ (IFN-γ) and interleukin-4 (IL-4) within a few hours. Interestingly, they are 
stimulated to produce only IFN-γ upon cross-linking with C-lectin type NK receptors, such as 
the NK1.1 molecules NKR-P1 and CD161c [110, 114, 115]. 
 
IL-4 is a multi-functional cytokine that plays a critical role in regulating immune responses 
within the body, as well as being a key component in tissue adhesion and inflammation. It is 
produced by TH2 cells, basophils and mast cells and regulates the differentiation of antigen-
stimulated naïve T cells [116]. iNKT cells have been linked to a variety of immune responses 
including responses to pathogens, tumours, tissue grafts, allergens and autoantigens. Thus 
iNKT cells bridge the gap between the innate and adaptive immune systems; a 
characteristic also attributed to innate B and T cells [117, 118]. 
 
Ontogenic programming of the unique features of iNKT cell function occurs at the stage 
involving Vα14-Jα18 TCR α-chain rearrangement and after interaction with the positively 
selecting CD1d-self-lipid ligand complex [113]. This is presumably why the iNKT cell lineage 
precursor in the thymus undergoes a major expansion upon contact with a CD1d-lipid 
compound, before the expression of the NK1.1 marker molecule.  
 
Soon after stimulation, the iNKT cell population dramatically decreases and the cells remain 
dormant for a short period of time, before eventually proliferating [119]. The cell’s effector 
functions, such as cytokine production remain very much intact even after down-regulation 
of the Vα14 receptor, indicating that Vα14 NKT cells resist becoming anergic upon receptor 
activation [119]. Matsuda et. al. [86] state that the differences expressed in the surface 
molecules and/ or the cytokines produced by the MHC molecules or the CD1d proteins is 
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likely to be responsible for the activation of cascade pathways that add to or result in the 
diverse phenotypes of iNKT cells in comparison to typical CD4+ and CD8+ T cells.  
 
1.8 iNKT cell effector functions 
The immune system is able to produce an immune response to virtually all molecules or 
cells [83]. The capacity of the human body to respond to self-antigens is ever-present, but 
more often than not results in anergy - a state of tolerance involving non-responsiveness to 
antigen rather than cell deletion [120]. This implies that mechanisms, such as, either the 
inactivation or deletion of autoreactive T and B cells or the suppression of autoimmunity by 
cells or cytokines exist to subdue autoimmune responses [121]. In certain individuals, these 
mechanisms are either absent or are overridden, culminating in a breakdown of self-
tolerance and the development of autoimmune disease, such as type 1 diabetes (T1D) and 
lupus (systemic lupus erythematosus; SLE) [122]. 
 
1.9 The TH1/ TH2 response 
There are two forms of CD4+ helper T (TH) cells, which play an integral part in the immune 
response to protein antigens [123]. They also aid in the production of antibodies by B cells. 
TH cells can be discriminated into two groups: TH1 and TH2. Each type of TH cell develops 
from uncommitted TH0 cells (naïve CD4+ T cells) [124, 125]. When initially stimulated by 
antigen loaded APCs, naïve CD4+ T cells begin to secrete an array of cytokines which 
manipulates their polarisation to either the TH1 or TH2 pathways [126]. Other influences 
include antigen concentration, the presence of certain hormones and the type of APC itself. 
TH1 cells release pro-inflammatory cytokines, such as IL-2, TNF-α and IFN-γ, all of which  
are involved in killing intracellular microbes, generating Tc cells, and potentially stimulating  
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Figure 1.13: Schematic representation of how IL-4/ IFN-γ can skew TH cell development. 
 
the phagocytic action of macrophages [125]. The anti-inflammatory cytokines IL-4, IL-10 and 
IL-13 are produced by TH2 cells and amongst other things are important in helping eradicate 
parasitic infections, and for B cell proliferation and differentiation [125]. TH cytokines are self-
regulating and can inhibit each other’s functions; both TH1 and TH2 are antagonists for each 
other (Figure 1.13). The initial response to infection involves TH1 or TH2 cytokines. The TH1 
response leads to the release of the pro-inflammatory cytokines, followed by the production 
of the TH2 anti-inflammatory cytokines.  Activated APCs, such as DCs and macrophages 
produce IL-12, which is critical in the development of TH1 cells. The production of IL-12 
stimulates IFN-γ production by iNKT cells, and NK cells, of which the latter in turn induces 
more IFN-γ production by APCs. iNKT cells produce large concentrations of IL-4 when 
stimulated through their TCR by CD1d-antigen complexes. IL-4 brings about the polarisation 
of TH0 cells towards the TH2 pathway. TH2 cells themselves secrete IL-4. The production of 
IL-6 by APCs triggers the secretion of IL-4 by naïve CD4+ T cells (Figure 1.14) [105, 115, 
125, 127, 128]. 
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Figure 1.14: Model of TH1/TH2 cell development and the prevention of TH1-mediated autoimmunity. 
(A) iNKT cells are activated by antigen-loaded CD1d-expressing APCs. This stimulates the 
production of cytokines such as IL-4, IL-6, IL-12, TGF-β, IFN-γ. These cause differentiation of 
naïve CD4+ iNKT cells into TH1 or TH2 cells. An increase in a particular cytokine can skew the 
immune response towards TH1 or TH2, depending on the cytokine environment. (B) α-GalCer-
loaded DCs interact with iNKT cells, promoting TH cells to produce cytokines such as IL-4,  
IL-10 and IL-12. Myeloid dendritic cells (MDCs) that prevent tissue damage are then recruited 
and activated in the regional lymph nodes (RLN) under the influence of IL-12. Regulatory TH2 
cells may suppress the activities of pathogenic TH1 cells at the site if the autoimmune attack 
thus preventing ongoing autoimmune attack. 
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An increase in a particular cytokine can skew the immune response towards either a TH1 or 
TH2 type depending on which is associated with protection [128]. High concentrations of IL-4 
(or IL-6) obstruct the TH1 cell developmental pathway, even if the cytokine IL-12 is present 
[129]. In a similar manner, IFN-γ secreted by TH1 cells blocks the proliferation of TH2 cells, 
but leaves the TH1 population unaffected (Figure 1.13). This is due to a lack of β-chain IFN-γ 
receptor expression. The production of IL-10 by TH2 cells also inhibits APC production of  
IL-12 [130]. 
 
Defective regulation of the anti-self response through TH1 and TH2 cells can lead to a 
breakdown of self-tolerance, which in turn can trigger the development of an  autoimmune 
disease (Figure 1.14) [129, 131].The discrete T-cell population of iNKT cells is stimulated to 
secrete cytokines, such as IL-4 and IFN-γ, by a TH1/TH2 response and is mediated by a 
CD1d:antigen complex [132, 133]. Glycolipids such as α-GalCer bind with CD1d proteins 
forming a compound that activates iNKT cells [95, 134]. The atypical ability to rapidly 
produce such cytokines suggests that iNKT cells are able to manipulate adaptive immune 
responses. α-GalCer has become an increasingly attractive analogue since the realisation of 
the important role it plays in regulating the development of a number of autoimmune 
diseases, such as systemic sclerosis, T1D and SLE [135]. α-GalCer polarises the 
differentiation of naïve CD4+ T cell precursors in mice towards the development of a TH2 
phenotype, and therefore highlights the exciting possibility that glycolipid antigens could 
prevent TH1 cell-mediated autoimmunity [102, 136-139]. Although, the glycolipid antigen 
also produces the TH1 lymphocyte IFN-γ, repeated exposure of murine spleen cells both in 
vitro and in vivo to α-GalCer. This is in contrast to exposure with LAM or other glycolipid 
antigens which results in a dramatic decrease in the production of IFN-γ and enhancement 
of the TH2 cytokines IL-10 and IL-4 [109]. 
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1.10 Type 1 diabetes (T1D) 
Type 1 diabetes (T1D) is characterised by lymphocyte-mediated destruction of insulin-
producing β-cells in the pancreatic islets of Langerhans. This process is mediated by T cells 
specific for β-cell antigens [140]. Antibodies to β-cell proteins can be simultaneously 
generated and used for predicting the occurrence of the condition in at-risk populations (see 
[141] for a review of β-cell protein and lipid autoantigens implicated in the development of 
type 1 diabetes). In a healthy individual, insulin increases the synthesis of glycogen from 
glucose by binding with insulin receptors allowing the cellular uptake of glucose from the 
blood stream [142].  Glycogen is the chief polysaccharide store of cells. The process of islet 
destruction culminating in inhibited insulin-production, leads to severe hyperglycaemia 
(raised blood glucose levels). Hepatic overproduction of glucose by glycogenolysis and 
gluconeogenesis leasd to subsequent impaired cellular uptake of blood glucose. 
Gluconeogenesis is the production of glucose gained from a source other than glycogen. If 
left untreated, hyperglycaemia can lead to central nervous system (CNS) depression, coma 
and eventually death [142].  
 
Organ-specific autoimmune diseases, such as T1D and multiple sclerosis (MS) are 
governed by uncontrolled TH1-cell reactions [128]. Destructive insulitis is paralleled by 
predominant secretion of IFN-γ, IL-2, IL-12, TNF-α, and IL-18, while the TH2 cytokine, IL-4 is 
associated with non-destructive insulitis [140, 143].  
 
The modulation of immune reactions from a TH1- to TH2-dominant reaction can successfully 
prevent autoimmunity [139, 144, 145]. Systemic treatment with the TH1 cell promoter IL-12, 
has been recorded as accelerating the onset of diabetes in non-obese diabetic (NOD) mice, 
whereas treatment with anti-IFN-γ, or IL-12 antagonists delays the development of T1D 
(Figure 1.15) [146-148]. NOD mice are genetically predisposed to develop the autoimmune 
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disease T1D [149]. The development of diabetes is initiated by the infiltration of lymphocytes 
into the islets of Langerhans at approximately 4 weeks of age. The majority of female NOD 
mice clearly develop diabetes by 30 weeks of age; in the NOD mouse model, the incidence 
of diabetes is more prevalent in the female of the species [117].  
 
Antigen recognition by inactivated CD4+ T lymphocytes leads them to differentiate into TH1 
or TH2 effector cells, depending on the tissue-specific microenvironment and cytokine milieu 
in which they develop, thus indicating that cytokine imbalance plays a vital part in the 
emergence of autoimmune diseases [115]. 
Figure 1.15: Potential mode of iNKT cell-mediated regulation of DC maturation in autoimmune 
diabetes. During the onset of type 1 diabetes, CD1d-expressing DCs activate iNKT cells under 
the influence of pro-inflammatory cytokines such as IL-12. This results in a change of the 
activated phenotype of DCs in pancreatic lymph nodes, suppressing pro-inflammatory cytokine 
production and thus preventing ongoing autoimmunity. In a host prone to T1D, impaired iNKT 
cell function results in continual pro-inflammatory autoimmune attack. Adapted from [150]. 
 
NOD mice are often used as models for T1D as the cell system involving CD1d proteins and 
NKT cells is phylogenetically conserved among mammals (Table 1.1) and thus pre-clinical 
studies carried out in mice are expected to have a direct correlation in humans. The human 
body, however, has a decreased number of iNKT cells in comparison to mice. The NOD 
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Table 1.1: Comparison of mouse and human iNKT cells. Adapted from  [66, 102] 
 
mouse strain spontaneously develops diabetes with many features common to those 
presented by humans with the same condition. Studies have found that NOD mice are Table  
.specifically deficient in iNKT cells in comparison to other strains, thus suggesting that iNKT 
cells may be involved in the development of T1D [66].  
 
It has been implied that results gained from utilising NOD murine cells could be biased 
towards a TH1-mediated autoimmunity. However, this was disproved by Araujo et al. [146], 
when the group successfully induced experimental allergic asthma in NOD mice, a typical 
TH2-mediated disease. 
 
 
Mouse 
 
Human 
(α-chain) 
 
Vα14-Jα18 
 
Vα24-Jα18 
TCR 
Repertoire: 
(β-chain) 
 
Vβ8.2, Vβ7, Vβ2 
 
Vβ11 
Co-Receptor 
 
CD4+ or DN 
 
CD4+, CD8αβ+, CD8αα+ or DN 
Cognate Antigen 
 
α-GalCer 
 
α-GalCer 
Antigen-presenting 
molecule 
 
mCD1d 
 
hCD1d 
Frequency (as a 
proportion of 
lymphocytes) 
 
Thymus (0.3-0.6%); Spleen (0.6-1%); 
Liver (12-20%); Bone Marrow (0.3-
0.5%); Blood (0.5-0.8%) 
 
Blood (0.01-1%); Liver <0.5%) 
Cytokine profile IL-4, IFN-γ, TNF-α, IL-13* 
 
IFN-γ, TNF-α†, IL-4, IL-13, IL-2, GM-
CSF, IL-6, IL-10, IFN-γ, TNF-α‡ 
 
NK Receptors Mostly NK1.1 (CD161)+ 
 
Mostly NK1.1 (CD161)+. Some CD4neg 
express 2B4, CD94, NKG2A 
 
 
*Vα14 iNKT cells have not been shown to differentially secrete cytokines. †Preferential cytokine production by 
CD4neg subset. ‡Preferential cytokine production by CD4+ subset. 
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1.11 Systemic lupus erythematosus (SLE) 
Systemic lupus erythematosus (SLE) is a multi-system fluctuating inflammatory disease that 
is extremely variable with regards to its clinical presentation [151]. It is an immune complex-
mediated disease characterised by chronic IgG antibody production directed at ubiquitous 
self-antigens present in all nucleated cells; SLE patients almost invariably express 
antinuclear antibodies (ANA). Symptoms can range from a mild disease associated with 
rashes and arthritis to a devastating illness coupled with renal failure and profound nervous 
system disturbances. Regardless of these clinical manifestations, it has been suggested that 
T cells are the driving force in the pathogenesis of this and other autoimmune diseases 
[152-154].  
 
IFN-γ contributes to tissue injury in lupus and Sieling et al. [155] demonstrated that 
DN T cells, incorporating CD1-restricted APCs derived from SLE patients, produce the TH2 
cytokine IL-4, which aids in B cell production of IgG and consequently dramatically 
decreases the activity of this antibody mediated disease. Oishi et al. [156] showed that the 
selective reduction of DN iNKT cells is related to the disease progression of SLE.  
 
The effects of α-GalCer on both the hereditary and induced models of SLE have been 
explored. Injection of α-GalCer in to the murine model for hereditary SLE, the MRL-lpr/lpr 
mouse, lessens inflammatory dermatitis, but has no effect on kidney disease [157]. This 
particular strain of mouse has a naturally decreased iNKT cell population [158]. Repeated α-
GalCer administration caused a marked clonal expansion of iNKT cells and an increase in 
serum immunoglobulin E (IgE) concentration, suggesting that α-GalCer polarises the 
immune system towards a TH2 response, inducing the suppression of SLE dermatitis.  
α-GalCer also induces a TH2 response in BALB/c mice, protecting the mouse from pristine-
induced SLE . This is in contrast to the SJL/L mouse, where the α-GalCer injection is seen 
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to exacerbate SLE caused by the hydrocarbon oil pristine, which can be correlated to the 
production of TH1 cytokines [117]. Miyamoto et al. [144] reported that an α-GalCer derivative 
(termed OCH) with a truncated aliphatic chain preferentially induced NKT cells to secrete the 
TH2 cytokine IL-4.  
 
Treatment of NZB/W mice (another murine model for hereditary SLE) with α-GalCer 
produces dichotomous results, according to the age of the animal. Van Kaer et al. [117] 
observed that a TH1 response exacerbating the disease, is induced in old NZB/W mice, yet 
a TH2 response is seen in younger mice of the same strain. Zeng et al. [159] have also 
noted that the activation of NKT cells in adult NZB/W mice by α-GalCer augments TH1-type 
responses (the secretion of IFN-γ) and autoantibody production, both of which contribute to 
lupus development. These findings give rise to the theory that SLE-like autoimmunity can be 
attributed to changes in the balance of TH1/TH2 immune response.  
 
1.12 iNKT cells: TCRs, down-regulation, and expansion 
The majority of iNKT cells (incorporating all Vα14 NKT cells and NK1.1-expressing T 
lymphocytes) recognise a glycolipid antigen:protein complex, comprising α-GalCer or related 
structure, and a CD1d molecule. In addition to cytokine production on activation, iNKT cells 
down-regulate immunity, including the suppression of anti-tumour responses via a 
mechanism involving the cytokine IL-13 and the promotion of tolerance induction [160]. 
Soon after stimulation (approximately 2 hours) by α-GalCer for example, TCRs are down-
regulated, with their levels eventually being restored after approximately 24 hours 
(Figure 1.16). After activation, the iNKT cell population dramatically decreases and the cells 
remain dormant for a while, before eventually proliferating. All the while, the cell’s effector 
functions such as cytokine production remain very much intact, even after down-regulation 
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of the TCR Vα14 receptor; this indicates that Vα14 NKT cells resist becoming anergic upon 
receptor activation [117, 119].  
 
In addition to iNKT cells being less functional in terms of IL-4 production in patients with 
T1D, the frequency of Vα24+ CD4-CD8- DN T cells has been exhibited to be lower in diabetic 
than in non-diabetic identical multiplets (i.e. twins or triplets). In the case of diabetes in the 
NOD mouse, a reduction in the numbers of iNKT cells is observed in the thymus, spleen, 
bone marrow and liver, and is controlled by a number of genetic loci [102, 161-165]. A 
reduction of iNKT cells in newly diagnosed insulin-dependent diabetics has also been 
reported, and although some patients of type 2 diabetes (T2D) have a lower level of NKT 
cells than non-diabetic counterparts (yet still not as low as patients with T1D), their 
CD4+CD25+ T cell numbers are normal [166]. The incidence of iNKT cells has also shown to 
be lower in patients suffering from other autoimmune diseases, such as MS (a chronic 
inflammatory disease of the CNS), SLE and systemic sclerosis, thus indicating that iNKT 
cells regulate autoimmune responses and play a crucial role in controlling the development 
of autoimmune diseases [114, 135, 167-170]. 
 
Hammond et al. [165] have been researching the effects of NKT cells in autoimmune 
disease therapy and iNKT cell deficiency in NOD mice which was found to be directly related 
to T1D propensity. This was demonstrated by the inhibition of the development of the 
spontaneous disease after transferral of as few as 1.5 x 105 thymic αβ+ DN cells. 
 
Administration of α-GalCer to female NOD mice has been revealed to ameliorate the 
development of diabetes, and results in the accumulation of iNKT cells and DCs in 
pancreatic lymph nodes (PLN). Injection of myeloid DC isolated from PLN, but not inguinal 
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Figure 1.16: iNKT cell response to α-GalCer activation. Within hours of administration to mice, α-GalCer 
binds to CD1d on APC surfaces and activates iNKT cells, initiating the secretion of cytokines 
such as IL-4 and IFN-γ. During the first few hours of activation, iNKT cells mainly produce IL-4. 
At this time, TCR expression is downregulated, returning to relatively normal levels at 
approximately 24h. It is at this point that iNKT cells produce higher concentrations of IFN-γ and 
undergo rapid proliferation. ~3days after injection, the iNKT cell population is maximal, and 
cytokine production is much decreased, although still detectable. Adapted from [117]. 
 
lymph nodes (lymph nodes isolated from the groin region) completely prevented the 
occurrence of diabetes in the female NOD mouse [162]. Interestingly, it has been reported 
that sulfatide-reactive T cells (T cells reactive to the myelin-derived lipid sulfatide, presented 
by CD1d) and not iNKT cells are increased several-fold in CNS tissue in EAE, the murine 
model for human MS [171]. Mercer et al. [111] commented on the number of studies to have 
shown that treating NOD mice with α-GalCer injections, or injecting iNKT cells activated ex 
vivo with α-GalCer, prevents both the development and recurrence of the condition. It is 
worth noting, however, that although agreeing that iNKT cells have a general role in natural 
protection against destructive autoimmunity, Lee et al. [172] contradicted the general 
consensus that patients with T1D have decreased NKT cell frequency and decreased IL-4 
production.  
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Additional studies have concluded that transgenic over expression of iNKT cells improves 
diabetes. It has been shown that α-GalCer effectively stimulates the number of detectable 
iNKT cells, before causing the number to deplete and that repeated stimulation with α-
GalCer and various structures based around this compound, expands the human 
Vα24+Vβ11+ populous, whilst retaining their CD4+ or CD4- phenotype [96, 136, 173-175]. 
 
1.13 Aims and objectives 
The importance of α-GalCer in the medical world is apparent from studies carried out 
relating to cytokine production, immune cell proliferation and autoimmune disease therapy. 
However, as previously discussed it does not provide the definitive solution for the 
prevention and treatment of conditions such as T1D.  
 
In conjunction with the induction of the anti-inflammatory TH2 cytokine IL-4, a substantial 
amount of the unfavourable TH1 cytokine IFN-γ is produced upon activation of iNKT cells by 
the CD1d:α-GalCer complex resulting in, for example, continued self or autoimmune attack. 
The aim of this thesis has been to synthesise a library of GSLs that are structurally 
analogous to the parent antigen α-GalCer, but with variations in the acyl chain, 
phytosphingosine base and sugar head, and to investigate the effects some of these 
compounds have on the immune system. By carrying out in vitro and in vivo assays, it was 
hoped that an antigen that provokes a skewed TH2 immune response could be found, and 
thus lead to a potential therapeutic regime that can be implemented as part of the care and 
treatment of patients with autoimmune disease, such as T1D. 
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Recently, analogues with greater deviations from the parent GSL α-GalCer have been 
investigated. Modulation of the 6’ carbon on the sugar head from a hydroxyl group to an 
amine or amide, linked with small molecules or incorporation of fatty acids have been 
scrutinized [72, 176]. Such analogues thus far have for the most part been based on the 
C18 base chain coupled with galactose. Therefore, the possibility of synthesising analogues 
with shorter base chains, such as the C9 analogue, with the inclusion of C6’ modulations 
could prove exciting in terms of their immunostimulatory properties. The incorporation of a 
sulfate group at C3’ of the sugar and a di-unsaturated fatty acid chain [177-180] could also 
heighten the immunomodulating character. Experimental results gained so far, and from 
other group’s data have reported that analogues entailing either a sulfate group or 
unsaturated acyl chain are successful activators of iNKT cells. Including both variations 
could lead to the discovery of a so-called super-antigen.  
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2. Variations in the phytosphingosine base 
2.1. Hydroxyl group variations 
α-GalCer (44) can be sub-divided into 3 main portions: a sugar ring, an N-acyl chain, and 
sphingosine derived base, of which the latter two components constitute the ceramide or 
lipid moiety (Figure 2.1). Diversity and variability can be introduced into all three sections in 
order to produce novel antigenic compounds.  
 
Figure 2.1: Functionality of α-Galactosyl Ceramide (α-GalCer). The GSL is comprised of a polar sugar 
head group, anomerically linked to a ceramide portion which itself is made up of an N-acylated 
phytosphingosine base.  
 
There is now interest in synthesising analogues of the parent glycolipid antigen that vary in 
the carbohydrate and lipid portions to investigate their immunostimulatory properties, in the 
hope of discovering more potent agents for specifically activating iNKT cells in different 
disease states.  
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Although the discovery of α-GalCer (44) has had a great impact on the immunological world, 
it does not provide a fault-free solution to the treatment and prevention of autoimmune 
diseases. Alongside the TH2 cytokine IL-4, a single dose of α-GalCer (44) induces the 
production of greater concentrations of the potentially detrimental TH1 cytokine IFN-γ [95, 
139, 181]. Thus, the development of analogues that have significantly greater TH2-inducing 
properties is an exciting prospect and one undertaken in this project.  
 
A negative effect exhibited in NZB/W mice (the mouse model of experimental autoimmune 
encephalitis, EAE) by α-GalCer (44) is the induction of an abnormal TH1-type immune 
response, resulting in intensified SLE [159]. The administration of α-GalCer (44) to apoE-/- 
mice (a hypercholesterolemic mouse model prone to the development of atherosclerosis) 
has been shown to induce a 50% increase in atherosclerotic lesion size, highlighting another 
problem associated with α-GalCer (44) [182]. However, no change was seen to lesion size 
of apoE-/-CD1d-/- mice showing that it is the CD1d protein that is needed to present  
α-GalCer (44).  
 
Another concern regarding the use of α-GalCer (44) encompasses side effects, such as 
significant liver toxicity, the triggering of abortion and even death have been induced by the 
injection of α-GalCer (44) into mice. On a more positive note, clinical trials of the compound 
in human cancer patients did not produce any detrimental side effects, possibly due to the 
naturally decreased population of iNKT cells in humans [65]. Nonetheless, it has become 
apparent that one cannot wholly rely on animal models to determine the effectiveness of 
immuno-intervention studies, due to quite profound differences between experimental 
murine models and human conditions [183]. 
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Two main areas of the parent α-GalCer structure with regards to the phytosphingosine base 
have been scrutinized; namely the chain length and the inclusion/ exclusion of the hydroxyl 
groups at positions C3 and C4. Figure 2.2 highlights the variations that can be introduced 
into the phytosphingosine base, and the effect they have on the antigenic activity of the 
GSL.  
 
 
 
Figure 2.2: The relationship between the structure of α-GalCer analogues and bio-reactivity. 
 
2.2. Hydroxyl group variations 
The effect hydroxyl groups have on achieving iNKT cell activation has been in the spotlight. 
It has been reported that the lack of a hydroxyl group at position 4 of the phytosphingosine 
base portion does not hinder α-GalCer (44) binding by mCD1, but does affect the binding of 
antigenic analogues to hCD1d [98]. However, when hydroxyl groups are absent from both 
carbon-3 and -4 of the phytosphingosine base, the antigen/protein complex does not 
significantly activate murine or human iNKT cells [98]. This could simply be a matter of 
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decreased solubility, or could be indicative that hydroxyl groups may interact with both CD1 
protein molecules and the T-cell receptors that are present on the surface of NKT cells. The 
binding of the antigens to CD1 molecules has been shown to be independent of the 
presence of hydroxyl groups in the C3 and C4 positions of the phytosphingosine base, 
suggesting that the hydroxyl groups are an integral part of activating NKT cells, but not 
essential for the binding of α-GalCer (44) with CD1d molecules [98, 184, 185].   
 
Varying the position of the coupled sugar with the ceramide portion of the CD1d ligand 
affects the NKT activation. When a galactose group was glycosylated at the 3-hydroxyl 
group of the ceramide in an α-configuration (Figure 2.3), a greater proliferation of murine 
spleen cells was observed than from α-GalCer (44), but with no immunostimulatory activity. 
Incidentally, the β-form of the analogue coupled at the C3 of the phytosphingosine base 
exhibited a weaker proliferative response [185].  
 
 
 
Figure 2.3: 3-α-Galactosylated variant of α-GalCer. This derivative has been shown to have a stronger 
proliferative response than the parent glycolipid, but no immunostimulatory activity. 
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2.3. Base chain length 
Sphingolipids comprise a group of approximately 400 naturally occurring compounds and 
are recognised as bioactive lipid molecules [186]. They are primarily signalling molecules, 
but also function as building blocks, forming the basis of the plasma membrane in eukaryotic 
cells [186]. Structurally, they are typified by a long chain base backbone, often comprising of 
18-20 carbon atoms with several hydroxyl functional groups. The naturally occurring 
sphingosine is a C18 hydrocarbon chain with a hydroxyl function at C1, an amine at C2, a 
hydroxyl group at C3 and a trans double bond between C4 and C5 [187]. Phytosphingosine 
is fully saturated with an additional hydroxyl group at C4, as opposed to the double bond 
(Figure 2.4). When coupled with a polar sugar head, such as galactose or glucose, and 
acylated at the amine group with a fatty acid, sphingolipids become GSLs, and can affect 
physiological processes, such as embryogenesis, neuronal cell and leukocyte differentiation, 
cell adhesion, and signal transduction [61]. GSLs are recognised by the immune system and 
individual GSLs are specific blood group antigens that can be detected in autoimmune 
diseases, such as Guillain-Barre Syndrome and T1D [188].  
 
 
Figure 2.4: Variations between the naturally occurring sphingosine (left) and phytosphingosine 
(right). 
 
α-GSLs are potent immunostimulants [186, 189]. When Brossay et al. [98] tested the 
cytokine production of α-GalCer analogues with variations in the phytosphingosine chain 
length, they discovered that both a 15-carbon and 11-carbon chain successfully stimulated 
cells to release IL-2, although on a somewhat less effective scale than the parent glycolipid. 
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This is not the case for hCD1d, which only presented the tested analogues with C18 and C15 
phytosphingosine chains to any effect. 
 
Miyamoto et al. [144] reported that an α-GalCer derivative, with a truncated aliphatic chain 
(termed OCH9) (47), preferentially induced iNKT cells to secrete the TH2 cytokine IL-4. 
Studies in IFN-γR-/- mice suggested that IFN-γ is not a pre-requisite for the adjuvant effect of 
α-GalCer (44). In conjunction with this finding, results illustrated enhanced T cell responses 
when using OCH9 (47), and reduced ability to secrete IFN-γ [144, 190, 191].  
 
Oki et al. [192] demonstrated IFN-γ production upon activation of iNKT cells by CD1d 
associated glycolipids, is more susceptible to the length of the phytosphingosine chain 
moiety, than that of IL-4. Their team also concluded that the number of carbon atoms in the 
chain shapes the duration of iNKT cell stimulation, and that IFN-γ expression requires longer 
T cell receptor stimulation than IL-4 secretion. More recently, OCH9 (47) has been shown by 
means of TH2 cell polarisation, to suppress collagen-induced arthritis (CIA, a murine model 
for the autoimmune disease rheumatoid arthritis) in SJL mice, which are characteristically 
prone to the development of autoimmune diseases and have a deficiency in their NKT cell 
population and function [193].  
 
2.4. Chemical synthesis 
2.4.1. Protection of D-lyxose 
The general procedure for producing deviations in the phytosphingosine base moiety of α-
GalCer (44) was based on the procedures of  Lin et al. [194]. This method, in contrast to 
many others reported, was concise with moderately high yields of the final phytosphingosine  
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Figure 2.5:  Scheme showing the protection of d-lyxose using acetone and trityl chloride 
 
product. The starting sugar (D-lyxose) used is relatively inexpensive with the desired 
required stereochemistry found in phytosphingosine (Figure 2.5). The isopropylidene ketal 
group is commonly used to protect 1,2- and 1,3-diols, especially in carbohydrates where it 
can selectively mask the hydroxyl groups. In compounds containing three hydroxyl groups 
on neighbouring carbon atoms, the 1,2-derivative of the acetonide (Figure 2.6) is generally 
favoured over 1,3- and 1,4-derivatives. However, this preference does depend quite heavily 
on the actual structure of the triol. In compounds where there is more than one acetonide 
possibility, the thermodynamically more favoured structure dominates. Secondary alcohols 
preferentially form cyclic acetals compared with primary alcohols. Conversely, when two 
trans secondary alcohols are present, the primary alcohol is preferred in forming the acetal 
   
Figure 2.6: The mechanism of D-lyxose acetonide formation, compound (1).  
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as this is thermodynamically more stable [195]. 
 
Triphenylmethyl ethers (Tr-OR) are used as protecting groups of alcohols as they are able to 
selectively protect primary alcohols in the presence of secondary alcohols, due to their bulky 
nature. Due to the fact that these protecting groups can be removed by mild acid hydrolysis, 
the acetal protecting group was introduced first. 
 
2.4.2. Wittig reaction 
There is a wide variety of commercially available Wittig salts and it is relatively easy to 
prepare non-commercial products from triphenylphosphine and a halogenated alkane 
(Figure 2.7). Several attempts at synthesising the Wittig reagent and resulting olefination 
product were undertaken (Figure 2.8). 
 
In the first instance, 2 M eq of triphenylphosphine, haloalkane and base were used, with the 
protected form of D-lyxose. Lithium bis(trimethylsilyl)amide (LHMDS) was the chosen base 
as stated by Lin et al. [194]. However, TLC analysis showed a significant amount of 
unreacted starting material. Several factors could have contributed to this, such as the 
presence of moisture in the reaction vessel or reagents, or simply the base being too weak 
(pKa ≈ 30 [196]. The reaction was thus repeated, substituting LHMDS  with n-butyl lithium (n-
BuLi), which although is a stronger base (pKa = 42) [197] still proved unsuccessful. An 
alternative method based around [198] was adopted in order to synthesise the various Wittig 
reagents and condensation products as reported in the experimental section (Figure 2.8). 
Using the method described by Plettenburg et al. [198], compounds (3), (4) and (5) were 
synthesised.  
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Figure 2.7:  The olefination of protected D-lyxose with various Wittig salts. Haloalkanes used:  1-
bromotridecane (X=Br, n=12), 1-bromooctane (X=Br, n=7), 1-bromodecane (X=Br, n=9), 1-
iodobutane (X=I, n=3). R=C9H19 (3); R=C6H13 (4); R=C3H7 (5).  
 
 
Figure 2.8: The formation of a Wittig reagent and subsequent olefination. R=C8H17 (4); R=C5H11 (5); 
R=C2H5 (6). 
X
R
P
Ph
Ph Ph
Ph3P R
H
X
Bu Li
Ph3P R
O
OH
TrO
O O
OH
O
TrO
O O
TrO O
OH
O
O
PPh3
R
TrO O
OH
O
O
PPh3
R
TrO
OH
O
O
R
3
PPh3 + X R +
O
O O
OH
TrO
TrO
OH
O
O
R
OH
O O
TrO R
≡
n
2
(3-5)
 
Chapter 2  Variations in the phytosphingosine base 
    
50 
2.4.3. Fluorinated Wittig salts 
This project aims to investigate analogues of α-GalCer (44), with variability introduced into 
the three different portions of the compound, in order to alter the immunomodulatory 
properties of the analogues. Fluorescent versions of these antigens can aid in tracking the 
intracellular distribution of GSLs and their metabolites [199, 200]. Fluorinated ceramide and 
dihydroceramide analogues have been shown to have increased apoptogenic activity, 
increasing the biological value and interest in fluorine-containing analogues of such 
compounds [201]. Thus, fully saturated, highly fluorinated versions of the phytosphingosine 
base portion were investigated. Using an experimental procedure by Buchanan et al. (2003) 
[202], an attempt to synthesise fluorinated versions of two of the Wittig reagents previously 
prepared was undertaken. Buchanan et al. (2003) [202] synthesised highly fluorinated fatty 
acids to be used in the synthesis of novel delivery agents in hyperpolarized xenon magnetic 
resonance imaging. The key step in their synthesis was the Wittig reaction between highly 
fluorinated phosphonium salts and an aldehyde. Highly fluorinated phosphonium salts can 
be prepared, provided that solvents with high boiling points (such as xylene) and an inert 
atmosphere (argon) are employed. Successfull Wittig reactions occurred when polar aprotic 
solvents, such as THF, non-lithiated bases and low reaction temperatures were employed. 
Potassium-tert-butoxide has also been shown to be a preferable base over either n-BuLi or 
sodium ethoxide-ethanol (NaOC2H5C2H5OH) in the Wittig reaction where an ylide is formed 
as an intermediate in the production of an alkene (for a review of K-t-BuO in synthesis, see 
[203]). Thus, 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluoro-10-iododecane, and 
triphenylphosphine were refluxed in anhydrous xylene for ~18h under argon in order to 
produce the fluorinated Wittig salt, which could then be coupled with (3aS,6R,6aS)-2,2-
dimethyl-6-trityloxymethyl-tetrahydro-furo[3,4-d]-1,3-dioxol-4-ol (3) as for the non-fluorinated 
Wittig salts. However, this did not prove successful, as after 48h, unreacted (2) was still 
present. Therefore the reaction was repeated using potassium-tert-butoxide, as a non-
lithiated base (pKa = 19 [204]). This reaction attempt was also unsuccessful. 
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Caesium carbonate (Cs2CO3) is an established inorganic base that can be successfully used 
in organic synthesis. This powerful base (pKa = 10.25 [205]) has been utilised in Horner-
Wittig reactions in the presence of isopropanol yielding the required unsaturated product in 
good yields, when other more common bases have not proved competent or give 
unsatisfactory yields [206]. Yamanoi et al. [207] effectively produced an E-olefin on reaction 
of a phosphonate with aldehyde in the presence of Cs2CO3. Owing to the fact that the Wittig 
reactions involving fluorinated reagents and bases, such as nBuLi and K-t-BuO were 
unsuccessful, a Horner-Wittig type reaction was attempted. The method was based around 
[207], using a pre-prepared fluorinated Wittig reagent with Cs2CO3 and isopropyl alcohol. 
Compound (2) (1.1eq) was added at 0°C and stirred for 18h whilst gradually being warmed 
to room temperature. NMR and TLC analysis indicated the disappearance of the fluorinated 
Wittig salt, but unfortunately, the desired fluorinated Wittig olefin had not formed. The 
reaction was repeated with 2 molecular equivalents of Cs2CO3, yet still the desired reaction 
had not proceeded.  
 
One problem surrounding the use of fluorinated Wittig salts is their insolubility. This could 
have contributed to the reaction failure, and thus a Wittig reaction was carried out, using  
1,4-dioxane as the solvent and n-BuLi as the corresponding base. The reaction was carried 
out at room temperature due to the relatively high freezing point of the solvent. The reaction 
was continued as for the reaction of (2) with the various unfluorinated Wittig salts, and NMR 
analysis showed a peak corresponding to possible ethylene protons, which were shifted 
slightly more downfield in comparison to unfluorinated olefins.  
 
The use of fluorinated Wittig reagents is of great interest, but yet also of frustration; it could 
prove to be a route to incorporate exciting functionality into the GSL analogues and this is a 
possible area for further investigation. 
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2.4.4. Catalytic hydrogenation 
In order to produce an active α-GalCer analogue, it is necessary to reduce the double bond 
resulting from the Wittig reaction at carbon 5 and 6 of the sphingosine base. Lin et al. [194] 
described a synthetic route to phytosphingosine from lyxose in 6 steps; with the double bond 
being catalytically reduced with a very high yield (91%) whilst the acetonide and trityl 
protecting groups remained intact (Figure 2.9). Taking this method, a Wittig reagent was 
subjected to treatment with palladium-barium sulfate under a hydrogen atmosphere. 
However, after a total of 72h 1H-NMR analysis showed the presence of ethylene protons, 
indicating the reduction had not succeeded. Palladium barium sulfate (Pd-Ba(SO4)2) was 
substituted with palladium-hydroxide (Pd(OH)2) on carbon, and stirred under a hydrogen 
atmosphere.  
 
 
Figure 2.9: The hydrogenation of a Wittig product. R=(CH2)8CH3 (4); R=(CH2)5CH3 (5); R=(CH2)2 CH3 
(6). 
 
After 48h, ethylene protons were still apparent in the 1H-NMR and thus ammonium formate 
and isopropanol were added. After a further 48h, 1H-NMR indicated the cleavage of the 
protecting groups. The spectroscopic analyses showed partial reduction of the double bond 
(1 ethylene proton still present). This suggests that one isomer of (3) used was successfully 
catalytically reduced, whilst the other is possibly hindered by the presence of the 
isopropylidene protecting group on the 3,4-diol of compound (3). 
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Although catalytic hydrogenation reactions are more than adequate in many cases, they 
tend to require relatively expensive equipment and the handling of hydrogen gas. This type 
of reduction procedure also has a tendency to be unspecific with regards to the 
stereochemistry and position of the hydrogenation owing to the reversible addition and 
abstraction of hydrogen to and from the alkene-based compound adsorbed onto the surface 
of the metal catalyst.  The prevalent backbone in sphingolipids is sphingosine, a biologically 
active molecule that is unsaturated between the 4th and 5th carbon of the base (and thus is 
missing a hydroxyl group at position 4). Owing to this fact, the possibility of incorporating 
aromatic rings into α-GalCer analogues, and the fact that unsaturated N-acylated chains are 
deemed more active than their saturated counterparts [208], a method of selectively 
reducing the double bond formed after Wittig reaction would be an extremely useful tool, 
and would open up the extent of GSL analogues that could be produced. Diimide reductions 
can be carried out in readily available laboratory equipment and are selective in as much as 
a single double bond can be reduced in a compound containing a number of unsaturations, 
such as a naturally derived fatty acid. In addition, allylic and benzylic groups do not 
experience hydrogenolysis with diimide reductions [209]. Hünig et al. [210] show that 
hydrogenation by di-imine/ hydrazine (the result of 2 molecules of diimide reacting with 
nitrogen gas) proceeds with at least 97-98% stereo-specificity.  
 
Diimide can be generated in a number of ways, of which the oxidation of hydrazines and the 
decarboxylation of benzenesulfonyl hydrazide are just a couple of examples [211, 212]. 
Cusack et al. [213] found that 2,4,6-tri-isopropylbenzenesulfonyl hydrazide (TPSH) in the 
presence of a base quite readily generates diimide. A synthetic procedure as outlined in 
[214] was used as a method of generating diimide and theoretically goes on to selectively 
reduce a double bond, such as that present in the olefins produced after Wittig reaction. 
However, 1H-NMR analysis indicated that although the double bond had been reduced, the 
isopropylidene and trityl protecting groups had also been cleaved.  
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2.4.5. Mesylation and azidation 
Due to the unsuccessful reduction involving both catalytic hydrogenation and diimide 
reduction, it was decided that the Wittig reaction product would have to be deprotected in 
order to rule out steric hindrance of the isopropylidene protecting group. The hydroxyl group 
at C2 first had to be protected with a group that would be suitable to azidation at a slightly 
later stage in the synthesis. This group also had to be stable to the reaction conditions used 
to remove the acetonide and trityl groups.  
 
A mesylate group was added to the hydroxyl group at C2 of the phytosphingosine base by 
the addition of methanesulfonylchloride (MeSO2Cl) before the isopropylidene and trityl 
groups could be cleaved by the addition of hydrochloric acid and methanol (MeOH)  
(Figure 2.10).  
 
Figure 2.10: Mesylation, deprotection, reduction and azidation of Wittig compounds. R=C12H25 (16); 
R=C9H19 (4), (7), (10), (13), (17); C6H13 (5), (8), (11), (14), (18); C3H7 (6), (9), (12), (15), (19). 
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Catalytic hydrogenation of the double bond then proceeded without complication using 5% 
palladium barium-sulfate as the catalyst. The addition of sodium azide resulted in the 
mesylate group being replaced with an azide group, with an inversion of stereochemistry at 
C2 (Figure 2.10). 
 
2.4.6. Silyl ether and benzoate protecting groups 
Silyl ethers are some of the most common protecting groups for hydroxyl groups, due to the 
fact that the reactivity of their formation and cleavage can be modified by altering the 
substituents on the silicon atom; their steric and electronic effects modulate the ease of 
cleavage in multiply functionalised substrates. Silyl groups can be easily removed by the 
addition of a chemical containing a fluoride ion. This is due to the high affinity that fluoride 
ions have for silicon atoms. This is quantified by the fact that a silicon-fluoride bond is 
30kcal/mol greater than a silicon-oxygen bond. Silyl ethers do have the ability to migrate 
between hydroxyl groups within a compound. Occasionally this can be advantageous, but 
more often than not is troublesome. Tert-butyldiphenylsilyl (TBDPS) groups are more stable 
than tert-butyldimethylsilyl (TBDMS) groups, which are frequently seen to migrate, and 
although the former is less stable to base, it is approximately 100 times more stable towards 
acidic hydrolysis than the TBDMS group. Tert-butyldiphenylsilyl chloride was used to 
introduce this group and is selective for primary hydroxyl groups i.e. the OH at C1, due to its 
bulky nature (Figure 2.11). The remaining two free hydroxyl groups were then protected 
using benzoyl chloride, the most common reagent used for the introduction of benzoyl 
groups, resulting in the formation of acid-stable, base-labile benzoate ester groups 
(Figure 2.11).  
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Figure 2.11: Reprotection of C1, C3 and C4 hydroxyl groups of the developing phytosphingosine 
base and C1 deprotection. R=C14H29 (16), (20), (24), (28); R=C11H23 (17), (21), (25), (29); 
R=C8H17 (18), (22), (26), (30); R=C5H11 (19), (23), (27), (31). 
 
The benzoate ester is one of the more common esters used in the protection of alcohols, 
due to it being more stable to hydrolysis than acetates and its tendency to migrate to 
adjacent hydroxyl groups is not nearly as strong as the migrating nature of acetate groups. 
Nevertheless, the benzoate group can be forced to migrate if their resulting position is more 
thermodynamically stable. 
 
After removal of the TBDPS group, using acetic acid and 1M tetrabutylammonium fluoride 
(TBAF) solution (due to the high affinity of silicon with a fluoride ion, as discussed above), 
the benzoyl-protected azido compound could undergo glycosylation specifically at C1 of the 
phytosphingosine-derived group, without the protecting groups being cleaved.  
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2.5. Glycosylation and N-acylation products with varying base chains.  
In order to synthesise analogues of α-GalCer (44), a number of chemical obstacles had to 
be overcome. Several groups have reported the synthesis of the parent glycolipid analogue, 
yet when these were investigated, problems were encountered and thus adaptations were 
made and in some steps of the chemical synthesis, alternative methods were sought out. 
These are discussed in some detail throughout the next chapters and possible explanation 
considered as to why certain reactions did not proceed according to the literature and/ or 
general chemical know-how. Figure 2.12 shows the general reactions involved in coupling 
the phytosphingosine base with sugar, and subsequent deprotection, reduction and  
N-acylation. 
 
Figure 2.12: Glycosylation, deprotection, azide reduction and N-acylation of varying 
phytosphingosine bases. R=C14H29 (28), (32), (36), (40); R=C11H23 (29), (33), (37), (41); 
R=C8H17 (30), (34), (38), (42); R=C5H11 (31), (35), (39), (43). 
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2.5.1. Glycosylation 
Glycosylation involves the displacement of the anomeric leaving group on one sugar 
(termed the glycosyl donor) and the subsequent coupling with the free hydroxyl group of the 
glycosyl acceptor. In the presence of water, hydrolysis products are formed where a 
hydroxyl group replaces the leaving group on the glycosyl donor; water molecules act as 
competitive nucleophiles. The reaction therefore must be performed under anhydrous 
conditions, with molecular sieves being added to scavenge for any remaining water 
molecules. Molecular sieves are zeolites that consist of a three-dimensional network of 
silica, aluminia tetrahedral. Water, naturally present in the zeolite network, is removed by 
heating, leaving cavities that can selectively absorb molecules of a specific size. 4Å 
molecular sieves absorb water, which once absorbed is trapped and thus can not affect the 
reaction mixture.  
 
Regioselectivity is a problem when the glycosyl acceptor has more than one hydroxyl group 
as any free alcohol can act as the nucleophile. Thus protecting groups are vital. As some 
glycosylations using glycosyl fluorides use a hard Lewis acid to activate the glycosyl donor, 
the protecting group must be acid-stable as discussed earlier. Hindered secondary hydroxyl 
groups of partially protected glycosyl acceptors are less efficient nucleophiles, but should 
still be protected to obtain the required regioselectivity.  
 
The presence of the ring oxygen facilitates a SN1 type reaction; its lone pairs aid the 
departure of the leaving group at the anomeric carbon, and they also help stabilize the 
resulting carbonium ion intermediate by resonance. Nucleophilic attack can occur from 
either the top or bottom face of the sugar ring structure (Figure 2.13). The nature of the 
solvent and protecting group on the neighbouring C2 hydroxyl group play important roles in 
determining the relative amounts of the two possible (α or β) products.  
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Figure 2.13: Nucleophilic attack on a glycosyl donor. The reaction can lead to two possible anomers on 
an anomeric glycosyl donor, where L indicates a leaving group and Nu represents the 
nucleophile. 
 
2.5.2. Basic transesterification; removing benzoyl protecting groups 
A benzoate ester can be cleaved by the addition of methanolic sodium hydroxide at room 
temperature. Addition of acetic acid prevents the migration of the benzoyl group, ensuring 
the desired compound is produced. Esters in the presence of an alcoholate anion base 
undergo base-catalysed transesterification, forming an anionic intermediate that can either 
dissociate back to the original ester or a new ester and alcohol. If there is a sufficiently large 
excess of sodium methoxide, the equilibrium point of the reaction will be displaced until 
virtually all the product is the new ester and alcohol, which in this case is a benzoic acid 
methyl ester and the glycosylated azido diol (Figure 2.14). The reaction must be carried out 
under strictly anhydrous conditions as the presence of water irreversibly dissociates the 
intermediate compound to the free acid. 0.5M to 2M sodium methoxide in anhydrous MeOH 
is one of the most common reagents used for basic transesterification (Figure 2.14). 
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Figure 2.14: Mechanism of base-catalysed transesterification. Sodium methoxide acts as a base 
attacking the carbonyl of the benzoate group, forming an anionic intermediate with the 
benzoate ester protecting group on the sphingosine hydroxyl groups. In the presence of a 
large excess of methanolic sodium methoxide, this forms the new benzoic acid methyl ester 
and free hydroxyl groups on the C3 and C4 positions of the sphingosine base.  
(C4 deprotection not shown, but occurs in an identical manner). 
 
2.5.3. Reduction of the azide group 
In order for an N-acyl group to be introduced producing a glycosyl ceramide, the azide 
functional group needs be converted to a reactive amine group. Traditionally, the azide 
group has been reduced to the amine by using hydrogen sulfide. Two methods 
conventionally used to reduce the azide are via the Staudinger reaction and also by 
employing hydrogen sulfide.  
 
2.5.3.1. Trimethylphosphine and the Staudinger reaction 
An effective method of reducing an azide group to an amine group is by the Staudinger 
reaction, which is a very mild azide reduction. The reaction involves triphenylphosphine 
reacting with the azide to generate a phosphazide, which then loses nitrogen gas to form an 
iminophosphorane. Aqueous work up leads to the amine and the very stable phosphine 
oxide (Figure 2.15). An alternative reagent which has been successfully employed in the  
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Figure 2.15: The general mechanism of the Staudinger reaction. The triphenylphosphine forms a 
phosphazide intermediate which produces nitrogen gas as a by-product in the formation of an 
iminophosphorane. This is then hydrolysed to give the amine and phosphine oxide. 
 
Staudinger reaction in place of triphenylphosphine, is trimethyphosphine [215]. Although the 
triphenyl phosphineoxide bi-product of the reaction using triphenylphosphine is stable, it has 
to be removed by chromatographic methods.  
 
Employing trimethylphosphine results in a volatile bi-product that is easily removed along 
with the reaction solvent by rotary evaporation, thus reducing potential loss of product during 
purification [216]. However the reactant itself is pyrophoric, with the potential to react 
violently when it comes into contact with humid air or water. Thus handling requirements are 
more stringent than with triphenylphosphine, and the azido compound must be moisture-
free.  
 
2.5.3.2. Reduction using hydrogen sulphide 
Although hydrogen sulfide is a toxic substance, its use in the azide reduction proceeded well 
and any residual sulfur containing compounds were successfully removed following the 
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addition of the N-acyl group and during purification. This method was employed because the 
Staudinger reaction, although successful in reducing the azide group, proved to interfere in 
some way at the later stages of N-acylation when the glycosyl iodide method of 
glycosylation was employed. Other groups had reported similar problems, and had 
overcome them by using hydrogen sulfide [217].  
 
2.6. Biological results and interpretation 
A number of groups have shown that an α-GalCer analogue with a truncated 
phytosphingosine chain, (OCH9) (47) exhibits a less stable binding interaction with CD1d 
than α-GalCer [144, 192]. The two pockets of the hCD1d protein adopt different 
conformations when empty, than when occupied by a lipid [71].  One theory is that the 
shortened phytosphingosine chain does not completely ‘fill’ the F’ pocket of the protein, 
possibly resulting in the phytosphingosine base chain of α-GalCer (44) being repositioned in 
the F’ channel which in turn affects the orientation of the α-linked sugar. Alternatively, 
sections of the F’ pocket could collapse if only partially filled, altering the internal structure of 
the CD1d α-helices, which in turn could modify the orientation of the sugar head group [218]. 
The effect of an altered sugar orientation is likely to result in a less prolonged TCR 
stimulation, and thus a possible skewing of the immune response. As shown by Miyamoto et 
al. [144], the immune response of B6 mice after an intra-peritoneal injection of α-GalCer 
(44), results in a rapid secretion of the TH2 cytokine IL-4, followed by a prolonged secretion 
of the TH1 cytokine IFN-γ. If an altered glycolipid antigen binds less stably with the TCR, and 
thus for a decreased amount of time, it was hypothesised that the immune response could 
effectively be altered to bias the initial TH2 response. Miyamoto et al. [144] went on to 
demonstrate this with murine cells and OCH9 (47), showing greater concentrations of the 
cytokine IL-4 being secreted and decreased IFN-γ production by iNKT cells over time, when 
compared with control and α-GalCer (44) (Figure 2.16).  
Chapter 2  Variations in the phytosphingosine base 
    
63 
 
Figure 2.16: Changes in serum cytokine levels after injection of α-GalCer (44) or OCH9 (47). B6 mice 
were injected intraperitoneally with 100µg kg-1 of glycolipid, and serum samples were obtained 
at indicated times after injection. Serum levels of IL-4 and IFN-γ were determined by a 
sandwich enzyme-linked immunosorbent assay (ELISA). Figure adapted from [144]. 
 
Taking this theory further, a number of biological evaluations were performed by McCarthy 
et al. at the Weatherall Institute of Molecular Medicine, University of Oxford, UK using a 
small library of α-GalCer analogues synthesised during this project, that varied in the chain 
length of the phytosphingosine base [218]. These included the affinity of hCD1d binding and 
the TCR binding affinity to hCD1d. A Fab antibody that specifically binds to C1R-hCD1d 
molecules loaded with α-GalCer (44) and other associated analogues (Fab 9B) was used to 
measure the dissociation of the analogues from soluble hCD1d over a period of time. The 
Fab 9B antibody fails to stain unpulsed C1R-hCD1d cells, or cells loaded with β-GalCer, 
which was used as a negative control. The rate of dissociation of each α-GalCer analogue 
from C1R-hCD1d cells over time, as measured by surface plasmon resonance (SPR) 
studies is shown in Figure 2.17A [218].  It is clear from these results that a decreased 
number of carbon atoms in the phytosphingosine chain of α-GalCer (44) increases the rate 
of dissociation from hCD1d molecules; the analogue OCH9 (47) has a half-life 
approximately 4 times shorter than α-GalCer (44).  
 
The dissociation constants (Kd) of α-GalCer (44) and three analogues (OCH15 (45), OCH12 
(46) and OCH9 (47)), that vary in the phytosphingosine chain length, were also determined. 
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The equilibrium constant Kd measures the tendency of a larger object to separate reversibly 
into smaller components. It corresponds to the concentration of antigen, at which the 
concentration of protein with antigen bound is equal to the concentration of protein with no 
antigen bound. A smaller dissociation constant results in a higher affinity between antigen 
and protein. In this case, it is a measure of the propensity of α-GalCer (44) to dissociate 
from the CD1d protein to which it is bound. The data in Figure 2.17B corresponds with the 
affinity measurements of the four GSLs tested (Figure 2.17A) and shows that analogues 
with truncated phytosphingosine bases have a greater degree of dissociation from CD1d 
than α-GalCer (44). The results also indicate that this effect dramatically increases with 
reduced chain length, and this is exemplified by Kd values of 123µM for OCH9 (47), 
compared with 1.29µM for α-GalCer (44) (Figure 2.17B). The affinity of complexed hCD1d-
α-GalCer with iNKT TCR was also investigated, and the results demonstrated that the 
binding of the hCD1d-α-GalCer complex was much more stable than that of the analogues 
with shortened phytosphingosine bases (Figure 2.18).  The complex incorporating OCH15 
(45) had an affinity for the TCR similar to that of α-GalCer (44), whereas the OCH12 (46) 
and OCH9 (47) analogues, respectively, had dramatically decreased affinities. This implies 
that optimal iNKT TCR binding requires the hCD1d F’ channel to be occupied by an α-
GalCer analogue with a phytosphingosine chain of 15 to 18 carbons. 
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Figure 2.17: Binding affinities of α-GalCer analogues to hCD1d. (A) Dissociation of α-GalCer analogues 
from hCD1d.The antigen-hCD1d complexes were loaded onto a sensor surface at t = 0. The 
amount of remaining hCD1d at given time points was measured using Fab 9B antibody and 
SPR. Dissociation values only shown for the first 100 mins, but with half-life values listed. 
Figure adapted from [218] (B) The mean dissociation constants from hCD1d of α-GalCer (44) 
and three analogues varying in the length of the phytosphingosine base chain: OCH15 (45), 
OCH12 (46), OCH9 (47). Experiments carried out at the Weatherall Institute of Molecular 
Medicine, University of Oxford, UK using analogues synthesized during this project. All 
compounds produced by methods outlined in Chapter 5. 
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Figure 2.18: Affinity and kinetics of iNKT TCR binding to hCD1d-α-GalCer complexes. The binding 
responses of 5 concentrations (increasing from 0.4 – 194µM) of hCD1d-α-GalCer complex 
injected with iNKT TCR for 5s are shown, with the equilibrium binding response (Kd) shown in 
the insets. Experiments carried out at the Weatherall Institute of Molecular Medicine, University 
of Oxford, UK using analogues synthesized during this project. Figure adapted from [218].  
 
To demonstrate that the binding affinities of the hCD1d-α-GalCer complexes with the TCR 
were not as a result of hCD1d loading with the α-GalCer analogues described, the rate 
constants kon and koff were determined by direct measurements of the TCR with hCD1d-α-
GalCer analogues complexed with α-GalCer (44), OCH15 (45), OCH12 (46), with the 
exception of OCH9 (47). Due to its exceptionally fast koff value (2.67 S-1 compared with 0.39 
S-1 of α-GalCer (44)) (Table 2.1), the kon value of OCH9 (47) was difficult to determine 
experimentally, but was instead calculated from koff/ Kd values gained. 
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hCD1d-α-GalCer 
complex 
koff (S-1) kon (M-1S-1) 
α-GalCer (44) 0.39 ± 0.01† 3.31 x 105 ± 2.5 x 104† 
OCH15 (45) 0.47 ± 0.06 2.04 x 105 ± 1.6 x 104 
OCH12 (46) 1.00 ± 0.12 3.7 x 104 ± 5 x 103 
OCH9 (47) 2.67 ± 0.12 2.3 x 104 ± 1 x 103* 
 
Table 2.1: Affinity and kinetic measurements of hCD1d-α-GalCer complexes with iNKT TCR. Unless 
stated, all values are the mean of two experiments. †Mean of three or more experiments. 
*Calculated from experimentally derived Kd and koff values. Experiments carried out at the 
Weatherall Institute of Molecular Medicine, University of Oxford, UK using analogues 
synthesized during this project. [218].  
 
From the smaller Kd values in Figure 2.18 and the smaller koff values in Table 2.1, one can 
surmise that α-GalCer analogues with longer phytosphingosine chains have a greater 
affinity for the iNKT TCR when complexed with the CD1d protein. A smaller Kd value is 
indicative of a stronger binding interaction. In relation to this, a much faster koff results in an 
increased Kd and thus indicates a weaker binding between the hCD1d-α-GalCer complex 
and the iNKT TCR.  
 
As hypothesised, a less stable binding interaction between α-GalCer (44), CD1d and the 
TCR has an effect on the immunological response of the iNKT cell. Unlike the results 
obtained using murine iNKT cells, the cytokine profile of OCH9 (47) was not biased towards 
a TH2 response when hCD1d was employed, but instead resulted in a decrease of both IL-4 
and IFN-γ production (Figure 2.19). However, the amounts of TH1 and TH2 cytokine were 
much more similar in OCH12 (46) and OCH9 (47), than in the parent glycolipid, α-GalCer 
(44) and OCH15 (45). 
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Figure 2.19: iNKT cell activation in vitro is modulated by the length of the phytosphingosine base 
chain in α-GalCer analogues. C1R-hCD1d cells were pulsed with 4 α-GalCer analogues as 
shown and used to stimulate human iNKT cells. The supernatant was assayed for IL-4 and 
IFN-γ production by ELISA. SD (error bars) from the mean of two duplicate experiments is 
shown. Experiments carried out at the Weatherall Institute of Molecular Medicine, University of 
Oxford, UK using analogues synthesized during this project. Figure adapted from [218].  
 
The ability of α-GalCer (44) and OCH9 (47) to stimulate the expansion of iNKT cells from 
peripheral blood lymphocytes (PBLs) from healthy donors was demonstrated at the 
Weatherall Institute of Molecular Medicine, University of Oxford, UK by McCarthy et al. [218] 
and by G. Bricard, J.S. Im and myself at the Albert Einstein College of Medicine, New York, 
USA using the analogues synthesised during this project. The frequency of iNKT cells was 
measured 21 days after stimulation of PBLs with mature autologous DCs, pulsed with either 
α-GalCer (44) or OCH9 (47) at various concentrations, and repeated on three different PBL 
samples. As shown in Figure 2.20, the parent glycolipid antigen α-GalCer (44) was much 
more successful at stimulating iNKT cell expansion than OCH9 (47) at all concentrations. 
 
Assuming OCH9 (47) adopts the same orientation as α-GalCer (44), the crystal structures of 
unloaded hCD1d and α-GalCer-loaded hCD1d can be used as comparative models. Both 
crystal structures have bee reported previously [71] and one can surmise from the results  
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Figure 2.20: iNKT cell expansion in vitro is modulated by the length of the α-GalCer 
phytosphingosine chain. (A) iNKT (Vα24+hCD1d-tetramer+) cell frequency from treatment 
with varying concentrations of α-GalCer analogues. The results are shown as the percentage 
of gated cells as determined by fluorescence-activated cell sorting (FACS) analysis. 
Experiments carried out at the Weatherall Institute of Molecular Medicine, University of Oxford, 
UK using analogues synthesized during this project. Data from [218]. (B) Mean percentage of 
gated and total iNKT cell (HDD.11 cells) frequency from ex vivo treatment with 100nM α-
GalCer analogue. Procedures completed at Albert Einstein College of Medicine, New York, 
USA using analogues synthesised during this project. (C) FACS analysis plots showing the 
gating of iNKT cells and the differences in cell expansion of HDD.11 cells after stimulation with 
α-GalCer (44) and OCH9 (47) compared with a control of DMSO after ex vivo 100nM GSL 
stimulation. Experiments carried out at Albert Einstein College of Medicine, New York, USA 
using analogues synthesised during this project.  
 
that the OCH9 (47) only partially fills the F’ channel of hCD1d, due to its shorter 
phytosphingosine chain.  
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Figure 2.21: Modelling of the effects of variations in lipid chain length on the structure of hCD1d. A 
Cα trace and selected side chains are shown in yellow for the hCD1d crystal structure with 
bound α-GalCer (44). Relevant regions of the structure of hCD1d in the absence of bound 
ligand are shown in green. Hydrogen bonds are depicted as dotted lines, and the assumed 
position of bound TCR is depicted schematically. The portion of α-GalCer corresponding to 
OCH9 (47), is drawn in blue. Side chains are positioned differently in the empty and partially-
filled structures. Based on these differences, residues within the F’ channel that are predicted 
to alter when hCD1d is bound with OCH9 (47), as opposed to α-GalCer (44), have been 
highlighted. Modelling carried out at the Weatherall Institute of Molecular Medicine, University 
of Oxford, UK. Adapted from [218]. 
 
Two residues that hydrogen bond to the sugar head of α-GalCer antigens are Asp151 and 
Thr154, as shown by mutagenesis studies by Burdin et al. [219] and Sidobre et al. [220]. 
 
Any substantial alterations in the positions of these residues would be expected to impact 
the network of hydrogen bonds, thus affecting the recognition of the antigen by the iNKT cell 
TCR, as it is the hydrogen bonding that dictates the position of the polar head-group.  
 
Modification of the phytosphingosine chain and the subsequent partially filled conformation 
of the F’ channel of hCD1d, results in predicted differences between hCD1d-OCH9 and 
hCD1d-α-GalCer structure of approximately 2Å between residues Leu139 and Thr154 in the 
main chain of the α2 helix of the CD1d molecule. 
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It is in this same putative TCR binding region that the two hydrogen-bonding residues are 
found. Thus, a shift in the α2 helix residue position directly correlates to a shift in the 
hydrogen bonding network position, which in turn affects the recognition of α-GalCer (44) 
antigen by the TCR. The model shown (Figure 2.21) and the experimental data gained, 
support the hypothesis that a conformational change in the hCD1d molecule and the extent 
of filling of the hCD1d F’ channel, both affect the TCR recognition of α-GalCer analogues.  
 
Differences between PBLs stimulated with α-GalCer (44) and OCH9 (47), in their cytokine 
profiles (Figure 2.16, Figure 2.19) and cell proliferation (Figure 2.20), can be attributed to the 
weaker binding of OCH9 (47) within the CD1d pocket and consequently with the TCR of 
iNKT cells, compared with that of the parent glycolipid, α-GalCer (44). It has been shown 
that in vivo activation of iNKT cells can assist in priming of antigen-specific immune 
responses [191]. Reduced lysis of DCs pulsed with shorter phytosphingosine chain α-
GalCer analogues suggests that more attention should be paid to the use of so-called 
‘weaker’ iNKT cell agonists, such as OCH9 (47), which, unlike α-GalCer (44), may ensure a 
longer lifespan of APCs which is paramount in clinical settings. 
 
The fact that the hypothetical model of OCH9 (47) bound hCD1d complexes mirrors the 
experimental results gained using glycolipids varying in the length of the phytosphingosine 
chain, effectively highlights the fact that α-GalCer (44) structure, with regards to the base 
chain length, does play a part in fine-tuning the affinity of the TCR to the hCD1d-GSL 
complex. This directly affects the downstream immunological processes, such as cytokine 
release and cell proliferation. Further experimentation is needed in order to broaden and 
expand these results, and investigate the mechanisms behind them in a fuller manner. 
However, these structural differences, and the observed effects they have on CD1d-TCR 
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binding, could play a vital part in the search for an antigen that could successfully prevent or 
treat autoimmune diseases such as type 1 diabetes.  
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3. Variations in the sugar head 
3.1. Introduction 
There are a number of possible variations of the sugar head of an α-GalCer antigen that can 
be adjusted to produce novel antigenic compounds, whilst still retaining their desired 
immunological properties. Figure 3.1 summarises some of the structural requirements that 
have previously been explored, how they relate to the reactivity of the resulting glycolipid 
antigen, and which features are vital for activation of iNKT cells [54, 95, 178, 180, 185, 221-
225], some of which have been investigated throughout this project. 
 
 
Figure 3.1: The relationship between the structure of α-GalCer analogues and bio-reactivity. 
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3.2. α vs. β anomeric linkage 
An α-anomer of a sugar refers to a pyranosyl or furanosyl carbohydrate where the anomeric 
group (at C1) is on the opposite side of the ring to the C6 carbon group; the CH2OH unit in 
the case of galactose and glucose, CH3 in the case of fucose. Hence a β-anomer has the 
anomeric group on the same side of the ring as the C6 functionality (Figure 3.2). 
 
Figure 3.2:  The structures of α- and β-anomeric positions in three sugars. (A) D-Galactose (B) D-
Glucose (C) L-Fucose. The red hydroxyl groups indicate the α-positioning, and the blue 
hydroxyl groups indicate the β-positioning. Note that in the L-enantiomer of fucose, the C6 
group sits below the ring, but the α-position is still on the opposite side of the ring to that group. 
 
Mammalian cells produce a variety of glycosyl ceramides that are structurally related to α-
GalCer (44). However, these natural compounds have a β-anomeric link and are not known 
to activate iNKT cells [70].  
 
The α-forms of D-GalCer (44) and D-GlcCer (50), incorporating galactose and glucose as the 
sugar moiety respectively, have been shown to have stronger antitumour and 
immunostimulatory activities than their β-counterparts [59, 226]. β-Forms of the antigens do 
however bind to CD1d [227], suggesting that the orientation of the sugar on the analogue is 
more important for TCR stimulation than it is for CD1d contact. When the murine CD1 
protein (mCD1) presents β-GalCer to iNKT cells, proliferative responses such as the release 
of IL-2 which is a typical T-cell response, ensuing activation, and cell-proliferation, are not 
observed [59, 96, 98, 224, 228]. Ortaldo et al. [96] concurred that the β-form of the α-GalCer 
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analogue does not stimulate cytokine production in C57BL/6 (B6) mice, and also showed 
that β-GalCer demonstrates lower intensity binding to iNKT cells compared with α-GalCer 
[96, 224].  
 
Interestingly, the β-configuration of compounds like β-L-AraCer play a key part in the 
expression of strong immunostimulatory activity [226]. β-GalCer has also been shown to 
have a strong immunostimulatory profile, albeit by increasing the concentration of pro-
inflammatory cytokines in the blood [229], revoking the beneficial effects of sulfatides. 
Sulfatide β-GSLs have been shown to be promiscuous CD1 ligands, successfully binding 
with CD1a, b and c [30, 93, 178]. They are present in pancreatic cells and are thought to 
play a part in islet pathology, decreasing the secretion of proinflammatory cytokines (IL-1β 
and TNF-α decreasing with a statistical significance), which are toxic to pancreatic β-cells at 
high concentrations [229]. This is a detrimental reaction, with regards to the conditions of 
both type 1 and type 2 diabetes (T1D and T2D, respectively), owing to the fact that the 
proinflammatory cytokines, such as IL-1β, IL-6, TNF-α and IFN-γ, are all known to influence 
pancreatic β-cells and have been implicated as pathogenic factors in both conditions [229, 
230].  
 
Singh et al. [227] went on to demonstrate that β-GalCer fails to stimulate iNKT cell 
responses with respect to TH1/ TH2 cytokine production, but does enhance another 
autoimmune disease, EAE, in mice. This could be though direct competition with an 
endogenous CD1d ligand, antagonising iNKT TCR recognition of the natural antigen. iNKT 
cells, activated by α-GalCer (44), are known to destroy leukaemic cell lines in a CD1d-
dependent manner in vitro [231]. Rogers et al. [175] showed tumour cell lysis by 
Vα24+Vβ11+ NKT cells is a highly specific process that results in failure or a very poor 
response when the analogue β-GalCer is employed. 
Chapter 3   Variations in the sugar head 
    
 77
3.3. O- and C-glycosidic linkage 
α-GalCer (44) is termed an O-glycoside due to the nature of the linkage between the sugar 
head and ceramide unit, via an oxygen atom. The majority of analogues of α-GalCer that 
have been synthesised and investigated to date, have also incorporated this O-glycosidic 
link. This possibly stems from the fact that the antigens, such as the naturally occurring 
sulfatide GSLs [30, 178], microbial ligands [46, 47, 179], KRN7000 [232] and the more 
recently discovered natural ligand of CD1d, iGb3 [54, 58], all have O-glycosidic linkages.  
 
Recently, there has been increased attention to the possibility of synthesising C-glycoside 
analogues of α-GalCer [233, 234], where there is a carbon atom between the sugar and 
ceramide moiety, in place of more commonly found oxygen atom. The interest behind a  
C-glycosidic linkage has sprung from the train of thought suggesting O-linked glycosides are 
more susceptible to enzymatic degradation by enzymes such as α-galactosidases [233]. 
Glycosidases catalyse the hydrolysis of glycosidic linkages, generating two smaller sugar 
molecules from a larger more complex molecule. Amongst others, they are involved in 
normal cellular function and anti-bacterial defence strategies, and are a major constituent of 
the human body [235]. Therefore, a C-glycoside that is inert to such degradation by these 
enzymes could be beneficial in terms of potential drug administration.  
 
When tested by Yang et al. [233], a C-glycoside analogue of α-GalCer (44) remained active 
in mice for a period of four days, whereas the corresponding O-glycoside analogue only 
remained active for one day. It was speculated that the endogenous enzymatic degradation 
of the O-glycoside, can be attributed to this difference in activity retention, although different 
binding mechanisms with the TCR or iNKT cells could also be a contributing factor [233]. 
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Figure 3.3: Cytokine production in human iNKT cells and DCs by α-GalCer (44) and its C-glycoside 
analogue. Supernatants from a 24h culture of DC and NKT cells with 100ng ml-1 of either α-
GalCer (44) or α-C-GalCer were analyzed for cytokine secretion by Luminex multiplexing 
technology. Data are median standard deviations from five independent experiments. Raw 
data from [236]. 
 
Despite its increased activation times,  the C-analogue of α-GalCer (α-C-GalCer) has been 
shown to have a skewed cytokine profile with a TH1 bias (Figure 3.3) [236]. When directly 
compared with α-GalCer (44), iNKT cells stimulated with 100ng ml-1 of α-C-GalCer had a 
cytokine profile with an IFN-γ:IL-4 ratio over twice that of the corresponding O-glycoside 
(ratios 9.6 and 4.2 respectively) (Figure 3.3) [236]; the C-glycoside shows a bias towards a 
TH1 cytokine response, much like its O-glycoside counterpart. In the case of autoimmune 
diseases, such as T1D and SLE, this is detrimental. 
 
The mechanism by which C-glycoside analogues of α-GalCer bind with CD1d proteins and 
stimulate iNKT cell responses is yet to be fully understood. One hypothesis is that the 
replacement of the anomeric oxygen with a carbon atom, results in a loss of one of the 
hydrogen bonds that are formed between the glycosidic head and CD1d protein, normally 
anchoring it in position [71, 234]. Removing one such hydrogen bond, could thus alter the 
orientation of the glycolipid within the protein, and subsequently alter the binding position of 
Glycolipid Analogue
1 2
C
on
ce
nt
ra
tio
n 
(p
g 
m
l-1
)
0
5000
10000
15000
20000
25000
IFN-γ 
IL-4 
α-GalCer α-C-GalCer
18367± 2958
4373 ± 586
4825 ± 894
498 ± 126
Chapter 3   Variations in the sugar head 
    
 79
the antigen: protein complex with the iNKT cell receptor.  However, Lu et al. [236] disproved 
this with modeling studies that showed similar overall geometry of the bound O- and  
C-α-GalCer analogues within the CD1d protein. They suggested that the differences could 
be attributed to variations in the solubility of the molecules, access to lipid-transfer proteins 
and receptor-mediated uptake, all of which are involved in antigen-presentation [236].  
 
The immunostimulatory activity of the C-analogue does suggest that this structural variation 
could provide another avenue to be explored through the synthesis of a C-glycoside 
analogue library, in the hope of discovering an antigen that could delay or prevent 
autoimmune diseases, without the TH1 bias shown by the C-GalCer analogues investigated 
thus far.  
 
3.4. Variation of the hydroxyl group on the sugar 
A structural difference of α-GalCer analogues that has been investigated is the configuration 
of the hydroxyl group at carbon 4 (C4’) of the sugar moiety [95, 223, 226]. When analysed 
by Motoki et al. [226], lymphocytic proliferation stimulatory activity of α-GalCer (44) was 
significantly greater than that of α-GlcCer (50); the two analogues differ only in the 
configuration of the hydroxyl group at C4’ of the sugar. This was also shown by Uchimara et 
al. [223] (Table 3.1).  
 
These results indicate that the hydroxyl group at position 4’ affects immunostimulatory 
activity. However, several years after Motoki’s study [226], Kawano et al. [95] concluded that 
α-GalCer (44) and α-GlcCer (50) display no functional differences when stimulating iNKT 
cells. However, an analogue incorporating mannose as the sugar head (α-ManCer), and 
having altered stereochemistry at the C2’ position of the carbohydrate portion compared  
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Table 3.1: Proliferation of spleen cells by α-GalCer (44) and α-GlcCer (50). 2.5 x 105 murine spleen 
cells were plated in triplicate in 100µL wells and cultured with varying concentrations of 
glycolipid for 2 days at 37°C, before being pulsed with 3H-TdR for 8h. 3H-TdR uptake was 
counted using a liquid scintillation counter. §P < 0.05; *P < 0.01; †P < 0.001 compared with 
vehicle-treated group. Experiments carried out by J.S. Im and myself at Albert Einstein College 
of Medicine, New York, USA using analogues synthesised during this project. 
 
with α-GalCer (44) and α-GlcCer (50), shows no immunostimulatory activity. Costantino et 
al. [237] showed that analogues of α-GalCer where the hydroxyl group at position 2 of the 
sugar is also glycosylated, are inactive, suggesting that it is the hydroxyl group at C2’ that 
determines the activity of the antigen.  
 
Cerebrosides with more complex sugar heads have been shown to exhibit 
immunostimulatory properties. Costantino et al. [224] investigated a number of novel 
glycosphingolipids with complex sugar heads. Two unique plakosides isolated from Plakortis 
simplex (β-galactosylceramides whose galactose residues are alkylated at the C2’ hydroxyl 
group by a 3,3-dimethylallyl group, and incorporate a cyclopropane ring in the N-acetylated 
chain of the ceramide) (Figure 3.4) proved to be immunomodulating [224]. Not only were 
these compounds stimulatory, it was shown that their activity can be reversed, causing 
immunosuppression, which can be ascribed to the presence of the prenylated galactose 
[224]. This provides evidence that the hydrophilic carbohydrate-based portion of the antigen 
 3H-TdR incorporation (cpm, mean ± standard deviation) 
Sample 0.1 ng/ml 1 ng/ml 10 ng/ml 100 ng/ml 
Vehicle 2841 ± 285 3186 ± 423 2851 ± 290 2884 ± 238 
α-GalCer (44) 9368 ± 1307* 15850 ± 644† 22733 ± 2862† 24535 ± 2331† 
α-GlcCer (50) 4276 ± 626§ 11381 ± 1510† 14634 ± 956† 17731 ± 2076† 
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Figure 3.4:  Plakoside A. One of the β-galactosylceramides isolated from Plakortis simplex. Plakoside B is 
identical, save for the base chain consisting of 24 carbons, with cis unsaturation at C7, and the 
cyclopropane ring at C13.  
 
is accountable for the activation of the TCRs, and that iNKT cells can distinguish glycolipids 
that differ not only in the substituents coupled to the sugar hydroxyl groups, but also in the 
orientation of one hydroxyl group present in the sugar [31, 35, 185, 224, 228]. 
 
Wu et al. [179] also demonstrated that variations at the C2’ position of the galactose head of 
α-GalCer alter the immunological activity of the analogues. However, the analysis inferred 
that unlike the plakosides, where immunological activity is preserved, substituting the 
hydroxyl group at C2’ with a fluorine atom, a hydrogen atom, and an acylated amine, whilst 
preserving the stereochemistry of the sugar, results in no biological activity. This was 
demonstrated by the lack of IL-2 secretion by iNKT cells after stimulation with these 
analogues. Retaining the hydroxyl group functionality at C2’, yet altering the conformation of 
the group from equatorial to axial also results in a distinct lack of biological activity [179].  
 
Modulations in C2’ resulting in no biological activity has also been observed when a second 
glycosylation of α-galactosyl or α-glucosyl is introduced [237]. Interestingly, adding a further 
sugar unit at C3’ of the galactose of α-GalCer (44), still retains immunostimulatory activity 
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and exhibits a statistically significant difference in lymphocyte proliferation compared with 
controls [237]. 
 
The introduction of other functional groups at the C6’ position have been investigated [222, 
238]. Replacing the hydroxyl group at C6’ of the sugar with amino functionality, and then 
coupling biotin and fluorophores with this amino group provides a means of observing 
antigenic compounds both in vivo and in vitro, thereby allowing quantification of the 
association between the glycolipid-bound protein CD1d and the iNKT cell receptor [238].  
 
Kamada et al. [72] suggested that the hydroxyl groups at the C4’ and C6’ positions of the 
sugar head group are not intrinsic to the recognition and subsequent formation of the CD1d-
glycolipid-iNKT cell complex. Consequently, incorporating a small molecule, such as biotin, 
or a fluorophore, such as prodan, at C6’ of the sugar (Figure 3.5) as means of a label should 
not affect the immunostimulatory properties of the glycolipid antigen.  
 
When IL-2 production by iNKT cell stimulation was compared between α-GalCer (44) and 
the biotin- and prodan-labelled analogues, there was similar production of IL-2 by the two 
labelled analogues. The former analogue was in fact reproducibly more efficient than the 
parent analogue α-GalCer (44) and the fluorophore analogue [238]. 
 
Substituting the hydroxyl group at C6’ with an amide linked to a small molecule such as a 
methyl group has also been shown to be effective in the activation of iNKT cells and 
subsequent cytokine secretion [222]. Liu et al. [222] synthesised an example of such 
molecule, with the addition of a double bond in the N-acyl chain of the ceramide moiety. This 
compound (PBS-57) successfully binds with CD1d and stimulates iNKT cells in a manner 
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Figure 3.5: Analogues with C6’ hydroxyl group alterations (A) α-GalCer labelled with the fluorophore 
prodan (B) α-GalCer labelled with biotin. 
 
comparable to that of α-GalCer (44) [222]. In addition, lower concentrations of PBS-57 were 
more active than α-GalCer (44), and this could be attributed to its increased solubility. One 
of the difficulties faced when using α-GalCer (44) is its solubility; therefore antigens modified 
in such a manner with an amide at C6’ of the sugar head, thereby increasing their solubility, 
could prove to be extremely useful in terms of possible therapeutics.  
 
Further, adding to the evidence that glycolipid antigens modified at the C6’ position of the 
sugar successfully activate iNKT cells has been demonstrated by Mattner et al. [176]. These 
workers reported that analogues incorporating a carboxylic acid at C6’ of a galactose or 
glucose head group (Figure 3.6A) strongly induced both mouse and human iNKT cell 
proliferation and IFN-γ cytokine secretion with a profile very similar to that of α-GalCer (44). 
The secretion of the TH1 cytokine IFN-γ is not completely unexpected when one examines 
the nature of the analogues. Glycosphingolipids incorporating a carboxylic group at C6’ 
originate from the Gram-negative bacterial genus Sphingomonas and IFN-γ production by 
iNKT cells is stimulated during microbial infection. Interestingly, in a manner similar to that of 
α-GalCer (44), the β-analogue of the glucuronosyl ceramide compound has been shown not 
to activate iNKT cells [179, 180].  
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Figure 3.6: α-GalCer analogues with variations on the sugar hydroxyl groups. (A) α-
Galacturonosylceramide. A glycolipid antigen isolated from Sphingomonas cell wall with 
variations at the C6’ position, the inclusion of a hydroxyl group at C2’’of the fatty acid and 
deletion of a hydroxyl group on the phytsphingosine base chain; (B) A Sulfatide glycolipid 
antigen with a sulphate group at the C3’ position of β-linked galactose, an unsaturated fatty 
acid group, and a sphingosine base chain. 
 
Wu et al. [179] also investigated the effect varying the functionality at C6’ of an α-GalCer 
analogue would have on the recognition and resulting activity of the antigen. A galacturonic 
acid analogue of bacterial origin, with a structure similar to that investigated by Mattner et al. 
[176], incorporating carbonyl functionality at C6’ in addition to the hydroxyl group, but 
without the presence of a hydroxyl group at C2’’ of the N-acyl chain (GSL-1) (Figure 3.7), 
retains some of α-GalCer’s stimulatory activity, albeit to a lesser extent [179]. Computer 
modelling of GSL-1 (Figure 3.7), docked to the crystal structure of murine CD1d protein,  
     
 
Figure 3.7:  An α-GalCer analogue of bacterial origin (GSL-1) incorporating varied C6’ functionality. 
The oxidation of the alcohol to a carboxylic acid at C6’, and the lack of hydroxyl group at C4 of 
the phytosphingosine base can alter the antigen’s biological profile [179, 180]. 
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allows the sugar head group to be exposed and presented for iNKT cell recognition [179]. 
Combining the oxidation of the alcohol to a carboxylic acid at C6’, with the deleted  
4-OH on the phytosphingosine chain, results in shifts both within the lipid binding groove 
(due to the lack of hydrogen bonding between the OH at C4, and an aspargine residue 
within the pocket), and above the A’ and F’ channels where the sugar head is exposed 
[180]. These effects have been shown by Wu et al. [180] through electron density and 
modelling studies. A distinct lack of definition in the electron density map of GSL-1 bound 
within the CD1d protein implies that the analogue has a greater degree of flexibility within 
the binding pocket than α-GalCer (44), and can result in an altered orientation of the sugar 
head [180]. The 6’-COOH substituent does not directly bind within the CD1d pockets and, 
therefore, the flexibility of the analogue within the binding grooves of CD1d can be attributed 
to the lack of OH at position 4 of the phytosphingosine chain [180].  
 
Although not directly involved in binding within the groove structure of CD1d, the sugar head 
group does play a large part in antigenic recognition, as it is this moiety that is identified by, 
and binds with, the TCR of the iNKT cell. Therefore, a conformational change in this part of 
the antigen could vary the degree of recognition and conversely affect the antigenic profile 
of the compound [180]. This has been shown by the decreased production of cytokines, 
such as IL-2, IL-4 and IFN-γ by iNKT cells, when exposed to α-galacturonosylceramide 
(Figure 3.6) and GSL-1 (Figure 3.7) compared with α-GalCer (44) (Figure 3.8) [179, 180].  
 
Sulfatides naturally exist in mammalian serum and are successfully presented by CD1a, 
CD1b and CD1c [30, 93, 177, 178, 229]. The endogenous sulfatide ligand, has structural 
similarities to α-GalCer (44) (Figure 3.6B) and is recognised by iNKT cells. A modulation of 
the C3’ hydroxyl group of α-GalCer to incorporate a sulfate group has proved successful in 
terms of iNKT cell stimulation [178-180]. This was in fact shown by Xing et al. [177] who  
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Figure 3.8: iNKT cell activation with α-GalCer (44) and GSL-1.  Production of IL-4 and IFN-γ by 
lymphocytes stimulated with glycolipid pulsed DCs. Adapted from [180]. 
 
demonstrated that an α-linked sulfatide analogue identical to α-GalCer except for the 
inclusion of a sulfate group, was a better immuno-stimulator than α-GalCer. 
 
Removal of the hydroxyl group at C6’ results in 6-deoxy galactose (fucose). Both the D- and 
L- enantiomers of fucose are found in nature, with the former occurring widely in plants and 
the latter being found in bacterial, plant and human glycosides, including several families of 
blood-group antigens [239]. L-Fucose is the immunodominant sugar of many complex 
carbohydrate antigens and its presence can increase the strength of antigenic responses 
[239]. Incorporating an α-L-fucosyl moiety, has been demonstrated to delay progression of 
lupus-like symptoms (lupus or SLE is an autoimmune disease characterized by IFN-γ 
cytokine tissue injury) in NZB/W F1 mice [240]. Conversely, α-GalCer (44) exacerbates the 
same symptoms in the same mouse model. NZB/W F1 mice have been found to have 
detectable levels of circulating IFN-γ, and the production of this cytokine is dramatically 
decreased in vitro when α-fucosylceramide (α-L-FucCer) (53) is introduced [240].  
 
α-GalCer 
GSL-1 
Chapter 3   Variations in the sugar head 
    
 87
Motoki et al. [226] have also demonstrated the immunostimulatory activities of α-L-FucCer 
(52), showing that it produces a markedly higher immune response in terms of lymphocyte 
proliferation than α-GalCer (44). It was also compared to analogues incorporating sugars in 
the furanose form, and it was clear to see that pyranosyl-antigens gave a far stronger 
immune response than their furanosyl counterparts [226].  
 
3.5. Results and Discussion 
3.5.1. Chemical Methods 
3.5.1.1. Glycosylation 
The synthesis of α-GalCer analogues involves having to overcome a number of chemical 
obstacles. Regioselectivity is a problem when the glycosyl acceptor has more than one 
hydroxyl group, as any free alcohol can act as the nucleophile. Thus protecting groups are 
vital. As the glycosylation uses a hard Lewis acid to activate the glycosyl donor, the 
protecting group must be stable to acidic conditions.  
 
3.5.1.2. Glycosylation using a glycosyl fluoride 
Glycosyl fluorides are more stable donors than the corresponding bromides or chlorides and 
can be readily synthesised from thioglycosides by treatment with 
diethylaminosulfurtrifluoride (DAST). This converts the free unprotected anomeric hydroxyl 
group to a fluoride, giving an α/β anomeric mix, the ratio of which is often solvent dependent 
(Figure 3.9).  
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Figure 3.9: The proposed mechanism for the formation of a glycosyl fluoride using DAST. 
 
3.5.1.3. Activated glycosyl fluoride donors 
In order for glycosylation to proceed successfully, the glycosyl donor must be activated. In 
the case of the benzyl ether protected galactosyl fluoride, this can be achieved by the 
addition of a hard Lewis acid, such as boron trifluroetherate or tin (II) chloride. Selective 
activation can be achieved by adding silver perchlorate to the reaction mixture. Tin (II) 
chloride acts as a base, causing the carbon-fluorine bond to become polarised, imparting 
electrophilic characteristics to the fluorine atom. The nucleophile (glycosyl acceptor), which 
in this case is the benzoyl protected azido alcohol compound, then attacks the δ-positive 
anomeric carbon atom (Figure 3.10). 
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Figure 3.10:  Activation of a glycosyl fluoride by tin (II) chloride. 
 
When using a glycosyl fluoride, THF is the preferred solvent, in addition to diethyl-ether 
[241]. Due to the bulky nature of the benzyl ether on C2’, THF co-ordinates with the glycosyl 
donor from the top face forming a β-intermediate. This results in the free hydroxyl group of 
the glycosyl acceptor molecule, attacking from the bottom face, producing an α-glycosylated 
compound (Figure 3.11).  
 
 
Figure 3.11:  Solvent influence on the stereochemical outcome of glycosylation. 
 
One alternative synthesis would be using a phytosphingosine base protected by an 
isopropylidene group at C3-OH and C4-OH. This method was applied to compound (16); 
using 2,2-dimethoxypropane, the cyclic acetal was formed at C3, C4, along with the 
formation of a hemiacetal at the hydroxyl group of C1. Being much less stable than the 
cyclic form, this terminal hemiacetal was easily cleaved by washing with cold 1M HCl, 
leaving the desired protected azido compound (Figure 3.12). However, when this compound 
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was used in glycosylation reactions with galactosyl fluoride, the isopropylidene group was 
not stable to the acidic conditions produced when using tin (II) chloride and silver 
perchlorate. 
 
 
Figure 3.12: Acetylation of azido-phytosphingosine base. Compound (16) was reacted with  
2,2-dimethoxypropane, forming the desired acetal and hemi-acetal at position C1. This was 
then removed by the addition of HCl, leaving the protected azido-phytosphingosine base.  
 
3.5.1.4. N-acylation using hexacosanoic acid   
Several groups have reported the synthesis of the parent glycolipid analogue, yet when 
these were investigated, problems were encountered and thus adaptations were made and 
in some steps of the chemical synthesis, alternative methods were sought out. These are 
discussed in some detail in chapters 2, 3 and 4 and possible explanations considered as to 
why certain reactions did not proceed according to the literature and/ or established 
chemistry.  
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Figure 3.13: Synthesis of α-GalCer, α-GlcCer and α-L-FucCer. R’=OH, R’’=H (32), (44); R’=H, R’’=OH 
(33), (50). 
 
chemistry. Figure 3.13 shows the general reactions involved in coupling the 
phytosphingosine base with sugar, and subsequent deprotection, reduction and N-acylation. 
 
3.5.1.5. Removal of the benzyl ether protecting groups 
After incorporating the C26 N-acyl chain, the final step in the synthesis using a glycosyl 
fluoride, is the deprotection of the pyranose ring. Benzyl ethers can be removed by catalytic 
hydrogenation, with palladium on carbon being the preferred catalyst. Platinum catalysed 
reactions can result in hydrogenation of the aromatic rings, as opposed to removal of the 
benzyl groups. The reaction is solvent dependent, with the reaction rates (mmH2/min/0.1g 
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catalyst) being as follows: THF (40) > hexanol (25) > hexane (6) > MeOH (5) > toluene (2) 
[195]. The presence of a non-aromatic amine can hinder O-debenzylation. When this 
synthetic method was employed in the laboratory, the desired compound (i.e. the 
unprotected glycosyl ceramide) was not produced and analysis by TLC showed numerous 
sugar-positive spots, suggesting the compound had been broken down during the 
debenzylation reaction.  This was the catalyst for investigating an alternative glycosylation 
technique. 
 
3.5.1.6. Glycosylation using a glycosyl iodide 
The development of glycosylation methods that employ milder reaction conditions and do 
not make use of alkylating agents, oxidising agents or heavy-metal salts has becoming 
increasingly desirable, especially given the need to synthesise tailor-made glycosides that 
can be used within the body to study and influence biological mechanisms [242, 243]. The 
use of glycosyl halides in glycosylation reactions is well-established, and a wide variety of 
glycosyl donors are available for use in these reactions. Anomeric halosugars, such as 
glycosyl bromides and glycosyl fluorides activated by heavy-metal salts are the more 
traditionally utilised compounds in glycosylations [244].  Over the past decade or so, the 
introduction of glycosyl iodides as effective glycosyl donors has been noted [245]. This is 
somewhat contradictory to the supposedly established view that glycosyl iodides are 
unsuitable agents due to their intense reactivity and unstable nature [246]. Studies by Hadd 
et al. [247] demonstrated the successful use of glycosyl iodides in the synthesis of O-linked 
glycosidic compounds, with high α-stereoselectivity. The group also showed that glycosyl 
iodides are highly efficient donors even under neutral conditions, and that the advantages of 
glycosyl iodides over corresponding bromides includes increased reaction rates, and 
successful reaction with sterically demanding acceptors, all of which add to the 
attractiveness of this method [247].  
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The use of glycosyl iodides to produce α-linked glycosides originated from work by Lemieux 
et al. [248, 249] who showed that glycosylations with glycosyl bromides produced α-
glycosides in good yields when bromide ions were employed. By treating α-glycosyl halides 
with quaternary ammonium halides, such as tetrabutylammonium iodide (TBAI), the 
established equilibrium between the α- and β-glycoside halides could be driven towards the 
more reactive β-glycosyl halides, which when attacked by a glycosyl acceptor, resulted in 
the formation of an α-linked glycoside (Figure 3.14) [246, 250]. van Well et al. [251] also 
demonstrated this using glycosyl iodide, and concluded that the decreased thermodynamic 
stability of the β-glycoside halide renders it more reactive than its α-analogue, and reacts 
with the glycosyl acceptor in an SN2 fashion to produce an α-linked glycosidic product.  
 
Figure 3.14: Halide-catalysed in-situ anomerisation. The addition of quaternary ammonium halide, 
results in the production of a β-glycosyl halide, which in turn produces an α-linked glycoside. 
X = Br or I [246].  
 
The difficulties encountered when using glycosyl fluorides led to the use of a method 
employing a glycosyl iodide as the donor. Not only did this overcome the issues faced when 
trying to separate the α- and β-glycosyl fluorides, it also enabled different protecting groups 
to be used on the sugar instead of the benzyl ethers that proved difficult to remove. Bickley 
et al. [244] reported that among several methods that can be used for the preparation of 
glycosyl iodides, one of the more efficient  reactions employs trimethylsilyl iodide, generating 
stable glycosyl iodides in high yields (91% versus 67% with KI). Du et al. [217] showed that 
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per-O-silylated sugars are very good precursors to glycosyl iodides, undergoing nucleophilic 
addition in a ready and facile manner, thus providing a stereoselective and efficient route to 
α-GalCer (44) and its analogues.  
 
The anomeric silyl ethers were generated by the reaction of the unprotected sugar with 
trimethylsilyl chloride, producing the per-O-trimethylsilylgalactopyranose. Reacting this 
compound with iodo trimethylsilane produced the glycosyl iodide, which was then reacted 
with TBAI (to produce the β-glycosyl iodide) and the glycosyl donor (azido-protected 
phytosphingosine), giving the α-linked galactosylceramide pre-cursor (Figure 3.15). 
 
The same method was used when synthesising the glucosylceramide intermediates (48), 
(49), and the final ceramide antigen (50), substituting the galactose starting material for 
glucose.  
 
Figure 3.15: Glycosylation, deprotection, azide reduction and N-acylation of varying 
phytosphingosine bases. (28) R=C14H29; (35), (39), (44) R=C14H29, R’=OH, R’’=H; (48), (49), 
(50) R=C14H29, R’=H, R’’=OH. 
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3.5.1.7. Variations on the C-6’ hydroxyl group 
α-Fucosylated oligosaccharides can be found in mammals. Fucose-containing glycans play 
a key part in a variety of physiological processes, such as blood transfusion reactions, host-
microbe interactions, and numerous ontogenic events, including signalling events [252]. 
Until recently, α-fucosyl compounds were almost exclusively chemically synthesised using 
2,3,4-tri-O-benzyl fucopyranosyl donors [253]. With the issues raised and encountered 
during the benzyl-protected galactosyl ceramide synthesis, an alternative method was 
sought to incorporate a fucose ring into the α-GalCer analogues. Fortunately, Uchiyama et 
al. [254] found a simple alternative to the use of tri-O-benzylfucopyranosyl donors for  
α-fucosylation, which was not too dissimilar to the methods employed in the glycosyl iodide 
glycosylation reactions described above. In a similar manner to the synthetic methods used 
for the protection of both galactose and glucose, L-fucose was reacted with trimethylsilyl 
chloride, triethylamine and dimethylformamide (DMF). The per-O-trimethylsilyl fucose was 
then treated with one equivalent of iodotrimethylsilane, producing the per-O-trimethylsilyl-α-
fucopyranosyl iodide. This glyscosyl iodide was then taken on and reacted in a similar 
manner to the glycosylation reactions for galactose and glucose (Figure 3.16). 
 
Figure 3.16: Glycosylation, deprotection, azide reduction and N-acylation in the synthesis of  
L-fucosylceramide. 
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3.6. Biological evaluation of glycolipid antigens α-GalCer (44), α-GlcCer (50) 
and α-L-FucCer (53).  
The results, shown by Uchimara et al. [223], demonstrate that the configuration of the 
hydroxyl group at C4’ of the sugar head has a profound affect on the biological activity of  
α-GalCer analogues. Figure 3.17 shows the decreased activity with regards to cell 
proliferation of α-GlcCer (50), from experimental procedures carried out by J.S. Im and 
myself at Albert Einstein College of Medicine, New York, USA using compounds 
synthesised throughout this project. The graph also shows the effect modifying the C6’ 
position of the sugar has on cell proliferation, and although the effect is not as pronounced 
as that of α-GalCer (44). An analogue without a hydroxyl group at C6’ of the sugar head 
group (α-L-FucCer, (53)), does  
 
Figure 3.17: The proliferation of NKT cells by various α-GalCer analogues. HDD.D11 NKT cells (50000 
cells/200 µL) were plated in a 96-well plate in triplicate and cultured with glycolipid samples at 
37°C for two days, and were pulsed for additional 8 h with 3H -TdR. 3H –TdR uptake into cells 
was counted using a liquid scintillation counter. The results shown are the mean values from 
each triplicate, with the exception of α-GalCer (44) which was the mean of 6 wells. Experiment 
carried out at Albert Einstein College of Medicine, New York, USA using analogues 
synthesized during this project. 
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stimulate iNKT cell proliferation in a concentration dependent manner and is more active 
than α-GlcCer (50). 
 
The fact that a modification at C6’ seems to affect the biological activity of α-GalCer 
analogues less than a modification at C4’, is also shown by the cytokine stimulation profiles 
of analogues prepared during this project. As depicted in Figure 3.18, the analogue, which is 
modified at C4’ of the sugar (α-GlcCer (50)), has a much weaker stimulatory profile than the 
parent α-GalCer (44) or the C6’ modified analogue, α-L-FucCer (53). It is also interesting to 
note that the cytokine response of iNKT cells upon stimulation with 100nM of α-L-FucCer 
(53) seems to favour the release of the TH2 cytokine IL-13. The ratio of TH1:TH2 cytokines 
upon activation by α-GalCer (44) is 1:1.62, whereas the ratio is 1:2.35 for TH1:TH2 cytokines 
after α-L-FucCer (53) stimulation. This shows that although the release of both the TH1 and 
TH2 cytokines is diminished with respect to α-GalCer (44), the α-L-FucCer analogue (53) 
seems to skew the immune response more towards that of a TH2 profile, as shown by the 
greater difference between the two different cytokines (Figure 3.19).  
 
The apparent differences between α-GalCer analogues with varying sugar heads have also 
been exhibited by Brigl et al. [255]. Previous experiments have implied that reactivity to  
α-GalCer (44) is dependent on the TCR α-chain [256, 257]. However, the ability of the TCR 
α-chain to recognise lipids outside the GSL family varies. Canonical iNKT cell clones vary in 
their autoreactive responses to CD1d-positive APCs, thus suggesting that recognition is not 
always conferred by the TCR α-chain. 
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Figure 3.18:  Cytokine profiles of α-GalCer analogues with variations in the sugar head group. The top 
panel shows the IFN-γ (TH1 cytokine) response and the bottom panel shows the IL-13 (TH2 
cytokine) response of iNKT cells to various α-GalCer analogues. Experiments carried out at 
Albert Einstein College of Medicine, New York, USA using analogues synthesized during this 
project 
 
Brigl et al. [255] showed that a variety of novel Vα24-negative/ Vβ11-positive CD1d-
restricted T cell clones respond differently to antigens such as α-GalCer (44), iGb3 and  
α-GlcCer (50), due to their noncanonical TCR α-chains, thus shedding light on the features 
that influence lipid antigen recognition. 
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Figure 3.19: TH2 skewing properties of α-L-FucCer (53). HDD.11 NKT cells (50,000 cells per well) and 
immature DCs (25,000 cells per well) were incubated with 125nM of analogue in DMSO and 
the cytokine production measured by ELISA. α-L-FucCer (53) skews the immune response 
towards a TH2 response, as shown by the greater proportion of the TH2 cytokine IL-13, than 
the TH1 cytokine IFN-γ, when compared with α-GalCer (44). Experiments carried out at Albert 
Einstein College of Medicine, New York, USA using analogues synthesized during this project. 
 
Five novel Vα24-negative/Vβ11-positive and 13 canonical Vα24-positive/Vβ11-positive 
human NKT cell clones were generated using α-GalCer-loaded CD1d tetramers. iNKT cells 
with Vα14- or Vα24-invariant TCRα-chains have been previously characterised as 
responding similarly to α-GalCer (44) and α-GlcCer (50), but failing to respond to α-ManCer 
[95, 258]. Strikingly, the Vα-chains of the Vα24-negative clones had highly conserved Jα18 
regions, resulting in CD3Rα loops practically identical to those of the canonical TCRs [255]. 
The Vα24-negative and Vα24-positive T cell clones generated were tested in parallel for 
their ability to respond to the α-GalCer (44) and α-GlcCer (50) analogues prepared during 
this project and tested by Brigl et al. [42]. All of the Vα24-positive CD1d-restricted T cell 
clones responded robustly to both α-GalCer (44) and α-GlcCer (50), whereas all of the 
Vα24-negative clones responded strongly to α-GalCer (44) but showed markedly lower 
responses to α-GlcCer (50) (Figure 3.20). There was little or no cytokine secretion in  
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Figure 3.20: Vα24-positive and Vα24–negative clones in response to α-GalCer (44) and α-GlcCer (50). 
Cytokine secretion by Vα24-positive and Vα24–negative clones in response to plate-bound 
recombinant CD1d molecules pretreated with two analogues synthesized throughout this 
project (α-GalCer (44) [filled circles], α-GlcCer (50) [open circles]), or vehicle alone (open 
squares). Assays were performed in triplicate, and error bars show the SD values of the mean. 
Similar results were obtained in three independent experiments. Experiments carried out by 
Brigl et al. at Department of Rheumatology, Immunology, and Allergy, Brigham and Women’s 
Hospital, Boston, USA. [255] 
 
response to vehicle-treated CD1d molecules by any of the clones, and no detectable 
response was observed when they were exposed to a negative control protein treated with 
α-GalCer (44), thus demonstrating the specificity and CD1d-dependence of the α-GalCer 
(44) and α-GlcCer (50) responses. These results indicated that the Vα24-negative and 
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Vα24-positive T cell clones differ in their specificity for sugar residues of α-GalCer 
analogues.  
 
To investigate this sugar specificity difference further, three Vα24-positive and three  
Vα24-negative T cell clones were tested for staining by human CD1d-Fc dimers loaded with 
either α-GalCer (44) or α-GlcCer (50) or treated with vehicle alone. The Vα24-positive 
T cells stained similarly with α-GalCer- and α-GlcCer-loaded CD1d dimers, whereas the  
Vα24-negative T cells showed significant positive staining only with the α-GalCer-loaded 
CD1d dimer (Figure 3.21). The titration curves for clones J3N.1 and J24N.70 appeared to 
approach saturation at a similar concentration of the α-GalCer-loaded CD1d dimer as that 
observed for the Vα24-positive clones tested, suggesting that the affinity of these Vα24-
negative TCRs for α-GalCer (44) may be close to that of canonical Vα24-positive TCRs 
(Figure 3.21). In contrast, the titration curve for clone J24N.22 reproducibly appeared to 
require higher dimer concentrations to reach saturation, suggesting that the TCR of this 
clone may have a lower affinity for α-GalCer (44) (Figure 3.21). Thus, variation in Vα-
encoded TCR α-chain regions may affect the strength of the interaction with α-GalCer (44), 
but the most significant effect appears to be on the ability to bind α-GlcCer (50). These 
results suggest that the weaker functional response of the Vα24-negative T cell clones to α-
GlcCer (50) is due to lower TCR affinity for this glycolipid compared with α-GalCer (44), 
whereas Vα24-positive TCRs appear to have similar affinity for both glycolipids.  
 
The results from the clone experiments provide new insights into TCR elements that 
determine lipid antigen specificity. Analysis of the five Vα24-negative T cell clones suggests 
that conservation of the CDR3α loop may be sufficient to permit recognition of α-GalCer (44) 
and related bacterial α-glycosphingolipids, despite substantial variation in the sequences 
and predicted conformations of the CDR1α and CDR2α loops. The finding that the Vα24- 
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Figure 3.21: Cytometric staining of Vα24-positive and Vα24–negative clones in response to α-GalCer 
and α-GlcCer. Flow cytometric staining of Vα24-positive and Vα24-negative T cell clones by 
CD1d-Fc dimers loaded with α-GalCer (44) (filled circles) or α-GlcCer (50) (open circles). 
Similar results were obtained in three independent experiments. Experiments carried out by 
Brigl et al. at Department of Rheumatology, Immunology, and Allergy, Brigham and Women’s 
Hospital, Boston, USA, using analogues synthesized during this project. Adapted from [255]. 
 
negative clones differed from their Vα24-positive counterparts, showing a reduced response 
to α-GlcCer (50), indicates that Vα-encoded TCR features affect glycan specificity, and 
suggests that the α-chain of the TCR plays a key part in the recognition of, and specificity 
for, α-GSLs. 
 
Crystal structures have been solved for human CD1d complexed with α-GalCer (44), and 
murine CD1d with a short-chain form of α-GalCer [71, 259, 260]. In these structures, the 
polar head group of α-GalCer (44) emerges from the CD1d binding pocket in a relatively 
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central location, and the sugar ring is angled toward the C-terminal end of the CD1d α2-helix 
(Figure 3.22). Previous crystal structures of TCRs complexed with MHC class I and II 
molecules have shown that the TCR α-chain docks over this end of the Ag-presenting 
molecule [261, 262]. Analyses of NKT cell responses to mutagenised CD1d molecules has 
suggested that their TCRs bind the Ag-presenting molecule in an overall similar manner to 
that observed for MHC class I and II-restricted TCRs [219], this positioning is consistent with 
the possibility that TCR α-chains play a dominant role in recognising α-GSLs. 
 
 
 
Figure 3.22: Side and top view of the crystal structure of human CD1d complexed with α-GalCer (44). 
CD1d heavy chains are shown as pink ribbons and the bound lipids are shown as ball-and-
stick representations with carbon atoms shown in black, oxygen in blue, nitrogen in orange. 
Left-hand side diagram β2-microglobulin is shown as a gold ribbon. Right-hand side diagram, 
for clarity only the α1 and α2 domains are shown, and Thr157 on the α2 helix has been 
coloured gold to provide a point of reference. Experiments carried out at the Department of 
Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, USA, using 
analogues synthesized during this project. Adapted from [255]. 
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Crystalographic visualisation techniques (Figure 3.22) carried out at the department of 
Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, USA , 
using compounds synthesized during this project, shows that the positioning of a key 
hydroxyl group of the galactose sugar is consistent with the finding that the Vα24-negative, 
CD1d-restricted TCRs can distinguish between α-GalCer (44) and α-GlcCer (50). The 
configuration of the 4’-OH of the sugar ring is the only structural difference between 
galactose and glucose, and thus appears highly accessible for TCR recognition. Since the 
position of this prominent hydroxyl would be altered in α-GlcCer (44), it seems reasonable 
that this difference might be able to affect TCR binding. The data suggests that the 
presence of a conserved amino acid motif at the beginning of the CDR1α loop may allow 
canonical NKT TCRs to accommodate the difference caused by the change in the 
positioning of this hydroxyl in galactose and glucose, in contrast to the Vα24-negative TCRs.  
 
The finding that the Vα24-negative T cell clones did not respond to iGb3 (Figure 3.23) 
shows that the ability to recognise α-GSLs is separate from the ability to respond to iGb3. 
This observation raises intriguing questions about which ligands drive the positive selection 
of human TCRs that can recognise α-GSLs. iGb3 has been proposed to be the major self 
antigen responsible for thymic selection of canonical Vα14-positive murine NKT cells [54], 
but whether this compound plays a similar role in selecting human NKT cells remains 
unknown. Since the Vα24-negative T cells were all isolated from peripheral blood of healthy 
adult donors, they are presumed to have undergone positive selection and may have been 
expanded in vivo because of their antigen-recognition properties. Moreover, since these 
clones resemble canonical Vα24-positive clones by using a TCRα rearrangement that has 
strictly maintained the germline Jα18 sequence and conserved the overall CDR3α loop 
length, they may have been selected in vivo by a process similar to that which selects Vα24-
positive NKT cells. Thus, although the requirement for iGb3 in the positive selection of 
canonical human Vα24-positive NKT cells remains unclear, our results suggest there are 
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additional mammalian antigens that can select human CD1d-restricted TCRs that are 
specific for α-GSLs. 
 
The possibility that multiple self antigens select CD1d-restricted T cells could explain the 
observation that NKT cell clones differ in their autoreactive responses. An ability to monitor 
a heterogeneous selection of self lipids could also have important implications for the 
  
Figure 3.23: Cytokine secretion by Vα24-positive (left hand panels) and Vα24-negative (right hand 
panels) clones in response to glycolipid-pulsed APCs. IL-4 production by the T cell clones 
was measured in response to APCs pulsed with the indicated concentration of α-GalCer (44) 
(filled circles), iGb3 (open circles), or vehicle alone (open squares). The filled squares indicate 
the response of the clones to the non-specific stimulator phytohaemaglutinin m (PHA-m). 
Experiments carried out by Brigl et al. at the Department of Rheumatology, Immunology, and 
Allergy, Brigham and Women’s Hospital, Boston, USA, partly using analogues sythesised 
during this project. Adapted from [255] 
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physiological functions of NKT cells. For example, different NKT cell clones could be 
sensitive to lipids loaded in distinct intracellular compartments, allowing them to become 
activated under differing circumstances. The finding that a human NKT cell clone exhibits a 
similar reactivity to phospholipids, as that observed previously for a murine NKT cell 
hybridoma [50], suggests that this lipid Ag specificity is evolutionarily conserved. Because 
CD1d has been shown to bind phospholipids in the endoplasmic reticulum (ER), this 
specificity may permit NKT cell monitoring of ER-derived lipids and, thus, perhaps 
monitoring of the integrity of ER biosynthetic processes. Such ability could be particularly 
valuable in viral infections; because NKT cells having autoreactive specificity for  
ER-derived lipids may be broadly sensitive to changes that occur upon viral subversion of 
cellular processes. 
   
 
 
 
 
Chapter 4 
 
 
 
 
 
Variations in the N-acyl chain 
 
Chapter 4  Variations in the N-acyl chain 
   
108 
4. Variations in the N-acyl chain 
4.1. Introduction 
Variations in the N-acyl chain of α-GalCer analogues have become of particular interest over 
recent years, with interest focusing on a number of aspects of ceramide diversity. This 
includes antigens with N-acyl chains derived from bacterial glycolipids [179, 180], more 
complex groups incorporated into the structure via N-acylation [184, 263, 264], and the 
length and degree of saturation of straight-chain hydrocarbon-based N-acyl chains [64, 98, 
237, 265-267].    
 
 
 
Figure 4.1: The relationship between the structure of α-GalCer analogues and bio-reactivity. 
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Figure 4.1 summarises some of the structural requirements that have previously been 
explored, how they relate to the reactivity of the resulting glycolipid antigen and which 
features are vital for activation of iNKT cells [64, 98, 179, 180, 184, 237, 263-267]; some of 
these features have been investigated throughout this project. 
 
4.2. Fluorescent analogues of α-GalCer 
Several studies have centred themselves around the synthesis of fluorescence-labelled 
antigens and CD1d tetramers [106, 107, 264, 268]. A novel glycolipid antigen labelled with 
the fluorescent group boron dipyrromethane difluoride (4,4-difluoro-5,7-dimethyl-4-bora-
3a,4a-diaza-s-indacene-3-propionic acid; BODIPY) was prepared and proved to be 
biologically active in the same typical test as α-GalCer (44) (Figure 4.2A) [264]. The 
BODIPY fluorescent probe was administered by intra-peritoneal (ip) injection to 8-week old 
mice and the biological activity monitored by the activation-induced disappearance of liver 
iNKT cells, reflecting the overall in vivo activation of the cells, with no prejudice for the 
specific cytokine released [264]. In fact, the type of cytokine produced may be dependant on 
the N-acyl chain of the α-GalCer analogue [139].  
 
Sakai et al. [184] synthesised both α- and β-biotinylated analogues of α-GalCer, and 
showed that only the biotinylated α-analogue of α-GalCer (biotin-α-GalCer) (Figure 4.2B) 
exhibited statistically significant binding to mCD1and hCD1d molecules compared to a 
control (P < 0.05) (Figure 4.3). Not only does this further add to the evidence that analogues 
of α-GalCer with altered acyl chains can be successfully presented by CD1d to iNKT cells in 
a manner comparable to α-GalCer (44) (Figure 4.3), it also concurs with the findings by 
Motoki et al. [226], Kobayashi et al. [59] and Ortaldo et al. [96], who showed that iNKT cells 
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Figure 4.2: Fluorescence-labelled α-GalCer analogues. (A) 5,7-dimethyl-4-bora-3a,4a-diaza-s-
indacene-3-propionic acid-α-GalCer (BODIPY-α-GalCer) (B) 11- (Bi-undecanoic acid [2,3-
dihydroxy-1-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-
amide(biotin-α-GalCer) (C) 6-7-Nitro-benzo(1,2,5)oxadiazol-4-ylamino-α-GalCer  
(NBD-α-GalCer). 
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Figure 4.3: The effects of α-GalCer (44) and biotinylated-α- and β-GalCer (biotin-α-GalCer and 
biotin-β-GalCer, respectively) on the proliferation of murine spleen cells. 2.5 x 105 cells/ 
100µl/ well of murine spleen cells were cultured with various concentrations of glycolipid 
antigen, before 0.5µCi/well [3H]TdR was added into each well and the resulting [3H]TdR uptake 
into the cells was measured by liquid scintillation. Each bar represents the mean count ± S.D. 
P < 0.05 α-GalCer and biotin-α-GalCer vs. vehicle-treated group. Adapted from [184]. 
 
can differentiate between the different glycosidic links when presented with a CD1d/ 
α-GalCer complex. 
 
Although, the ability of biotin-α-GalCer to stimulate iNKT cells has been demonstrated, its 
capacity to successfully stimulate cytokines has been questioned. Naidenko et al. [97] 
showed that the addition of a biotin group did not eliminate the ability of the α-GalCer 
analogue to be presented to NKT cells by mCD1 protein, but they did demonstrate the 
antigen incorporating a biotin group is a weaker antigen. The ineffectual ability of biotin-α-
GalCer at secreting IL-2 was shown by a 3- to 5-fold lower cytokine release when incubated 
with either murine or human CD1d molecules [97]. These experiments also clarified that 
both β-GalCer and a biotinylated version of β-GalCer display little or no immunostimulatory 
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activity and do not enhance the APC function of DCs in mice and humans, even at 
concentrations as high as 100ng/ml [97]. 
 
In a similar investigation, Sakai et al. [263] synthesised a fluorescent analogue of α-GalCer 
incorporating a 7-nitrobenz-2-oxa-1,3-diazole (NBD) group at the terminus of the N-acyl 
chain (Figure 4.2C). This proved to be significantly potent at spleen cell proliferation 
stimulatory activity (Figure 4.4) [263]. In fact, at lower concentrations the NBD-α-GalCer 
analogue was notably more potent than α-GalCer (44) at spleen cell proliferation 
(Figure 4.4), illustrating the fact that the immunostimulatory properties of α-GalCer (44) are 
dependent on the chemical structure of the fatty acid side chain in the ceramide portion of 
the molecule. In conjunction with these findings, one can surmise that the lack of recognition 
 
Figure 4.4: The effects of α-GalCer (44), NBD-α-GalCer and biotin-α-GalCer on the proliferation of 
murine spleen cells. 2.5 x 105 cells/ 100µl/ well of murine spleen cells were cultured with 
various concentrations of glycolipid antigen, before 0.5µCi/well of [3H]TdR was added into 
each well and the resulting [3H]TdR uptake into the cells was measured by liquid scintillation. 
Each bar represents the mean count ± S.D. P < 0.05 α-GalCer and biotin-α-GalCer vs. vehicle-
treated group. Adapted from [263]. 
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between biotin-α-GalCer (Figure 4.2B) and CD1d in transfected cells is due to the limited 
binding capacity, expressed by weaker stimulatory activity in comparison with α-GalCer (44) 
and NBD-α-GalCer [263]. The analogue containing an NBD group may have a higher affinity 
of interaction with CD1d, thus being a potential agent for use in studying the mechanism of 
CD1d presentation.  
 
4.3. N-acyl chain length and saturation 
The N-acyl chain of α-GalCer (44) sits in one of the pockets of the antigen binding site of the 
CD1d protein [218]. Studies have shown that analogues with acyl chains consisting of 26 
carbons are optimal for stimulating CD1d-restricted T cell responses [95]. Acyl chain lengths 
that are shorter, by as little as two carbons, are significantly less active, illustrating that the 
acyl chain configuration plays a key part in their recognition by CD1d [228]. Brossay et al. 
[98] however, established that an α-GalCer analogue that differed only from the parent by 
incorporating an acyl chain length totalling two carbons was successfully presented by 
mCD1 to the iNKT cell receptor.  This was exemplified by the release of high concentrations 
of the cytokine IL-2. The successful presentation of a short-chain fatty acids suggests that 
only one of the CD1 protein pockets needs to be filled by the aliphatic hydrocarbon chain of 
the antigen, rendering the hydrophilic sugar-based head of the antigen available to 
adequately stimulate the TCR of the iNKT cell [98]. However, when the acyl chain was 
substituted for a bulky aromatic group, the analogue failed to produce an antigenic response 
in mCD1 cells [98].  
 
Altering the lipid chain length of the α-GalCer (44) molecule has gained interest over recent 
years. Moody et al. [269] hypothesised and subsequently demonstrated that the size of the 
lipid moiety controls the kinetics, sub-cellular localisation, efficiency of antigen loading into 
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the CD1 groove, and ultimately the presentation by different types of CD1 expressing APCs. 
The perceptible distinctions in cellular requirements for the presentation of antigens can be 
explained by alkyl chain length controlling the entry of long-chain lipids into efficient 
endosomal antigen-presentation pathways and short-chain lipids into less efficient non-
endosomal pathways. The X-ray crystal structure of murine CD1d indicates that the groove 
in the protein structure is big enough to maximally house 31 or 32 methylene units. This 
figure correlates with the lipid moiety size of PI eluted directly from cellular CD1d molecules 
[269]. 
 
α-GalCer (44) is well established as an antigenic molecule that binds with CD1d molecules 
and activates iNKT cells [181], yet the biology surrounding this phenomenon and 
endogenous antigen coupling is still somewhat of a mystery. It is known that phospholipids 
such as PI (Figure 1.1B) are naturally occurring and are antigenic, binding to CD1d 
molecules and stimulating iNKT cells [70]. mCD1d has been shown to specifically bind the 
PI fraction of cellular GPI, which is a natural ligand of the protein [52]. One hypothesis is that 
PI acts as a chaperone in the assembly of the CD1 family of molecules in the ER, and 
conserves the integrity of the hydrophobic groove in the protein structure. The hypothesis by 
Park et al. [270] proceeds by suggesting that PI remains in the ER until the protein binds an 
antigenic glycolipid. Rauch et al. [208] demonstrated that recognition of one phospholipid, 
phosphatidylethanolamine (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine; PE) is 
dependent on the degree of unsaturation within the acyl chain length, and the double-bond 
configuration of the unsaturated bonds. From an iNKT 24.8.Å cell hybridoma study, it has 
been shown that increasing unsaturation in synthetic PEs with 18-carbon acyl chains 
resulted in strong recognition by the iNKT cell hybridoma [271]. The PE with greatest 
recognition incorporated two double bonds in each of the two acyl chains, but at the same 
time it was also shown that synthetic PEs containing only one unsaturated fatty acid chain 
resulted in 24.8.A iNKT cell hybridoma stimulation [271]. Although, this particular cell line 
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fails to recognise α-GalCer (44) and is instead specific for phospholipids, it simply 
represents one end of the scale of CD1d-restricted iNKT cells. Sitting at the opposite end, 
are iNKT cells that are not autoreactive but are stimulated by α-GalCer (44). In the central 
core of this band sit iNKT cells that are autoreactive and recognise both α-GalCer (44) and 
phospholipids. This implies that α-GalCer analogues with two cis double bonds in the acyl 
chain are going to be significantly more active than those incorporating saturated fatty acid 
chains.  
 
The suggestion that unsaturated α-GalCer analogues are more active than saturated ones 
was demonstrated by Yu et al. [266]. A number of N-acyl variants of α-GalCer were 
synthesised and subsequently tested for their iNKT cell stimulatory properties. It was found 
that a synthetic analogue incorporating a C20 fatty acid with four cis double bonds 
(C20:4) (71) induced proliferation and cytokine secretion by murine splenocytes [266].  
 
In response to these results, a panel of synthetic analogues were produced and tested in a 
similar manner [266]. Various analogues of α-GalCer with N-acyl substituents incorporating 
varying degrees of unsaturation and carbon-chain length were synthesised (Figure 4.5A). 
These were then subjected to screening for their ability to activate an iNKT cell hybridoma 
and their ability to induce cytokine production (Figure 4.5B).  
 
Truncating the acyl chain from 26 carbons to 20 carbons (C20:0) (79) resulted in a marked 
decrease in cytokine production. However, incorporating double bonds into the C20 chain 
amplified activity similar to that of α-GalCer (44), with a C20 chain  with one (78), two (73) 
and four (72) cis double bonds providing the greatest activity of the C20 library.  
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Administration of the C20:2 analogue (73) (incorporating unsaturation at C11’’ and C14’’) 
resulted in a slightly smaller concentration of IL-4 and the IFN-γ response was drastically 
reduced, compared to C20:1 (cis double bond) (78) and α-GalCer (44) (Figure 4.5). It seems 
that the insertion of two double bonds into the acyl chain is accountable for this increased  
 
Figure 4.5: α-GalCer analogues varying in the length and saturation of the N-acyl chain and their 
immunological activity (A) N-acyl variant analogue structures. Using the core structure, 
various fatty acids were synthesised with altered carbon chain lengths and degrees of 
unsaturation in order to analyse their recognition by iNKT cell hybridomas (B) C57BL/6 
splenocyte cultures. IL-4, IFN-γ, and IL-2 cytokine levels were recorded in response to 3.2 nM 
of the various glycolipid analogues depicted in (A). Figure adapted from [266]. 
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potency as an analogue with 18 carbons and 2 double bonds in the acyl chain (C18:2) (80), 
exhibited similar potency to the C20:2 analogue (73).  
 
Interestingly, an analogue with trans orientation around the double bond (C20:1t (77)) 
showed a considerably lower stimulatory cytokine profile compared with the corresponding 
cis analogue (C20:1c (78)), suggesting that cis orientation of the double bond has a greater 
stimulatory effect on iNKT cells. 
 
The difference exhibited between the beneficial effects of C20:2 (73) and C24:0 (68) with 
regards to T1D in mice has been highlighted by Forestier et al. [272]. Using two different α-
GalCer analogues, these workers demonstrated that there was a significant difference 
between the incidence of glucosuria (P = 0.0424 C24:0 (68) vs. C20:2 (73)) and the survival 
rate of female NOD mice (P = 0.0318 C24:0 (68) vs. vehicle, and P = 0.0006 C20:2 (73) vs 
vehicle). There was a significant difference in survival between mice injected with the two 
analogues at 30 weeks (P = 0.0049), and at 53 weeks of age the insulinitis index of the 
C20:2 (73) group compared to vehicle was statistically significant (P = 0.002) [272].  
 
The incorporation of a polyethylene glycol (PEG) molecule as an alternative to a 
hydrocarbon-based fatty acid has a number of possible advantages over the usual hydro-
carbon based fatty acid. Not only would PEG vastly improve the aqueous solubility of the 
analogues, rendering them far easier in terms of handling and administration, but it has also 
been proved to be inert towards most biological macromolecules [273]. Polymeric 
biomaterials incorporating structures, such as PEG have been extensively used in the 
medical world since the 1950s [273].  
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PEG is a hydroxyl-terminated linear polyether with a repeating unit within the general 
structure -(CH2CH2O)n- which accounts for the hydrophilicity of such compounds. PEG-
bound biomaterials form the basis of preparations such as laxatives, sexual lubricants, skin 
creams, bowel preparations, and drug regimes for such conditions as hepatitis C [274]. 
Together with its status as an FDA approved compound, its aforementioned physical and 
commercial properties are highly favourable in terms of investigating potential new drug 
therapies for human use. It has also been shown that drugs that have modified protein, 
peptide or non-peptide molecules by the linking of one of more PEG chains, so called 
PEGylated  drugs, have increased body-residence time [273, 275], another attractive quality 
of a PEG-incorporated glycolipid antigen.  
 
4.4. Microbial glycolipid antigens  
The diverse group of α-GalCer analogues that have been found to bind to each of the 
human CD1 isoforms encompasses both mammalian and bacterial lipids [2, 37], suggesting 
a role for CD1 proteins in bacterial immunity. Wu et al. [179] synthesised and isolated a 
number of α-GalCer analogues and tested them for their immunological activity. Bacterial 
glycolipids from the outer membrane of Sphingomonas wittichii and from the causative 
agent of Lyme disease, Borrelia burgorferi, were isolated and analysed (Figure 4.6) [179]. Of 
the bacterial glycolipids analysed, those derived from the Sphingomonas species showed 
considerable activity, although they were not as potent  
α-GalCer (44) (Figure 4.7). Although, these analogues have been shown to bind with CD1d 
and stimulate iNKT cells, one can not conclusively state this is due to the altered N-acyl 
chain, as the structures of both GSL-1 and GSL-2 vary in other parts of the antigen structure 
compared to α-GalCer (44). 
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Figure 4.6: Bacterial glycosphingolipids. GSL-1 and GSL-2 are derived from Sphingomonas wittichiia 
and GSL-3 from Borrelia burgorferi  [179]. 
  
 
 
Figure 4.7: Cytokine production by iNKT cells in response to bacterial glycolipids. (A) Dose-
dependent IL-2 secretion by Sphingomonas GSLs (GSL-1 and GSL-2) compared with  
α-GalCer, as determined by ELISA. (B) IFN-γ and IL-4 release by human iNKT cells after 
stimulation with10µg/mlglycopid antigen and determined by ELISA. Figure adapted from [179].  
 
(A) (B) 
O
OH
HO
OH
O
(CH2)13CH3
OH
NH
(CH2)12CH3O
OH
O
O
OH
HO
OH
O
(CH2)13CH3
OH
NH
O
OH
O
(CH2)10CH3
OH
O
OH
HO
OH
O
O
O
O
OH
C15H31
O
C7H15
GSL-1 GSL-2
GSL-3
Chapter 4  Variations in the N-acyl chain 
   
120 
Wu et al. [180] went on to investigate further the effect bacterial glycolipids have on the 
activation of iNKT cells. A synthetic analogue of the Sphingomonas derived GSL-1, which 
more closely resembled α-GalCer (44) (a galactose head coupled to a ceramide with a C18 
sphingosine base and a C14 N-acyl chain) was analysed for IL-4 and IFN-γ production 
against GSL-1 and α-GalCer (44) [180]. The results showed that this synthetic analogue of 
GSL-1 gave a cytokine production profile for both IL-4 and IFN-γ more similar to α-GalCer 
than GSL-1 [180]. This suggests that the N-acyl chain, as opposed to the other subtle 
variations in the structure of GSL-1, is the contributing factor in its ability to activate iNKT 
cells.   
 
It has recently been reported that diacylglycerol lipids from Borrelia burgdorferi are 
recognised by iNKT cells and that their antigenic potency is dependent on acyl chain length 
and saturation [47]. It was demonstrated that murine iNKT cells more efficiently recognise 
mCD1d molecules loaded with diacylglycerol analogues with C16 acyl chains. This is in 
contrast to human iNKT cells that recognise hCD1d proteins loaded with diacylglycerol 
analogues of 18 carbons in length [47].  This is more than likely due to the shorter length of 
the mCD1d F’ channel [69, 71].  
 
The results gained do not however provide an answer as to whether the enhanced potency 
of diacylglycerol analogues is caused by their more stable binding to the CD1d protein, or 
because of a higher affinity with the TCR of the iNKT cell. Thus, different length acyl chains 
were incorporated into the structure of α-GalCer and varying degrees of unsaturation were 
added, in order to analyse the role of the lipid chain occupying the A’ channel of hCD1d 
molecules in modulating TCR affinity and/ or stability of hCD1d-GSL complexes. 
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4.5. Results and discussion 
4.5.1. Chemical synthesis 
In order for N-acylation to take place, an activating agent is required. 1-(3-
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride is a water soluble condensing 
reagent used as a carboxyl group activating agent for amide bonding with primary amines. 
Typically it is utilised in the pH range 4.0-6.0 without buffers. The first step in the reaction is 
the addition of the carboxylic acid to one of the C=N bonds of the carbodiimide, generating 
an O-acylated derivative of urea. This is a reactive acylating agent; there is a strong 
preference for eliminating the substituted urea unit. The result is formation of a stable amide 
carbonyl group (Figure 4.8). 
 
4.5.1.1. N-Hydroxysuccinimide esters of carboxylic acids and their use in  
N-acylation 
N-Hydroxysuccinimide esters of the appropriate carboxylic acids needing to be N-acylated 
onto the developing GSL were prepared and activated by the carbodiimide. Hammarstrom 
et al. [276] described the synthesis of ceramides using direct coupling of fatty acids and 
mixed carbodiimide. However, the product yields were relatively low (30-37.5%). The 
selective N-acylation of unprotected aminosugars with esters derived from  
N-hydroxysuccinimide as activated acylating agents has proven to be a versatile and 
general approach to acylamidosugars [277]. A wide range of acyl groups can be introduced 
along with other functionalities, such as labile phosphate groups [278]. Several years after 
Hammarstrom reacted fatty acids directly with ceramides in the presence of mixed 
carbodiimides [276], Ong et al. [279] successfully acylated the amino group of a number of 
ceramides employing N-hydroxysuccinimide esters of fatty acids in high yield and purity with 
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Figure 4.8: General mechanism of N-acylation using a water-soluble carbodiimide. 
 
no visible side-products. This was also true in the reactions carried out by Lazarevic et al. 
[278], who also showed that no O-acylation products were observed despite the presence of 
several unprotected hydroxyl groups. In the synthesis of α-GalCer analogues that vary in the 
N-acyl chain, the N-hydroxysuccinimide ester route was adopted, with the ester being 
prepared if they weren’t commercially available (Figure 4.9). 
  
Figure 4.9: Schematic representation of the reaction between N-hydroxysuccinimide and a fatty 
acid to produce an N-hydroxysuccinimide ester. R = C25H51 (43); C23H47 (54); 
(CH2)13CH=CH(CH2)7CH3 (55); (CH2)2(CH=CHCH2)6CH3 (56); (CH2)3(CH=CHCH2)5CH3 (57); 
(CH2)3(CH=CHCH2)4(CH2)3CH3 (58); (CH2)9(CH=CHCH2)2(CH2)3CH3 (59); Z-
(CH2)9CH=CH(CH2)7CH3 (60); E-(CH2)9CH=CH(CH2)7CH3 (61); C19H39 (62); 
(CH2)7(CH=CHCH2)2(CH2)3CH3 (63); C8H15 (64); CH2PhCH3 (65) 
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4.5.2. PEGylation 
PEGylation, the incorporation of one or more PEG groups into a protein, peptide or non-
peptide molecule was first described in the 1970s, when two scientists successfully modified 
the enzyme catalase, whilst retaining its biological activity [275]. Since that time, a large 
number of chemical and enzymatic procedures for conjugating PEG have been discovered 
[275].  
 
Amino groups were the first targets of PEGylation by acylation or alkylation, but now thiol, 
hydroxyl and amide groups can all be successfully conjugated with PEG [275]. Amine 
conjugation by acylation is a commonly used method of incorporating PEG into a molecule 
[275]. One method of carrying out this acylation is by producing a PEG derivative with a 
succinimide group. The carboxylic group of the PEG molecule is activated as an N-hydroxy 
succinimidyl ester, which can then acylate an amine [275]. It is this method that was 
employed in this project to incorporate PEG chains into the glycolipid antigen, in place of a 
saturated or unsaturated hydrocarbon acyl chains. 
 
The inclusion of polyethylene glycol (PEG)n as a component of a protein reagent imparts 
improved solubility, improved stability, protection from proteolytic digestion, increased half-
life in biological applications, reduced aggregation, reduced immunogenicity to the modified 
protein and minimized interference for both in vitro and in vivo applications [273, 275]. With 
these advantages in mind two analogues of α-GalCer were synthesised using two 
N-acylated PEG chains in place if the N-acyl hydrocarbon chain (Figure 4.10).  
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Using the N-hydroxysuccinimide method of introducing an N-acyl chain to the GSL, a library 
of α-GalCer analogues was synthesised as outlined in Table 4.1 and Figure 4.11. In addition 
to varying the sugar head group and phytosphingosine base chain length, the N-acyl chain 
was varied not only on the parent antigenic structure (α-GalCer (44)), but also on α-GlcCer 
(50) and α-L-FucCer (53) both with C18 phytosphingosine bases, and with α-GalCer with C18, 
C15, C12 and C9 bases. The latter analogues had only the key N-acyl chains coupled to them, 
namely C26, C20:2 and C18:2. These N-acyl chains are of particular interest with regards to 
iNKT stimulation and CD1d recognition, when coupled with α-GalCer (44), and have 
exhibited strong immunostimulatory profiles [266, 269, 272]. 
 
 
 
Figure 4.10: Two α-GalCer analogues incorporating PEG molecules, (85) and (86). 
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 Parent GSL 
 α-GalCer(44) 
α-GlcCer
(50) 
α-GalCer
(44) 
α-GalCer 
(44) 
α-GalCer 
(44) 
α-L-FucCer
(53) 
 
R=C14H29 
R’=OH 
R’’=H 
R=C14H29 
R’=H 
R’’=OH 
R=C11H23 
R’=OH 
R’’=H 
R=C8H17 
R’=OH 
R’’=H 
R=C5H11 
R’=OH 
R’’=H 
R=C14H29 
R’’’ (39) (49) (40) (41) (42)  
C25H51 (44) (50) (45) (46) (47) (53) 
C23H47 (68) (88)     
(CH2)13CH=CH(CH2)7CH3 (69)      
(CH2)2(CH=CHCH2)6CH3 (70) (89)     
(CH2)3(CH=CHCH2)5CH3 (71)      
(CH2)3(CH=CHCH2)4(CH2)3CH3 (72) (90)     
(CH2)9(CH=CHCH2)2(CH2)3CH3 (73) (91) (74) (75) (76) (96) 
E-(CH2)9CH=CH(CH2)7CH3 (77) (93)     
Z-(CH2)9CH=CH(CH2)7CH3 (78) (92)     
C19H39 (79) (94)     
(CH2)7(CH=CHCH2)2(CH2)3CH3 (80) (95) (81) (82) (83) (97) 
C7H15 (84)      
(CH2CH2O)4CH3 (85)      
(CH2CH2O)8CH3 (86)      
CH2PhCH3 (87)      
 
Table 4.1: Compound classification of α-GalCer, α-GlcCer and α-L-FucCer analogue library. See 
Figure 4.11 for definition of R, R’, R’’ and R’’’. 
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Figure 4.11: Azide reduction and N-acylation with N-hydroxysuccinimide esters of fatty acids to 
produce a library of α-GalCer analogues. (A) Synthesis using galactose and glucose 
coupled compounds. (B) Synthesis using fucosylated compound. For explanation of R, R’, R’’ 
and R’’’ see Table 4.1. 
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4.6. Biological evaluation of glycolipid antigens varying in the N-acyl chain.  
Altering the length, degree of unsaturation and functionality of the N-acyl chain of   α-GalCer 
analogues exhibits profound effects on the immunological response [64, 97, 98, 179, 180, 
184, 263, 264, 267, 271]. In the hunt for a so-called ‘super antigen’, it has been 
demonstrated that analogues incorporating cis double bonds in the N-acyl chain skews the 
immune response towards a predominantly TH2 effect [266, 272].   
 
The effect two analogues of α-GalCer (C20:2 (73) and C20:4 (71)) have on in vivo cytokine 
production was investigated by S. Porcelli and co-workers at the Albert Einstein College of 
Medicine, New York, USA using analogues prepared during this project and C57BL/6 
female mice obtained from the Jackson Laboratory, Maine, USA (Figure 4.12). This 
particular strain of mouse is a general purpose strain, particularly suited for use in diabetes-
related investigations, due to its susceptibility to hyperglycaemia and hyperinsulinaemia 
[280]. The results clearly show that treatment with C20:2 (73) skews the immunological 
profile of C57BL/6 mice towards a TH2 response, with comparable IL-4 (a TH2 cytokine) 
production, and dramatically reduced IFN-γ (a TH1 cytokine) release. 
 
As shown by Forestier et al. [272], novel analogues of α-GalCer varying in the N-acyl chain 
have a profound effect on the development of diabetes in NOD mice and can elicit more 
selective expression of iNKT cell functions. C20:2 (73) show greater IL-4 production and 
decreased IFN-γ production in comparison to α-GalCer (44) (Figure 4.12), and the analogue 
C24:0 (68) (incorporating a fully saturated C24 fatty acid chain) (C24:0). It has also been 
shown to exhibit a dramatic effect on glucosuria incidence in NOD mice, preventing the 
condition in 100% of animals treated up to 25 weeks of age (Figure 4.13). The results 
gained after the treatment of female NOD mice (predisposed to developing clinical 
symptoms of T1D [149]) with either α-GalCer (44), C20:2 (73) or vehicle alone, clearly show 
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Figure 4.12: In vivo cytokine skewing by α-GalCer analogues. Serum levels of IL-4 and IFN-γ after a 
single injection of α-GalCer (44), C20:4 (71) or C20:2 (72). C57BL/6 mice (11-13 weeks old) 
were given a single i.p. injection of 4.8nmol of the analogues or phosphate buffered solution 
(PBS)/vehicle (VEHI) control. Serum levels were assayed 2 and 20 hours later using ELISA. 
Bars show means of three mice with standard deviation. Experiments carried out by S. Porcelli 
and co-workers at Albert Einstein College of Medicine, New York, USA using analogues 
synthesized during this project. 
 
 
Figure 4.13: Prevention of diabetes in female NOD mice by α-GalCer analogues. Female NOD wild 
type (w.t.) mice were treated with α-GalCer (44) and C20:2 (73) and the percentage of animals 
not presenting with glucosuria, in comparison to an untreated animal, was recorded. Starting at 
4–6 weeks of age, female NOD mice received seven weekly i.p. injections of glycolipid at a 
concentration of 4µg/mouse in 250µl of vehicle (PBS plus 0.04% Tween 20) or vehicle alone. 
T1D was assessed from 10 weeks by monitoring mice weekly for the presence of glucose in 
the urine (glucosuria) determined using Diastix reagent strips (Bayer). Mice were considered 
diabetic when two consecutive positive measurements were obtained and the time of onset of 
diabetes was recorded as the date of the first of the two consecutive readings. Experiments 
carried out by S. Porcelli and co-workers at Albert Einstein College of Medicine, New York, 
USA using analogues synthesized during this project 
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the protective effect of the C20:2 (73) analogue in the context of the development of 
glucosuria, a physiological indication of the development of T1D (Figure 4.13). In addition to 
the beneficial effects on glucosuria, treatment with C20:2 (73) displayed a huge percentage 
increase in mouse survival, with no mortality up to approximately 37 weeks, and 70% 
survival after 40 weeks. This is compared to a steady decline in surviving mice treated with 
α-GalCer (44) after approximately 20 weeks, with only 40% survival after 40 weeks. 
 
These results demonstrate that variation within the structure of the N-acyl chain of α-GalCer 
analogues plays a part in modifying their antigenic activity. Figure 4.14A shows the 
expansion of iNKT cells from PBLs 21 days after stimulation with mature DCs pulsed with 
analogues, varying in the length and saturation of the N-acyl chain. One can see decreased 
activity with regard to iNKT cell expansion of the analogue with 4 double bonds, C20:4 (72), 
similar to the results gained from α-GalCer (44), and C20:2 (73). The latter analogue has 
already shown its ability to skew the immune response (Figure 4.12) and the fact that is able 
to stimulate iNKT cell expansion in a similar vein to α-GalCer (44) widens its scope as an 
effective immuno-modulator. From the FACS analysis plots (Figure 4.14B), one can see also 
that C20:2 (73) stimulates greater iNKT cell expansion than C20:4 (72), as shown by the 
greater density in the upper right quadrant of the FACS plots. However, one can not 
conclude that this is directly related to the unsaturated N-acyl chain, as C20:4 (68) had a 
dramatically decreased effect on iNKT cell expansion. 
 
The antigen-binding site of mouse and human CD1d (hCD1d) molecules is composed of two 
channels: A′ and F′ which connect directly to the surface. The F’ channel accommodates the 
phytosphingosine chain, and the A’ channel contains the N-acyl chain of α-GalCer (44)  
[69, 178, 259, 260, 281]. Although the A′ channel can accommodate an alkyl chain up to 26 
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Figure 4.14: iNKT cell expansion in vitro is modulated by the N-acyl chain of α-GalCer. (A) Mean 
percentage of gated and total iNKT cell (HDD.11 cells) frequency from ex vivo treatment with 
100nM α-GalCer analogues measured by FACS analysis. (B) FACS analysis plots showing the 
gating of iNKT cells and the differences in cell expansion of HDD.11 cells after stimulation with 
α-GalCer (44), C24:0 (68), C20:4 (72) and C20:2 (73) compared with a control of DMSO after 
ex vivo 100nM GSL stimulation. Experiments carried out by G. Bricard and myself at Albert 
Einstein College of Medicine, New York, USA using analogues synthesized during this project 
  
carbon atoms long, the F′ channel has a decreased capacity with a maximum chain length 
of 18 carbons long. hCD1d molecules in which the A′ and F′ channels are not filled (they are 
in the nonlipid-bound state) have an altered conformation compared to hCD1d proteins 
bound to a glycolipid antigen such as α-GalCer (44) [71]. Whereas the entrance of the cavity 
is wider in the empty conformation, the volumes of the A′ and F′ channels are reduced, due 
to the conformational shifts in the side chains of several tryptophan residues [218]. The 
recently solved crystal structures of CD1d–α-GalCer–specific TCR and docking models  are 
consistent with the TCR binding footprint encompassing the polar head of the lipid ligand 
and portions of the CD1d α1 and α2 helices but do not support direct interactions between 
the TCR and the lipid alkyl chains [92, 100].  
 
(A) (B)
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In order to further examine the role of each alkyl chain in α-GalCer (44) and related 
compounds, McCarthy  et al. [218] carried out kinetic experiments to assess the degree of 
control exhibited by both the phytosphingosine chain (Chapter 2) and the N-acyl chain of α-
GalCer on the dissociation rate. A small library of lipids prepared during the course of this 
project and varying in the N-acyl chain, were analysed for their rate of dissociation from their 
complexed state with hCD1d, thus giving the affinity each analogue has for TCR binding 
[218].  
 
In the same manner that the affinity of phytosphingosine analogues were tested, Fab 9B 
was used by McCarthy et al. [218] to measure dissociation of N-acyl chain analogues 
prepared during this project from soluble hCD1d over a period of time (Figure 4.15).  These 
results show that decreasing the length of the N-acyl chain does have an affect on the rate 
of dissociation from hCD1d molecules; the rate of dissociation of C20:0 (79) is 2.15-fold 
faster than that of C20:2 (73) (half-life of 170 min and 367 min respectively at 25°C) and 
approximately 3.5 times slower than α-GalCer (44). However,  the rate of dissociation of an 
unsaturated analogue is raised compared to its corresponding fully saturated analogue 
[218].  The analogue incorporating an N-acyl chain with 11 carbons and one double bond 
(C11:1), although having a chain length more than half as long as α-GalCer (44), has a 
greater half-life than C20:0 (79), suggesting that a double-bond in the N-acyl chain may play 
a part in retaining the bonding association between the analogue and CD1d protein. 
 
The dissociation constants (Kd) of α-GalCer (44) and three analogues (C20:2 (73), C20:0 
(79) and C11:1) that vary in the N-acyl chain length and saturation were also determined, 
measuring the tendency of α-GalCer (44) to dissociate from the CD1d protein to which it is 
bound. The data in Figure 4.16 corresponds with the affinity measurements of the four GSLs 
tested (Figure 4.15A) and shows that analogues with truncated N-acyl chains do affect the  
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Figure 4.15: Binding affinities of α-GalCer analogues to hCD1d. (A) Dissociation of α-GalCer analogues 
from hCD1d.The antigen-hCD1d complexes were loaded onto a sensor surface at t=0. The 
amount of remaining hCD1d at given time points was measured using Fab 9B antibody and 
SPR. Dissociation values only shown for the first 100 mins, but with half-life values listed. 
Figure adapted from [218] (B) The mean dissociation constants from hCD1d of α-GalCer (44) 
and three analogues varying in the length and degree if unsaturation of the N-acyl chain: 
C20:2 (73), C20:0 (79), C11:1. Experiments carried out by McCarthy et al. at the Weatherall 
Institute of Molecular Medicine, University of Oxford, UK using in part, analogues synthesized 
during this project. 
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degree of dissociation from CD1d compared with α-GalCer (44). The results also indicate 
that the effect of incorporating unsaturated N-acyl chains reverts the dissociation rate back 
to a value nearer to α-GalCer (44). This is illustrated by Kd values of 2.73µM for C20:0 (79) 
and 1.81µM for C20:2 (73), compared with 1.29µM for α-GalCer (44) (Figure 4.15B). 
Although, the N-acyl variants of α-GalCer do show some degree of difference in binding 
affinities compared with α-GalCer (44), the phytosphingosine analogues OCH15 (45), 
OCH12 (46), and OCH9 (47), exhibit a greater level of control over the affinity of TCR 
binding to hCD1d-glycolipid complexes and subsequent iNKT cell activation. The affinity of 
complexed hCD1d-α-GalCer with iNKT TCR was also investigated (Figure 4.16) and 
showed that C20:2 (73) has an affinity for the TCR similar to that of α-GalCer (44), whereas 
C11:1 and C20:0 (79) exhibited decreased affinities for the iNKT cell receptor.  
 
 
Figure 4.16: Affinity and kinetics of iNKT TCR binding to hCD1d-α-GalCer complexes. The binding 
responses of 5 concentrations (increasing from 0.4 – 194µM) of hCD1d-α-GalCer complex 
injected with iNKT TCR for 5s are shown, with the equilibrium binding response (Kd) shown in 
the insets. Experiments carried out by McCarthy et al. at the Weatherall Institute of Molecular 
Medicine, University of Oxford, UK using in part, analogues synthesized during this project. 
Figure adapted from [218].  
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Surprisingly, the difference between C11:1 and C20:0 was not as large as expected, despite 
the truncation of the N-acyl chain.  This could be attributed to the double bond at C10 of the 
acyl chain and implies that optimal iNKT TCR binding require the hCD1d A’ channel to be 
occupied by an α-GalCer analogue with an N-acyl chain, incorporating some degree of 
unsaturation around C10 (C20:2) (73) has two double bonds at C11 and C14). To test this 
hypothesis further, the experiment would need to be repeated using a larger library of 
analogues incorporating one or two double bonds at various carbon atoms along the N-acyl 
chain, but the results thus far (Figure 4.15 and Figure 4.16) suggest that unsaturation of 
bonds in the N-acyl chain of α-GalCer favours the formation of more stable hCD1d-glycolipid 
complexes. 
 
 To demonstrate that the binding affinities of the hCD1d-α-GalCer complexes with the TCR 
were not a result of hCD1d loading with the α-GalCer analogues described, the rate 
constants kon and koff were determined by direct measurements of the TCR with  
hCD1d-α-GalCer analogues complexed with α-GalCer (44), C20:2 (73), C20:0 (79), and 
C11:1 (Table 4.2). From the smaller Kd values in Figure 4.16 and the smaller koff values in  
hCD1d-α-GalCer 
complex 
koff (s-1) kon (M-1s-1) 
α-GalCer (44) 0.39 ± 0.01† 3.31 x 105 ± 2.5 x 104† 
C20:2 (73) 0.46 ± 0.06 2.46 x 105 ± 2.3 x 104 
C20:0 (79) 0.58 ± 0.07 2.38 x 104 ± 4.6 x 104 
C11:1 0.59 ± 0.04 1.65 x 104 ± 3.5 x 104 
Table 4.2: Affinity and kinetic measurements of hCD1d-α-GalCer complexes with iNKT TCR. Unless 
stated, all values are the mean of two experiments. †Mean of three or more experiments. 
Experiments carried out by McCarthy et al. at the Weatherall Institute of Molecular Medicine, 
University of Oxford, UK using in part, analogues synthesized during this project. Table 
adapted from [218]. 
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Table 4.2 one can surmise that α-GalCer analogues with at least one double bond have a 
greater affinity for the iNKT TCR when complexed with the CD1d protein. 
 
The binding of hCD1d molecules with analogues of α-GalCer that have shorter lipid chains 
may result in the partial collapse of unfilled portion of the A’ and F’ channels, which in turn 
could result in surface-exposed structural changes.  Thus, analogues containing identical 
polar heads and varied acyl chains were synthesised in this project to study the affinity of 
soluble iNKT TCR to hCD1d molecules loaded with the synthetic analogues. In a similar 
manner, the partial filling of F’ channel of hCD1d was investigated by shortening the N-acyl 
chain in an α-GalCer analogue using modelling exercises. This predicted changes in the 
position of the α1 helix from residues Phe58 through to Phe70, but in contrast to the 
differences resulting from using a truncated phytosphingosine chain, the changes using 
shortened N-acyl chains are in a region that is peripheral to the iNKT cell TCR docking area 
and have no influence on the orientation of the polar head group of the analogue 
(Figure 4.17) [218]. This further suggests that, although a structural variation in the N-acyl 
chain affects the binding of the analogue to the CD1d molecule, it does not play a part in 
modulating TCR recognition.   
 
By demonstrating that the presence of two cis double bonds in the N-acyl chain at positions 
C11 and C14 (C20:2 (73)) [178], reduces the rate of dissociation from hCD1d molecules as 
compared with its fully saturated analogue, one can surmise that the N-acyl chain plays a 
pivotal role in the stability of the hCD1d-glycolipid stability. Unlike C20:0 (79), C20:2 (73) has 
been shown to successfully load into mCD1d molecules that lack an endosomal targeting 
motif, further suggesting that double bonds at C11 and C14 facilitate the lipid binding to 
CD1d molecules [266].  
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Figure 4.17: Modeling of the effects of variation in lipid chain length on the hCD1d structure. A Cα 
trace and selected side chains are shown for the hCD1d crystal structure with bound α-GalCer 
(44) (yellow), and relevant regions of the structure of hCD1d in the absence of bound ligand 
are shown in green. Hydrogen bonds are depicted as dotted lines. The putative position of 
bound TCR is indicated schematically. The portion of α-GalCer that corresponds to a ligand 
with a shortened acyl chain (C11:1) is highlighted in blue, and the side chains that are 
predicted to shift positions are highlighted, based on a comparison of the empty and fully 
occupied (i.e., α-GalCer bound) hCD1d A′ channel. Figure adapted from [218]. 
 
The N-acyl chain of α-GalCer (44) and associated analogues is anchored within the A’ 
channel of the CD1d protein. By circumnavigating a central pole made up of Phe70, Trp40 
and Cys12 residues at the junctions of the A’ and F’ channels, the acyl chain enters the A’ 
channel [71] and secures the position of the analogue within the CD1d molecule. The 
observed differences between the dissociation rates of C20:0 (79) and C20:2 (73) 
(Figure 4.15 and Figure 4.16) suggests that the preformed kink in the N-acyl chain of the 
latter analogue (caused by the presence of the unsaturated bonds) may stabilise binding of 
the glycolipid by favouring the tightly curved conformation required for binding in the A’ 
channel [218]. 
 
A less stable binding interaction between an α-GalCer analogue, CD1d and the TCR has an 
effect on the immunological response of the iNKT cell. The cytokine profile of C20:2 (73) is 
biased towards a TH2 response when coupled with hCD1d (Figure 4.12). This could be 
attributed to the binding differences within the hCD1d channel (as compared with α-GalCer 
(44)), and thus could open up the possibility that more analogues incorporating such 
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unsaturated functionality could prove to be a vital characteristic of a glycolipid analogue that 
could prevent and treat autoimmune diseases such as T1D. Although both the N-acyl chain 
and phytosphingosine chain control the stability of lipids bound to hCD1d molecules, it is the 
latter chain that seems to control the affinity of TCR binding to hCD1d-glycolipid complexes.  
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5. Materials and methods 
Chemical reagents were obtained from Aldrich, Lancaster, Fischer and Pierce. All solvent 
extractions from reaction work-up were dried over anhydrous sodium sulfate, prior to 
evaporation in situ. Nuclear Magnetic Resonance (NMR) spectra chemical shift values (δ) 
are given in ppm and were obtained using deuterated chloroform (CDCl3) and deuterated 
methanol (D3COD). 1H NMR spectra were measured on a Bruker AC300 spectrometer 
operating at 300MHz, Bruker AV400 operating at 400MHz and a Bruker DRX500 operating 
at 500MHz. The references used were the residual solvent signals of: CDCl3 at 7.25ppm 
and D3COD at 3.30ppm. 13C NMR spectra were run on a Bruker AV300 spectrometer, 
operating at 75MHz. The references were the residual solvent signals of CDCl3 at 77.0ppm 
and D3COD at 49.0ppm. The spectra were run 1H decoupled, using the PENDANT 
sequence, which edits CH and CH3 signals from the quaternary and CH2 signals. Mass 
spectrometric data was analysed using an electrospray (Micromass LCT time-of-flight mass 
spectrometer) and an electron impact (VG ZabSpec magnetic sector mass spectrometer). 
Anhydrous acetone was prepared by mixing with dry CaSO4 for ~2h, followed by filtration 
and distillation. Anhydrous THF was prepared by distillation with LiAlH4. Anhydrous DCM 
was prepared by distillation with P2O5. All CC was performed on Silica Gel 60 (Fluka 60741, 
particle size 0.063-0.2mm). All TLC was performed on TLC aluminium sheets silica gel 60 
F254 (Merck Z293024). Molecular sieves used were 4Å powder < 5 micron, and molecular 
sieve 4 Å beads 4-8 Mesh (both purchased from Aldrich).  
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5.1. Chemical synthesis 
5.1.1. General chemical procedures 
Specific amounts are given in each individual synthesis  
5.1.1.1. The formation of Wittig salts and subsequent olefination 
Triphenylphosphine (3M eq) and 1-bromoalkane were stirred together at 140°C for 4.5h. 
The flask was gradually cooled and the compound dissolved in THF. The solution was 
cooled (-10°C) and the nBuLi (2.5M solution in hexanes; 2.8M eq) was added drop wise. 
The reaction mixture was stirred for 30mins, before a solution of  
(3aS, 4R, 6R, 6aS)-2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3, 4-d]-1,3-dioxol-4-ol (2) 
(1M eq) in THF was added and stirred for 18h whilst the temperature was gradually raised to 
RT. The reaction was quenched with MeOH, followed by 80% MeOH in H2O, and the 
reaction mixture was extracted with heptane (4 x 20ml). The organic portions were 
combined, dried (NaSO4), concentrated and dried in vacuo. Purification by CC (heptane: 
ethyl acetate [EtOAc], 20:1) [198]. 
 
5.1.1.2. Addition of a mesyl group 
The 1-trityl-3,4-ispropylidene protected base (1M eq) prepared using the procedure outlined 
in section 5.1.1.1 was dissolved in dry dichloromethane and pyridine (3:1). 
Methanesulfonylchloride (1.6M eq) was added and the solution was stirred overnight at 
31°C under argon. TLC was used to monitor the reaction 8:1 (petrol:EtOAc). Ethanol was 
added and the mixture stirred for 1h at RT. The solution was concentrated and a mixed 
solvent of heptane:MeOH:water (10:7:3) was added. The aqueous portion was thrice re-
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extracted with heptane. The organic layers combined, dried (NaSO4), concentrated and 
dried in vacuo [282]. 
 
5.1.1.3. Deprotection of the mesylated base  
The mesylated base was dissolved in dry DCM:MeOH (2:1). Concentrated HCl (~1/8 volume 
of DCM:MeOH) was added drop wise and the mixture stirred at RT for 1.5h. NaHCO3 
powder was added until the solution was neutral, followed by filtration and washing with 
EtOAc. The organic extract was concentrated, and washed with saturated brine and EtOAc. 
The aqueous layer was thrice re-extracted with EtOAc. The organic layers were combined, 
dried (NaSO4), concentrated, dried in vacuo, and purified by CC (silica gel 60), (15% EtOAc 
in petrol as the starting eluting solvent system) [282]. 
 
5.1.1.4. General procedure for catalytic reduction 
The deprotected mesylated base was dissolved in minimal THF. 5% Pd-Ba(SO4)2 (10% of 
the weight of mesylated base) was added to the solution, and degassed three times. The 
solution was stirred for 24h at RT under a H2 atmosphere. The mixture was filtered through 
Celite and washed with chloroform (CHCl3):MeOH (1:1). The filtrate was concentrated and 
dried in vacuo [282]. 
 
5.1.1.5. Introduction of an azide group 
The reduced mesylated base (1M eq) was dissolved in DMF (~10ml per gram of reduced 
mesylated base). Sodium azide (2M eq) was added and the solution stirred at 95°C for 6h. 
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The solution was concentrated and EtOAc was added to the residue and the mixture 
extracted with H2O. The organic layers were combined, washed with saturated brine, dried 
(Na2SO4), concentrated and dried in vacuo. The resulting compound was purified by CC 
(silica gel 60) 9:1 (heptane:EtOAc) [282]. 
 
5.1.1.6. Addition of a TBDPS protecting group 
The azido-triol base (8 M eq) was dissolved in DCM:pyridine (6.25:1).  
4-(4-dimethylaminopyridine) (1M eq). Tert-butyldiphenylsilylchloride (14.4 M eq) was added 
at 0˚C and stirred for 36h at RT. Hydrochloric acid (1M) was added at 0˚C and the reaction 
mixture diluted with CHCl3. The organic portion was extracted, dried (Na2SO4) and 
concentrated. The residue was purified by column chromatography (petrol:EtOAc [20:1]) 
[283]. 
 
5.1.1.7. Addition of benzoate groups 
To a solution of TBDPS-protected azido-diol (1M eq) in pyridine was added benzoyl chloride 
(6M eq) and DMAP (catalytic amount). The solution was stirred at RT for 18h. Cooled water 
was added to the reaction mixture and extracted with CHCl3. The organic layer was washed 
with water, dried (Na2SO4) and concentrated, before being purified by CC (2% EtOAc in 
petrol) [284].  
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5.1.1.8. Removal of the TBDPS group 
Acetic acid (1.1M eq) and a 1M solution of tetrabutylammonium fluoride (TBAF) (1.1M eq) 
were added to a solution of TBDPS benzoyl protected azido-diol (1M eq) in dry THF. The 
mixture was stirred at RT and monitored by TLC (petrol:EtOAc, 9:1). After 2h the solution 
was passed through a 200ml silica gel 60 column and washed with THF. The solution was 
then concentrated and purified by CC (starting eluting solvent 100% petrol, gradually 
increasing proportion of EtOAc) [195]. 
 
5.1.1.9. Preparation of pertrimethylsilyl-D-pyranoses 
A solution of free pyranose in dry DMF was prepared. Triethylamine (1.1M eq for each free 
hydroxyl group) was added and the solution cooled to 0°C.  Redistilled chlorotrimethylsilane 
(1.1M eq for each free hydroxyl group) was added and stirred at RT for 6h. Pentane and 
crushed ice were added and the aqueous layer thrice extracted with pentane. The combined 
organic portions were washed twice with water, saturated NaCl solution, dried (Na2SO4) and 
concentrated [285]. 
 
5.1.1.10. Coupling of pertrimethylsilylated sugars with benzoate-protected azido-
phytosphingosine analogues 
The pertrimethylsilylated pyranose (3M eq) was dissolved in dry DCM. Iodotrimethylsilane 
(3M eq) was added at RT and the solution stirred under argon for 20min. After 
concentration, dry benzene was added and azeotroped twice with benzene. The yellow-
orange residue was dissolved in benzene and kept under argon. Meanwhile, activated 
MS 4Å, tetrabutylammonium iodide (6M eq), the benzoate protected azido phytosphingosine 
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analogue (1M eq) and diisopropylethylamine (4.5M eq) were added to a 2-necked flask fitted 
with a condenser. Benzene was added and the solution stirred at 70°C for 20min. The 
glycosyl iodide solution was cannulated into the two-necked flask and stirred for a further 
hour at 70°C. The reaction was monitored by TLC (petrol: EtOAc) (3:1). EtOAc was added 
and the solution cooled to 0°C, before being filtered through Celite. The filtrate was twice 
washed with saturated Na2S2O3 solution, and then saturated NaCl solution, before being 
dried (Na2SO4) and concentrated. The residue was dissolved in MeOH. Dowex 50 WX8-200 
ion exchange resin was added and the mixture refluxed for 45min. The resin was removed 
from the residue by filtration, and the residue washed with MeOH and concentrated, before 
being purified by CC (80% EtOAc in petrol) [217].  
 
5.1.1.11. Removal of benzoate protecting groups 
The 2-(2-azido-3,4-bis-benzoyloxy-alkyloxy)-sugar (1M eq) was dissolved in minimal dry 
THF and MeOH. 0.5M Sodium methoxide solution in MeOH (1.5M eq) was added and 
stirred at room temperature and monitored by TLC (9:1 petrol: EtOAc). Upon completion, 
Dowex© 50WX8-200 resin (washed with 1M HCl, H2O and MeOH) was added until the 
solution reached pH7. The resin was then removed by filtration and the filtrate concentrated 
before being purified by FCC (CHCl3: MeOH) [286]. 
 
5.1.1.12. Preparation of N-hydroxy succinimide esters of various carboxylic acids  
The carboxylic acid was dissolved in dry DCM. N-(3-dimethylaminopropyl)-N’-ethyl 
carbodiimide hydrochloride (1.1M eq), N-hydroxysuccinimide (1.2M eq), and dimethylamino 
pyridine DMAP (10% of acid weight) were added and the solution stirred at 40°C and 
monitored by TLC (pet ether 40-60: Et2O) (6:4). On completion, the reaction mixture was 
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poured into water and extracted with Et2O. The organic layer washed with saturated NaCl 
solution, dried (Na2SO4), filtered and concentrated [287].  
 
5.1.1.13. Azide reduction and subsequent N-acylation 
The azido compound (1M eq) was dissolved in pyridine:Et3N:H2O (18:5:8). Hydrogen sulfide 
was bubbled through the mixing solution for ~24h. The solution was concentrated. The 
crude amine was dissolved in pyridine:H2O (9:1). The N-hydroxysuccinimide ester of a fatty 
acid (1.4M eq) was added and the solution stirred overnight at 50°C. EtOAc was added and 
the solution washed with H2O, then saturated NaCl solution, before being dried (MgSO4), 
concentrated and purified by FCC (CHCl3: MeOH, 2:1) and preparative TLC [288, 289]. 
 
5.2. Protection of D-lyxose 
 
D-Lyxose (20g, 0.133mol) was suspended in acetone (300ml). Conc. H2SO4 (a few drops) 
was added and the mixture stirred at RT for 18h. Molecular Sieve 4 Å (Aldrich) (10g) was 
C8H14O5 
Mol. Wt.: 190.1938 g mol-1 
(3aS, 4R, 6R, 6aS)-6-hydroxymethyl-2,2-dimethyl-
tetrahydro-furo [3, 4-d]-1,3-dioxol-4-ol (1) 
O
OH
O
O O
Ph
Ph
Ph
O
OH
HO
O O
C27H28O5 
Mol. Wt.: 432.5082 g mol-1 
(3aS, 4R, 6R, 6aS)-2,2-dimethyl-6-trityloxymethyl-
tetrahydro-furo [3, 4-d]-1,3-dioxol-4-ol (2) 
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added and the mixture filtered. The residue was washed with acetone. The washes were 
combined, concentrated and dried in vacuo, producing (3aS, 4R, 6R, 6aS)-6-hydroxymethyl-
2,2-dimethyl-tetrahydro-furo [3, 4-d]-1,3-dioxol-4-ol (1), which was recrystallised using 
anhydrous toluene. The resulting crystals (25.29g, 0.133mol) were dissolved in anhydrous 
pyridine (160ml). Trityl chloride (25.95g, 0.093mol) was added and the solution stirred for 
18h under argon at RT. The solution was concentrated in vacuo and the resulting solid (3aS, 
4R, 6R, 6aS)-2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3, 4-d]-1,3-dioxol-4-ol (2) purified 
by CC (petrol:EtOAc [20:1]), affording a colourless syrup. Yield 42.85g, 74.37%.  
 
(3aS, 4R, 6R, 6aS)-6-hydroxymethyl-2,2-dimethyl-tetrahydro-furo [3, 4-d]-1,3-dioxol-4-
ol  (1) [282] 
 
 δ 1H (CDCl3): 5.43 (1H, s), 4.82-4.79 (1H, q, J=3.80, 2.10, 3.79 Hz), 4.63-4.61 (1H, d, 
J=5.92 Hz), 4.30-4.25 (1H, dd, J=4.95, 4.22, 5.22 Hz), 3.93-3.90 (2H, dd, J=2.73, 1.72 Hz), 
1.45 (3H, s), 1.31 (3H, s) δ 13C (CDCl3): 113.85 (QC), 102.01 (C-1), 86.76 (C-4), 81.43, 
80.97 (C-2,3) 62.27 (C-5), 27.00, 25.61 (Acetonide methyl C).  
 
(3aS, 4R, 6R, 6aS)-2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo [3, 4-d]-1,3-dioxol-4-
ol (2) [282] 
δ 1H (CDCl3):  7.19-7.5 (15H, m), 5.37 (1H, s), 4.77 (1H, dd, J=3.71 Hz), 4.58 (1H, d, J=5.90 
Hz), 4.29-4.37 (1H, m), 3.35-3.47 (2H, m), 1.3 (3H, s), 1.27 (3H, s).  δ 13C (CDCl3):  144.00 
(QC), 128.86, 127.77, 126.97 (Aromatic C), 101.25 (C-1), 85.46 (C-4), 80.15, 79.73 (C-2,3) 
61.88 (C-5), 26.56, 25.01 (Acetonide methyl C). m/z (ES) 455.1 (M+ + [Na]+ 100%). αD-
16.10° IR:3200-3400cm-1 (br OH stretch), 3100-3160 (Ar stretch) 
Chapter 5  Materials and methods 
   
147 
5.3. The Wittig reaction 
5.3.1. (R)-1-[(4S,5R)-2,2-Dimethyl-5-(undec-1-enyl)-1,3-dioxolan-4-yl]-2-trityloxy-
ethanol (3) 
 
Prepared by the general procedure for Wittig salt and subsequent olefination (5.1.1.1), using 
triphenylphosphine (1.822g, 6.945mmol), 1-bromodecane (1.536g, 6.945mmol), nBuLi 
(2.58ml, 6.482mmol), and (3aS, 4R, 6R, 6aS)-2,2-dimethyl-6-trityloxymethyl-tetrahydro-
furo[3, 4-d]-1,3-dioxol-4-ol (2) (1g, 2.315mmol), affording a colourless syrup. Yield 712mg, 
55.24%. δ 1H (CDCl3): 7.19-7.48 (Ar-H, 15H, m), 5.47-5.58 (H-1’, H-2’, 2H, m), 4.91   (H-5 
trans, 0.7H, m), 4.40-4.46 (H-5 cis, 0.3H, m), 4.25 (H-4 cis, 0.3H, dd, J=4.63, 4.65 Hz ), 4.21 
(H-4 trans, 0.7H, dd, J=4.39, 4.40 Hz), 3.72-3.79 (H-1’’ trans, 0.7H, m), 3.68-3.70 (H-1’’ cis, 
0.3H, m), 3.22 (H-2’’a cis, 0.3H, dd, J=5.07, 5.14 Hz), 3.15 (H-2’’a trans, 0.7H, dd, J=5.27, 
9.47Hz), 3.08-3.13 (H-2’’b cis [0.7H], H-2’’b trans [0.3H], m), 1.71-2.03 (H-3’ab,  2H, m), 1.56 
(H-Aabc trans 3H, s), 1.47 (H-Babc trans, 3H, s), 1.39, 1.38 (H-Aabc H-Babc cis, 3H, each s), 
1.11-1.35 (H-4’ab – H-10’ab, 14H, m), 0.87 (H-11’abc, 3H, t, J=6.65 Hz).  δ 13C (CDCl3): 145.73 
(C-2), 137.17 (C-1’), 130.56, 129.65, 128.87 (Aromatic C), 126.84 (C-2’), 79.54 (C-1’’), 74.88 
(C-4), 70.8 (C-5), 66.51 (C-2’’), 34.02, 31.34, 31.17, 30.01 (C-3’ – C-10’) 29.25, 27.01 (C-A, 
-B), 16.04(C-11’).  m/z (ES): 580.4 (M+ + [Na]+ + [H]+ 30%), 579.1 (M+ + [Na]+ 100%). 
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HRMS: Calculated for C37H48O4 [M + Na]+, 579.3450, found 579.3454. αD: -47.6°. IR: 3200-
3400cm-1 (br OH), 3100-3160cm-1  (Ar), 1650-1680 cm-1 (alkene). 
 
5.3.2. (R)-1-[(4S,5R)-2,2-Dimethyl-5-(oct-1-enyl)-1,3-dioxolan-4-yl]-2-trityloxy-
ethanol (4) 
 
n-Hepyltriphenylphosphonium bromide (9.269g, 21mmol) was dissolved in dry THF (100ml). 
nBuLi (2.5M solution in hexanes) (7.7ml, 19.2mmol) was added to the solution and stirred at 
-50°C for 40mins. A solution of (3aS, 4R, 6R, 6aS)-2,2-dimethyl-6-trityloxymethyl-tetrahydro-
furo[3, 4-d]-1,3-dioxol-4-ol (2) (3.32g, 7.68mmol) in dry THF (15ml) was added to the 
reaction mixture which was allowed to warm to RT overnight. The general procedure for 
olefination (5.1.1.1) was then followed.  This afforded a colourless syrup. Yield 2.594g, 66%.  
δ 1H (CDCl3):  7.19-7.48 (Ar-H, 15H, m), 5.47-5.58 (H-1’, H-2’, 2H, m), 4.91 (H-5 trans, 0.7H, 
m), 4.43 (H-5 cis, 0.3H, m), 4.25 (H-4 cis, 0.3H, m), 4.21 (H-4 trans, 0.7H, m), 3.68-3.81 (H-
1’’ trans, 0.7H, m), 3.51-3.56 (H-1’’ cis, 0.3H, m), 3.22 (H-2’’a cis, 0.3H, dd , J=4.92, 9.52), 
3.18 (H-2’’a trans, 0.7H, m), 3.07-3.17 (H-2’’b cis, H-2’’b trans, 1H, m), 1.91-2.09 (H-3’ab,  2H, 
m), 1.54 (H-Aabc trans 3H, s), 1.49 (H-Babc trans, 3H, s), 1.39, 1.38 (H-Aabc H-Babc cis, 3H, 
each s), 1.19-1.39 (H-4’ab – H-7’ab, 8H, m), 0.88 (H-8’abc 3H, t, J= 5.68).  δ 13C (CDCl3): 145.9 
(C-2), 137.3 (C-1’), 129.1, 129.9, 130.8 (Aromatic C), 127.1 (C-2’), 79.5 (C-1’’), 75.1 (C-4), 
71.3 (C-5), 67.1 (C-2’’), 34.2, 31.3, 31.1, 29.7, 25.0 (C-3’ – C7’) 29.8, 27.1 (C-A, -B), 17.1 
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(C-8’).  m/z (ES) 538.5 (M+ + [Na]+ + [H]+ 10%), 537.5 (M+ + [Na]+ 100%),  243.2 (M+  
- CH3(CH2)5-CH=CH-CH(OC(CH3)2O)CH-CH(OH)-CH2-O 80%). αD: -50.5°. IR: 3200-
3400cm-1 (br OH), 3100-3160cm-1  (Ar), 1600-1680 cm-1 (alkene). 
 
5.3.3. (R)-1-[(4S,5R)-2,2-Dimethyl-5-(pent-1-enyl)-1,3-dioxolan-4-yl]-2-trityloxy-
ethanol (5) 
 
Triphenylphosphine (18.36g, 70mmol) and 1-iodobutane (10.73g, 58.34mmol) were stirred 
together in refluxing toluene for 8h. Then as general procedure for Wittig salt and 
subsequent olefination (5.1.1.1), using nBuLi (18.05ml, 45.11mmol), and (3aS, 4R, 6R, 
6aS)-2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3, 4-d]-1,3-dioxol-4-ol (2) (6.97g, 
16.11mmol) affording a white solid [290]. Yield 6.455g, 84.78%. δ 1H (CDCl3): 7.19-7.49 (Ar-
H, 15H, m), 5.57-5.61 (H-1’, H-2’ trans, 1.4H, m),  5.53-5.56 (H-1’, H-2’ cis, 0.6H, m),  4.93 
(H-5, trans, 0.7H, m), 4.45 (H-5, cis, 0.3H, t, J=7.4), 4.28 (H-4, cis, 0.3H, m), 4.22 (H-4, 
trans, 0.7H, m), 3.77 (H-1’’, trans, 0.7H, m), 3.69 (H-1’’, cis, 0.3H, m), 3.25 (H-2a’’, cis, 0.3H, 
dd, J=5.13, 9.48Hz), 3.18 (H-2a’’, trans, 0.7H, m), 3.07-3.15 (H-2b’’, 1H, m), 1.92-2.06 (H-
3ab’, trans, 1.4H, m), 1.75-1.86 (H-3ab’, cis, 0.6H, m),  1.58 (H-Aabc trans 3H, s), 1.52 (H-Babc 
trans, 3H, s), 1.39, 1.37 (H-Aabc H-Babc cis, 3H, each s), 1.22-1.32 (H-4’ab, 2H, m), 0.87  
(H-5’abc, 3H, t, J=7.3Hz). δ 13C (CDCl3): 144.1 (C-2), 135.8 (C-1’), 127.3, 128.0, 128.9 
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(Aromatic C), 125.5 (C-2’), 79.5 (C-1’’), 73.3 (C-4), 69.4 (C-5), 65.2 (C-2’’), 30.6, 30.1  
(C-3’, -4’) 28.5, 25.7 (C-A, -B), 14.9 (C-5’).  m/z (ES): 496.3 (M+ +[Na]+ + [H]+ 10%), 495.3 
(M+ + [Na]+ 100%). HRMS: Calculated for C31H36O4 [M + Na]+ 495.2511, found 495.2511. 
αD: -7.0° m.p. 101-107°C IR: 3200-3400cm-1 (br OH), 3100-3160cm-1  (Ar), 1650-1680 cm-1 
(alkene). 
 
5.4. Addition of a mesylate group 
5.4.1. Methanesulfonic acid (R)-1-[(4R,5R)-2,2-dimethyl-5-(undec-1-enyl)-1,3-
dioxolan-4-yl]-2-trityloxy-ethyl ester (7) 
 
Prepared by the general procedure for mesylation (5.1.1.2) using (R)-1-[(4S,5R)-2,2-
dimethyl-5-(undec-1-enyl)-1,3-dioxolan-4-yl]-2-trityloxy-ethanol (3) (10.77g, 19.34mmol), 
dichloromethane (90ml), pyridine (30ml), methanesulfonylchloride (2.5ml, 32.19mmol), 
ethanol (3ml), heptane:MeOH:water (10:7:3) (100ml), affording an opaque oil. Yield 12.19g, 
99.3%. δ 1H (CDCl3): 7.19-7.48 (Ar-H, 15H, m), 5.40-5.48 (H-2’ trans, 0.7H, m), 5.28-5.37 
(H-1’ trans, 0.7H, m), 5.20-5.25 (H-2’ cis, 0.3H, m), 4.97-5.06 (H-1’ cis, 0.3H, m), 4.79-4.85 
(H-1’’, 0.7H, m), 4.74 (C-5 trans, 0.7H, m), 4.62-4.66 (H-1’’ cis, 0.3H, m), 4.61 (C-5 cis, 0.3H, 
m), 4.49 (C-4 trans, 0.7H, dd, J=5.63, 8.66Hz), 4.2 (C-4 cis, 0.3H, dd, J=4.22, 9.40Hz), 3.56 
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(H-2’’a, 1H, dd, J=1.58, 11.36Hz), 3.45 (H-2’’b, 1H, dd, J=2.91, 10.83Hz), 3.04-3.17 (H-Aabc, 
3H, m), 1.59-1.82 (H-3’, 2H, m), 1.48 (H-Babc, trans, 3H, s), 1.47 (H-Cabc, trans, 3H, s), 1.38, 
1.36 (H-Aabc H-Babc cis, 3H, each s), 1.08-1.32 (H-4’ab-H-10’ab, 14H, m), 0.88  
(H-11’abc, 3H, t, J=6.45Hz). δ 13C (CDCl3): 144.27 (C-2), 137.26 (C-2’), 129.70, 128.93, 
128.19 (Ar C), 124.55 (C-1’), 81.97 (C-1’’), 77.10 (C-5), 73.19 (C-4), 64.12 (C-2’’), 40.13  
(C-A), 33.1, 32.4, 30.47, 30.25, 30.18 (C-3’-10’) 26.77, 26.60 (C-B, C), 23.89 (C-11’)  
m/z (ES): 673.2 (M+ + [K]+ 40%), 657.2 (M+ + [Na]+ 100%), 617.2 (M+ + [Na]+ - CH=CHCH2 
7%), 561.2 (M+ + [Na]+ - OMs 35%), 503.2 (M+ + [Na]+ - CH=CH(CH2)8CH3 8%), 415.1  
(M+ + [Na]+ - Tr 15%), 319.2 (M+  - (TrOCH2 + CH2CH2CH3) 7%), 243.1  
(M+ - OCH2CH(OMs)CHOC(CH3)2OCHCH=CH(CH2)8CH3 63%). αD: -50.0°. IR: 3200-
3400cm-1 (br OH), 3100-3160cm-1 (Ar), 1650-1680 cm-1 (alkene), 1000-1350cm-1 (S=O). 
 
5.4.2. Methanesulfonic acid (R)-1-[(4R,5R)-2,2-dimethyl-5-(oct-1-enyl)-1,3-
dioxolan-4-yl]-2-trityloxy-ethyl ester (8) 
 
Prepared by the general procedure for mesylation (5.1.1.2) using (R)-1-[(4S,5R)-2,2-
Dimethyl-5-(oct-1-enyl)-1,3-dioxolan-4-yl]-2-trityloxy-ethanol (4) (2.594g, 5.04mmol), 
dichloromethane (25ml), pyridine (7.5ml), methanesulfonylchloride (0.624ml, 8.064mmol), 
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ethanol (0.75ml), heptane:MeOH:water (10:7:3) (100ml), affording an opaque oil. Yield 
3.02g, 100%. δ 1H (CDCl3): 7.17-7.52 (Ar-H, 15H, m), 5.27-5.52 (C-1’, C-2’ trans, 2H, m),  
5.17-5.25 (C-2’ cis, 0.3H, m), 5.03 (C-1’ cis, 0.3H, m), 4.82 (C-1’’, 1H, m), 4.75 (H-5, 1H, m), 
4.58-4.69 (H-4, 1H, m), 4.48 (H-2’’a trans, 0.7H, dd, J=5.96, 8.42Hz), 4.24 (H-2’’a cis, 0.3H, 
dd, J=6.97, 14.03Hz), 3.57 (H-2’’b cis, 0.3H, m), 3.45 (H-2’’b trans, 0.7H, dd, J=2.68, 
10.75Hz), 2.99-3.18 (H-Aabc, 3H, m), 1.57-1.82 (H-3’ab, 2H, m), 1.48 (H-Babc, trans, 3H, s), 
1.41 (H-Cabc, trans, 3H, s), 1.39, 1.38 (H-Aabc H-Babc cis, 3H, each s), 1.10-1.33 (H-4’ab-H-
7’ab, 10H, m), 0.85 (H-8’abc, 3H, t, J=6.77Hz). δ 13C (CDCl3): 144.8 (C-2), 137.8 (C-2’), 130.2, 
129.4, 128.7 (Ar C), 125.1 (C-1’), 82.5 (C-1’’), 77.6 (C-4), 73.7 (C-5), 64.61 (C-2’’), 39.9 (C-
A), 35.1, 30.9, 30.2 (C-3’-5’) 29.5 (C-B), 29.0 (C-6’), 28.1 (C-C), 24.5 (C-7’) 16.8 (C-8’).  
m/z (ES): 633.2 (M+ + [K]+ + [H]+ 70%), 315.1 (M+ - Ph3C-O -(CH2)4- 100%), 219.1 (M+ + 
[Na]+ - Ph2COCH2 82%). αD: -47.6°. IR: 3200-3400cm-1 (br OH), 3100-3160cm-1 (Ar),  
1650-1680 cm-1 (alkene), 1000-1350cm-1 (S=O). 
 
5.4.3. Methanesulfonic acid (R)-1-[(4R,5R)-2,2-dimethyl-5-(pent-1-enyl)-1,3-
dioxolan-4-yl]-2-trityloxy-ethyl ester (9) 
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Prepared by the general procedure for mesylation (5.1.1.2) using (R)-1-[(4S,5R)-2,2-
dimethyl-5-(pent-1-enyl)-1,3-dioxolan-4-yl]-2-trityloxy-ethanol (5) (6.46g, 13.66mmol), 
dichloromethane (45ml), pyridine (20.3ml), methanesulfonylchloride (1.8ml, 22.74mmol), 
ethanol (2ml), heptane:MeOH:water (10:7:3) (70ml), affording an off-white solid. Yield 
6.125g, 81.4%. δ 1H (CDCl3): 7.21-7.49 (Ar-H, 15H, m), 5.89 (H-2’ trans, 0.7H, m), 5.75 (H-2’ 
cis, 0.3H, m), 5.52 (H-1’ trans, 0.7H, m), 5.48 (H-1’ cis, 0.3H, m), 5.07 (H-1’’ trans, 0.7H, m), 
4.78 (H-1’’ cis, 0.3H, m), 4.50 (H-5, 1H, m), 4.34 (H-4, 1H, m), 4.26 (H-2’’a, 1H, dd, J=5.94, 
9.13Hz), 3.92 (H-2’’b, 1H, dd, J= 2.53, 10.72), 3.14 (H-Aabc, 3H, d, J=4.85Hz), 2.12 (H-3’ab, 
1H, m), 1.44 (H-4’ab, 2H, m) 0.82 (H-5’abc, 3H, t). δ 13C (CDCl3): 141.4 (C-2), 135.3 (C-2’), 
126.9, 126.8, 126.1 (Ar C), 121.9 (C-1’), 79.2 (C-1’’), 74.3 (C-5), 70.2 (C-4), 61.3 (C-2’’), 
37.2 (C-A), 34.6 (C-3’), 22.1 (C-4’), 13.65 (C-5’).  m/z (ES): 589.1 (M+ + [K]+ 18%), 573.1  
(M+ + [Na]+ 75%), 477.2 (M+ + [Na]+ - OMs 47%), 419.1 (M+ + [Na]+ - 
CHOC(CH3)2OCHCH=CH(CH2)2 35%), 243.1 (M+ - 
OCH2CH(OMs)CHOC(CH3)2OCHCH=CH(CH2)8CH3 100%). αD: -5.4°. m.p.: 97-100°C. IR: 
3200-3400cm-1 (br OH), 3100-3160cm-1 (Ar), 1650-1680 cm-1 (alkene), 1000-1350cm-1 
(S=O). 
 
5.5. Deprotection of the phytosphingosine base 
5.5.1. Methanesulfonic acid (1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-tetradec-
4-enyl ester (10) 
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Prepared by the general procedure for deprotection of mesylated base (5.1.1.3) using 
methanesulfonic acid (R)-1-[(4R,5R)-2,2-dimethyl-5-(undec-1-enyl)-1,3-dioxolan-4-yl]-2-
trityloxy-ethyl ester (7) (12.918g, 0.02mol), DCM (100ml), MeOH (70ml), conc. HCl (10.5ml, 
12M), affording an off-white solid. Yield 3.142g, 46.1%. δ 1H (CDCl3): 5.71-5.89 (H-4, 1H, m), 
5.43-5.59 (H-5, 1H, m), 4.89-4.96 (H-1, 1H, m), (H-3 trans, 0.7H, t, J=8.3Hz), 4.08-4.13 (H-3 
cis, 0.3H, t, J=7.2Hz), 4.0-3.94 (H-1’a, H-2, 2H, m), 3.75-3.68 (H-1b, 1H, m), 3.2 and 3.19  
(H-Aabc, 3H, each s), 2.53 (OH-2,-3,-1’, 3H, br s), 2.05-2.25 (H-6ab, 2H, m), 1.18-1.49  
(H-7ab – H-13ab, 14H, m), 0.89 (H-14abc, 3H, t, J=6.2Hz). δ 13C (CDCl3): 137.88 (C-5), 127.78 
(C-4), 82.29 (C-1), 74.39 (C-3), 67.64 (C-2), 63.93 (C-1’), 39.32 (C-A), various signals 
32.59-23.38 (C-6 -13), 14.81 (C-14).  m/z (ES): 376.1 (M+ + [Na]+ 5%), 375.1 (M+ + [Na]+ 
100%), 279.2 (M+ + [Na]+ - OMs, 68%) αD: -54.0°. m.p.: 72-90°C. IR: 3200-3400cm-1 (br 
OH), 1650-1680 cm-1 (alkene), 1000-1350cm-1 (S=O). 
 
5.5.2. Methanesulfonic acid (1R,2S,3S)-2,3-dihydroxy-1-hydroxymethyl-undec-4-
enyl ester (11) 
 
Prepared by the general procedure for deprotection of mesylated base (5.1.1.3) using 
methanesulfonic acid (R)-1-[(4R,5R)-2,2-dimethyl-5-(oct-1-enyl)-1,3-dioxolan-4-yl]-2-
trityloxy-ethyl ester (8) (4.375g, 7.38mmol), dry DCM (45ml), MeOH (20ml), and 
HO1
1'
1 2 3
4
5
6
7
8
9
10
11
O 14 OH
15
OH
16
S
17
O 18
A
O
C13H26O6S 
Mol. Wt.: 310.4079 g mol-1 
Chapter 5  Materials and methods 
   
155 
concentrated HCl (5ml, 12M), affording an cream-coloured oil. Yield 1.092g, 47.67%. δ 1H 
(CDCl3): 5.71-5.91 (H-5, 1H, m), 5.43-5.59 (H-4, 1H, m), 4.95 (H-1, 1H, m), 4.32-4.38 (H-3, 
1H, m), 4.06-4.13 (H-1’a, 1H, m), 3.95-4.02 (H-2, 1H, m), 3.68-3.71 (H-1’b, 1H, dd, J=3.1, 
7.1Hz), 3.21 (H-Aabc, 3H, s), 3.19 (H-Aabc, 3H, s), 2.41 (OH-2, -3, -1’, 3H, br s), 2.01-2.24  
(H-6ab, 2H, m), 1.2-1.49 (H-7ab – 10ab, 8H, m), 0.9 (3H, t, J=6.5Hz). δ 13C (CDCl3): 137.3 (C-
5), 127.3 (C-4), 81.6 (C-1), 74.8 (C-3), 67.1 (C-2), 63.4 (C-1’), 38.8 (C-A), 31.8, 29.6, 29.1, 
28.0, 22.7 (C-6-10), 24.9 (C-11). m/z (ES): 311.1 (M+ + [H]+ 100%). αD: -52.8°. IR: 3200-
3400cm-1 (br OH), 1650-1680 cm-1 (alkene), 1000-1350cm-1 (S=O). 
 
5.5.3. Methanesulfonic acid (1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-oct-4-enyl 
ester (12) 
 
Prepared by the general procedure for deprotection of mesylated base (5.1.1.3) using 
methanesulfonic acid (R)-1-[(4R,5R)-2,2-dimethyl-5-(pent-1-enyl)-1,3-dioxolan-4-yl]-2-
trityloxy-ethyl ester (9) (6.125g, 11.1 mmol), DCM (80ml), MeOH (40ml), conc. HCl (7ml, 
12M), affording an off-white wax.  Yield 1.957g, 65.7%. δ 1H (CDCl3): 5.74-5.86 (H-5 trans, 
1H, m), 5.68-5.72 (H-5 cis, 0.2H, m), 5.50-5.58 (H-4, 1H, m), 4.96-5.02 (H-1, 1H, m), 4.32-
4.38 (H-3, 1H, dd, J=6.8, 14.1Hz),  4.24-4.28 (H-1’a, 1H, dd, J=2.3, 4.8Hz), 4.16-4.20 (H-1, 
1H, d, J=3.3Hz), 3.84-3.88 (H-1’b, 1H, dd, J=2.5, 4.6Hz), 3.10-3.14 (H-Aabc, 3H, d, J=3.1), 
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1.88-2.06 (H-6ab, 2H, m), 1.34-1.44 (H-7ab, 2H, m), 0.82-0.92 (H-8abc, 3H, t, J=6.9Hz). δ 13C 
(CDCl3): 137.32 (C-5), 124.12 (C-4), 85.88 (C-1), 82.86 (C-3), 76.41 (C-2), 70.99  
(C-1’), 38.40 (C-A), 34.98 (C-6), 22.49 (C-7), 13.79 (C-8).  m/z (ES): 291.2 (M+ + [Na]+ 
100%). αD: -90°. mp: 79-81°C. IR: 3200-3400cm-1 (br OH), 1650-1680 cm-1 (alkene), 1000-
1350cm-1 (S=O). 
 
5.6. Reduction of the double bond 
5.6.1. Methanesulfonic acid (1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-tetradecyl 
ester (13) 
 
Prepared by the general procedure for catalytic reduction (5.1.1.4) using methanesulfonic 
acid (1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-tetradec-4-enyl ester (10) (3.142g, 
8.9mmol), Pd-Ba(SO4)2 (0.3g), affording creamy-white crystals. Yield, 2.789g, 88%. δ 1H 
(MeOD): 4.99-5.05 (H-1, 1H, m), 3.98- 4.04 (H-1’ab, 2H, m), 3.55-3.62 (H-3, 1H, m), 3.45-
3.49 (H-2, 1H, m), 3.15 (H-Aabc, 3H, s), 1.48-1.86 (H-4a, H-6a, 2H, m), 1.22-1.43 (H-5b, H-6ab, 
H-7b, H-8ab-H13ab, 18H, m), 0.89 (H-14abc, 3H, t, J=6.8Hz). δ 13C (MeOD): 85.36 (C-1), 75.63 
(C-2), 72.83 (C-3), 64.13 (C-1’),  40.14 (C-A), various peaks 36.8 – 25.9 (C-4-13), 16.2  
(C-14). m/z (ES): 377.2 (M+ + [Na]+ 100%), 281.2 (M+ +[Na]+ - OMs 95%). HRMS: 
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Calculated for C16H34O6S [M + Na]+ 377.1974, found 377.1980. αD: -180°. m.p.: 124-130°C. 
IR: 3200-3400cm-1 (br OH), 1000-1350cm-1 (S=O). 
 
5.6.2. Methanesulfonic acid (1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-undecyl 
ester (14) 
 
Prepared by the general procedure for catalytic reduction (5.1.1.4) using methanesulfonic 
acid (1R,2S,3S)-2,3-dihydroxy-1-hydroxymethyl-undec-4-enyl ester (11) (1.092g, 
3.52mmol), Pd-Ba(SO4)2 (110mg), affording a colourless syrup. Yield 0.946g, 86%.  
δ 1H (MeOD): 4.74-4.78 (H-1, 1H, m), 3.62-3.78 (H-1’ab, 2H, m), 3.31-3.47 (H-3, 1H, m), 
3.18-3.21 (H-2, 1H, m), 3.06 (H-Aabc, 3H, s), 1.48-1.56 (H-4a, H-6a, 2H, m), 1.22-1.43 (H-4b, 
H-5ab, H-6b, H7ab-H-10ab, 12H, m), 0.73 (H-11abc, 3H, t, J=6.5Hz). δ 13C (CDCl3): 83.9 (C-1), 
74.7 (C-2), 71.5 (C-3), 63.3 (C-1’),  40.1 (C-A), 34.2, 33.1, 30.9, 30.8, 30.5, 26.5, 23.8  
(C- 4-10), 15.1 (C-11). m/z (ES): 335.2 (M+ + [Na]+ 100%), 239.2 (M+  + [Na]+ - OMs  30%). 
HRMS: Calculated for C13H28O6S [M + Na]+ 335.1504, found 335.1520. αD: -32.2°. IR: 3200-
3400cm-1 (br OH), 1000-1350cm-1 (S=O). 
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5.6.3. Methanesulfonic acid (1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-octyl 
ester (15) 
 
Prepared by the general procedure for catalytic reduction (5.1.1.4) using methanesulfonic 
acid (1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-oct-4-enyl ester (12) (1.957g, 7.29mmol), 
Pd-Ba(SO4)2 (200mg), affording a cream-coloured wax. Yield 1.906g 97.4%. δ 1H (CDCl3): 
4.84-4.88 (H-1, 1H, m), 3.78-3.88 (H-1’ab, 2H, m), 3.49-3.55 (H-3, 1H, m), 3.43-3.47 (H-2, 
1H, dd, J=2.2, 8.3), 3.15 (H-Aabc, 3H, s), 2.76 (OH-1’, -2, -3, 3H, br s), 1.75-1.67 (H-4a, 1H, 
m,) 1.53-1.46 (H-6a, 1H, m), 1.38- 1.19 (H-4b, H-5ab, H-6b, H-7ab, 6H, m,),  0.88 (H-8abc, 3H, t, 
J=6.8).  δ 13C (CDCl3): 82.90 (C-1), 73.61 (C-2), 70.47 (C-3), 62.25 (C-1’), 38.35 (C-A), 
33.14 (C-4), 32.03 (C-5), 25.19 (C-6), 22.74 (C-7), 14.01 (C-8). m/z (ES): 293.4 (M+ + [Na]+ 
100%). HRMS: Calculated for C10H22O6S [M+ + Na+] 293.1035, found 293.1026. αD: -80.0°. 
m.p.: 71-78°C. IR: 3200-3400cm-1 (br OH), 1000-1350cm-1 (S=O). 
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5.7. Azidation 
5.7.1. (2S,3S,4R)-2-Azido-octadecane-1,3,4-triol (16) 
 
A solution of sodium azide (1.19g, 18.3mmol) in water (3ml) was cooled to 0°C. 
Dichloromethane (5ml) was added and the resulting biphasic mixture stirred vigorously and 
treated with trifluoromethanesulfonic anhydride (1.046, 3.7mmol). The reaction was stirred at 
0°C for 2h, the organic phase was separated and the aqueous phase washed thrice with 
DCM. The organic extracts were combined, washed with saturated sodium chloride solution, 
and dried (Na2SO4) yielding the trifluoromethanesulfonic azide solution in DCM. 
Phytosphingosine (590mg, 1.86mmol) was dissolved in water (6ml) and potassium 
carbonate (384mg, 2.78mmol) and copper sulfate (CuSO4.5H2O) (2.8mg, 16µmol) were 
added to the solution, followed by MeOH (12ml) and the TfN3 solution. More MeOH was 
added until the solution was homogenous, and the reaction mixture stirred overnight at RT. 
The organic phase was extracted, washed with NaCl, dried (Na2SO4), and concentrated in 
vacuo. The resulting (2S,3S,4R)-2-azido-octadecane-1,3,4-triol (16) was purified by column 
chromatography (heptane:EtOAc) (9:1), affording a  solid. Yield: 490mg, 76.7%.  
δ 1H (MeOD): 3.81-3.86 (H-1a, 1H, dd, J=3.0, 11.1), 3.64-3.71 (H-1b, 1H, dd, J=7.9, 11.2), 
3.36-3.54 (H-3, -4, 2H, m), 3.22-3.55 (H-2, 1H, m), 1.42-1.65 (H-5ab, H-7a, 3H, m), 1.21-1.47 
(H-6ab, H-7b, H-8ab-H17ab, 23H, m), 0.89 (H-18abc, 3H, t, J=6.5). δ 13C (MeOD): 76.4 (C-3), 
73.2 (C-4), 67.0 (C-2), 62.9 (C-1), 33.4, 31.2, 30.8, 27.1, 24.1 (C-5 - 17), 14.8 (C-18).  
m/z (ES): 366.3 (M+ + [Na]+ 100%). HRMS: Calculated for C18H37N3O3: [M + Na]+ 366.2733, 
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found 366.2727. αD:+5.7°. m.p.: 92-93°C. IR: 3200-3400cm-1 (br OH), 2040-2080cm-1 
(azide). 
 
5.7.2. (2S,3S,4R)-2-Azido-pentadecane-1,3,4-triol (17) 
Prepared by the general procedure for the introduction of an azide group (5.1.1.5), using 
methanesulfonic acid (1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-tetradecyl ester (13) 
(2.642g, 7.45mmol), DMF (20ml), sodium azide (0.969g, 14.91mmol), affording a translucent 
oil. Yield: 1.609g, 71.65%. δ 1H (MeOD): 3.92-3.98 (H-1a, 1H, dd, J=3.3, 11.4), 3.74-3.84  
(H-1b, 1H, m), 3.58-3.66 (H-4, 1H, m), 3.1-3.58 (H-3, 1H, m), 3.32-3.36 (H-2, 1H, m),  
1.51-1.76 (H-5ab, H-7a, 3H, m), 1.18-1.47 (H-6ab, H-7b, H-8ab-H14ab, 17H, m), 0.91 (H-15abc, 
3H, t, J=6.6). δ 13C (MeOD): 73.9 (C-3), 70.8 (C-4), 64.6 (C-2), 60.4 (C-1), 31.8, 31.0, 28.7, 
28.4, 24.7, 21.7 (C-5 - 14). m/z (ES): 325.3 (M+ + [Na]+ + [H]+ 5%), 324.2 (M+ + [Na]+ 100%). 
HRMS: Calculated for C15H31N3O3 [M + Na]+ 324.2263, found 324.2275. αD: +31.4°. IR: 
3200-3400cm-1 (br OH), 2040-2080cm-1 (azide). 
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5.7.3. (2S,3S,4R)-2-Azido-dodecane-1,3,4-triol (18) 
 
Prepared by the general procedure for the introduction of an azide group (5.1.1.5), using 
methanesulfonic acid (1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-undecyl ester (14) 
(0.946g, 3.03mmol), DMF (10ml), sodium azide (0.39g, 6.06mmol), affording a colourless 
syrup. Yield: 690mg, 87%. δ 1H (MeOD): 3.88-3.95 (H-1a, 1H, dd, J=3.3, 11.1), 3.71-3.8  
(H-1b, 1H, m), 3.54-3.63 (H-4, 1H, m), 3.48-3.53 (H-3, 1H, m), 3.28-3.32 (H-2, 1H, m),  
1.47-1.73 (H-5ab, H-7a, 3H, m), 1.20-1.45 (H-6ab, H-7b, H-8ab-H-11ab, 11H, m), 0.89 (H-12abc, 
3H, t, J=6.2).  δ 13C (MeOD): 75.9 (C-3), 72.8 (C-4), 66.2 (C-2), 62.4 (C-1), 33.8, 32.9, 30.7, 
30.3, 26.6, 23.6 (C-5 - 11).  m/z (ES): 282.2 (M+ + [Na]+ 100%). HRMS: Calculated for 
C12H25N3O3 [M + Na]+ 282.1794, found 282.1794. αD: +45.0°. IR: 3200-3400cm-1 (br OH), 
2040-2080cm-1 (azide). 
 
5.7.4. (2S,3S,4R)-2-Azido-nonane-1,3,4-triol (19) 
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Prepared by the general procedure for the introduction of an azide group (5.1.1.5), using 
methanesulfonic acid (1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-octyl ester (15) (0.744g, 
2.75mmol), DMF (10ml), sodium azide (0.36g, 5.5mmol), affording a white solid. Yield: 
297mg, 49.7%. δ 1H (MeOD): 3.82-3.86 (H-1a, 1H, dd, J=4.9, 11.5Hz), 3.71-3.77 (H-1b, 1H, 
m), 3.58-3.64 (H-3, H-4, 2H, m), 3.44-3.47 (H-2, 1H, q, J=4.5, 9.9Hz), 1.45-1.56 (H-5a, H-7a, 
2H, m), 1.38-1.44 (H-5b, 1H, m), 1.27-1.14 (H-6ab, H-7b, H-8ab, 5H, m), 0.79 (H-9abc, 3H, t, 
J=6.1).  δ 13C (MeOD):  74.02 (C-3), 71.87 (C-4), 62.71 (C-2), 60.95 (C-1), 31.47 (C-5), 
31.29 (C-6), 24.95 (C-7), 22.09 (C-8), 13.49 (C-9).  m/z (ES): 240 (M+ + [Na]+ 100%). 
HRMS: Calculated for C9H19N3O3 [M + Na+] 240.1324, found 240.1315. αD: +144.0°.  
m.p.: 71-78°C. IR: 3200-3400cm-1 (br OH), 2040-2080cm-1 (azide). 
 
5.8. Addition of tert-butyldiphenyl silyl protecting group 
5.8.1. (2S,3S,4R)-2-azido-1-(tert-butyl-diphenyl-silanyloxy)-octadecane-3,4-diol 
(20) 
 
Prepared by the general procedure for the addition of a tert-butyldiphenyl silyl protecting 
group (5.1.1.6) using (2S,3S,4R)-2-azido-octadecane-1,3,4-triol (16) (5.878g, 17.1mmol), 
dichloromethane (200ml), pyridine (30ml), 4-DMAP (300mg), tert-butyldiphenylsilylchloride 
(6.58g, 6.23ml, 23.94mmol), affording a colourless oil. Yield: 9.095g (91%). δ 1H (CDCl3): 
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7.35-7.70 (Ar-H, 10H, m), 4.01 (H-1a, 1H, dd, J=3.7, 10.5Hz), 3.89 (H-1b, 1H, dd, J=5.6, 
10.9Hz), 3.68 (H-3, H-4, 2H, m), 3.54 (H-2, 1H, m), 2.02 (OH-3, -4, 2H, br s), 1.36-1.55 (H-
5a, H-7a, 2H, m), 1.19-1.34 (H-5b, H-6ab, H-7b, H-8ab-H17ab, 24H, m), 1.06 (H-Babc, H-Cabc, H-
Dabc, 9H, s), 0.82 (H-18abc, 3H, t, J=6.4Hz). δ 13C (CDCl3): 133.6, 128.1, 125.9 (Ar C), 72.6 
(C-3), 70.4 (C-4), 62.2 (C-1), 61.4 (C-2), 27.7, 27.4, 24.8, 23.7 (C-5 – 17). m/z (ES): 605.5 
(M+ + [Na]+ + [H]+ 20%) 604.4 (M+ + [Na]+ 100%). HRMS: Calculated for C34H55N3O3Si  
[M + Na]+ 604.3915, found 604.3910. αD: +2.8°. IR: 3200-3400cm-1 (br OH), 3100-3000 (Ar), 
2040-2080cm-1 (azide).  
 
5.8.2. (2S,3S,4R)- 2-Azido-1-(tert-butyl-diphenyl-silanyloxy)-pentadecane-3,4-diol 
(21) 
 
Prepared by the general procedure for the addition of a tert-butyldiphenyl silyl protecting 
group (5.1.1.6) using (2S,3S,4R)-2-azido-pentadecane-1,3,4-triol (17) (1.574g, 5.22mmol), 
dichloromethane (50ml), pyridine (8ml), 4-DMAP (80mg), tert-butyldiphenylsilylchloride 
(2.574g, 2.43ml, 9.37mmol)., affording a colourless oil. Yield: 1.2g (42.6%). δ 1H (CDCl3): 
7.37-7.69 (Ar-H, 10H, m), 3.99-4.03 (H-1a, 1H, dd, J=4.1, 11.1Hz), 3.87-3.92 (H-1b, 1H, dd, 
J=5.5, 10.9Hz), 3.66-3.68 (H-3, H-4, 2H, m), 3.51-3.57 (H-2, 1H, m), 1.19-1.57  
(H-5ab – H14ab, 22H, m) 1.06 (H-Babc, H-Cabc, H-Dabc, 9H, s), 0.84-0.88 (H-15abc, 3H, t, J=6.7). 
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δ 13C (CDCl3): 136.204, 130.601, 128.473 (Ar-C), 74.689 (C-3), 72.910 (C-4), 64.724 (C-1), 
63.940 (C-2), 32.494 – 26.235 multiple signals (C-5 – 14), 27.318 (C-A,B,C). m/z (ES): 
563.4 (M+ + [Na]+ + [H]+ 30%), 562.3 (M+ + [Na]+ 100%). HRMS: Calculated for 
C31H49N3O3Si [M + Na]+ 562.3441, found 562.3459. αD: +35.7°. IR: 3200-3400cm-1 (br OH), 
3100-3000 (Ar), 2040-2080cm-1 (azide).  
 
5.8.3. (2S,3S,4R)- 2-Azido-1-(tert-butyl-diphenyl-silanyloxy)-dodecane-3,4-diol 
(22)  
Prepared by the general procedure for the addition of a tert-butyldiphenyl silyl protecting 
group (5.1.1.6) using (2S,3S,4R)-2-azido-dodecane-1,3,4-triol (18) (577mg, 2.22mmol), 
dichloromethane (20ml), pyridine (2ml), 4-dimethylaminopyridine (35mg), tert-
butyldiphenylsilylchloride (1.094mg, 1.04ml, 4mmol), affording a colourless oil. Yield: 450mg 
(40.7%). δ 1H (CDCl3): 7.66-7.69 (Ar-H, 10H, m), 3.99-4.04 (H-1a, 1H, dd, J=4.2, 11.0Hz), 
3.86-3.92 (H-1b, 1H, dd, J=5.4, 10.9Hz), 3.65-3.67 (H-3, H-4, 2H, m), 3.54-3.58 (H-2, 1H, 
m), 2.03 (OH-3, -4, 2H, br s), 1.35-1.54 (H-5ab, H-7a, 3H, m), 1.20-1.32 (H-6ab, H-7b,  
H-8ab – H-11ab, 11H, m), 1.06 (H-Babc, H-Cabc, H-Dabc, 9H, s), 0.84-0.86 (H-12abc, 3H, t, 
J=6.8Hz). δ 13C (CDCl3): 136.705, 131.103, 128.973 (Ar C), 75.213 (C-3), 73.425 (C-4), 
65.226 (C-1), 64.460 (C-2), 32.932 – 23.741 (multiple signals, C-5 – 11), 27.824 (C-B,C,D), 
16.150 (C-12). m/z (ES): 521.75 (M+ + Na+ + H+ 8%), 520.74 (M+ + Na+ 100%). HRMS: 
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Calculated for C28H43N3O3Si [M + Na]+ 520.7447, found 520.7460. αD: +45°. IR: 3200-
3400cm-1 (br OH), 3100-3000 (Ar), 2040-2080cm-1 (azide).  
 
5.8.4. (2S,3S,4R)-2-Azido-1-(tert-butyl-diphenyl-silanyloxy)-nonane-3,4-diol (23) 
Prepared by the general procedure for the addition of a tert-butyldiphenyl silyl protecting 
group (5.1.1.6) using (2S,3S,4R)-2-azido-nonane-1,3,4-triol (19) (352mg, 1.62mmol), 
dichloromethane (75ml), pyridine (7.5ml), 4-DMAP (20mg), and  
tert-butyldiphenylsilylchloride (0.62g, 0.59ml, 2.268mmol), affording a colorless oil. Yield 
168mg, 23%. δ 1H (CDCl3): 7.37-7.68 (Ar-H, 10H, m), 3.99-4.02 (H-1a, 1H, dd, J=4.4, 11.4),  
3.88-3.91 (H-1b, 1H, dd, J=5.8, 11.4), 3.66-3.68 (H-3, H-4 2H, m), 3.53-3.56 (H-2, 1H, q, 
J=4.5, 6.2, 10.3), 2.45-2.46 (OH-3, 1H, d, J=4.8) 1.93-1.94 (OH-4, 1H, d, J= 4.4), 1.46-1.54 
(H-5a, H-7a, 2H, m), 1.38-1.44 (H-5b, 1H, m), 1.23-1.34 (H-6ab, H-7b, H-8ab, 5H, m), 1.06 (H-
Babc, H-Cabc, H-Dabc, 9H, s), 0.89-0.86 (H-9abc, 3H, t, J=6.7). δ 13C (CDCl3): 135.58 (C-Ar), 
132.56, 132.50 (QC-Ar), 129.99 (C-Ar), 127.87 (C-Ar), 74.14 (C-3), 72.34 (C-4), 64.13 (C-1), 
63.39 (C-2), 3.82, 31.72 (C-5,6), 26.72 (C-B, -C, -D), 25.28 (C-7), 22.56 (C-8), 13.99 (C-9). 
m/z (ES): 479.7 (M+ + [Na]+ + [H]+ 12%), 478.7 (M+ + [Na]+ 100%). HRMS: Calculated for 
C25H37N3O3Si [M + Na]+ 478.2502, found 478.2507. αD: +19.5°. IR: 3200-3400cm-1 (br OH), 
3100-3000cm-1 (Ar), 2040-2080cm-1 (azide). 
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5.9. Adding benzoate protecting groups 
5.9.1. ((2S,3S,4R)-2-Azido-3,4-bis-benzoyloxy-octadecyloxy)-tert-butyl-diphenyl-
silane (24) 
 
Prepared by the general procedure for addition of benzoate groups (5.1.1.7) using 
(2S,3S,4R)-2-azido-1-(tert-butyl-diphenyl-silanyloxy)-octadecane-3,4-diol (20) (9.095g, 
15.6mmol), pyridine (60ml),  benzoyl chloride (13.16g, 10.86ml, 93.6mmol), and DMAP 
(65.97mg, 0.54mmol), affording a colourless oil. Yield: 10.379g, 84%. δ 1H (CDCl3): 7.19-
7.95 (Ar-H, 20H, m), 5.49 (H-3, H-4, 2H, m), 3.98 (H-1a, 1H, m), 3.84 (H-1b, H-2, 2H, m), 
1.73-1.86 (H-5ab, 2H, m), 1.19-1.41 (H-6ab – H-17ab, 24H, m), 1.04 (H-Babc, H-Cabc, H-Dabc, 
9H, s), 0.87 (H-18abc, 3H, t, J=6.9Hz). δ 13C (CDCl3): 165.3 (C-E, -F), 135.2, 132.6, 129.4, 
129.3, 128.1, 128.0, 127.3 (Ar C), 72.7 (C-3), 71.9 (C-4), 63.8 (C-1), 62.8 (C-2), 31.6, 29.3, 
29.1, 29.0 (C-5 – 17).  m/z (ES): 813.6 (M+ + [Na]+ + [H]+ 20%), 812.6 (M+ + [Na]+ 100%). 
HRMS: Calculated for C48H63N3O5Si [M + Na]+ 812.4435, found 812.4443. αD: +6.8°.  
IR: 3100-3000cm-1 (Ar), 2040-2080cm-1 (azide), 1750-1750cm-1 (C=O). 
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5.9.2. ((2S,3S,4R)-2-Azido-3,4-bis-benzoyloxy-pentadecyloxy)-tert-butyl-diphenyl-
silane (25)  
Prepared by the general procedure for addition of a benzoate group (5.1.1.7) using 
(2S,3S,4R)- 2-azido-1-(tert-butyl-diphenyl-silanyloxy)-pentadecane-3,4-diol (21) (902mg, 
1.67mmol), pyridine (10ml), DMAP (6.1mg, 0.05mmol), benzoylchloride (1. 26g, 1.04ml, 
8.98mmol). This was then taken crude onto the next step (5.10.2).  
 
5.9.3. ((2S,3S,4R)-2-Azido-3,4-bis-benzoyloxy-dodecyloxy)-tert-butyl-diphenyl-
silane (26) 
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Prepared by the general procedure for addition of benzoate groups (5.1.1.7) using 
(2S,3S,4R)- 2-azido-1-(tert-butyl-diphenyl-silanyloxy)-dodecane-3,4-diol (22) (413mg, 
829µmol), pyridine (5ml), DMAP (3.1mg, 25µmol) and benzoylchloride (55mg, 0.45ml, 
4.46mmol). This was taken crude onto the next step (5.10.3). 
 
5.9.4. ((2S,3S,4R)-2-Azido-3,4-bis-benzoyloxy-nonyloxy)-tert-butyl-diphenyl-
silane (27) 
Prepared by the general procedure for addition of benzoate groups (5.1.1.7) using 
(2S,3S,4R)-2-azido-1-(tert-butyl-diphenyl-silanyloxy)-nonane-3,4-diol (23) (168mg, 
0.37mmol) in pyridine (5ml),  benzoyl chloride (0.312g, 0.26ml, 2.22mmol), and DMAP 
(1.6mg, 13µmol), affording a ceamy-white syrup. Yield: 214mg, 87.12%. δ 1H (CDCl3): 8.16-
7.30 (Ar-H [TBDPS and Bz PGs), 20H, m), 5.52-5.48 (H-3, H-4, 2H, m), 3.98-3.94 (H-1a, 1H, 
m), 3.87-3.82 (H-1b, H-2, 2H, m), 1.83-1.78 (H-5ab, 2H, m), 1.42-1.23 (H-6ab, H-7ab, H-8ab, 
6H, m), 1.04 (H-Babc, H-Cabc, H-Dabc, 9H, s), 0.85-0.83 (H-9abc, 3H, t, J=6.70). δ 13C (CDCl3): 
165.63, 165.03 (C-E, -F), 135.52-132.98 (multiple signals, C-Ar), 132.71, 132.45 (QC-Ar), 
130.56-129.64 (multiple signals, C-Ar), 129.45, 129.25, (QC-Ar), 128.85-128.35 (multiple 
signals, C-Ar), 73.11 (C-3), 72.25 (C-4), 64.11 (C-1), 63.18 (C-2), 31.51 (C-7), 29.74 (C-5), 
26.62 (C-B, -C, -D) 25.04 (C-6), 22.41 (C-8), 19.02 (C-A), 13.91 (C-9). m/z (ES): 687.4  
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(M+ + [Na]+ + [H]+ 20%), 686.4 (M+ + [Na]+ 100%), 249.1 (M+ + [K]+ - tBuSi(Ph)2-O-CH2-
CH(N3)-CH(O)-CH(O)-(CH2)4-CH3 35%). HRMS: Calculated for C39H45N3O5Si [M + Na]+ 
686.3026, found 686.3030. αD: +13.6°. IR: 3100-3000cm-1 (Ar), 2040-2080cm-1 (azide), 
1750-1750cm-1 (C=O). 
 
5.10. Removing the TBDPS group 
5.10.1. (2S,3S,4R)-2-Azido-3,4-bis-benzoyloxy-octadecan-1-ol (28) 
Prepared by the general procedure for the removal of a TBDPS group (5.1.1.8) using acetic 
acid (0.87g, 14.454mmol, 0.563ml), TBAF (14.454mmol, 14.454ml), and ((2S,3S,4R)-2-
azido-3,4-bis-benzoyloxy-octadecyloxy)-tert-butyl-diphenyl-silane (24) (10.379g, 13.14mmol) 
in dry THF (30ml), affording a white solid. Yield: 4.419g, 60.95%. δ 1H (CDCl3): 7.48-8.07 
(Ar-H, 10H, m), 5.56 (H-3, H-4, 2H, m), 3.98 (H-1a, 1H, m), 3.8 (H-1b, H-2, 2H, m), 1.82-1.99 
(H-5ab, 2H, m), 1.18-1.51 (H-6ab – H17ab, 24H, m), 0.89 (H-9abc, 3H, t, J=6.4).  
δ 13C (CDCl3): 165.5 (C=O), 133.4, 133.0, 129.7, 129.5 (Ar C), 128.9 (Ar QC), 128.4, 128.2 
(Ar C), 73.0 (C-3), 72.7 (C-4), 62.8 (C-2), 61.9 (C-1), 31.7, 29.4, 29.3, 29.1, 22.4 (C-5 - 17).  
m/z (ES): 575.4 (M+ + [Na]+ + [H]+ 15%), 574.3 (M+ + [Na]+ 100%). HRMS: Calculated for 
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C32H45N3O5 [M + Na]+ 574.3257, found 574.3265. αD: +2.2°.  m.p.: 48-50°C. IR: 3200-
3400cm-1 (br OH), 3100-3000cm-1 (Ar), 2040-2080cm-1 (azide), 1750-1750cm-1 (C=O). 
 
5.10.2. (2S,3S,4R)-Azido-3,4-bis-benzoyloxy-pentadecan-1-ol (29)  
 
Prepared by the general procedure for removal of a TBDPS group (5.1.1.8) using crude 
((2S,3S,4R)-2-azido-3,4-bis-benzoyloxy-pentadecyloxy)-tert-butyl-diphenyl-silane (25) (1g, 
1.34mmol), THF (20ml), acetic acid (0.088ml, 1.47mmol), TBAF (384mg, 0.426ml, 
1.47mmol), affording an opaque oil. Yield 504mg, 74%. δ 1H (CDCl3): 7.25-8.11 (Ar-H, 10H, 
m), 5.54 (H-3, H-4, 2H, m), 4.80-4.84 (H-1a, 1H, q, J=7.3, 14.6), 3.67-4.03 (H-1b, H-2, 2H, 
m), 1.77-1.97 (H-5ab, 2H, m), 1.09-1.46 (H-6ab – H-14ab, 18H, m), 0.83-0.88 (H-9abc, 3H, t, 
J=6.6Hz). δ 13C (CDCl3): 162.5 (C-A, -B), 135.798- 130.603 (multiple signals, Ar C), 75.425 
(C3), 75.059 (C4), 65.288 (C2), 64.276 (C1), 34.021-27.598 (multiple signals, C5 - 14), 
16.235 (C15). m/z (ES): 532.7 (M+ + [Na]+ 100%). HRMS: Calculated for C29H39N3O5  
[M + Na]+ 532.6370, found 532.6361. αD: +157.9°. IR: 3200-3400cm-1 (br OH),  
3100-3000cm-1 (Ar), 2040-2080cm-1 (azide), 1750-1750cm-1 (C=O). 
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5.10.3. (2S,3S,4R)-2-Azido-3,4-bis-benzoyloxy-dodecan-1-ol (30) 
Prepared as the general procedure for removal of a TBDPS group (5.1.1.8) using crude 
((2S,3S,4R)-2-azido-3,4-bis-benzoyloxy-dodecyloxy)-tert-butyl-diphenyl-silane (26) (812mg, 
1.15mmol), THF (20ml), acetic acid (75.96mg, 75.96µml, 1.265mmol), TBAF (0.766ml,  
0.766mmol), affording a colourless oil. Yield 246mg, 45.7%. δ 1H (CDCl3): 7.26-7.89 (Ar-H, 
10H, m), 5.32-5.39 (H-3, H-4, 2H, m), 3.65-3.82 (H-1a, 1H, m), 3.54.3.60 (H-1b, H-2, 2H, m), 
1.62-1.82 (H-5ab, 2H, m), 1.06-1.30 (H-6ab – H-11ab, 12H, m), 0.65-0.70 (H-12abc, 3H, t, 
J=6.7). δ 13C (CDCl3): 136.434- 131.057 (multiple signals, Ar C), 76.149 (C3), 75.355 (C4), 
66.187 (C2), 64.756 (C1), 34.519-25.318 (multiple signals, C5 - 11), 16.676 (C12).  
m/z (ES): 491.2 (M+ + [H]+ 10%), 490.2 (M+ + [Na]+ 100%) HRMS: Calculated for C26H33N3O5 
[M + Na]+ 490.2318, found 490.2308. αD: +8.8°. IR: 3200-3400cm-1 (br OH), 3100-3000cm-1 
(Ar), 2040-2080cm-1 (azide), 1750-1750cm-1 (C=O). 
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5.10.4. (2S,3S,4R)-2-Azido-3,4-bis-benzoyloxy-nonan-1-ol (31) 
 
Prepared by the general procedure for the removal of a TBDPS group (5.1.1.8) using acetic 
acid (20mg, 19µl, 0.354mmol), TBAF (454µl, 454µmol), and ((2S,3S,4R)-2-azido-3,4-bis-
benzoyloxy-nonyloxy)-tert-butyl-diphenyl-silane (27) (214mg, 322µmol) in dry THF (10ml), 
affording an opaque oil. Yield: 124mg, 90.5%. δ 1H (CDCl3): 7.48-8.07 (Ar-H, 10H, m), 5.49-
5.56 (H-3, H-4, 2H, m), 3.98-4.01 (H-1a, 1H, m), 3.75-3.82 (H-1b, H-2, 2H, m), 1.82-1.99 (H-
5ab, 2H, m), 1.18-1.51 (H-6ab – H-8ab, 6H, m), 0.89 (H-9abc, 3H, t, J=6.8). δ 13C (CDCl3): 
166.07, 165.74 (C-A, -B), 133.74-129.71 (multiple signals, C-Ar), 129.26, 129.11 (QC-Ar), 
128.61, 128.46 (C-Ph), 73.28 (C-3), 72.94 (C-4), 63.11 (C-2), 62.13 (C-1), 31.50 (C-7), 
29.73 (C-5), 25.21 (C-6), 22.42 (C-8), 13.91 (C-9). m/z (ES): 449.3 (M+ + [Na]+ + [H]+ 10%), 
448.2 (M+ + [Na]+ 100%). HRMS: Calculated for C23H27N3O5Na [M + Na]+ 448.1848, found 
448.1829. αD: +81.4°. IR: 3200-3400cm-1 (br OH), 3100-3000cm-1 (Ar), 2040-2080cm-1 
(azide), 1750-1750cm-1 (C=O). 
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5.11. Glycosyl iodide precursors 
5.11.1. (3R,4S,5S,6R)-2,3,4,5-Tetrakis-trimethylsilanyloxy-6-
trimethylsilanyloxymethyl-tetrahydropyran (32) 
 
Prepared by the general procedure for trimethly silylation (5.1.1.9) using D-galactose (1.8g, 
10mmol), DMF (80ml), Et3N (5.57g, 7.67ml, 55mmol) and chlorotrimethylsilane (5.98g, 
6.96ml, 55mmol), affording a colourless viscous syrup. Yield 5.12g (94.63%). δ 1H (CDCl3):  
5.03 (H-2, 1H, d, J=7.3Hz), 3.48-3.91(H-3, H-4, H-5 H-6, H-7ab, 6H, m), 0.08-0.14 (H-TMS, 
45H, m) δ 13C (CDCl3): 94.2978 (C-1) 72.0191, 70.8496, 70.2041, 69.6680 (C-2 - C-5), 
60.9238 (C-6), 0.3304 – 0.7958 (multiple signals, C-TMS). m/z (ES): 564.4 (M+ + [H]+  
+ [Na]+ 25%), 563.1 (M+ + [Na]+ 100%). HRMS: Calculated for C21H52O6Si5 [M + Na]+ 
563.2508, found 563.2500. αD: -98.0°. 
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5.11.2. (3R,4S,5R,6R)-2,3,4,5-Tetrakis-trimethylsilanyloxy-6-
trimethylsilanyloxymethyl-tetrahydropyran (33) 
 
Prepared by the general procedure for trimethly silylation (5.1.1.9) using D-glucose (1.8g, 
10mmol), DMF (80ml), Et3N (5.57g, 7.67ml, 55mmol), and chlorotrimethylsilane (5.98g, 
6.96ml, 55mmol), affording a yellow-tinged translucent syrup. Yield 4.62g, 85.39%. δ 1H 
(CDCl3):  4.97-4.98 (H-2, 1H, d, J=3.24Hz), 3.28-3.77 (H-3, H-4, H-5 H-6, H-7ab  6H, m), 
0.04-0.16 (H-TMS, 45H, m). δ 13C (CDCl3): 93.38 (C1) 71.25, 69.98, 69.70, 68.76 (C2-5), 
59.38 (C6), 0.32 – -0.78 (multiple signals C-TMS). m/z (ES): 564.3 (M+ + [H]+  15%), 563.1 
(M+ + [Na]+  100%), 491.3 (M+ + [H]+ + [Na]+ - TMS 25%). HRMS: Calculated for C21H52O6Si5 
[M + Na]+ 563.2508, found 563.2501. αD: +82.0°. 
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5.11.3. (2S,3R,4R,5S)-2-Methyl-3,4,5,6-tetrakis-trimethylsilanyloxy-tetrahydropyran 
(34) 
 
L-Fucose (1g, 6.09mmol) and triethylamine (4.4ml, 31.55mmol, 5.18M eq) were dissolved in 
dry DMF (50ml). Trimethylsilyl chloride (3.44g, 4ml, 31.55mmol) was added at 0°C and the 
reaction stirred at room temperature overnight. The solution was diluted with pentane 
(100ml), and extracted with water (3 x 30ml). The organic portions were combined, dried 
(MgSO4), filtered and concentrated, affording a white solid [291]. Yield 2.363g, 85.65%. δ 1H 
(CDCl3): 4.98-5.01 (H-2, 1H, m), 3.87-4.05 (H-2, 1H, m), 3.76-3.80 (H-3, H-4, 2H, m), 3.56-
3.58 (H-6, 1H, m), 1.07-1.11 (H-7abc, 3H, m), 0.04-0.15 (H-TMS, 36H, m). δ 13C (CDCl3): 
93.83 (C2) 75.33, 69.90, 68.89, 65.92 (C3-6), 16.06 (C7), 0.00 – -0.50 (multiple signals  
C-TMS). m/z (ES): 564.3 (M+ + [H]+  15%), 563.1 (M+ + [Na]+  100%), 491.3  
(M+ + [H]+ + [Na]+ - TMS 25%). HRMS: Calculated for C18H44O5Si4 [M + Na]+ 475.2264, 
found 475.2280. αD: -210.0°. m.p.: 109-115°C. 
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5.12. Glycosylation 
5.12.1. (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-Azido-3,4-bis-benzoyloxy-octadecyloxy)-
6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol (35) 
 
Prepared by the general procedure for the coupling of sugars with phytosphingosine 
analogues (5.1.1.10) using pertrimethylsilylated galactose (32) (2.94g, 5.44mmol), DCM 
(40ml), iodotrimethylsilane (1.09g, 0.77ml, 5.44mmol), benzene (6ml, then 2 x 1ml, then 
3ml), MS 4Å (1.5g), tetrabutylammonium iodide (4.02g, 10.88mmol), (2S,3S,4R)-2-Azido-
3,4-bis-benzoyloxy-octadecan-1-ol (28) (1g, 1.81mmol), diisopropylethylamine (1.05g, 
1.42ml, 8.16mmol), benzene (6ml), MeOH (30ml), and Dowex© 50WX8-200 resin (10g), 
affording a yellow-tinged oil.  Yield 740mg, 57.3%. δ 1H (CDCl3): 7.47-8.14 (Ar-H, 10H, m), 
5.78-5.84 (H-3, 1H, q, J=4.5, 2.7, 6.6Hz), 5.59-5.67 (H-4, 1H, m), 4.94-4.98 (H-2’, 1H, d, 
J=2.4), 4.26-4.33 (H-7a, 1H, dd, J=2.7, 10.5Hz), 4.01-4.09 (H-2, H-5’, 2H, m), 3.95-3.99  
(H-4’, 1H, m), 3.87-3.95 (H-1ab, H-3’, H-6’, 4H, m), 3.71-3.79 (H-7b, 1H, dd, J=5.1, 10.5), 
2.36 (OH-3, -4, -5, -7, 4H, br s), 1.82-2.03 (H-5ab, 2H, m), 1.21-1.53 (H-6ab – H17ab, 34H, m), 
0.91-0.98 (H-18abc, 3H, t, J=6.7). δ 13C (CDCl3): 129.74-135.11 (multiple signals, Ar-C), 
100.39 (C-2’), 69.01-74.14 (C-4, C-3, C-4’, C-6’, C-5’, C-3’), 61.62 (C-7’), 21.59-30.86  
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(C-5 – C17), 15.40 (C-18). m/z (ES): 737.8 (M+ + [Na]+ + [H]+ 15%), 736.8 (M+ + [Na]+ 
100%), HRMS: Calculated for C38H55N3O10 [M + Na]+ 736.8573, found 736.8591. αD: +54.0°.  
IR: 3200-3400cm-1 (br OH), 3100-3000cm-1 (Ar), 2040-2080cm-1 (azide), 1750-1750cm-1 
(C=O).  
 
5.12.2. (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-Azido-3,4-bis-benzoyloxy-pentadecyloxy)-
6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol (36) 
 
Prepared by the general procedure for the coupling of sugars with phytosphingosine 
analogues (5.1.1.10) using pertrimethylsilylated galactose (32) (1.606g, 2.97mmol), DCM 
(20ml), iodotrimethylsilane (594mg, 0.43ml, 2.97mmol), benzene (5ml, then 2 x 1ml, then 
2ml), MS 4Å (800mg), tetrabutylammonium iodide (2.19g, 5.94mmol), (2S,3S,4R)-azido-3,4-
bis-benzoyloxy-pentadecan-1-ol (29) (504mg, 0.991mmol), diisopropylethylamine (576mg, 
0.78ml, 4.45mmol), benzene (10ml), MeOH (30ml), and Dowex© 50WX8-200 resin (7g), 
affording a pale yellow oil. Yield 175mg, 26.29%. δ 1H (CDCl3): 7.37-8.02 (Ar-H, 10H, m), 
5.62-5.66 (H-3, 1H, m), 5.48-5.55 (H-4, 1H, m), 4.80 (H-2’, 1H, d, J=2.41Hz), 4.16-4.12 (H-
7’a, 1H, m), 3.90-3.95 (H-2, H-5’, 2H, m), 3.83-3.85 (H-4’, 1H, m), 3.71-3.74 (H-1ab, H-3’, H-
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6’, 4H, m), 3.63-3.69 (H-7’b, 1H, m), 1.82-1.92 (H-5ab, 2H, m), 1.15-1.30 (H-6ab – H-14ab, 
16H, m), 0.81-0.85 (H-15abc 3H, t, J=6.9Hz).  δ 13C (CDCl3): 139.5 – 135.1 (multiple signals, 
Ar C), 106.5 (C-1’), 79.5 (C-4), 78.1(C-3), 77.8 (C-3’), 76.1 (C-5’), 75.5(C-4’), 75.2 (C-2’), 
73.6 (C-6’), 68.0 (C-1), 66.5 (C-2), 40.5 – 28.9 (multiple signals, C-5 –C-14), 19.5 (C-15). 
m/z (ES): 711.9 (M+ + [K]+ + [H]+ 10%), 694.7 (M+ + [Na]+ 100%). HRMS: Calculated for 
C35H49N3O10 [M + Na]+ 694.7675, found 694.7686. αD: +81.4°. IR: 3200-3400cm-1 (br OH), 
3100-3000cm-1 (Ar), 2040-2080cm-1 (azide), 1750-1750cm-1 (C=O).  
 
5.12.3. (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-Azido-3,4-bis-benzoyloxy-dodecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (37) 
 
Prepared by the general procedure for the coupling of sugars with phytosphingosine 
analogues (5.1.1.10) using pertrimethylsilylated galactose (32) (852mg, 1.578mmol), DCM 
(15ml), iodotrimethylsilane (316mg, 0.23ml, 1.578mmol), benzene (3ml, then 2 x 1ml, then 
1ml), MS 4Å (500mg), tetrabutylammonium iodide (1.17g, 3.156mmol), (2S,3S,4R)-azido-
3,4-bis-benzoyloxy-dodecan-1-ol (30) (246mg, 0.53mmol), diisopropylethylamine  
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(1.05g, 1.42ml, 8.16mmol), benzene (6ml), MeOH (20ml), and Dowex© 50WX8-200 resin 
(5g), producing an off-white solid. Yield 110 mg, 32.96%. δ 1H (CDCl3): 7.38-7.98 (Ar-H, 
10H, m), 5.61-5.64 (H-3, 1H, m), 5.48-5.52 (H-4, 1H, m), 4.79 (H-2’, 1H, s), 4.11-4.13 (H-7’a, 
1H, dd, J=2.9, 8.0Hz), 3.90-3.93 (H-2, H-5’, 2H, m), 3.82-3.85 (H-4’, 1H, m),  
3.71-3.75 (H-1ab, H-3’, H-6’, 4H, m), 3.63-3.67 (H-7’b, 1H, q, J=6.0, 10.4, 4.8Hz), 1.81-1.94 
(H-5ab, 2H, m), 1.18-1.42 (H-6ab – H-11ab 12H, m), 0.78-0.81 (H-12abc, 3H, t, J=6.7Hz)   
δ 13C (CDCl3):  166.8, 166.286 (C-A, -B), 134.238-128.683 (multiple signals, Ar C), 100.219 
(C-2’), 73.696 (C-4), 72.563 (C-3), 71.407 (C-4’), 70.598 (C-6’), 70.227 (C-5’), 69.456 (C-3’), 
67.867 (C-7’), 62.160 (C-1), 61 164 (C-2), 32.136-22.933 (multiple signals, C-5 –C-11), 
14.176 (C-12). m/z (ES): 668.1 (M+ + [K]+ 5%), 653. 1 (M+ + [Na]+ + [H]+ 10%), 652.1  
(M+ + [Na]+ 100%). HRMS: Calculated for C32H43N3O10 [M + Na]+ 652.2846, found 652.2840.  
αD: +92.4°. m.p.: 53-65°C. IR: 3200-3400cm-1 (br OH), 3100-3000cm-1 (Ar), 2040-2080cm-1 
(azide), 1750-1750cm-1 (C=O). 
   
5.12.4. (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-Azido-3,4-bis-benzyloxy-nonyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (38) 
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Prepared by the general procedure for the coupling of sugars with phytosphingosine 
analogues (5.1.1.10) using pertrimethylsilylated galactose (32) (0.266g, 0.494mmol), DCM 
(5ml), iodotrimethylsilane (97mg, 0.07ml, 0.494mmol), benzene (2ml, then 2 x 1ml, then 
2ml), MS 4Å (200mg), tetrabutylammonium iodide (3.65mg, 0.988mmol), (2S,3S,4R)-2-
azido-3,4-bis-benzoyloxy-nonan-1-ol (31) (0.7mg, 0.16mmol), diisopropylethylamine 
(97.5mg, 0.13ml, 0.741mmol), benzene (3ml), MeOH (5ml), and Dowex© 50WX8-200 resin 
(2g), affording a pale yellow translucent oil. Yield: 0.043g, 45.73%. δ 1H (CDCl3): 7.38-7.96 
(Ar-H, 10H, m), 5.59-5.61 (H-3, 1H, m), 5.40-5.50 (H-4, 1H, m), 4.80 (H-2’, 1H, s), 4.10-4.13 
(H-7’a, 1H, dd, J=3.0, 7.9Hz), 3.91-3.94 (H-2, H-5’, 2H, m), 3.80-3.84 (H-4’, 1H, t, J=6.0Hz), 
3.70-3.75 (H-1ab, H-3’, H-6’, 4H, m), 3.62-3.67 (H-7’b, 1H, m), 1.81-1.91 (H-5ab, 2H, m), 1.15-
1.41 (H-6ab – H-8ab 6H, m), 0.80-0.85 (H-9abc, 3H, t, J=6.4Hz).   
δ 13C (CDCl3): 167.12, 167.00 (C-A, -B), 127.44-133.37 (multiple signals, Ar C), 101.36  
(C-2’), 73.15 (C-4), 72.01 (C-3), 70.98 (C-4’), 70.56 (C-6’), 70.21 (C-5’), 69.69 (C-3’), 68.10 
(C-7’), 62.41 (C-1), 61.00 (C-2), 21.94-33.34 (multiple signals, C-5 – C-8), 13.92 (C-9).  
m/z (ES): 611.62 (M+ + [Na]+ + [H]+ 10%), 610.62 (M+ + [Na]+ 100%). HRMS: Calculated for 
C29H37N3O10 [M + Na]+ 610.6183, found 610.9192. αD: +36.1°. IR: 3200-3400cm-1 (br OH), 
3100-3000cm-1 (Ar), 2040-2080cm-1 (azide), 1750-1750cm-1 (C=O).  
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5.13. Removal of benzoate protecting groups 
5.13.1. 2-(2-Azido-3,4-dihydroxy-octadecyloxy)-6-hydroxymethyl-tetrahydro-pyran-
3,4,5-triol (39) 
 
Prepared by the general procedure for the removal of benzoyl protecting groups (5.1.1.11) 
using 2-(2-azido-3,4-bis-benzoyloxy-octadecyloxy)-6-hydroxymethyl-tetrahydro-pyran-3,4,5-
triol (35) (740mg, 1.04mmol), THF (20ml), MeOH (10ml), 0.5M NaOMe in MeOH (84mg, 
3.12ml, 1.56mmol; then 54mg, 2ml, 1mmol), affording a white solid. Yield 417mg, 79.3%. 
δ 1H (CDCl3): 4.71-4.81 (H-2’, 1H, d, J=3.6Hz), 3.99-4.05 (H-1a, 1H, dd, J=3.4, 10.5Hz), 
3.84-3.87 (H-6’, 1H, d, J=3.0), 3.71-3.78 (H-5’, 1H, m), 3.56-3.71 (H-1b, H-3’, H-4’, H7’ab, 5H, 
m), 3.42-3.55 (H-2, H-3, H-4, 3H, m), 1.33-1.53 (H-5a, H-7a, 2H, m), 1.05-1.32 (H-5b, H-6ab, 
H-7b, H-8ab– H17ab, 24H, m), 0.73-0.79 (H-18abc, 3H, t, J=6.6Hz). δ 13C (CDCl3): 100.25  
(C-2’), 74.89 (C-3), 71.73 (C-4), 71.09 (C-5’), 69.98 (C-3’) 68.55 (C-6’), 68.01 (C-4’), 67.64 
(C-1), 64.93, 64.36 (C-2, C-6’), 35.19 (C-5), 32.75 (C-6), 31.31 (C-8 – C-16), 26.24 (C-7), 
15.71 (C-18). m/z (ES): 529.4 (M+ + [Na]+ + [H]+ 5%), 528.4 (M+ + [Na]+ 100%), 242.3  
(M+ + [Na]+ + [Na]+  - Gal-O-CH2-CH(N3)-CH(OH)-CH(OH) 25%). HRMS: Calculated for 
C24H47N3O8 [M + Na]+ 528.3261, found 528.3238. αD: +44.0° m.p.: 121-137°C.  
IR: 3200-3400cm-1 (br OH), 2040-2080cm-1 (azide). 
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5.13.2. (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-Azido-3,4-dihydroxy-pentadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (40) 
 
Prepared by the general procedure for the removal of benzoyl protecting groups using 
(5.1.1.11) 2-(2-azido-3,4-bis-benzoyloxy-pentadecyloxy)-6-hydroxymethyl-tetrahydro-pyran-
3,4,5-triol (36) (156mg, 0.23mmol), THF (5ml), MeOH (2ml), 0.5M NaOMe in MeOH 
(27.6mg, 1.02ml, 0.51mmol), affording a yellow oil. Yield 21mg, 20.9%. δ 1H (CDCl3:MeOD, 
2:1): 4.86-4.88 (H-2’, 1H, d, J=3.7 Hz), 4.06-4.13 (H-1a, 1H, dd, J=3.4, 10.8Hz), 3.91-3.92 
(H-6’, 1H, d, J= 2.8Hz), 3.83-3.85 (H-5’, 1H, t, J=5.6), 3.69-3.80 (H-1b, 3’, 4’, 7’ab, 5H, m), 
3.60-3.65 (H-2, H-3, 2H, m), 3.54-3.59 (H-4, 1H, m), 1.60-1.67 (H-5a 1H, m), 1.49-1.58 (H-7a 
1H, m), 1.20-1.43 (H-5b, H-6ab, H-7b, H-8ab – H-14ab, 18H, m,), 0.82-0.86 (H-15abc, 3H, t, 
J=6.8Hz). δ 13C (CDCl3:MeOD, 2:1): 100.25 (C-2’), 74.84 (C-3), 72.37 (C-4), 71.59 (C-5’), 
70.72 (C-3’), 70.36 (C-6’), 69.42 (C-4’), 68.09 (C-1), 62.39, 62.39 (C-2, 7’), 33.09 (C-5), 
32.38 (C-6), 30.19-29.79 (multiple signals, C-8-13), 26.20 (C-7), 23.09 (C-14), 14.25 (C-15). 
m/z (ES):  487.66 (M+ + [Na]+ + [H]+ 5%), 486.66 (M+ + [Na]+ 100%). HRMS: Calculated for 
C24H47N3O8 [M + Na]+ 486.6357, found 586.6364. αD: +81.4° IR: 3200-3400cm-1 (br OH), 
2040-2080cm-1 (azide).  
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5.13.3. (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-Azido-3,4-dihydroxy-dodecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (41) 
 
Prepared by the general procedure for the removal of benzoate protecting groups (5.1.1.11) 
using 2-(2-azido-3,4-bis-benzoyloxy-dodecyloxy)-6-hydroxymethyl-tetrahydro-pyran-3,4,5-
triol (37) (95mg, 0.15mmol), THF (5ml), MeOH (2ml), 0.5M NaOMe in MeOH (1.8eq, 
14.6mg, 0.54ml, 0.27mmol), affording a colourless oil. Yield 55.6mg, 88%.  
δ 1H (CDCl3:MeOD, 2:1): 4.84-4.87 (H-2’, 1H, d, J=3.6 Hz), 4.06-4.10 (H-1a, 1H, dd, J=3.6, 
10.6Hz), 3.91 (H-6’, 1H, s), 3.79-3.83 (H-5’, 1H, t, J=5.5), 3.74-3.78 (H-1b, 3’, 4’, 7’ab, 5H, m), 
3.67-3.64 (H-2, H-3, 2H, m), 3.58-3.66 (H-4, 1H, m), 1.46-1.59 (H-5a 1H, m), 1.33-1.43 (H-7a 
1H, m), 1.19-1.32 (H-5b, H-6ab, H-7b, H-8ab – H-11ab, 12H, m,), 0.79-0.84 (H-12abc, 3H, t, 
J=6.7Hz). δ 13C (CDCl3:MeOD, 2:1):101.45 (C-2’), 75.67 (C-3), 71.21 (C-4), 71.15 (C-5’), 
69.33 (C-3’), 69.16 (C-6’), 68.58 (C-4’), 68.09 (C-1), 62.59, 62.29 (C-2, 7’), 30.09 (C-5), 
29.14 (C-6), 29.01-27.98 (multiple signals, C-8-11), 25.30 (C-7), 13.15 (C-12).  
m/z (ES): 445.4937 (M+ + [Na]+ + [H]+ 5%), 444.4857 (M+ + [Na]+ 100%).  HRMS:  
Calculated for C24H47N3O8 [M + Na]+ 444.4857, found 444.4850. αD: +198.4° IR: 3200-
3400cm-1 (br OH), 2040-2080cm-1 (azide).  
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5.13.4. (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-Azido-3,4-dihydroxy-nonyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (42) 
 
Prepared by the general procedure for the removal of benzoyl protecting groups using 2-(2-
azido-3,4-bis-benzoyloxy-nonyloxy)-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol (38) 
(43mg, 73.2µmol), THF (2ml), MeOH (1ml), 0.5M NaOMe in MeOH (2eq, 3.95mg, 0.146ml, 
146.4µmol), affording a colourless oil.  Yield 23.6mg, 85.0%. δ 1H (CDCl3:MeOD, 2:1): 4.81-
4.86 (H-2’, 1H, d, J=3.4 Hz), 4.05-4.10 (H-1a, 1H, dd, J=3.5, 10.6Hz), 3.93-3.95 (H-6’, 1H, d, 
J=2.7Hz), 3.79-3.82 (H-5’, 1H, t, J=5.6), 3.71-3.76 (H-1b, 3’, 4’, 7’ab, 5H, m), 3.63-3.67 (H-2, 
H-3, 2H, m), 3.55-3.69 (H-4, 1H, m), 1.40-1.51 (H-5a 1H, m), 1.35-1.44 (H-7a 1H, m), 1.11-
1.29 (H-5b, H-6ab, H-7b, H-8ab 12H, m,), 0.81-0.88 (H-9abc, 3H, t, J=6.4Hz).  
δ 13C (CDCl3:MeOD, 2:1): 100.32 (C-2’), 76.57 (C-3), 72.77 (C-4), 71.45 (C-5’), 70.21 (C-3’), 
69.86 (C-6’), 68.97 (C-4’), 68.01(C-1), 61.58, 61.49 (C-2, 7’), 32.61 (C-5), 30.08 (C-6), 
29.01(C-8), 26.36 (C-7), 15.15 (C-8). m/z (ES): 403.4140 (M+ + [Na]+ + [H]+ 10%), 402.406 
(M+ + [Na]+ 100%).  HRMS:  Calculated for C24H47N3O8 [M + Na]+ 402.4060, found 402.4064. 
αD: +48.3° IR: 3200-3400cm-1 (br OH), 2040-2080cm-1 (azide).  
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5.14. Synthesis of N-hydroxy succinimide esters 
5.14.1. Hexacosanoic acid 2,5-dioxo-pyrrolidin-1-yl ester (43) 
 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using hexacosanoic acid (0.2g, 0.504mmol) dry DCM (6ml), N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (107mg, 0.558mmol) and N-
hydroxysuccinimide (69.6mg, 0.604mmol). Yield 0.277g of a white foamy solid (92.88%).  
δ 1H (CDCl3): 2.80-2.86 (H-3’ab, H-4’ab, 4H, m), 2.56-2.63 (H-2ab, 2H, t, J=7.49Hz) 1.68-1.79 
(H-3ab, 2H, m), 1.14-1.43 (H-4ab - H-25ab, 44H, m), 0.84-0.90 (H-26abc, 3H, t, J=6.6Hz). δ 13C 
(CDCl3): 67.33 (C-3’, C-4’, d), 23.60-27.71 (multiple signals, C-2-25), 12.44 (C-26).   
m/z (ES): 542.7 (M+ + [Na]+ + [K]+ + [H]+ 10%), 541.7 (M+ + [Na]+ + [K]+ 100%).  
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5.15. Addition of an N-acyl chain 
5.15.1. Hexacosanoic acid [(1S,2S,3R)-2,3-dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-
trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-
amide (44) 
 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (250mg, 0.494mmol), hexacosanoic acid 
2,5-dioxo-pyrrolidin-1-yl ester (43) (325mg, 0.658mmol) affording a white solid. Yield: 
203mg, 47.8%. δ 1H (CDCl3:MeOD, 2:1): 4.85-4.88 (H-2’, 1H, d, J=3.8Hz), 3.96-3.98 (H-1, 
1H, m), 3.70-3.75 (H-4’, 1H, m), 3.61-3.67 (H-8a, 1H, dd, J=4.7, 11.1Hz), 3.72-3.77 (H-3’, H-
6’, 2H, m), 3.66-3.71 (H-5’, H-7’ab, 3H, m), 3.45-3.48 (H-8b, 1H,dd, J=4.5, 10.8Hz), 3.31-3.34 
(H-2, H-3, 2H, m), 2.01-2.06 (H-2’’ab, 2H, t, J=7.6Hz), 1.40-1.45 (H-3’’a, H-4’’a, H-4a, 3H, m), 
1.10-1.35 (H-3’’b, H-4’’b, H-4b, H-5ab – H13ab, H-5’’ab – H-25’’ab, 70H, m), 0.75-0.81 (H-14abc, 
H-26’’abc, 6H, J=6.7Hz). δ 13C (CDCl3:MeOD, 2:1): 178.6 (C-1’’), 103.8 (C-2’), 77.6 (C-2), 
74.2 (C-3), 69.8 (C-6’), 68.5 (C-5’), 68.2 (C4’), 66.4 (C-3’), 65.1 (C-8), 63.5 (C-7’), 50.1 (C-
1), 24.8-39.7(multiple signals C-2’’ – C-25’’, C-5 – C-16), 18.5, 17.9 (C-26’’, C-17).  
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m/z (ES): 881.7 (M+ + [Na]+ + [H]+ 45%), 880.6 (M+ + [Na]+ + 100%). HRMS: Calculated for 
C50H99NO9 [M + Na]+ 880.7239, found 880.7218. αD:+10.1° m.p.: 135-138°C  
IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O)., 1500-1650cm-1 (N-H). 
 
5.15.2. Hexacosanoic acid [(1S,2S,3R)-2,3-dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-
trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-tetradecyl]-
amide (45) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-pentadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (40) (45mg, 97.1µmol), hexacosanoic acid 2,5-
dioxo-pyrrolidin-1-yl ester (43) (47.4mg, 0.134 mmol), affording a white solid. Yield: 41.2mg, 
52%. δ 1H (CDCl3:MeOD, 2:1): 4.84-4.86 (H-2’, 1H, d, J=3.7Hz), 4.13-4.16 (H-1, 1H, m), 
3.87-3.89 (H-4’, 1H, d, J=2.98Hz), 3.81-3.86 (H-8a, 1H, dd, J=4.81, 11.0Hz), 3.72-3.77 (H-3’, 
H-6’, 2H, m), 3.66-3.71 (H-5’, H-7’ab, 3H, m), 3.61-3.66 (H-8b, 1H, m), 3.46-3.51 (H-2, H-3, 
2H, m), 2.13-2.17 (H-2’’ab, 2H, t, J=7.5Hz), 1.46-1.65 (H-3’’a, H-4’’a, H-4a, 3H, m), 1.11-1.35 
(H-3’’b, H-4’’b, H-4b, H-5ab – H13ab, H-5’’ab – H-25’’ab, 70H, m), 0.81-0.85 (H-14abc, H-26’’abc, 
6H, J=6.8Hz). δ 13C (CDCl3:MeOD, 2:1):102.50 (C-2’), 76.77 (C-2), 74.94 (C-3), 73.66 (C-6’), 
C47H93NO9 
Mol. Wt.: 816.2427 g mol-1
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73.12 (C-5’), 72.88 (C4’), 71.86 (C-3’), 70.76 (C-8), 65.02 (C-7’), 64.47 (C-1), 25.57-35.14 
(multiple signals C-2’’ – C-25’’, C-4 – C-13), 16.93 (d, C-26’’, C-14).  m/z (ES): 853.7 (M+ + 
[H]+ + 2 x H2O 5%), 852.7 (M+ + 2 x H2O 20%),  838.6 (M+ + [Na]+ + 100%).  
HRMS: Calculated for C50H99NO9 [M + Na]+ 838.6760, found 838.6748.  αD: +26.7°  
m.p.: 127-132°C IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O)., 1500-1650cm-1 (N-H). 
 
5.15.3. Hexacosanoic acid [(1S,2S,3R)-2,3-dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-
trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-undecyl]-
amide (46) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-dodecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (41) (50mg, 0.119mmol), hexacosanoic acid 2,5-
dioxo-pyrrolidin-1-yl ester (43) (71.7mg, 0.145mmol), affording a white solid. Yield: 3.32mg, 
36%. δ 1H (CDCl3:MeOD, 2:1): 4.84-4.86 (H-2’, 1H, d, J=3.8Hz), 4.12-4.16 (H-1, 1H, m), 
3.87-3.89 (H-4’, 1H, d, J=3.1Hz), 3.81-3.85 (H-8a, 1H, dd, J=4.8, 10.5Hz), 3.72-3.77 (H-3’, 
H-6’, 2H, m), 3.66-3.72 (H-5’, H-7’ab, 3H, m), 3.61-3.66 (H-8b, 1H, m), 3.47-3.51 (H-2, H-3, 
2H, m), 2.14-2.18 (H-2’’ab, 2H, t, J=7.7Hz), 1.46-1.65 (H-3’’a, H-4’’a, H-4a, 3H, m), 1.16-1.34 
C44H87NO9 
Mol. Wt.: 774.1629 g mol-1
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(H-3’’b, H-4’’b, H-4b, H-5ab – H10ab, H-5’’ab – H-25’’ab, 57H, m), 0.81-0.85 (H-11abc, H-26’’abc, 
6H, J=6.6Hz). δ 13C (CDCl3:MeOD, 2:1): 101.80 (C-2’), 76.89 (C-2), 74.17 (C-3), 72.97 (C-
6’), 73.00 (C-5’), 72.56 (C4’), 71.80 (C-3’), 70.13 (C-8), 65.54 (C-7’), 64.37 (C-1), 24.77-
36.04 (multiple signals C-2’’ – C-25’’, C-4 – C-10), 17.03 (d, C-26’’, C-11).  m/z (ES): 797.6  
(M+ + [Na]+ + [H]+ 50%), 796.5 (M+ + [Na]+  100%). HRMS: Calculated for C44H87NO9 [M + 
Na]+ 797.6289, found 797.6279.  αD: +15.6° m.p.: 115-120°C IR: 3200-3400cm-1 (br OH), 
1750-1750cm-1 (C=O), 1500-1650cm-1 (N-H). 
 
5.15.4. Hexacosanoic acid [(1S,2S,3R)-2,3-dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-
trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-octyl]-amide 
(47) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-nonyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (42) (15mg, 39.5µmol), hexacosanoic acid 2,5-
dioxo-pyrrolidin-1-yl ester (43) (19.6mg, 39.6µmol), affording a white solid. Yield: 12.mg, 
42.8%. δ 1H (CDCl3:MeOD, 2:1): 4.84-4.89 (H-2’, 1H, d, J=3.4Hz), 4.13-4.16 (H-1, 1H, m), 
3.86-3.89 (H-4’, 1H, d, J=2.98Hz), 3.81-3.86 (H-8a, 1H, dd, J=4.6, 10.5Hz), 3.72-3.78 (H-3’, 
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H-6’, 2H, m), 3.66-3.72 (H-5’, H-7’ab, 3H, m), 3.60-3.66 (H-8b, 1H, m), 3.47-3.52 (H-2, H-3, 
2H, m), 2.13-2.18 (H-2’’ab, 2H, t, J=7.9Hz), 1.53-1.67 (H-3’’a, H-4’’a, H-4a, 3H, m), 0.94-1.46 
(H-3’’b, H-4’’b, H-4b, H-5ab – H6ab, H-5’’ab – H-25’’ab, 49H, m), 0.79-0.86 (H-7abc, H-26’’abc, 6H, 
J=67.3Hz). δ 13C (CDCl3:MeOD, 2:1): 103.60 (C-2’), 77.67 (C-2), 75.49 (C-3), 73.66 (C-6’), 
73.21 (C-5’), 72.68 (C4’), 71.68 (C-3’), 70.67 (C-8), 65.20 (C-7’), 64.74 (C-1), 23.75-33.41 
(multiple signals C-2’’ – C-25’’, C-4 – C-6), 16.93 (d, C-26’’, C-7).  m/z (ES): 755.6 (M+ + [H]+ 
+ [Na]+ 25%), 754.5 (M+ + [Na]+ + 100%). HRMS: Calculated for C41H81NO9 [M + Na]+ 
754.5809, found 754.5812.  αD: +12.6° IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O)., 
1500-1650cm-1 (N-H). 
 
5.16. Glycosylation with glucose 
5.16.1. (2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-Azido-3,4-bis-benzyloxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (48) 
 
Prepared by the general procedure for the coupling of sugars with phytosphingosine 
analogues (5.1.1.10) using pertrimethylsilylated glucose (33) (1g, 1.85mmol), DCM (15ml), 
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iodotrimethylsilane (370mg, 0.26ml, 1.85mmol), benzene (3ml, then 2 x 1ml, then 3ml), MS 
4Å (600mg), tetrabutylammonium iodide (1.37g, 3.7mmol), (2S,3S,4R)-2-azido-3,4-bis-
benzoyloxy-octadecan-1-ol (28) (340mg, 0.616mmol), diisopropylethylamine (360mg, 
0.48ml, 2.775mmol), benzene (6ml), MeOH (10ml), and Dowex© 50WX8-200 resin (6g), 
affording a pale orange syrup. Yield 175mg, 39.79%, δ 1H (CDCl3): 7.25-8.22 (Ar-H, 10H, 
m), 5.59-5.65 (H-3, 1H, m), 5.45-5.53 (H-4, 1H, m), 4.72-4.75 (H-2’, 1H, d, J=3.4Hz), 4.04-
4.13 (H-7’a, 1H, dd, J=3.1, 10.6Hz), 3.8-3.91 (H-2, H-5’, 2H, m), 3.64-3.80 (H-4’, 1H, m), 
3.48-3,64 (H-1ab, H-3’, H-6’, 4H, m), 3.37-3.48 (H-7’b, 1H, m), 1.66-1.89 (H-5ab, 2H, m), 1.11-
1.31 (H-6ab – H-17ab 6H, m), 0.81-0.87 (H-18abc, 3H, t, J=6.5Hz)  δ 13C (CDCl3):  168.5, 
168.09 (C-A, -B), 132.24-133.37 (multiple signals, Ar C), 131.99, 131.48 (QC-Ar), 101.70 (C-
2’), 76.79 (C-4), 75.45 (C-3), 74.62 (C-4’), 74.48 (C-6’), 72.28 (C-5’), 69.74 (C-1), 64.18 (C-
7’) 63.09 (C-1), 63.00 (C-2), 25.19-34.41 (multiple signals, C-5 – C-17), 16.62 (C-18).  
m/z (ES): 737.1 (M+ + [Na]+ + [H]+ 20%), 636.3 (M+ + [Na]+ 100%), HRMS: Calculated for 
C38H55N3O10 [M + Na]+ 736.3785, found 736.3807. αD: +80.0° IR: 3200-3400cm-1 (br OH), 
3100-3000cm-1 (Ar), 2040-2080cm-1 (azide), 1750-1750cm-1 (C=O). 
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5.17. Removal of benzoate protecting groups 
5.17.1. (2S,3R,4S,5S,6R)-2-(2-Azido-3,4-dihydroxy-octadecyloxy)-6-hydroxymethyl-
tetrahydro-pyran-3,4,5-triol (49) 
 
Prepared by the general procedure for the removal of benzoyl protecting groups (5.1.1.11) 
using (2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-azido-3,4-bis-benzoyloxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (48) (150mg, 0.21mmol), THF (4ml), MeOH 
(2ml), 0.5M NaOMe in MeOH (1.5eq, 17.02mg, 0.63ml, 0.315mmol), affording an off-white 
solid. Yield 86mg, 80.99%. δ 1H (CDCl3:MeOD, 2:1): 4.56-4.62 (H-2’, 1H, d, J=3.8 Hz), 3.81-
3.91 (H-1a, 1H, dd, J=2.9, 10.9Hz), 3.55-3.62 (H-6’, 1H, dd, J= 2.3), 3.46-3.55 (H-5’, 1H, m), 
3.31-3.45 (H-1b, 3’, 4’, 7’ab, 5H, m), 3.18-3.24 (H-2, 1H, dd, J=3.7, 9.7Hz), 3.05-3.14 (H-3, H-
4, 2H, m), 1.25-1.45 (H-5a, H-7a, 2H, m), 0.9-1.18 (H-5b, H-6ab, H-7b, H-8ab – H-17ab, 12H, 
m,), 0.59-0.65 (H-18abc, 3H, t, J=6.5Hz). δ 13C (CDCl3:MeOD, 2:1):105.47 (C-2’), 80.26 (C-3), 
79.86 (C-4), 78.45 (C-5’), 78.08 (C-3’), 77.91 (C-6’), 76.38 (C-4’), 73.51 (C-1), 67.99 (C-7’), 
67.67 (C-2), 31.79-38.58 (multiple signals C-5 – C-17), 19.89 (C-18). m/z (ES):  529.3 (M+ + 
[Na]+ + [H]+ 20%), 528.3 (M+ + [Na]+ 100%).  HRMS:  Calculated for C24H47N3O8 [M + Na]+ 
528.3261, found 528.3249. αD: +210.0° m.p.: 125-136°C IR: 3200-3400cm-1 (br OH), 2040-
2080cm-1 (azide). 
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5.18. Addition of an N-acyl chain 
5.18.1. Hexacosanoic acid [(1S,2S,3R)-2,3-dihydroxy-1-((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-
amide (50) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (49) (45mg, 88.99µmol), hexacosanoic acid 2,5-
dioxo-pyrrolidin-1-yl ester (43) (56.9mg, 115µmol), affording a white solid. Yield: 42mg, 56%. 
δ 1H (CDCl3:MeOD, 2:1): 4.80-4.82 (H-2’, 1H, d, J=3.7Hz), 4.12-4.16 (H-1, 1H, m), 4.01-4.04 
(H-4’, 1H, m), 3.81-3.85 (H-8’a, 1H, dd, J=4.6, 10.8Hz), 3.73-3.77 (H-5’, 1H, dd, J=2.72Hz), 
3.49-3.68 (H-6’, H-7’ab, H-8’b, H-2, H-3, 6H, m), 3.38-3.42 (H-3’, 1H, dd, J= 3.7, 9.6Hz), 2.14-
2.18 (H-2’’ab, 2H, m), 1.46-1.65 (H-3’’a, H-4’’a, H-4a, 3H, m), 1.11-1.35 (H-3’’b, H-4’’b, H-4b, H-
5ab – H16ab, H-5’’ab – H-25’’ab, 69H, m), 0.81-0.85 (H-17abc, H-26’’abc, 6H, J=6.8Hz). δ 13C 
(CDCl3:MeOD, 2:1): 102.50 (C-2’), 76.77 (C-2), 74.94 (C-3), 73.66 (C-6’), 73.12 (C-5’), 
72.88 (C4’), 71.86 (C-3’), 70.76 (C-8’), 65.02 (C-7’), 64.47 (C-1), 25.57-35.14 (multiple 
signals C-2’’ – C-25’’, C-4 – C-13), 16.93 (d, C-26’’, C-14).  m/z (ES): 868.3 (M+ + [H]+ + 
[Na]+ 10%), 867.3 (M+ + [Na]+ + 100%). HRMS: Calculated for C49H97NO9 [M + Na]+ 
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867.2935, found 867.2947.  αD: +24.0° m.p.  135-139°C IR: 3200-3400cm-1 (br OH), 1750-
1750cm-1 (C=O)., 1500-1650cm-1 (N-H). 
 
5.19. Glycosylation with L-fucose 
5.19.1. (2R,3S,4R,5S,6S)-2-((2S,3S,4R)-2-Azido-3,4-bis-benzyloxy-octadecyloxy)-6-
methyl-tetrahydro-pyran-3,4,5-triol (51) 
 
Pertrimethylsilylated L-fucose (34) (1g, 2.21mmol) was dissolved in anhydrous DCM (10ml). 
Iodotrimethylsilane (442mg, 0.315ml, 2.21mmol) was added and the solution stirred at RT 
for 20min.  A solution of (2S,3S,4R)-2-azido-3,4-bis-benzoyloxy-octadecan-1-ol (28) 
(0.3445g, 0.8096mmol) and 2,6-di-tert-di-butylphenol (0.493g, 0.597ml, 2.58mmol) in 
anhydrous toluene (5ml) was azeotroped thrice, before being dissolved in anhydrous DCM 
and added to the fucose solution and stirred at RT for 18h. MeOH (30ml) was added and 
stirred at RT for 30min. The solution was neutralised with triethylamine, before being 
concentrated. The compound was purified by CC (Petrol: EtOAc; 20:80) affording a pale 
yellow oil. Yield  181mg, 32.04%. δ 1H (CDCl3): 7.36-7.86 (Ar-H, 10H, m), 5.58-5.64 (H-3, 
1H, m), 5.47-5.55 (H-4, 1H, m), 4.80-4.91 (H-2’, 1H, d, J=2.8Hz), 3.88-4.00 (H-3’, H-5’, H-6’, 
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3H, m), 3.62-3.80 (H-1ab, H-2, H-4’, 4H, m), 1.76-1.91 (H-5ab, 2H, m), 1.10-1.43 (H-6ab – H-
17ab 24H, m), 1.06-1.09 (H-7’abc, 3H, d, J=6.6Hz), 0.81-0.88 (H-18abc, 3H, t, J=6.6Hz).   
δ 13C (CDCl3): 130.45-135.64 (multiple signals, Ar C), 100.91 (C-2’), 62.60-74.99 (multiple 
signals C-2, C-3, C-4, C-3’, C-4’, C-5’, C-6’) 69.27 (C-1), 24.61-33.84 (multiple signals, C-5 – 
C-17), 31.93 (C-7’), 15.43 (C-18). m/z (ES): 721.5 (M+ + [Na]+ + [H]+ 20%), 720.5 (M+ + [Na]+ 
100%), HRMS: Calculated for C38H55N3O10 [M + Na]+ 720.3836, found 720.3811.  αD: -20.0° 
IR: 3200-3400cm-1 (br OH), 3100-3000cm-1 (Ar), 2040-2080cm-1 (azide), 1750-1750cm-1 
(C=O). 
 
5.20. Removal of benzoate protecting groups 
5.20.1. (2R,3S,4R,5S,6S)-2-((2S,3S,4R)-2-Azido-3,4-dihydroxy-octadecyloxy)-6-
methyl-tetrahydro-pyran-3,4,5-triol (52) 
 
Prepared by the general procedure for the removal of benzoyl protecting groups (5.1.1.13) 
using (2R,3S,4R,5S,6S)-2-((2S,3S,4R)-2-azido-3,4-bis-benzoyloxy-octadecyloxy)-6-methyl-
tetrahydro-pyran-3,4,5-triol (51) (181mg, 0.259mmol), THF (5ml), MeOH (2ml), 0.5M 
NaOMe in MeOH (1.5eq, 20.99mg, 0.78ml, 0.3885mmol), affording an off-white solid.  
Yield 67mg, 52.8%. δ 1H (CDCl3:MeOD, 2:1):  4.55-4.57 (H-2’, 1H, d, J=3.1 Hz), 3.03-3.71 
(H-1ab, H-2 – H-4, H-2’ – H-6’, 10H, m) 1.34-1.45 (H-5a, H-7a, 2H, m), 0.93-1.26 (H-5b,  
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H-6ab, H-7b, H-8ab – H-17ab, H-7’abc,  27H, m), 0.57-0.63 (H-18abc, 3H, t, J=6.6Hz). δ 13C 
(CDCl3:MeOD, 2:1): 100.60 (C-2’), 72.22-73.98 (C-3, C-4, C-3’ C-6’), 70.27 (C-1), 68.16 (C-
5’), 63.46 (C-2), 24.29-33.53 (multiple signals, C-8-17), 17.83 (C-7’), 15.39 (C-18).   
m/z (ES): 513.5 (M+ + [Na]+ + [H]+ 8%), 512.5 (M+ + [Na]+ 100%)  HRMS Calculated for 
C24H47N3O7 [M + Na]+ 512.3312, found 512.3301. αD: -168.0°. m.p.: 55-62°C IR: 3200-
3400cm-1 (br OH), 2040-2080cm-1 (azide).  
 
5.21. Addition of an N-acyl chain 
5.21.1. Hexacosanoic acid [(1S,2S,3R)-2,3-dihydroxy-1-((2R,3S,4R,5S,6S)-3,4,5-
trihydroxy-6-methyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-amide 
(53) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2R,3S,4R,5S,6S)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
methyl-tetrahydro-pyran-3,4,5-triol (42) (35mg, 71.5µmol), hexacosanoic acid 2,5-dioxo-
pyrrolidin-1-yl ester (43) (49.7mg, 0.101mmol), affording a white solid. Yield: 29.5mg, 49%. 
δ 1H (CDCl3:MeOD, 2:1): 4.71-4.74 (H-2’, 1H, d, J=3.7Hz), 4.14-4.18 (H-1, 1H, m), 3.91-3.96 
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(H-4’, H-5’, 2H, m), 3.68-3.72 (H-8a, 1H, dd, J=3.9, 9.9Hz), 3.61-3.68 (H-3, H-4, 2H, m), 
3.52-3.55 (H-3’, 1H, t, J=5.99Hz), 3.43-3.49 (H-6’, 1H, m), 3.39-3.42 (H-8b, 1H, dd, J=3.9, 
9.9Hz), 2.12-2.17 (H-2’’ab, 2H, m), 1.43-1.62 (H-3’’a, H-4’’a, H-4a, H-5a, H-6a, 5H, m), 1.14-
1.31 (H-7’abc, H-3’’b, H-4’’b, H-4b, H-5b, H-6b, H-7ab – H-16ab, H-5’’ab – H-25’’ab, 70H, m), 0.81-
0.85 (H-14abc, H-26’’abc, 6H, J=6.9Hz). δ 13C (CDCl3:MeOD, 2:1): 102.50 (C-2’), 76.77 (C-
2), 74.94 (C-3), 73.66 (C-6’), 73.12 (C-5’), 72.88 (C4’), 71.86 (C-3’), 70.76 (C-8), 64.47 (C-
1), 25.57-35.14 (multiple signals C-7’, C-2’’ – C-25’’, C-4 – C-13), 16.93 (C-26’’, C-14). 
m/z (ES): 865.8 (M+ + [H]+ + [Na]+ 20%), 864.8 (M+ +  [Na]+ 100%). HRMS: Calculated for 
C50H99NO8 [M + Na]+ 864.7268, found 864.7240.  αD: -10.0°. m.p.: 130-135°C. IR: 3200-
3400cm-1 (br OH), 1750-1750cm-1 (C=O)., 1500-1650cm-1 (N-H). 
 
5.22. Synthesis of N-hydroxy succinimide esters 
5.22.1. Tetracosanoic acid 2,5-dioxo-pyrrolidin-1-yl ester (54) 
 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using tetracosanoic acid (100mg, 0.27mmol), DCM (5ml), N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (55.9mg, 0.2916mmol), N-hydroxy 
succinimide (37.3mg, 0.324mmol) and DMAP (10mg), affording a whitish solid. Yield 76mg, 
60.42%. δ 1H (CDCl3): 2.80-2.84 (H-3’ab, H-4’ab, 4H, m), 2.56-2.62 (H-2ab, 2H, t, J=7.51Hz) 
1.67-1.79 (H-3ab, 2H, m), 1.20-1.44 (H-4ab - H-23ab, 40H, m), 0.84-0.89 (H-24abc, 3H, t, 
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Mol. Wt.: 465.7089 g mol-1 
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J=6.7Hz). δ 13C (CDCl3): 30.80-23.41 (multiple signals, C-2-23), 16.86 (C-29).   
m/z (ES): 489.4 (M+ + [Na]+ + [H]+ 10%), 488.4 (M+ + [Na]+ 100%) HRMS: Calculated for 
C28H51NO4 [M + Na]+ 488.3710, found 488.3716. 
 
5.22.2. (15Z)-Tetracos-15-enoic acid 2,5-dioxo-pyrrolidin-1-yl ester (55) 
 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using (15Z)-tetracos-15-enoic acid (500mg, 1.36mmol), DCM (10ml), N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (287mg, 1.49mmol), N-hydroxy 
succinimide (188mg, 1.63mmol), and DMAP (50mg), affording a white solid. Yield 510mg, 
78.49%. δ 1H (CDCl3): 5.36-5.48 (H-15, H-16, 2H, m), 2.76-2.80 (H-3’ab, H-4’ab, 4H, m), 2.54-
2.60 (H-7ab, 2H, t, J=7.51Hz) 1.45-2.08 (H-2ab - H-14ab, H-17ab – H-23ab, 40H, m), 0.84-0.89 
(H-24abc, 3H, t, J=6.4Hz).δ 13C (CDCl3): 128.26, 127.89 (C-15, C16), 22.94-28.13 (multiple 
signals, C-2 – C14, C-17 – C23), 18.99 (C-24).  m/z (ES):  500.7 (M+ + [Na]+ 100%), 478.7 
(M+ + 10%). 
C29H51NO4 
Mol. Wt.: 477.7195 g mol-1
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5.22.3. (4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid 2,5-dioxo-
pyrrolidin-1-yl ester (56) 
 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using 4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid (100mg, 
0.304mmol), DCM (5ml), N-(3-dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride 
(64.1mg, 0.334mmol), N-hydroxy succinimide (42.0mg, 0.365mmol) and DMAP (10mg). 
Yield 84mg, 64.9%. δ 1H (CDCl3): 5.23-5.34 (H-4, H-5, H-7, H-8, H-10, H-11, H-13, H-14, H-
16, H-17, H-19, H-20, 12H, m), 2.76-2.80 (H-3’ab, H-4’ab, 4H, m), 2.70-2.80 (H-2ab, H-3ab, H-
6ab, H-9ab, H-12ab, H-15ab, H-18ab, H-21ab, 16H, m) 0.84-0.91 (H-22abc, 3H, t, J=7.4Hz). δ 13C 
(CDCl3): 128.26-127.02 (multiple signals, C-4, C-5, C-7, C-8, C-10, C-11, C-13, C-14, C-16, 
C-17, C-19, C-20), 31.35, 34.16 (C-3’ C-4’), 20.46-29.9 (multiple signals, C-2, C-3, C-6, C-9, 
C-12, C-15, C-18, C-21), 14.01 (C-22). m/z (ES): 465.2 (M+ + [K]+ + [H]+15%), 251.1 (M+ + 
[H]+ - CH=CH-CH2-CH=CH-CH2-CH=CH-CH2-CH=CH-CH2-CH3 10%).  
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Mol. Wt.: 425.5604 g 
mol-1
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5.22.4. (5Z,8Z,11Z,14Z,17Z)-Eicosa-5,8,11,14,17-pentaenoic acid 2,5-dioxo-
pyrrolidin-1-yl ester (57) 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid (25mg, 82.66 
µmol), DCM (2ml), N-(3-dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride 
(17.43mg, 90.9 µmol), N-hydroxy succinimide (11.43mg, 99.19 µmol) and DMAP (3mg), 
affording an creamy oil. Yield 32mg, 97.38%. δ 1H (CDCl3): 5.13-5.40 (H-5, H-6, H-8, H-9, H-
11, H-12, H-14, H-15, H-17, H-18, 10H, m), 2.60-2.84 (H-3’ab, H-4’ab, 4H, m), 2.44-2.54 (H-
2ab, 2H, m) 0.96-2.22 (H-3ab, H-4ab, H-7ab, H-10ab, H-13ab, H-16ab, H-19ab, 14H, m) 0.79-0.89 
(H-20abc, 3H, t, J=7.5Hz). δ 13C (CDCl3): 170.73, 159.19 (C-2’, C-5’, C-1), 118.62-133.36 
(multiple signals, C-5, C-6, C-8, C-9, C-11, C-12, C-14, C-15, C-17, C-18), 32.35, 35.16 (C-
3’ C-4’), 29.1-29.6 (multiple signals, C-2, C-3, C-4, C-7, C-10, C-13, C-16, C-19), 8.40 (C-
20).  m/z (ES): 439.3 (M+ + [K]+ + [H]+ 15%), 265.1 (M+ + [H]+ - CH=CH-CH2-CH=CH-CH2-
CH=CH-CH2-CH3 90%), 237.1 (M+ - CH-CH2-CH=CH-CH2-CH=CH-CH2-CH=CH-CH2-CH3). 
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Mol. Wt.: 397.5503 g mol-1
Chapter 5  Materials and methods 
   
201 
5.22.5. (5Z,8Z,11Z,14Z)-Eicosa-5,8,11,14-tetraenoic acid 2,5-dioxo-pyrrolidin-1-yl 
ester (58) 
 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using arachidonic acid ((5Z,8Z,11Z,14Z)-eicosa-5,8,11,14-tetraenoic acid) 
(100mg, 0.329mmol), DCM (5ml), N-(3-dimethylaminopropyl)-N’-ethyl carbodiimide 
hydrochloride (69.3mg, 0.361mmol), N-hydroxy succinimide (45.4mg, 0.394mmol) and 
DMAP (10mg), affording yellow-cream crystals. Yield 98mg, 74.18%. δ 1H (CDCl3): 5.15-
5.32 (H-5, H-6, H-8, H-9, H-11, H-12, H-14, H-15, 8H, m), 2.63-2.77 (H-3’ab, H-4’ab, 4H, m), 
1.01-2.32 (H-2ab, H-3ab, H-4ab, H-7ab, H-10ab, H-13ab, H-16ab – H-19ab, 20H, m) 0.68-0.79 (H-
20abc, 3H, t, J=7.1Hz). δ 13C (CDCl3): 132.34-135.26 (multiple signals, C-5, C-6, C-8, C-9, C-
11, C-12, C-14, C-15), 38.41-27.34 (multiple signals C-3’, C-4’, C-2, C-3, C-4, C-7, C-10, C-
13, C-16, C-19), 18.73 (C-20).  m/z (ES): 460.4 (M+ + 2 x H2O + [Na]+ 100%), 400.3 (M+ + 
[H]+ + [Na]+ + H2O – CH3CH2CH2 40%), 389.3 (M+ + [H]+ + [Na]+ + 2 x H2O – 
CH2CH2CH2CH2-CH3 60%), 375.3 (M+ + H2O + -O-C(O)- 10%). 
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Mol. Wt.: 405.6139 g mol-1 
5.22.6. (11Z,14Z)-Eicosa-11,14-dienoic acid 2,5-dioxo-pyrrolidin-1-yl ester (59) 
 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using eicosadienoic acid (100mg, 0.324mmol), DCM (3ml), N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (68.4mg, 0.357mmol), N-hydroxy 
succinimide (44.7mg, 0.388mmol), DMAP (10mg), affording an off-white solid. Yield 124mg, 
94.37%. δ 1H (CDCl3): 5.25-5.27 (H-11’, H-12’, H-14’, H-15’, 4H, m), 2.78-2.90 (H-3’ab, H-
4’ab, 4H, m), 2.72-279 (C-13), 2.27-2.34 (H-2ab), 1.89-2.09 (H-10ab, H-16ab, 4H, m),  1.65-
1.78 (H-3ab, 2H, m) 1.13-1.47 (H-4ab – H-9ab, H-17ab – H-19ab, 18H, m) 0.82-0.89 (H-20abc, 
3H, t, J=7.2Hz). δ 13C (CDCl3): 178.65 (C=O), 131.35, 129.13 (multiple signals, C-11, C-12, 
C-14, C-15), 76.4 (C-2), 23.73-40.48 (multiple signals C-3’, C-4’, C-3 - C-9, C-13, C16-C19), 
15.21 (C-20).  m/z (ES): 429.6 (M+ + [Na]+ + [H]+ 5%), 428.6 (M+ + [Na]+ 100%). m.p. 105-
111°C. 
 
5.22.7. (11E)-Eicos-11-enoic acid 2,5-dioxo-pyrrolidin-1-yl ester (60) 
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Mol. Wt.: 405.5708 g mol-1 
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Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using (11E)-eicos-11-enoic acid (50mg, 0.16mmol), DCM (2ml), N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (33.95mg, 0.117mmol), N-hydroxy 
succinimide (22.3mg, 0.19mmol), DMAP (5mg), affording a white solid. Yield 60.1mg, 
92.61%. δ 1H (CDCl3): 5.21-5.31 (H-11’, H-12’, 2H, m), 2.64-2.81 (H-3’ab, H-4’ab, 4H, m), 
2.42-2.51 (H-2), 0.79-2.09 (H-3ab – H-10ab, H-13ab – H-19ab, 30H, m),  0.69-0.77 (H-20abc, 
3H, t, J=7.4Hz). δ 13C (CDCl3): 131.96 (d, C-11, C-12), 27.21-34.21 (multiple signals C-2 - C-
10, C-13-C19), 12.27 (C-20).  m/z (ES): 466.3 (M+ + [Na]+ + [H]+ + 2 x H2O 5%), 465.3 (M+ + 
[Na]+ + 2 x H2O 100%), 430.2 (M+ + [Na]+ 50%). 
 
5.22.8. (11Z)-Eicos-11-enoic acid 2,5-dioxo-pyrrolidin-1-yl ester (61) 
 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using (11Z)-eicos-11-enoic acid (100mg, 0.32mmol), DCM (3ml), N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (67.67mg, 0.353mmol), N-hydroxy 
succinimide (44.1mg, 0.383 mmol), DMAP (10mg), affording a white solid. Yield 122mg, 
93.5%. δ 1H (CDCl3): 5.30-5.39 (H-11’, H-12’, 2H, t, J=5.6Hz), 2.79-2.88 (H-3’, H-4’, 4H, m), 
2.56-2.64 (H-2, m), 1.15-2.06 (H-3ab – H-10ab, H-13ab – H-19ab, 30H, m),  0.83-0.91 (H-20abc, 
3H, t, J=6.9Hz). δ 13C (CDCl3): 128.70, 128.62 (C-11, C-12), 23.33-29.70 (multiple signals C-
2 – C-10, C-13 – C-19), 12.87 (C-20). m/z (ES): 447.3 (M+ + [K]+ + [H]+ + 100%). 
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5.22.9. Eicosanoic acid 2,5-dioxo-pyrrolidin-1-yl ester (62) 
 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using eicosanoic acid (200mg, 0.64mmol), DCM (10ml), N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (136mg, 0.708 mmol), N-
hydroxysuccinimide (88.4mg, 0.767mmol) and DMAP (20mg), affording white solid. Yield: 
240mg, 91.5%. δ 1H (CDCl3): 5.16-5.30 (H-9, H-10, H-12, H-13, 4H, m), 2.79-2.86 (H-3’ab, H-
4’ab, 4H, m), 2.61-2.68 (H-2ab, 2H, t, J=6.3Hz), 2.42-2.56 (H-11ab, 2H, m) 1.87-2.03 (H-8ab, H-
14ab, 4H, m),  0.99-1.69 (H-3ab – H-7ab, H-15ab – H-17ab, 16H, m), 0.69-0.81 (H-18abc, 3H, t, 
J=67.2Hz). δ 13C (CDCl3): 174.39 (C=O), 132.69-134.69 (C-9, C-10, C-12, C13) 27.00-35.99 
(multiple signals C-3’, C-4’, C-2 – C-8, C-11, C-14 – C-17), 19.37 (C-18).  m/z (ES): 436.4 
(M+ + [Na]+ + 2 x H2O 100%), 365.3 (M+ [Na]+ + 2 x H2O - CH2-CH2-CH2-CH2-CH3) 
 
5.22.10. (9Z, 12Z)-Octadeca-9,12-dienoic acid 2,5-dioxo-pyrrolidin-1-yl ester (63) 
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Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using octadeca-9,12-dienoic acid (1g, 3.57mmol), DCM (10ml), N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (761mg, 3.97mmol), N-
hydroxysuccinimide (494mg, 4.28mmol), and DMAP (100mg), affording an off-white solid . 
Yield 1.27g, 94.2%. δ 1H (CDCl3): 2.79-2.86 (H-3’ab, H-4’ab, 4H, m), 2.56-2.62 (H-2ab, 2H, t, 
J=7.5Hz), 1.67-1.79 (H-3ab, 2H, m),  1.20-1.44 (H-4ab – H-19ab, 32H, m), 0.83-0.90 (H-20abc, 
3H, t, J=6.8Hz). δ 13C (CDCl3): 24.81-30.16 (multiple signals C-3’, C-4’, C-2 – C-19), 15.99 
(C-20).  m/z (ES): 432.2 (M+ + [Na]+ + 100%) HRMS: Calculated for C24H43NO4 [M + Na]+ 
432.3088, found 432.3090. 
 
5.22.11. Octanoic acid 2,5-dioxo-pyrrolidin-1-yl ester (64) 
 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using octanoic acid (100mg, 0.11ml, 0.69mmol), DCM (3ml), N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (146mg, 0.76mmol), N-hydroxy 
succinimide (95.3mg, 0.83mmol), affording white foamy solid. Yield 71mg, 42.6%.  δ 1H 
(CDCl3): 2.76-2.93 (H-3’ab, H-4’ab, 4H, m), 2.54-2.66 (H-2ab, 2H, t, J=7.8Hz), 2.27-2.40 (H-
3ab, 2H, t, J=7.8Hz) 1.59-1.83 (H-4ab, H-5ab, 4H, m),  1.12-1.51 (H-6ab – H-7ab, 4H, m), 0.82-
0.93 (H-8abc, 3H, t, J=6.9Hz). δ 13C (CDCl3): 28.75-33.18 (multiple signals C-3’, C-4’, C-2 – 
C-7, 14.07 (C-8).  m/z (ES): 308.2 (M+ + [Na]+ + (CH3)2N (DMAP) 100%). 
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5.22.12. m-Tolyl-acetic acid 2,5-dioxo-pyrrolidin-1-yl ester (65) 
 
Prepared by the general procedure for N-hydroxy succinimide carboxylic acid ester 
(5.1.1.12) using m-tolylacetic acid (500mg, 3.33mmol), DCM (10ml), N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (0.7g, 3.66mmol), N-
hydroxysuccinimide (461mg, 3.99mmol) and DMAP (50mg), affording a yellow translucent 
oil. Yield 699mg, 84.9%. δ 1H (CDCl3): 7.01-7.24 (H-4, H-6, H-7, H-8, 4H, m), 3.86-3.91 (H-
3’ab, H-4’ab, 4H, m), 2.59-2.84 (H-2ab, 2H, m), 2.02-2.15 (H-9abc, 3H, m) δ 13C (CDCl3): 
127.53-131.28 (C-4, C-6, C-7, C-8) 38.79 (C-2), 26.84, 26.64 (C-3’, C-4’), 22.58 (C-9).   
m/z (ES): 306.2 (M+ + [Na]+ + 2 x H2O 100%). 
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5.23. Addition of an N-acyl chain 
5.23.1. Tetracosanoic acid [(1S,2S,3R)-2,3-dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-
trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-
amide (68) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (57mg, 112.7µmol), tetracosanoic acid 2,5-
dioxo-pyrrolidin-1-yl ester (54) (76mg, 163µmol), affording a white solid. Yield: 74.8mg, 80%. 
δ 1H (CDCl3:MeOD, 2:1): 4.75-4.78 (H-2’, 1H, d, J=3.6Hz), 3.95-3.98 (H-1, 1H, m), 3.79-3.81 
(H-4’, 1H, d, J=2.98Hz), 3.71-3.76 (H-8a, 1H, dd, J=4.81, 11.0Hz), 3.56-3.58 (H-3’, H-6’, 2H, 
m), 3.50-3.54 (H-5’, H-7’ab, 3H, m), 3.47-3.49 (H-8b, 1H, m), 3.31-3.46 (H-2, H-3, 2H, m), 
2.13-2.15 (H-2’’ab, 2H, t, J=7.5Hz), 1.45-1.64 (H-3’’a, H-4’’a, H-4a, 3H, m), 1.15-1.35 (H-3’’b, 
H-4’’b, H-4b, H-5ab – H16ab, H-5’’ab – H-25’’ab, 67H, m), 0.65-.80 (H-17abc, H-26’’abc, 6H, 
J=6.8Hz). δ 13C (CDCl3:MeOD 2:1):96.66 (C-2’), 74.53 (C-2), 71.8 (C-3), 70.53 (C-6’), 70.03 
(C-5’), 69.49 (C4’), 68.68 (C-3’), 67.23 (C-8), 61.55 (C-7’), 50.25 (C-1), 25.43-36.1 (multiple 
signals C-2’’ – C-25’’, C-4 – C-16), 13.40 (C-26’’, C-17). m/z (ES): 853.7 (M+ + [Na]+ + [H]+ 
30%), 852.7 (M+ + [Na]+ + 100%). HRMS: Calculated for C48H95NO9 [M + Na]+ 852.6905, 
O
8'
1 2 3 C14H29
4-17
HN16 OH
OH
5'
4'
3'
2'
O
1'
6'
7'
OH
HO
OH
OH
1'' C23H47
2''-26''
O
C48H95NO9 
Mol. Wt.: 830.2692 g mol-1
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found 852.6915. αD: +2.5.0°. m.p.: 125-129°C IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 
(C=O)., 1500-1650cm-1 (N-H). 
 
5.23.2. (15Z)-Tetracos-15-enoic acid [2,3-dihydroxy-1-(3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-amide (69) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (470mg, 929µmol), tetracos-15-enoic acid 
2,5-dioxo-pyrrolidin-1-yl ester (55) (717mg, 1.55mmol), affording a white solid.  Yield: 
371mg, 48.2%. δ 1H (CDCl3:MeOD, 2:1): 5.52-5.53 (H-15’’, H-16’’, 2H, m), 4.85-4.88 (H-2’, 
1H, d, J=3.7Hz), 4.14-4.19 (H-1, 1H, m), 3.87-3.90 (H-4’, 1H, d, J=3.7Hz), 3.82-3.87 (H-8a, 
1H, dd, J=4.8, 10.3Hz), 3.74-3.82 (H-3’, H-6’, 2H, m), 3.69-3.74 (H-5’, H-7’ab, 3H, m), 3.63-
3.68 (H-8b, 1H, m), 3.49-3.57 (H-2, H-3, 2H, m), 2.15-2.21 (H-2’’ab, 2H, t, J=7.7Hz), 1.95-
2.02 (H-3’’a, H-4’’a, H-4a, 3H, m), 1.05-1.68 (H-3’’b, H-4’’b, H-4b, H-5ab – H16ab, H-5’’ab – H-
14’’ab, H-17’’ab – H-23’’ab, 61H, m), 0.81-0.87 (H-17abc, H-24’’abc, 6H, J=7.5Hz). δ 13C 
(CDCl3:MeOD 2:1): 134.41 (C-15’’, C-16’’), 104.30 (C-2’), 78.67 (C-2), 75.37 (C-3), 74.85 
(C-6’), 74.38 (C-5’), 73.52 (C4’), 71.90 (C-7’), 69.88 (C-3’), 66.41 (C-8’), 50.06 (C-1), 40.98 
(C-2’’), 27.18-37.01 (multiple signals C-3’’ – C-14’’, C-17’’ – C-23’’, C-4 – C-16), 13.40 (C-
C48H93NO9 
Mol. Wt.: 828.25  g mol-1O
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24’’, C-17). m/z (ES): 851.7 (M+ + [Na]+ + [H]+ 40%), 850.7 (M+ + [Na]+ + 100%). HRMS: 
Calculated for C48H95NO9 [M + Na]+ 850.6748, found 850.6785. αD: +7.6.0°. m.p.: 132-137°C 
IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1600-1675cm-1 (C=C), 1500-1650cm-1  
(N-H). 
5.23.3. (4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid 
[(1S,2S,3R)-2,3-dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-amide (70) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (35mg, 69.2µmmol), docasa-
4,7,10,13,16,19-hexaenoic acid 2,5-dioxo-pyrrolidin-1-yl ester (56) (42mg, 98.7µmol), 
affording a white solid. Yield: 5mg, 10%. δ 1H (CDCl3:MeOD, 2:1): 5.34-5.39 (H-4’’, H-5’’, H-
7’’, H-8’’, H-10’’, H-11’’, H-13’’, H-14’’, H-16’’, H-17’’, H-19’’, H-20’’, 12H, m), 4.81-4.83 (H-2’, 
1H, d, J=3.75Hz), 4.02-4.04 (H-1, 1H, m), 3.75-3.81 (H-4’, 1H, m), 3.71-3.74 (H-8a, 1H, m), 
3.58-3.62 (H-3’, H-6’, 2H, m), 3.51-3.55 (H-5’, H-7’ab, 3H, m), 3.45-3.48 (H-8b, 1H, m), 3.35-
3.42 (H-2, H-3, 2H, m), 2.56-2.80 (H-6’’, H-9’’, H-12’’, H-15’’, H-18’’, 5H, m), 2.16-2.21 (H-
2’’ab, 2H, t, J=7.3Hz), 1.45-1.60 (H-3’’a, H-4a, H-5a, 3H, m), 1.19-1.39 (H-3’’b, H-4b, H-5b, H-
6ab – H16ab, H-21’’ab 27H, m), 0.78-0.83 (H-17abc, H-22’’abc, 6H, J=7.0Hz). m/z (ES): 813.1 
(M+ + [Na]+ + 100%). HRMS: Calculated for C48H95NO9 [M + Na]+ 813.1105, found 813.1130. 
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αD: +10.0°. m.p.: 135-139°C. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1600-
1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.4. (5Z,8Z,11Z,14Z,17Z)-Eicosa-5,8,11,14,17-pentaenoic acid [(1S,2S,3R)-2,3-
dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-
tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-amide (71) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (25mg, 49.4µmol), eicosa-5,8,11,14,17-
pentaenoic acid 2,5-dioxo-pyrrolidin-1-yl ester (57) (31mg, 77.56µmol), affording white solid. 
Yield: 7.5mg, 20%. δ 1H (CDCl3:MeOD, 2:1): 5.28-5.40 (H-5’’, H-6’’, H-8’’, H-9’’, H-11’’, H-
12’’, H-14’’, H-15’’, H-17’’, H-18’’, 10H, m), 4.35-4.38 (H-2’, 1H, d, J=3.1Hz), 4.08-4.09 (H-1, 
1H, m), 3.95-3.99 (H-4’, 1H, m), 3.78-3.80 (H-8a, 1H, dd, J=4.0, 10.5 Hz), 3.59-3.64 (H-3’, H-
6’, 2H, m), 3.49-3.54 (H-5’, H-7’ab, 3H, m), 3.43-3.45 (H-8b, 1H, m), 3.35-3.42 (H-2, H-3, 2H, 
m), 3.01-3.05 (H-7’’, H-10’’, H-13’’, H-16’’, 4H, m), 2.20-2.23 (H-2’’ab, 2H, t, J=7.4Hz), 1.48-
1.62 (H-3’’a, H-4a, H-5a, 3H, m), 1.18-1.42 (H-3’’b, H-4b, H-5b, H-4’’ab, H-6ab – H16ab, H-19’’ab 
– H21’’ab 33H, m), 0.78-0.81 (H-17abc, H-20’’abc, 6H, J=7.3Hz). δ 13C (CDCl3:MeOD 2:1): 
C44H77NO9 
Mol. Wt.: 764.0835 g mol-1 
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127.65-130.8 (multiple signals, C-5’’, C-6’, C-8’’, C-9’’, C-11’’, C-12’’, C-14’’, C-15’’, C-17’’, 
C-18’’), 101.60 (C-2’), 75.45 (C-2), 72.48 (C-3), 69.69 (C-6’), 69.55 (C-5’), 69.09 (C4’), 68.88 
(C-3’), 65.37 (C-8), 60.14 (C-7’), 47.25 (C-1), 24.12-38.21 (multiple signals C-2’’, C-3’’, C-4’’, 
C-7’’, C-10’’, C-13’’, C-16’’, C19’’, C-4 – C-16), 13.40 (C-20’’, C-17). m/z (ES): 788.1 (M+ + 
[Na]+ + [H]+ 20%), 787.1 (M+ + [Na]+ 100%). HRMS: Calculated for C44H77NO9 [M + Na]+ 
787.0732, found 787.0740. αD: +7.1°. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 
1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.5. (5Z,8Z,11Z,14Z)-Eicosa-5,8,11,14-tetraenoic acid [(1S,2S,3R)-2,3-dihydroxy-
1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-
yloxymethyl)-heptadecyl]-amide (72) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (24mg, 47.46µmol), eicosa-5,8,11,14-
tetraenoic acid 2,5-dioxo-pyrrolidin-1-yl ester (58) (27.7mg, 68.9µmol), affording a white 
solid. Yield: 9mg, 25%. δ 1H (CDCl3:MeOD, 2:1): 5.23-5.70 (H-5’’, H-6’’, H-8’’, H-9’’, H-11’’, 
H-12’’, H-14’’, H-15’’, 8H, m), 4.70-4.75 (H-2’, 1H, m), 4.25-4.28 (H-1, 1H, m), 4.01-4.04 (H-
4’, 1H, m), 3.80-3.85 (H-8’a, 1H, dd, J=3.9, 10.8 Hz), 3.54-3.68 (H-3’, H-6’, 2H, m), 3.49-3.54 
(H-5’, H-7’ab, 3H, m), 3.41-3.46 (H-8’b, 1H, m), 3.38-3.40 (H-2, H-3, 2H, m), 2.25-2.36 (H-7’’, 
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H-10’’, H-13’’, 3H, m), 1.98-2.10 (H-2’’ab, 2H, m), 1.45-1.55 (H-3’’a, H-4a, H-5a, 3H, m), 1.15-
1.40 (H-3’’b, H-4b, H-5b, H-4’’ab, H-6ab – H16ab, H-16’’ab – H19’’ab 27H, m), 0.71-0.89 (H-17abc, 
H-20’’abc, 6H, J=7.6Hz). δ 13C (CDCl3:MeOD 2:1): 129.45-130.80 (multiple signals, C-5’’, C-
6’, C-8’’, C-9’’, C-11’’, C-12’’, C-14’’, C-15’’), 100.30 (C-2’), 77.55 (C-2), 73.98 (C-3), 70.19 
(C-6’), 69.31 (C-5’), 69.00 (C4’), 67.97 (C-3’), 66.47 (C-8’), 59.53 (C-7’), 47.74 (C-1), 25.15-
38.14 (multiple signals C-2’’, C-3’’, C-4’’, C-7’’, C-10’’, C-13’’, C-16’’ – C19’’, C-4 – C-16), 
13.40 (C-20’’, C-17). m/z (ES): 790.1 (M+ + [Na]+ + [H]+ 50%), 789.1 (M+ + [Na]+ 100%), 
HRMS: Calculated for C44H77NO9 [M + Na]+ 789.0891, found 789.0905. αD: +7.5°.  
m.p.: 126-129°C. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1600-1675cm-1 (C=C), 
1500-1650cm-1 (N-H). 
 
5.23.6. (11Z,14Z)-Eicosa-11,14-dienoic acid [(1S, 2S, 3R)-2,3-dihydroxy-1-((2S, 3R, 
4S, 5R, 6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-
yloxymethyl)-heptadecyl]-amide (73) 
 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
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hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (110mg, 217.5µmol), eicosa-11,14-dienoic 
acid 2,5-dioxo-pyrrolidin-1-yl ester (59) (134mg, 330µmol), affording a white solid. Yield: 
108mg, 65%. δ 1H (CDCl3: MeOD, 2:1): 5.03-5.13 (H11’’, H12’’, H14’’, H15’’, 4H, m), 4.64-
4.66 (H-2’, 1H, d, J=3.75Hz,), 3.93-3.97 (H-1, 1H, m), 3.66-3.67 (H-4’, 1H, d, J=2.91Hz), 
3.60-3.63 (H-8’a, 1H, dd, J=4.67, 10.76Hz), 3.52-3.55 (H-6’, H-3’, 2H, m), 3.43-3.49 (H-5’, H-
7’ab, 3H, m), 3.39-3.41 (H-8’b, 1H, d, J=4.53Hz), 3.26-3.29 (H-2, H-3, 2H, m), 2.51-2.55 (H-
13’’ab, 2H, t, J=6.60Hz), 1.90-1.94 (H-2’’ab, 2H, t, J=7.60Hz), 1.77-1.80 (H-10’’ab, H-16’’ab, 4H, 
q, J=6.82Hz), 1.27-1.42 (H-4a, H-5a, H-3’’ab, 4H, m), 0.99-1.12 (H-4b, H-5b, H-6ab – H-16ab, H-
4’’ab – H-9’’ab, H-17’’ab – H-19’’ab, 42H, m), 0.64-0.60 (H-17abc, H-20’’abc, 6H, t, J=6.97Hz) δ 
13C (CDCl3: MeOD, 2:1): 175.04 (C-1’’), 130.52, 130.47, 128.41, 128.37 (C-11’’, 12’’, 14’’, 
15’’), 100.26 (C-2’), 75.14 (C-2), 72.43 (C-3), 71.37 (C-6’), 70.77 (C-7’), 70.25 (C-4’), 69.44 
(C-3’), 67.78 (C-8’), 62.26 (C-5’), 50.97 (C-1), 36.88 (C-2’’), 32.92-29.77 (multiple signals, C-
4 – C-15, C-3’’ – C-9’’), 27.64, 27.59 (C-10’’, C-16’’), 26.33, 26.29 (C-17’’, C-18’’), 26.02 (C-
13’’), 23.07, 22.96 (C-16,  C-19’’), 14.25, 14.31 (C-17,  C-20’’). m/z (ES): 793.6 (M+ + [Na]+ + 
[H]+ 25%), 793.6 (M+ + [Na]+ + 100%) HRMS Calculated for C44H83NO9 [M + Na]+ 792.5966, 
found 792.5956. αD: +13.2° m.p. 129-139°C IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 
(C=O), 1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
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5.23.7. (11Z,14Z)-Icosa-11,14-dienoic acid [(1S,2S,3R)-2,3-dihydroxy-1-
((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-
yloxymethyl)-tetradecyl]-amide (74) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-pentadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (40) (45mg, 97.1µmol), eicosa-11,14-dienoic acid 
2,5-dioxo-pyrrolidin-1-yl ester (59) (56.8mg, 140µmol), affording a white solid. Yield: 33.6mg, 
47.5%. δ 1H (CDCl3: MeOD, 2:1): 5.25-5.32 (H11’’, H12’’, H14’’, H15’’, 4H, m), 4.75-4.77 (H-
2’, 1H, d, J=3.61Hz,), 4.10-4.18 (H-1, 1H, m), 3.86-3.88 (H-4’, 1H, d, J=3.5Hz), 3.81-3.85 (H-
8’a, 1H, dd, J=4.8, 10.4Hz), 3.72-3.78 (H-6’, H-3’, 2H, m), 3.67-3.70 (H-5’, H-7’ab, 3H, m), 
3.39-3.41 (H-8’b, 1H, d, J=4.8Hz), 3.47-3.52 (H-2, H-3, 2H, m), 2.18-1.19 (H-13’’ab, 2H, t, 
J=6.5Hz), 1.90-2.04 (H-2’’ab, 2H, m), 1.42-1.65 (H-4a, H-5a, H-3’’ab, 4H, m), 1.18-1.39 (H-4b, 
H-5b, H-6ab – H-13ab, H-4’’ab – H-10’’ab, H-13’’ab, H-16’’ab – H-19’’ab, 42H, m), 0.64-0.60 (H-
14abc, H-20’’abc, 6H, t, J=7.3Hz) δ 13C (CDCl3: MeOD, 2:1): 169.04 (C-1’’), 128.82-130.74 (C-
11’’, 12’’, 14’’, 15’’), 101.80 (C-2’), 74.91 (C-2), 72.56 (C-3), 71.09 (C-6’), 70.77 (C-7’), 70.33 
(C-4’), 68.48 (C-3’), 67.17 (C-8’), 61.11 (C-5’), 48.73 (C-1), 34.42 (C-2’’), 22.10-30.02 
(multiple signals, C-4 – C-13, C-3’’ – C-10’’, C-13’’, C-16’’ – C-19’’), 17.51, 18.16 (C-14, C-
20’’). m/z (ES): 752.0 (M+ + [Na]+ + [H]+ 5%), 751.0 (M+ + [Na]+ + 100%). HRMS: Calculated 
C41H77NO9 
Mol. Wt.: 728.0514 g mol-1
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for C44H83NO9 [M + Na]+ 751.0411, found 751.0429. αD: +26.0°. m.p.: 127-135°C IR: 3200-
3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.8. (11Z,14Z)-Eicosa-11,14-dienoic acid [(1S,2S,3R)-2,3-dihydroxy-1-
((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-
yloxymethyl)-undecyl]-amide (75) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation using 
(2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-dodecyloxy)-6-hydroxymethyl-
tetrahydro-pyran-3,4,5-triol (41) (54mg, 128.2µmol), Eicosa-11,14-dienoic acid 2,5-dioxo-
pyrrolidin-1-yl ester (59) (77.3mg, 190µmol), affording a white solid. Yield: 55.4mg, 63%.  
δ 1H (CDCl3: MeOD, 2:1): 5.25-5.30 (H11’’, H12’’, H14’’, H15’’, 4H, m), 4.80-4.84 (H-2’, 1H, 
d, J=3.7Hz,), 4.12-4.16 (H-1, 1H, m), 3.87-3.89 (H-4’, 1H, d, J=3.7Hz), 3.79-3.85 (H-8’a, 1H, 
dd, J=4.5, 10.5Hz), 3.72-3.77 (H-6’, H-3’, 2H, m), 3.67-3.69 (H-5’, H-7’ab, 3H, m), 3.49-3.65 
(H-8’b, 1H, m), 3.46-3.51 (H-2, H-3, 2H, m), 2.12-2.18 (H-13’’ab, 2H, t, J=6.5Hz), 1.95-2.02 
(H-2’’ab, 2H, m), 1.46-1.66 (H-4a, H-5a, H-3’’ab, 4H, m), 1.16-1.32 (H-4b, H-5b, H-6ab – H-10ab, 
H-4’’ab – H-10’’ab, H-13’’ab, H-16’’ab – H-19’’ab, 42H, m), 0.78-0.87 (H-11abc, H-20’’abc, 6H, t, 
J=7.5Hz) δ 13C (CDCl3: MeOD, 2:1): 170.45 (C-1’’), 130.65-133.13 (C-11’’, 12’’, 14’’, 15’’), 
C38H71NO9 
Mol. Wt.: 685.9717 g mol-1
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102.00 (C-2’), 75.71 (C-2), 72.99 (C-3), 72.09 (C-6’), 70.46 (C-7’), 70.03 (C-4’), 69.38 (C-3’), 
68.17 (C-8’), 60.24 (C-5’), 45.62 (C-1), 34.20 (C-2’’), 25.44-30.82 (multiple signals, C-4 – C-
10, C-3’’ – C-10’’, C-13’’, C-16’’ – C-19’’), 17.51, 18.16 (C-11,  C-20’’). m/z (ES): 725.9 (M+ + 
[K]+ + [H]+ 2%), 724.9 (M+ + [K]+ + 100%), 301.2 (M+ + [H]+ + [K]+ - C6H11O6 (galactose) - 
C20H35O (eicosa-11,14-dienoic acid) 25%).  HRMS: Calculated for C44H83NO9 [M + Na]+ 
708.9614, found 708.9624. αD: +13.5° IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 
1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.9. (11Z,14Z)-Eicosa-11,14-dienoic acid [(1S,2S,3R)-2,3-dihydroxy-1-
((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-
yloxymethyl)-octyl]-amide (76) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-nonyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (42) (30mg, 79.1µmol), eicosa-11,14-dienoic acid 
2,5-dioxo-pyrrolidin-1-yl ester (59) (46.3mg, 114µmol), affording a white solid. Yield: 27.5mg, 
54%. δ 1H (CDCl3: MeOD, 2:1):  5.24-5.39 (H11’’, H12’’, H14’’, H15’’, 4H, m), 4.65-4.69 (H-
2’, 1H, d, J=3.5Hz,), 3.93-4.02 (H-1, 1H, m), 3.87-3.90 (H-4’, 1H, m), 3.77-3.82 (H-8’a, 1H, 
dd, J=4.6, 10.5Hz), 3.72-3.77 (H-6’, H-3’, 2H, m), 3.60-3.65 (H-5’, H-7’ab, 3H, m), 3.54-3.58 
C35H65NO9 
Mol. Wt.: 643.8919g mol-1
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(H-8’b, 1H, m), 3.50-3.53 (H-2, H-3, 2H, m), 2.15-2.20 (H-13’’ab, 2H, t, J=6.5Hz), 1.94-2.04 
(H-2’’ab, 2H, m), 1.52-1.64 (H-4a, H-5a, H-3’’ab, 4H, m), 1.18-1.35 (H-4b, H-5b, H-6ab – H-7ab, 
H-4’’ab – H-10’’ab, H-13’’ab, H-16’’ab – H-19’’ab, 30H, m), 0.85-0.88 (H-8abc, H-20’’abc, 6H, t, 
J=6.9Hz) δ 13C (CDCl3: MeOD, 2:1): 131.54-133.15 (C-11’’, 12’’, 14’’, 15’’), 99.80 (C-2’), 
74.76 (C-2), 72.38 (C-3), 71.99 (C-6’), 70.22 (C-7’), 69.75 (C-4’), 69.08 (C-3’), 67.89 (C-8’), 
61.00 (C-5’), 46.51 (C-1), 33.80 (C-2’’), 22.66-31.12 (multiple signals, C-4 – C-7, C-3’’ – C-
10’’, C-13’’, C-16’’ – C-19’’), 16.51, 18.16 (C-8,  C-20’’). m/z (ES): 667.9 (M+ + [Na]+ + [H]+ 
15%), 666.9 (M+ + [Na]+ 100%). HRMS: Calculated for C35H65NO9 [M + Na]+ 666.8816, found 
666.8820. αD:+13.8° m.p. 124-135°C IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 
1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.10. (11E)-Eicos-11-enoic acid [(1S, 2S, 3R)-2,3-dihydroxy-1-((2S, 3R, 4S, 5R, 
6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-
heptadecyl]-amide (77) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (50.97mg, 100.7µmol), (11E)-eicosa-11-
enoic acid 2,5-dioxo-pyrrolidin-1-yl ester (61) (49.5mg, 159µmol), affording a white solid. 
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Yield: 38.1mg, 49%. δ 1H (CDCl3: MeOD, 2:1):  5.31-5.34 (H11’’, H12’’, 2H, m), 4.84-4.86 
(H-2’, 1H, d, J=3.6Hz,), 4.12-4.15 (H-1, 1H, m), 3.88-3.89 (H-4’, 1H, d, J=3.3Hz), 3.81-3.85 
(H-8’a, 1H, dd, J=4.6, 10.4Hz), 3.72-3.77 (H-6’, H-3’, 2H, m), 3.65-3.72 (H-5’, H-7’ab, 3H, m), 
3.61-3.65 (H-8’b, 1H, dd, J=4.6, 10.8Hz), 3.47-3.50 (H-2, H-3, 2H, m), 2.13-2.17 (H-2’’ab, 2H, 
t, J=7.4Hz), 1.87-1.93 (H-3’’ab, H-4ab, 4H, m), 1.43-1.65 (H-4’’ab, H-10’’ab, H-13’’ab, 6H, m), 
1.01-1.30 (H-5ab – H-16ab, H-5’’ab – H-9’’ab, H-14’’ab – H-19’’ab, 46H, m), 0.80-0.84 (H-17abc, 
H-20’’abc, 6H, t, J=6.8Hz) δ 13C (CDCl3: MeOD, 2:1):130.31-132.5 (C-11’’, 12’’), 100.08 (C-
2’), 73.33 (C-2), 73.01 (C-3), 72.24 (C-6’), 70.56 (C-7’), 70.02 (C-4’), 69.87 (C-3’), 67.9 (C-
8’), 62.38 (C-5’), 46.38 (C-1), 34.77 (C-2’’), 21.87-30.20 (multiple signals, C-4 – C-16, C-3’’ – 
C-10’’, C-13’’ – C-19’’), 15.82, 16.41 (C-17,  C-20’’). m/z (ES): 795.6 (M+ + [Na]+ + [H]+ 20%), 
794.7 (M+ + [Na]+  100%). HRMS Calculated for C35H65NO9 [M + Na]+ 794.6122, found 
794.6115. αD: +18.0° m.p. 122-138°C IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 
1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.11. (11Z)-Eicos-11-enoic acid [(1S, 2S, 3R)-2,3-dihydroxy-1-((2S, 3R, 4S, 5R, 
6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-
heptadecyl]-amide (78) 
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Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (63.7mg, 125.9µmol), (11Z)-eicosa-11-enoic 
acid 2,5-dioxo-pyrrolidin-1-yl ester (60) (59.5mg, 191.6µmol), affording a white solid. Yield 
67mg, 69%. δ 1H (CDCl3: MeOD, 2:1): 5.27-5.31 (H11’’, H12’’, 2H, t, J=4.6Hz), 4.84-4.86 (H-
2’, 1H, d, J=3.4Hz,), 4.13-4.17 (H-1, 1H, m), 3.87-3.89 (H-4’, 1H, d, J=2.9Hz), 3.81-3.86 (H-
8’a, 1H, dd, J=4.7, 10.8Hz), 3.73-3.77 (H-6’, H-3’, 2H, m), 3.67-3.72 (H-5’, H-7’ab, 3H, m), 
3.61-3.67 (H-8’b, 1H, m), 3.47-3.52 (H-2, H-3, 2H, m), 2.13-2.18 (H-2’’ab, 2H, t, J=7.6Hz), 
1.94-1.99 (H-3’’ab, H-4ab, 4H, m), 1.46-1.65 (H-10’’ab, H-13’’ab, 4H, m), 1.17-1.32 (H-5ab – H-
16ab, H-4’’ab – H-9’’ab, H-14’’ab – H-19’’ab, 46H, m), 0.81-0.85 (H-17abc, H-20’’abc, 6H, t, 
J=6.8Hz). δ 13C (CDCl3: MeOD, 2:1): 130.31-132.7 (C-11’’, 12’’), 101.80 (C-2’), 74.43 (C-2), 
73.91 (C-3), 73.34 (C-6’), 71.66 (C-7’), 71.12 (C-4’), 69.97 (C-3’), 68.59 (C-8’), 63.88 (C-5’), 
46.48 (C-1), 35.17 (C-2’’), 20.26-32.10 (multiple signals, C-4 – C-16, C-3’’ – C-10’’, C-13’’ – 
C-19’’), 15.95, 16.31 (C-17,  C-20’’). m/z (ES): 795.8 (M+ + [Na]+ + [H]+ 15%), 794.7 (M+ + 
[Na]+  100%). HRMS: Calculated for C35H65NO9 [M + Na]+ 794.6122, found 794.6133. αD: 
+20.0°. m.p.: 127-133°C IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1600-1675cm-1 
(C=C), 1500-1650cm-1 (N-H). 
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5.23.12. Eicosanoic acid [(1S, 2S, 3R)-2,3-dihydroxy-1-((2S, 3R, 4S, 5R, 6R)- 3,4,5-
trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-
amide (79) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (55mg, 98.9µmol), eicosanoic acid 2,5-
dioxo-pyrrolidin-1-yl ester (62) (56.7mg, 138.5µmol), affording a white solid. Yield: 49mg, 
64%. δ 1H (CDCl3:MeOD, 2:1): 4.78-4.82 (H-2’, 1H, d, J=3.7Hz), 3.96-3.99 (H-1, 1H, m), 
3.81-3.83 (H-4’, 1H, d, J=3.1Hz), 3.72-3.76 (H-8a, 1H, dd, J=4.8, 10.7Hz), 3.58-3.60 (H-3’, 
H-6’, 2H, m), 3.52-3.55 (H-5’, H-7’ab, 3H, m), 3.47-3.49 (H-8b, 1H, m), 3.32-3.47 (H-2, H-3, 
2H, m), 2.15-2.19 (H-2’’ab, 2H, t, J=7.6Hz), 1.48-1.63 (H-3’’a, H-4’’a, H-4a, 3H, m), 1.19-1.40 
(H-3’’b, H-4’’b, H-4b, H-5ab – H16ab, H-5’’ab – H-19’’ab, 57H, m), 0.80-0.83 (H-17abc, H-20’’abc, 
6H, J=6.9Hz). δ 13C (CDCl3:MeOD 2:1): 98.85 (C-2’), 76.52 (C-2), 73.49 (C-3), 71.88 (C-6’), 
70.65 (C-5’), 69.17 (C4’), 68.24 (C-3’), 66.91 (C-8), 62.35 (C-7’), 51.26 (C-1), 26.30-36.10 
(multiple signals C-2’’ – C-19’’, C-4 – C-16), 15.60 (C-20’’, C-17). m/z (ES): 796.6 (M+ + 
[Na]+ + 100%). HRMS: Calculated for C44H87NO9 [M + Na]+ 796.6279, found 796.6276.  
αD: +5.6°. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1500-1650cm-1 (N-H). 
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5.23.13. (9Z, 12Z)-Octadeca-9,12-dienoic acid [(1S, 2S, 3R)-2,3-dihydroxy-1-((2S, 3R, 
4S, 5R, 6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-
yloxymethyl)-heptadecyl]-amide (80) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (45mg, 88.99µmol), (9Z,12Z)-Octadeca-
9,12-dienoic acid 2,5-dioxo-pyrrolidin-1-yl ester (63) (56.44mg, 0.149mmol), affording a 
white solid.Yield 27mg, 42%. δ 1H (CDCl3: MeOD, 2:1): 5.21-5.35 (H9’’, H10’’, H12’’, H13’’, 
4H, m), 4.60-4.63 (H-2’, 1H, d, J=3.65Hz,), 4.10-4.18 (H-1, 1H, m), 3.98-4.07 (H-4’, 1H, d, 
J=3.2Hz), 3.79-3.83 (H-8’a, 1H, dd, J=4.6, 10.8Hz), 3.62-3.75 (H-6’, H-3’, 2H, m), 3.58-361 
(H-5’, H-7’ab, 3H, m), 3.46-3.52 (H-8’b, 1H, m), 441-3.44 (H-2, H-3, 2H, m), 2.82-2.88 (H-
11’’ab, 2H, m), 2.18-2.21 (H-2’’ab, 2H, t, J=7.8Hz), 1.82-2.01 (H-8’’ab, H-14’’ab, 4H, m), 1.43-
1.66 (H-4a, H-5a, H-3’’ab, 4H, m), 1.15-1.39 (H-4b, H-5b, H-6ab – H-16ab, H-4’’ab – H-8’’ab, H-
15’’ab – H-17’’ab, 40H, m), 0.81-0.93 (H-17abc, H-18’’abc, 6H, t, J=7.0Hz) δ 13C (CDCl3: MeOD, 
2:1): 175.34 (C-1’’), 131.02, 130.97, 128.91, 128.87 (C-9’’, 10’’, 12’’, 13’’), 100.76 (C-2’), 
75.64 (C-2), 72.63 (C-3), 71.87 (C-6’), 70.27 (C-7’), 69.56 (C-4’), 69.04 (C-3’), 67.98 (C-8’), 
62.56 (C-5’), 50.47 (C-1), 36.38 (C-2’’), 29.77-31.57 (multiple signals, C-4 – C-16, C-3’’ – C-
8’’, C-11’’, C-14’’ – C17’’), 15.75, 14.81 (C-17,  C-18’’). m/z (ES): 64.0 (M+ + [Na]+ + [H]+ 
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30%), 763.0 (M+ + [Na]+ 100%). HRMS: Calculated for C42H79NO9 [M + Na]+ 763.0677, found 
763.0686. αD: 6.1° mp.: 121-135°C  IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 
1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.14. (9Z,12Z)-Octadeca-9,12-dienoic acid [(1S,2S,3R)-2,3-dihydroxy-1-
((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-
yloxymethyl)-tetradecyl]-amide (81) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (40) (49.5mg, 106.78µmol), (9Z,12Z)-Octadeca-
9,12-dienoic acid 2,5-dioxo-pyrrolidin-1-yl ester (63) (66.3mg, 0.18mmol), affording a white 
solid. Yield: 35mg, 47.8%. δ 1H (CDCl3: MeOD, 2:1): 5.28-5.36 (H9’’, H10’’, H12’’, H13’’, 4H, 
m), 4.84-4.88 (H-2’, 1H, d, J=4.0Hz,), 4.15-4.19 (H-1, 1H, m), 3.86-3.89 (H-4’, 1H, d, 
J=2.8Hz), 3.81-3.85 (H-8’a, 1H, dd, J=5.0, 11.1Hz), 3.74-3.77 (H-6’, H-3’, 2H, m), 3.67-3.72 
(H-5’, H-7’ab, 3H, m), 3.62-3.67 (H-8’b, 1H, m), 3.46-3.54 (H-2, H-3, 2H, m), 2.22-225 (H-
11’’ab, 2H, t, J=7.8Hz), 2.15-2.18 (H-2’’ab, 2H, t, J=7.7Hz), 1.46-1.66 (H-18’’ab, H-14’’ab, 4H, 
m), 1.18-1.40 (H-4ab – H-13ab, H-3’’ab – H-7’’ab, H-15’’ab – H-17’’ab, 36H, m), 0.80-0.87 (H-
14abc, H-18’’abc, 6H, t, J=6.9Hz). m/z (ES): 738.9 (M+ + [k]+ + [H]+ 100%) HRMS: Calculated 
C39H73NO9 
Mol. Wt.: 699.9983 g mol-1
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for C39H73NO9 [M + Na]+ 722.988, found 722.9861. αD: +24.6° m.p.: 128-137°C IR: 3200-
3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.15. (9Z,12Z)-Octadeca-9,12-dienoic acid [(1S,2S,3R)-2,3-dihydroxy-1-
((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-
yloxymethyl)-undecyl]-amide (82) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-dodecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (41) (49mg, 116.3µmol), (9Z,12Z)-octadeca-9,12-
dienoic acid 2,5-dioxo-pyrrolidin-1-yl ester (63) (73.3mg, 0.19mmol), affording a white solid. 
Yield: 31mg, 41%. δ 1H (CDCl3: MeOD, 2:1): 5.30-5.34 (H9’’, H10’’, H12’’, H13’’, 4H, m), 
4.84-4.87 (H-2’, 1H, d, J=3.7Hz,), 4.14-4.18 (H-1, 1H, m), 3.87-3.90 (H-4’, 1H, d, J=2.87Hz), 
3.82-3.86 (H-8’a, 1H, dd, J=4.8, 10.9Hz), 3.7-3.76 (H-6’, H-3’, 2H, m), 3.66-3.72 (H-5’, H-7’ab, 
3H, m), 3.61-3.66 (H-8’b, 1H, m), 3.47-3.50 (H-2, H-3, 2H, m), 2.21-2.25 (H-11’’ab, 2H, t, 
J=8Hz), 2.14-2.18 (H-2’’ab, 2H, t, J=7.5Hz), 1.45-1.67 (H-8’’ab, H-14’’ab, 4H, m), 1.18-1.37 (H-
4ab – H-10ab, H-3’’ab – H-7’’ab, H-15’’ab – H-17’’ab, 30H, m), 0.80-0.88 (H-14abc, H-18’’abc, 6H, t, 
J=7.0Hz). δ 13C (CDCl3: MeOD, 2:1): 127.57-131.49 (C-9’’, 10’’, 12’’, 13’’), 101.5 (C-2’), 
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75.14 (C-2), 73.36 (C-3), 72.85 (C-6’), 71.18 (C-7’), 70.92 (C-4’), 70.04 (C-3’), 68.31 (C-8’), 
62.48 (C-5’), 51.11 (C-1), 37.00 (C-2’’), 27.65-34.22- (multiple signals, C-4 – C-10, C-3’’ – C-
8’’, C-11’’, C14’’-C17’’), 15.06, 14.91 (C-11,  C-18’’). m/z (ES): 681.9 (M+ + [Na]+ + [H]+ 
10%), 680.9 (M+ + [Na]+ 100%). HRMS: Calculated for C39H73NO9 [M + Na]+ 680.9299, found 
680.9305. αD: +10.9°. m.p.: 126-136°C. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 
1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.16. (9Z,12Z)-Octadeca-9,12-dienoic acid [(1S,2S,3R)-2,3-dihydroxy-1-
((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-
yloxymethyl)-octyl]-amide (83) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-nonyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (42) (27.4mg, 72.2µmol), (9Z,12Z)-octadeca-
9,12-dienoic acid 2,5-dioxo-pyrrolidin-1-yl ester (63) (37.4mg, 99.04µmol), affording a white 
solid. Yield: 16mg, 36%. δ 1H (CDCl3: MeOD, 2:1): 5.31-5.38 (H9’’, H10’’, H12’’, H13’’, 4H, 
m), 4.83-4.87 (H-2’, 1H, d, J=3.75Hz,), 4.14-4.18 (H-1, 1H, m), 3.86-3.89 (H-4’, 1H, d, 
J=3.05Hz), 3.83-3.87 (H-8’a, 1H, dd, J=4.9, 10.6Hz), 3.75-3.78 (H-6’, H-3’, 2H, m), 3.65-3.71 
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(H-5’, H-7’ab, 3H, m), 3.61-3.65 (H-8’b, 1H, m), 3.47-3.50 (H-2, H-3, 2H, m), 2.22-2.24 (H-
11’’ab, 2H, t, J=7.8Hz), 2.15-2.18 (H-2’’ab, 2H, t, J=7.65Hz), 1.40-1.69 (H-8’’ab, H-14’’ab, 4H, 
m), 1.21-1.40 (H-4ab – H-7ab, H-3’’ab – H-7’’ab, H-15’’ab – H-17’’ab, 30H, m), 0.80-0.88 (H-8abc, 
H-18’’abc, 6H, t, J=7.2Hz). δ 13C (CDCl3: MeOD, 2:1): 126.56-130.49 (C-9’’, 10’’, 12’’, 13’’), 
100.8 (C-2’), 74.64 (C-2), 73.26 (C-3), 71.65 (C-6’), 71.20 (C-7’), 70.63 (C-4’), 70.01 (C-3’), 
68.43 (C-8’), 62.38 (C-5’), 50.71 (C-1), 35.67 (C-2’’), 27.55-35.22- (multiple signals, C-4 – C-
7, C-3’’ – C-8’’, C-11’’, C14’’-C17’’), 15.00, 13.21 (C-8,  C-18’’). m/z (ES): 655.8 (M+ + [K]+ + 
[H]+ 28%), 654.8 (M+ + [K]+ 100%). HRMS: Calculated for C33H61NO9 [M + Na]+ 638.8285, 
found 638.8292. αD: +15.1°. m.p.: 121-131°C. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 
(C=O), 1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.17. Octanoic acid [(1S, 2S, 3R)-2,3-dihydroxy-1-((2S, 3R, 4S, 5R, 6R)-3,4,5-
trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-
amide (84) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
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hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (125.5mg, 248.2µmol), Octanoic acid 2,5-
dioxo-pyrrolidin-1-yl ester (64) (64.9mg, 269µmol), affording a white solid. Yield: 108mg, 
72%. δ 1H (CDCl3:MeOD, 2:1): 4.84-4.88 (H-2’, 1H, d, J=3.8Hz), 4.16-4.25 (H-1, 1H, m), 
3.89-3.92 (H-4’, 1H, d, J=3.0Hz), 3.83-3.87 (H-8’a, 1H, dd, J=4.7, 10.7Hz), 3.74-3.79 (H-3’, 
H-6’, 2H, m), 3.68-3.72 (H-5’, H-7’ab, 3H, m), 3.63-3.67 (H-8’b, 1H, dd, J=4.7, 10.7Hz), 3.49-
3.55 (H-2, H-3, 2H, m), 2.16-2.2 (H-2’’, 2H, t, J=7.7Hz), 1.48-1.66 (H-3’’a, H-4’’a, H-4a, 3H, 
m), 1.17-1.38 (H-4b, H-5ab – H-16ab, H-3’’b, H-4’’b, H-5’’ab – H -7’’ab, 33H, m), 0.88-0.82 (H-
17abc, H-8’’abc, 6H, m) δ 13C (CDCl3:MeOD, 2:1): 100.34 (C-2’), 75.15 (C-2), 72.55 (C-3), 
71.41 (C-6’), 70.88 (C-5’), 70.48 (C-4’), 69.52 (C-3’) , 67.82 (C-8’), 62.36 (C-7’), 51.05 (C-1), 
36.93 (C-2’’), 32.95 (C-4), 32.46-29.59 (multiple signals, C5-16, 6’’-7’’), 26.44, 26.40 (C-3’’, 
4’’), 23.16 (C-5’’), 14.29, 14.26 (C-18, C-8’’). m/z (ES): 629.8 (M+ + [Na]+ + [H]+ 8%), 628.7 
(M+ + [Na]+ 100%). HRMS: Calculated for C33H61NO9 [M + Na]+ 628.4401, found 628.4389. 
αD: +4.8° m.p.: 115-123°C. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1500-
1650cm-1 (N-H). 
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5.23.18. N-[(1S,2S,3R)-2,3-Dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-3-
propionamide (85) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (31mg, 631µmol), methyl-PEO4-NHS ester 
(Pierce Biotechnology) (referred to here as (66)) (29.2mg, 88mmol). Butanol was used 
instead of EtOAc in the work up, affording an opaque oil. Yield: 374mg, 85%. δ 1H 
(CDCl3:MeOD, 2:1): 4.85-4.87 (H-2’, 1H, d, J=3.8Hz), 4.23-4.27 (H-1, 1H, m), 3.90-3.93 (H-
4’, 1H, d, J=4.6Hz), 3.87-3.90 (H-8’a, 1H, m), 3.79-3.82 (H-3’, H-6’, 2H, t, J=6.1Hz), 3.74-
3.78 (H-8’b, 1H, dd, J=4.2, 9.9Hz), 3.68-3.74 (H-5’, H-7’ab, 3H, m), 3.59-3.64 (H-3’’ab – H-
9’’ab, 14H, m), 3.51-3.55 (H-2, H-3, H-10’’abc, 5H, m), 2.45-2.49 (H-2’’, 2H, t, J=6.1Hz), 1.48-
1.72 (H-4a, H-5a, 2H, m), 1.21-1.33 (H-4b, H-5b, H-6ab – H-16ab, 24H, m), 0.84-0.88 (H-17abc, 
3H, t, J=7.1Hz) δ 13C (CDCl3:MeOD, 2:1): 170.4 (C-1’’), 98.9 (C-2’), 78.2 (C-2), 70.1 (C-3), 
70.0 (C-8’), 69.8 (C-6’), 67.8 (C-4’), 65.4 (C-3’), 65.5-72.8 (multiple signals, C-3’’ – C-9’’), 
61.5 (C-7’), 57.3 (C-5’), 53.2 (C-10’’),  38.5 (C-2’’), 29.59-31.8 (multiple signals, C4-16), 17.7 
(C-18). m/z (ES): 721.8 (M+ + [Na]+ + [H]+ 20%), 720.8 (M+ + [Na]+ 100%). HRMS  
Calculated for C34H67NO13 [M + Na]+ 720.4510, found 720.4491. αD: +7.7°. IR: 3200-3400cm-
1 (br OH), 1750-1750cm-1 (C=O), 1400-1420cm-1 (C-O), 1500-1650cm-1 (N-H). 
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5.23.19. N-[(1S,2S,3R)-2,3-Dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-3-(2-ethoxy)-
ethoxy]-ethoxy}-ethoxy)-propionamide (86) 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (30mg, 59.3µmol), methyl-PEO8-NHS ester 
(Pierce Biotechnology) (referred to as (67)) (44.62mg, 87.64mmol). Butanol was used 
instead of EtOAc in the work-up, affording an opaque oil. Yield: 38.4mg, 74%. δ 1H 
(CDCl3:MeOD, 2:1): 4.54-4.59 (H-2’, 1H, d, J=3.75Hz), 4.15-4.20 (H-1, 1H, m), 3.92-3.94 (H-
4’, 1H, m), 3.88-3.93 (H-8’a, 1H, m), 3.80-3.83 (H-3’, H-6’, 2H, m), 3.75-3.78 (H-8’b, 1H, dd, 
J=4.2, 9.9Hz), 3.70-3.74 (H-5’, H-7’ab, 3H, m), 3.50-3.64 (H-3’’ab – H-17’’ab, 30H, m), 3.49-
3.50 (H-2, H-3, H-18’’abc, 5H, m), 2.43-2.48 (H-2’’, 2H, t, J=6.1Hz), 1.50-1.67 (H-4a, H-5a, 2H, 
m), 1.181-1.35 (H-4b, H-5b, H-6ab – H-16ab, 24H, m), 0.81-0.85 (H-17abc, 3H, t, J=7.0Hz) δ 13C 
(CDCl3:MeOD, 2:1): 101.2 (C-2’), 80.4 (C-2), 78.8 (C-3), 78.5 (C-8’), 76.1 (C-6’), 76.0 (C-4’), 
72.5 (C-3’), 68.5-75.5 (multiple signals, C-3’’ – C-17’’), 63.5 (C-7’), 59.8 (C-5’), 54.9 (C-18’’),  
39.7 (C-2’’), 31.8-38.9 (multiple signals, C4-16), 19.9 (C-18). m/z (ES): 897.7 (M+ + [Na]+ + 
[H]+ 30%), 896.6 (M+ + [Na]+ 100%). HRMS: Calculated for C42H83NO17 [M + Na]+ 896.5559, 
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found 896.5566. αD: +5.8°. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1400-
1420cm-1 (C-O), 1500-1650cm-1 (N-H). 
 
5.23.20. N-[(1S,2S,3R)-2,3-Dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-2-m-tolyl-
acetamide (87) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5R,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (39) (25mg, 49.44µmol), m-tolyl-acetic acid 2,5-
dioxo-pyrrolidin-1-yl ester  (17.04mg, 68.9µmol), affording an opaque oil. Yield: 21mg, 70%. 
δ 1H (CDCl3:MeOD, 2:1): 6.89-7.25 (H-3’’, H-6’’, H-7’’), 4.66-4.70 (H-2’, 1H, d, J=4.6Hz), 
3.67-3.70 (H-1, 1H, m), 3.63-3.66 (H-4’, 1H, d, J=3.8Hz), 3.55-3.61 (H-8’a, 1H, dd, J=4.1, 
9.9Hz), 3.49-3.54 (H-3’, H-6’, 2H, m), 3.45-3.49 (H-8’b, 1H, m), 3.36-3.44 (H-5’, H-7’ab, 3H, 
m), 3.29-3.34 (H-2’’ab, H-9’’abc, 2H, m), 3.13-3.20 (H-2, H-3, 2H, m), 1.33-1.46 (H-4a, H-5a, 
2H, m), 0.97-1.18 (H-4b, H-5b, H-6ab – H-16ab, 24H, m), 0.65-0.73 (H-17abc, 3H, t, J=7.3Hz). δ 
13C (CDCl3:MeOD, 2:1): 178.5 (C-1’’), 138.8, 140.2 (C-4’’, C-8’’), 129.1-132.9 (C-3’’, C-5’’, C-
6’’, C-7’’), 102.7 (C-2’), 71.9-77.7 (C-2, C-3, C-3’, C-4’, C-5’, C-6’),  70.35 (C-8’), 64.9 (C-7’), 
53.5 (C-1), 46.3 (C-2’’), 28.12-35.7 (C-4 – C-16), 24.12 (C-9’’), 16.9 (C-17).  m/z (ES): 635.3 
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(M+ + [Na]+ + [H]+ 20%), 634.4 (M+ + [Na]+ 100%). HRMS: Calculated for C33H57NO9 [M + 
Na]+ 634.3931, found 634.3954. αD: +17.7°. IR: 3200-3400cm-1 (br OH), 3000-3100cm-1 (Ar), 
1750-1750cm-1 (C=O), 1500-1650cm-1 (N-H). 
 
5.23.21. Tetracosanoic acid [(1S,2S,3R)-2,3-dihydroxy-1-(3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-amide (88) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation using 
(2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-hydroxymethyl-
tetrahydro-pyran-3,4,5-triol (49) (55mg, 108.8µmol), tetracosanoic acid 2,5-dioxo-pyrrolidin-
1-yl ester (54) (72.8mg, 160µmol), affording a white solid. Yield: 48.7mg, 54%. δ 1H 
(CDCl3:MeOD, 2:1): 4.8-4.82 (H-2’, 1H, d, J=3.8Hz), 4.12-4.16 (H-1, 1H, m), 4.02-4.04 (H-4’, 
1H, m), 3.81-3.85 (H-8a, 1H, dd, J=4.9, 10.6Hz), 3.73-3.77 (H-5’, 1H, dd, J=2.4, 12Hz), 3.64-
3.68 (H-3’, H-6’, H-5’, 3H, m), 3.62-3.64 (H-7ab, 2H, m), 3.49-3.55 (H-2, H-3, 2H, m), 3.38-
3.42 (H-8’b, 1H, dd, J=3.8, 9.8Hz), 2.13-2.18 (H-2’’ab, 2H, t, J=7.5Hz), 1.46-1.65 (H-3’’a, H-
4’’a, H-4a, 3H, m), 1.15-1.35 (H-3’’b, H-4’’b, H-4b, H-5ab – H16ab, H-5’’ab – H-23’’ab, 65H, m), 
0.81-.85 (H-17abc, H-24’’abc, 6H, J=6.9Hz). δ 13C (CDCl3:MeOD 2:1): 96.87 (C-2’), 74.51 (C-
2), 71.0 (C-3), 70.53 (C-6’), 70.03 (C-5’), 69.49 (C4’), 68.68 (C-3’), 67.23 (C-8), 61.55 (C-7’), 
51.25 (C-1), 25.43-36.1 (multiple signals C-2’’ – C-23’’, C-4 – C-16), 15.40 (C-24’’, C-17). 
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m/z (ES): 853.9 (M+ + [Na]+ + [H]+ 20%), 852.9 (M+ + [Na]+ + 100%) HRMS: Calculated for 
C48H95NO9 [M + Na]+ 852.6905, found 852.6920. αD: +12.9°. m.p.: 125-129°C IR:3200-
3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1500-1650cm-1 (N-H). 
 
5.23.22. (4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid 
[(1S,2S,3R)-2,3-dihydroxy-1-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-
pyran-2-yloxymethyl)-heptadecyl]-amide (89) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (49) (33mg, 65.3µmol), (4Z,7Z,10Z,13Z,16Z,19Z) 
-docosa-4,7,10,13,16,19-hexaenoic acid 2,5-dioxo-pyrrolidin-1-yl ester (56) (42mg, 
98.7µmol), affording a white solid. Yield: 3mg, 6% δ 1H (CDCl3:MeOD, 2:1): 5.55-5.49 (H-4’’, 
H-5’’, H-7’’, H-8’’, H-10’’, H-11’’, H-13’’, H-14’’, H-16’’, H-17’’, H-19’’, H-20’’, 12H, m), 4.91-
4.94 (H-2’, 1H, d, J=3.7Hz), 4.15-4.19 (H-1, 1H, m), 3.89-3.99 (H-4’, 1H, m), 3.81-3.85 (H-
8’a, 1H, m), 3.62-3.66 (H-3’, H-6’, 2H, m), 3.58-3.61 (H-5’, H-7’ab, 3H, m), 3.50-3.57 (H-8’b, 
1H, m), 3.45-3.48 (H-2, H-3, 2H, m), 2.60-2.75 (H-6’’, H-9’’, H-12’’, H-15’’, H-18’’, 5H, m), 
2.26-2.31 (H-2’’ab, 2H, t, J=7.1Hz), 1.55-1.80 (H-3’’a, H-4a, H-5a, 3H, m), 1.25-1.42 (H-3’’b, H-
4b, H-5b, H-6ab – H16ab, H-21’’ab 27H, m), 0.88-0.93 (H-17abc, H-22’’abc, 6H, J=7.5Hz).  
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m/z (ES): 813.0 (M+ + [Na]+ + 100%). HRMS: Calculated for C48H95NO9 [M + Na]+ 813.1105, 
found 813.1113. αD: +12°. m.p.: 135-141°C IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 
(C=O), 1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.23. (5Z,8Z,11Z,14Z)-Eicosa-5,8,11,14-tetraenoic acid [(1S, 2S, 3R)-2,3-
dihydroxy-1-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-
yloxymethyl)-heptadecyl]-amide (90) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (49) (20mg, 39.55µmol), (5Z,8Z,11Z,14Z)-eicosa-
5,8,11,14-tetraenoic acid 2,5-dioxo-pyrrolidin-1-yl ester (58) (24.3mg, 60.49µmol), affording 
a white solid.  Yield: 3mg, 10%. δ 1H (CDCl3:MeOD, 2:1): 5.34-5.75 (H-5’’, H-6’’, H-8’’, H-9’’, 
H-11’’, H-12’’, H-14’’, H-15’’, 8H, m), 4.75-4.81 (H-2’, 1H, m), 4.31-4.35 (H-1, 1H, m), 4.11-
4.16 (H-4’, 1H, m), 3.90-3.96 (H-8’a, 1H, dd, J=4.1, 10.6 Hz), 3.59-3.71 (H-3’, H-6’, 2H, m), 
3.55-3.59 (H-5’, H-7’ab, 3H, m), 3.46-3.50 (H-8’b, 1H, m), 3.41-3.44 (H-2, H-3, 2H, m), 2.32-
2.37 (H-7’’, H-10’’, H-13’’, 3H, m), 2.06-2.14 (H-2’’ab, 2H, m), 1.56-1.62 (H-3’’a, H-4a, H-5a, 
3H, m), 1.22-1.49 (H-3’’b, H-4b, H-5b, H-4’’ab, H-6ab – H16ab, H-16’’ab – H19’’ab 27H, m), 0.85-
0.91 (H-17abc, H-20’’abc, 6H, J=7.4Hz). δ 13C (CDCl3:MeOD 2:1): 131.6-135.4 (multiple 
signals, C-5’’, C-6’, C-8’’, C-9’’, C-11’’, C-12’’, C-14’’, C-15’’), 101.80 (C-2’), 78.62 (C-2), 
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74.98 (C-3), 71.90 (C-6’), 70.64 (C-5’), 69.98 (C4’), 68.39 (C-3’), 67.47 (C-8), 60.55 (C-7’), 
49.21 (C-1), 26.61-39.54 (multiple signals C-2’’, C-3’’, C-4’’, C-7’’, C-10’’, C-13’’, C-16’’ – 
C19’’, C-4 – C-16), 15.55 (C-20’’, C-17). m/z (ES): 790.2 (M+ + [Na]+ + [H]+ 10%), 789.2  
(M+ + [Na]+ 100%), HRMS: Calculated for C44H77NO9 [M + Na]+ 789.0891, found 789.0899. 
αD: +2.8°. m.p.: 136-145°C IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1600-
1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.24. Eicosa-11,14-dienoic acid [(1S, 2S, 3R)-2,3-dihydroxy-1-(3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-amide (91) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (49) (40mg, 79.1µmol), (11Z,14Z)-eicosa-11,14-
dienoic acid 2,5-dioxo-pyrrolidin-1-yl ester (59) (46.3mg, 114µmol), affording a white solid. 
Yield: 24.9mg, 41%. δ 1H (CDCl3: MeOD, 2:1):  5.24-5.36 (H11’’, H12’’, H14’’, H15’’, 4H, m), 
4.80-4.84 (H-2’, 1H, d, J=4.4Hz,), 4.11-4.15 (H-1, 1H, m), 3.80-3.86 (H-8’a, 1H, dd, J=4.9-
10.3Hz), 3.73-3.78 (H-7’a, 1H, dd, J=3, 11.3Hz), 3.61-3.70 (H-8’b, H-7’b, 2H, m), 3.56-3.70 
(H-4’, 1H, t, J=9.3), 3.48-3.55 (H-2, H-3, H-6’, 3H, m), 3.48-3.53 (H-3’, H-5’, 2H, m), 2.70-
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2.75 (H-13’’ab, 2H, t, J=7.4Hz), 2.13-2.19 (H-2’’ab, 2H, m), 1.54-1.69 (H-3’’ab, H-4’’ab, 4H, m), 
1.05-1.44 (H-5’’ab – H-19’’ab, H-5ab – H-16ab, 54H, m), 0.80-0.85 (H-17abc, H-20’’abc, 6H, t, 
J=6.4, 7.1Hz). δ 13C (CDCl3: MeOD, 2:1): 169.04 (C-1’’), 128.82-130.74 (C-11’’, 12’’, 14’’, 
15’’), 101.80 (C-2’), 74.91 (C-2), 72.56 (C-3), 71.09 (C-6’), 70.77 (C-7’), 70.33 (C-4’), 68.48 
(C-3’), 67.17 (C-8’), 61.11 (C-5’), 48.73 (C-1), 34.42 (C-2’’), 22.10-30.02 (multiple signals, C-
4 – C-16, C-3’’ – C-10’’, C-13’’, C-16’’ – C-19’’), 17.51, 18.16 (C-17,  C-20’’). m/z (ES): 794.1 
(M+ + [Na]+ + [H]+ 10%), 793.1 (M+ + [Na]+ + 100%). HRMS: Calculated for C44H83NO9 [M + 
Na]+ 793.1209, found 793.1223. αD: +6.4°. m.p.: 137-145°C. IR: 3200-3400cm-1 (br OH), 
1750-1750cm-1 (C=O), 1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.25. (11Z)-Eicos-11-enoic acid [2,3-dihydroxy-1-(3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-amide (92) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (49) (63mg, 124.6µmol), (11Z)-eicosa-11enoic 
acid 2,5-dioxo-pyrrolidin-1-yl ester (60) (59.5mg, 191.6µmol). Yield: 29.8mg, 31%. δ 1H 
(CDCl3: MeOD, 2:1):  5.28-5.31 (H11’’, H12’’, 2H, t, J=4.9Hz), 4.79-4.82 (H-2’, 1H, d, 
J=3.4Hz,), 4.12-4.16 (H-1, 1H, m), 3.80-3.85, (H-8’a, 1H, dd, J=4.9, 10.9Hz), 3.73-3.77 (H-
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7’a, 1H, dd, J=2.4, 11.4Hz), 3.61-3.68 (H-8’b, H-7’b, 2H, m), 3.56-3.61 (H-4’, 1H, t, J=8.9Hz), 
3.48-3.55 (H-2, H-3, H-6’, 3H, m), 3.38-3.42 (H-5’, 1H, dd, J=3.9, 9.9Hz), 2.13-2.18 (H-2’’ab, 
2H, t, J=7.4Hz), 1.94-1.99 (H-3’’ab, H-4ab, 4H, m), 1.45-1.65 (H-10’’ab, H-13’’ab, 4H, m), 1.18-
1.32 (H-5ab – H-16ab, H-4’’ab – H-9’’ab, H-14’’ab – H-19’’ab, 46H, m), 0.81-0.85 (H-17abc, H-
20’’abc, 6H, t, J=6.9Hz). δ 13C (CDCl3: MeOD, 2:1): 130.31-132.7 (C-11’’, 12’’), 101.80 (C-2’), 
74.43 (C-2), 73.91 (C-3), 73.34 (C-6’), 71.66 (C-7’), 71.12 (C-4’), 69.97 (C-3’), 68.59 (C-8’), 
63.88 (C-5’), 46.48 (C-1), 35.17 (C-2’’), 20.26-32.10 (multiple signals, C-4 – C-16, C-3’’ – C-
10’’, C-13’’ – C-19’’), 15.95, 16.31 (C-17,  C-20’’). m/z (ES): 795.6 (M+ + [Na]+ + [H]+ 20%), 
794.6 (M+ + [Na]+  100%). HRMS: Calculated for C35H65NO9 [M + Na]+ 794.6122, found 
794.6132. αD: +18.2°. m.p.: 128-132°C IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 
1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.26. (11E)-Eicos-11-enoic acid [2,3-dihydroxy-1-(3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-amide (93) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (49) (52mg, 102.8µmol), (11E)-eicosa-11enoic 
acid 2,5-dioxo-pyrrolidin-1-yl ester (61) (49.5mg, 159µmol), affording a white solid. Yield: 
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23mg, 29%. δ 1H (CDCl3: MeOD, 2:1):  5.28-5.31 (H11’’, H12’’, 2H, t, J=3.4Hz), 4.79-4.82 
(H-2’, 1H, d, J=3.4Hz,), 4.12-4.16 (H-1, 1H, m), 3.80-3.85, (H-8’a, 1H, dd, J=4.9, 10.9Hz), 
3.73-3.77 (H-7’a, 1H, dd, J=2.4, 11.4Hz), 3.61-3.68 (H-8’b, H-7’b, 2H, m), 3.56-3.61 (H-4’, 1H, 
t, J=8.9Hz), 3.48-3.55 (H-2, H-3, H-6’, 3H, m), 3.38-3.42 (H-5’, 1H, dd, J=3.9, 9.9Hz), 2.13-
2.18 (H-2’’ab, 2H, t, J=7.4Hz), 1.94-1.99 (H-3’’ab, H-4ab, 4H, m), 1.45-1.65 (H-10’’ab, H-13’’ab, 
4H, m), 1.18-1.32 (H-5ab – H-16ab, H-4’’ab – H-9’’ab, H-14’’ab – H-19’’ab, 46H, m), 0.81-0.85 (H-
17abc, H-20’’abc, 6H, t, J=6.9Hz). δ 13C (CDCl3: MeOD, 2:1): 130.31-132.7 (C-11’’, 12’’), 
101.80 (C-2’), 74.43 (C-2), 73.91 (C-3), 73.34 (C-6’), 71.66 (C-7’), 71.12 (C-4’), 69.97 (C-3’), 
68.59 (C-8’), 63.88 (C-5’), 46.48 (C-1), 35.17 (C-2’’), 20.26-32.10 (multiple signals, C-4 – C-
16, C-3’’ – C-10’’, C-13’’ – C-19’’), 15.95, 16.31 (C-17,  C-20’’). m/z (ES): 795.8 (M+ + [Na]+ 
+ [H]+ 30%), 794.8 (M+ + [Na]+  100%). HRMS: Calculated for C35H65NO9 [M + Na]+ 
794.6122, found 794.6108. αD: +20° m.p.: 125-130°C. IR: 3200-3400cm-1 (br OH), 1750-
1750cm-1 (C=O), 1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
 
5.23.27. Eicosanoic acid [2,3-dihydroxy-1-(3,4,5-trihydroxy-6-hydroxymethyl-
tetrahydro-pyran-2-yloxymethyl)-heptadecyl]-amide (94) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
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hydroxymethyl-tetrahydro-pyran-3,4,5-triol (49) (50mg, 98.8µmol), eicosanoic acid 2,5-
dioxo-pyrrolidin-1-yl ester (62) (59.8mg, 146µmol), affording a white solid. Yield: 46.6mg, 
61%. δ 1H (CDCl3:MeOD, 2:1): 4.81-4.82 (H-2’, 1H, d, J=4.6Hz), 4.11-4.16 (H-1, 1H, m), 
3.83-3.85 (H-8’a, 1H, dd, J=3.9, 10.7Hz), 3.74-3.77 (H-7’a, 1H, dd, J=2.8, 12.2Hz), 3.63-3.68 
(H-8’b, H-7’b, 2H, m), 3.58-3.61 (H-4’, 1H, m,), 3.50-3.55 (H-2, H-3, H-6’, 3H, m), 3.39-3.42 
(H-3’, 1H, dd, J=3.9, 9.7Hz), 3.31-3.35 (H-5’, 1H, m), 2.15-2.19 (H-2’’ab, 2H, t, J=7.6Hz), 
1.48-1.64 (H-3’’a, H-4’’a, H-4a, H-5a, 4H, m), 1.19-1.39 (H-4b, H-5b, H-6ab – H-16ab, H-3’’b, H-
4’’b, H-5’’ab – H-19’’ab, 56H, m), 0.83-0.85 (H-17’’abc, H-20’’abc, 6H, t, J=6.7Hz ) δ 13C 
(CDCl3:MeOD, 2:1):175.09 (C-1’’), 99.88 (C-2’), 74.93 (C-2), 74.41 (C-4’), 72.83 (C-6’), 
72.56, 72.47 (C-3, 3’), 67.64 (C-8’), 62.05 (C-7’), 50.93 (C-1), 49.84 (C-5’) , 36.89 (C-2’’), 
32.81 (C-3’’), 32.41 (C-4), 30.17-23.13 (various signals, C-5 – C-16, C-4’’ – C-19’’), 14.27, 
14.25 (C-17, C-20’’). m/z (ES): 797.80 (M+ + [Na]+ + [H]+ 20%), 796.8 (M+ + [Na]+ + 100%). 
HRMS: Calculated for C44H87NO9 [M + Na]+ 796.6279, found 796.6288. αD: +5.6°. m.p.: 132-
138°C. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1500-1650cm-1 (N-H). 
 
5.23.28. Octadeca-9,12-dienoic acid [2,3-dihydroxy-1-(3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydropyran-2-yloxymethyl)-heptadecyl]-amide (95) 
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Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2S,3R,4S,5S,6R)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
hydroxymethyl-tetrahydro-pyran-3,4,5-triol (49) (50mg, 98.8µmol), Octadeca-9,12-dienoic 
acid 2,5-dioxo-pyrrolidin-1-yl ester (63) (59mg, 160µmol), affording a white solid. Yield: 
22mg, 31%. δ 1H (CDCl3: d4-MeOH, 2:1):  5.23-5.27 (H11’’, H12’’, H14’’, H15’’, 4H, m), 4.79-
4.84 (H-2’, 1H, d, J=4.7Hz,), 4.11-4.15 (H-1, 1H, m), 3.80-3.87 (H-8’a, 1H, d, J=2.91Hz), 
3.73-3.78 (H-7’a, 1H, dd, J=3.5, 11.8Hz), 3.63-3.69 (H-7’b, H-8’b, 2H, dd, J=5.12, 12.12), 
3.60-3.63 (H-4’, 1H, m), 3.44-3.58 (H-2, H-3, H-6’, 2H, m), 3.38-3.42 (H-3’, 1H, dd, J=4.3, 
9.8Hz), 3.31-3.33 (H-5’, 1H, m), 2.6-2.75 (H11’’ab, 2H, t, J=7.8Hz), 2.13-2.20 (H-2’’ab, 2H, t, 
J=7.8), 1.97-2.04 (H-8’’ab, 2H, t, J=7.60Hz), 1.53-1.68 (H-14’’ab, H-4ab, 4H, m), 1.27-1.42 (H-
5a, H-6a, H-3’’ab, 4H, m), 1.09-1.25 (H-6b – H-16ab, H-4’’ab – H-9’’ab, H-17’’ab – H-19’’ab, 40H, 
m), 0.80-0.85 (H-17abc, H-18’’abc, 6H, t, J=6.3Hz) δ 13C (CDCl3: d4-MeOH, 2:1): 175.04 (C-
1’’), 130.52, 130.47, 128.41, 128.37 (C-11’’, 12’’, 14’’, 15’’), 99.88 (C-2’), 74.93 (C-2), 74.41 
(C-3), 72.54 (C-6’), 72.01 (C-7’), 71.53 (C-4’), 70.84 (C-3’), 68.43 (C-8’), 60.31 (C-5’), 51.09 
(C-1), 36.95 (C-2’’), 29.77-35.72 (multiple signals, C-4 – C-16, C-3’’ – C-8’’, C-11’’, C-14’’ – 
C-17’’), 14.25, 14.31 (C-17,  C-18’’). m/z (ES):  766.0 (M+ + [Na]+ + [H]+ 15%), 765.0 (M+ + 
[Na]+ + 100%). HRMS: Calculated for C42H79NO9 [M + Na]+ 765.0677, found 765.0684. αD: 
+35.0°. m.p.: 149-150°C. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 1600-1675cm-1 
(C=C), 1500-1650cm-1 (N-H). 
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5.23.29. (11Z,14Z)-Nonadeca-11,14-dienoic acid [(1S,2S,3R)-2,3-dihydroxy-1-
((2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-
yloxymethyl)-heptadecyl]-amide (96) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2R,3S,4R,5S,6S)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
methyl-tetrahydro-pyran-3,4,5-triol (52) (42mg, 85.78µmol), (11Z,14Z)-eicosa-11,14-dienoic 
acid 2,5-dioxo-pyrrolidin-1-yl ester (59) (46.3mg, 114µmol), affording a white syrup. Yield: 
9.7mg, 15%. δ 1H (CDCl3: d4-MeOH, 2:1): 5.23-5.36 (H11’’, H12’’, H14’’, H15’’, 4H, m), 4.71-
4.75 (H-2’, 1H, d, J=3.88Hz,), 4.13-4.18 (H-1, 1H, m), 3.91-3.97 (H-2, H-3, 2H, m), 3.68-3.73 
(H-3’, 1H, dd, J=3.5, 9.9Hz), 3.66-3.68 (H-8’a, 1H, d, J=3.5Hz), 3.60-3.65 (H-5’, 1H, m), 
3.51-3.56 (H-4’, 1H, t, J=6.2Hz), 3.39-3.44 (H-8’b, 1H, dd, J=3.8, 10.3Hz), 2.7-2.75 (H-13’’ab, 
2H, t, J=7.3Hz), 2.12-2.20 (H-2’’ab, 2H, t, J=7.8Hz), 1.96-2.04 (H-10’’ab, H-16’’ab, 4H, m), 
1.53-1.65 (H-3’’ab, H-4a, H-5a, 4H, m), 0.99-1.46 (H-4b, H-5b, H-6ab – H-16ab, H-4’’ab – H-9’’ab, 
H-17’’ab – H-19’’ab, 42H, m), 0.81-0.85 (H-17abc, H-20’’abc, 6H, t, J=7.3Hz). m/z (ES): 778.2 
(M+ + [Na]+ + [H]+ 45%), 777.2 (M+ + [Na]+ + 100%). HRMS: Calculated for C44H83NO8 [M + 
Na]+ 777.1215, found 777.1210. αD:-4.4°. IR: 3200-3400cm-1 (br OH), 1750-1750cm-1 (C=O), 
1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
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5.23.30. (9Z,12Z)-Octadeca-9,12-dienoic acid [(1S,2S,3R)-2,3-dihydroxy-1-
((2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-
yloxymethyl)-heptadecyl]-amide (97) 
 
Prepared by the general procedure for azide reduction and subsequent N-acylation 
(5.1.1.13) using (2R,3S,4R,5S,6S)-2-((2S,3S,4R)-2-azido-3,4-dihydroxy-octadecyloxy)-6-
methyl-tetrahydro-pyran-3,4,5-triol (52) (125mg, 255.3µmol), (9Z,12Z)-octadeca-9,12-
dienoic acid 2,5-dioxo-pyrrolidin-1-yl ester (63) (162mg, 430µmol), affording a white syrupy 
oil. Yield: 95.1mg, 51.3%. δ 1H (CDCl3: MeOD, 2:1): 5.23-5.36 (H9’’, H10’’, H12’’, H13’’, 4H, 
m), 4.71-4.75 (H-2’, 1H, d, J=3.88Hz,), 4.13-4.18 (H-1, 1H, m), 3.91-3.97 (H-2, H-3, 2H, m), 
3.68-3.73 (H-3’, 1H, dd, J=3.5, 9.9Hz), 3.66-3.68 (H-8’a, 1H, d, J=3.5Hz), 3.60-3.65 (H-5’, 
1H, m), 3.51-3.56 (H-4’, 1H, t, J=6.2Hz), 3.39-3.44 (H-8’b, 1H, dd, J=3.8, 10.3Hz), 2.7-2.75 
(H-13’’ab, 2H, t, J=7.3Hz), 2.12-2.20 (H-2’’ab, 2H, t, J=7.8Hz), 1.96-2.04 (H-11’’ab, H-14’’ab, 
4H, m), 1.53-1.65 (H-3’’ab, H-4a, H-5a, 4H, m), 0.99-1.46 (H-7’abc, H-4b, H-5b, H-6ab – H-16ab, 
H-4’’ab – H-8’’ab, H-15’’ab – H-17’’ab, 42H, m), 0.81-0.85 (H-17abc, H-18’’abc, 6H, t, J=7.3Hz). 
m/z (ES): 750.1 (M+ + [Na]+ + [H]+ 10%), 749.1(M+ + [K]+ + 100%). HRMS: Calculated for 
C42H79NO8 [M + Na]+ 749.0683, found 749.0671. αD: -18°. IR: 3200-3400cm-1 (br OH), 1750-
1750cm-1 (C=O), 1600-1675cm-1 (C=C), 1500-1650cm-1 (N-H). 
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5.24. Biological assays 
5.24.1. Materials and methods 
Human Vα24 iNKT cell lines were generated from healthy donors by Brigl et al [255], and 
McCarthy et al [218] at Brigham and Women’s Hospital, Boston, USA and Weatherall 
Institute of Molecular Medicine, John radcliffe Hospital, Oxford, UK, respectively. PBMC 
were purified from patients’ buffy coat by layering over Lymphoprep (Nycomed, Asker, 
Norway). Monocytes were then positively selected using magnetic beads coated with anti-
CD14 monoclonal antibodies (mAbs) (MACS; Miltenyi Biotec, Bergisch Gladbach, 
Germany). and frozen in Roswell Park Memorial Institute medium (RPMI) medium (Sigma-
Aldrich) until needed [218, 292].  
 
5.24.1.1. Protein expression and purification 
Purified hCD1d and β2M proteins were refolded with α-GalCer (44), C20:0 (79), C20:2 (73), 
C11:1, OCH15 (45), OCH12 (46), OCH9 (47), by oxidative refolding chromatography, and 
the rate of dissociation from hCD1d molecules of each GSL was analysed. Purified CD1d 
heavy chain and β2m were synthesized by using a prokaryotic expression system (pET, 
Novagen). Both recombinant proteins CD1d and β2m were expressed in the Escherichia coli 
strain BL21 and purified from inclusion bodies. Soluble protein fractions were concentrated 
to a volume of 3 ml and biotinylated. Biotinylated monomeric CD1d–β2m–glycolipid 
complexes were separated from soluble protein aggregates and free biotin by ÄKTA FPLC 
size exclusion chromatography by using a Superdex 75HR10/300 GL gel filtration column 
(Amersham Pharmacia) and conjugated to Streptavidin-PE (Sigma–Aldrich) [218, 292-294]. 
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5.24.1.2. Preparation of soluble heterodimeric TCRs  
Vα24 and Vβ11 iNKT cell TCR sequences were amplified by polymerase chain reaction 
(PCR) from the cDNA of an established iNKT cell clone. The α- and β-chains were 
individually cloned into pGMT7 bacterial expression vectors encoding the c-Jun and v-Fos 
fragments, respectively. TCR chains were expressed separately as inclusion bodies in the 
E. coli strain BL21-DE3 (pLysS) by induction in mid-log phase with 0.5mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). Inclusion bodies were isolated by sonication, followed by 
successive wash and centrifugation steps using 0.5% Triton X-100. Finally, the inclusion 
bodies were dissolved in 6M guanidine, 10mM dithiothreitol (DTT), 10mM 
ethylenediaminetetra-acetate (EDTA), buffered with 50mM 
tris(hydroxymethyl)aminomethane (Tris) pH 8.1 and stored at –80°C. Soluble TCR was 
refolded by rapid dilution of a mixture of the dissolved α- and β-chain inclusion bodies into 
5M urea, 0.4M L-arginine, 100mM Tris pH 8.1, 3.7mM cystamine, 6.6mM β-
mercaptoethylamine (4°C) to a final concentration of 60mg/l. The refold mixture was 
dialysed for 24 h against 10 vol of demineralized water, then against 10 vol of 10mM Tris pH 
8.1 at 4°C. The refolded protein was then filtered and loaded onto a POROS 50HQ column 
(Applied Biosystems). The column was washed with 10mM Tris pH 8.1 prior to elution with a 
0±500mM NaCl gradient in the same buffer. Fractions were analysed by Coomassie-stained 
sodium docecyl sulfate (SDS) ± 10% NuPAGE (Novagen, WI), and TCR-containing fractions 
were pooled and further purified by gel filtration on a Superdex 75PG 26/60 column 
(Amersham Biosciences, Uppsala, Sweden) pre-equilibrated in phosphate-buffered saline. 
Fractions comprising the main peak were pooled and analysed further. The final purified 
1G4 dsTCR was analysed by Coomassie-stained SDS ± 10% NuPAGE under reducing and 
non-reducing conditions, and an aliquot of protein was buffer exchanged into HBSE (N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid [HEPES] pH 7.4, 150mM NaCl, 3mM 
EDTA) and concentrated prior to activity determination by SPR. Soluble biotinylated TCR 
was made by inserting a 15–amino acid Avi-Tag recognition peptide (Avidity) after the c-Jun 
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fragment of the α-chain; the α-chain Jun fragment was amplified by PCR and sub-cloned 
into a pGMT7 vector encoding the AviTag peptide. This new α protein was expressed, 
refolded with the β- chain, and purified as before. The TCR heterodimer was biotinylated 
with BirA enzyme before the final SD75 gel filtration and were tetramerized by mixing at a 
4:1 molar ratio with Extravidin-PE (Sigma-Aldrich) [218, 295].  
 
5.24.1.3. Surface Plasmon Resonance (SPR) 
The affinity and kinetic properties of Vα24 NKT TCR binding to hCD1d–lipid complexes were 
determined using BIAcore 2000 (BIAcore AB, St. Albans, UK) in HEPES buffered saline 
(HBS) (BIAcore). HBS contains 10mM HEPES (pH 7.4), 150mM NaCl, 3.4mM EDTA, and 
0.005% Surfactant P20. Streptavidin (Sigma) and the JM22z TCR were covalently coupled 
to Research Grade CM5 sensor chips (BIAcore) via primary amines using the standard 
amine coupling kit (BIAcore). For coupling, streptavidin was injected at 0.5mg/ml in 10mM 
sodium acetate (pH 5.5). The purified biotinylated hCD1d–lipid complexes were immobilized 
onto streptavidin-coated CM5 sensor chips (Biacore) at a level of ~1,000 response U. 
Biotinylated proteins were immobilized at the indicated levels by injection at 50-150µg/ml for 
0.5-10min over streptavidin-coupled surfaces. For coupling, JM22z was injected at 14µg/ml 
in 10mM sodium acetate (pH 5). Coupling levels ranged from 3200 to 11400 RU. To avoid 
multivalent aggregates, soluble proteins used in SPR experiments were purified by gel-
filtration on a Superdex S-200 column, stored at 4°C, and used within 48 hr with minimum 
amounts of concentrating. In all experiments, hCD1d–β-GalCer molecules were used as 
negative controls. Equilibrium binding was performed at a flow rate of 10µl/min from the 
lowest TCR concentration. To exclude any effect of lipid dissociation, which would result in a 
gradual decrease in the level of immobilized CD1d–lipid during the course of the 
experiment, the affinity was determined with both increasing (from low to highest) and 
decreasing (from highest to lowest) concentrations of TCR. The affinity values obtained 
Chapter 5  Materials and methods 
   
244 
were not significantly different, indicating that lipid dissociation during the course of the 
experiments had a negligible effect on the affinity measurements. The data was plotted 
using Origin software (OriginLab), and Kd values were calculated using the standard 
hyperbolic model. Kinetics of the TCR–hCD1d/lipid interactions was measured at 50µl/min. 
Equilibrium dissociation constants (Kd) and kon and koff were obtained by nonlinear curve 
fitting of the binding curves obtained after subtracting the response in the reference flow 
cells with equations derived from the simple 1:1 Langmuir binding model using the BIA 
evaluation program (version 3.02.2; Biacore). SPR was also used to estimate the 
dissociation rate of GSL from hCD1d molecules. 1,000 response U of hCD1d monomers 
loaded with either α-GalCer (44), OCH9 (47), OCH12 (46), OCH15 (45), C20:0 (79), C20:2 
(73), or C11:1 were immobilized on a streptavidin-coated sensor chip. As a negative control, 
hCD1d–β-GalCer biotinylated monomers were used. The amount of hCD1d–GSL remaining 
at a particular time was measured by injecting saturating amounts (30 µl at 500 nM) of Fab 
9B antibody [218, 296]. 
 
5.24.1.4. iNKT TCR tetramer staining 
C1R-hCD1d cells were pulsed with 10µM, 5µM, 1µM, 500nM, and 100nM of lipid for 16h at 
37°C and washed twice in RPMI. Cells were incubated with iNKT cell TCR tetramers at 
37°C for 30min and washed again twice with ice-cold PBS/1% fetal calf serum (FCS). 
Samples were analyzed on a flow cytometer (FACSCalibur; BD Biosciences), and the data 
were processed using CellQuest software (BD Biosciences) [218].  
 
5.24.1.5. Enzyme-linked immunsorbent assay (ELISA) 
C1R-hCD1d cells were pulsed for 2h with GSLs and diluted to 106 cells/ml. 105 cell-pulsed 
targets were incubated at 37°C with 104 iNKT cells in a final volume of 200µl. After 18h, the 
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supernatants were harvested, and the concentrations of IFN-γ and IL-4 were determined by 
ELISA according to the manufacturer’s instructions (Mabtech) [218]. 
 
5.24.1.6. iNKT cell expansion 
Peripheral blod mononuclear cells (PBMCs) were isolated from healthy donors’ buffy coats 
by density gradient centrifugation over Lymphoprep (Nycomed). Monocytes were positively 
selected using anti-CD14 mAb–coated magnetic beads (MACS; Miltenyi Biotec), and 
monocyte-depleted lymphocyte fractions (CD14 negative) were frozen until needed. 
Monocytes were cultured with 50ng/ml granulocyte-macrophage colony-stimulating factor 
(GM-CSF) (Novartis) and 1,000 U/ml IL-4 in six-well plates at 4 × 105 cells/ml (3ml/well). 
After 5d, maturation was induced using bacterial lipopolysaccharide (LPS) (1 µg/ml LPS of 
Salmonella abortusequi; Sigma-Aldrich). Immature and mature monocyte-derived DCs were 
phenotypically analyzed for maturation markers. 2 × 105 monocyte-derived DCs were pulsed 
with GSL for 2h in 24-well plates in 200µl RPMI 1640. 2 × 106 autologous lymphocytes were 
added in 1.8ml of medium (5% human serum). After 3d, 25 IU/ml IL-2 was added to cultures. 
Thereafter, cultures were fed every 3–4 d with fresh medium containing 1,000 U/ml IL-2. 
iNKT cell frequencies were determined using APC CD1d tetramer and Vα24 antibody 
(Serotec) [218]. 
 
5.24.1.7. Structural modeling 
The structural effects of binding lipid chains of various lengths to hCD1d were assessed by 
comparison of the hCD1d–α-GalCer and empty hCD1d crystal structures (Protein Data Bank 
code 1ZT4). Structural superposition used the Structure Homology Program, and analysis 
was performed using the interactive graphics display program O [297]. 
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5.24.1.8. T cell proliferation 
For proliferation assays, 2 x 105 PBMC were plated per well in round-bottom 96-well plates. 
T cell medium was made by supplementing 500 ml of RPMI 1640 medium with 50 ml of FCS 
(HyClone), penicillin (Invitrogen Life Technologies), streptomycin (Invitrogen Life 
Technologies), 20 mM HEPES (Invitrogen Life Technologies), and 4 ml of 1 N NaOH 
solution. Proliferation was measured after culture for 3 days with α-GalCer or associated 
analogues at concentrations ranging 100mg/ml DMSO and diluted into culture mediam to 
the indicated final concentrations, followed by a 6-h pulse of 1 µCi of [3H]thymidine before 
harvesting and counting β emissions using a Microbeta Trilux scintillation counter (Wallac). 
 
5.24.1.9. Measurement of cytokine secretion by in vitro-activated iNKT cells 
Human iNKT cell clones at 5 x 104/well were stimulated with 5 x 104 human DCs (derived by 
in vitro culture of peripheral blood monocytes for 3 days in medium supplemented with GM-
CSF and IL-4) in the presence of the indicated concentrations of α-GalCer analogs. Levels 
of human IL-13 and IFN-γ, and were measured at 48h in culture supernatants by capture 
ELISA.  
 
5.24.1.10. Preparation of soluble CD1d fusion proteins and tetramers 
Single-chain β2m- CD1d-Fc fusion proteins were produced in mammalian cells and purified 
from culture supernatants by protein A affinity chromatography. The resulting dimeric CD1d-
Fc fusion proteins were formed into complexes with fluorescently labeled soluble protein A 
molecules and purified by size exclusion chromatography on a Superose 6 column 
(Amersham Biosciences). 
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5.24.1.11. Derivation of CD1d-restircted T cell clones 
T cells sorted using CD1d-tetramers were cultured at 37°C with 5% CO2 in RPMI 1640 
culture medium containing 10% fetal bovine serum (FBS), 2% human AB serum, 1% 
penicillin and streptomycin, and 1% L-glutamine in the presence of irradiated allogeneic 
PBMC and phytohaemagglutinin (PHA). After 5–10 days of culture, 200U/ml recombinant 
human IL-2 (Chiron) was added to the medium. 
 
5.24.1.12. T cell responses to APCs 
APCs were either CD1d-transfected 721.221 cells or in vitro-derived immature dendritic cells 
(DCs) generated from human peripheral blood monocytes purified by CD14-positive 
magnetic bead selection (Miltenyi Biotec) that were cultured for 3 days with 200 U/ml and 
300 U/ml rIL-4 and GM-CSF, respectively. DCs were pulsed for 12–16 h with glycolipid 
antigens at the indicated concentrations or with vehicle (DMSO) alone and then washed and 
co-incubated with a 1:1 ratio of CD1d-restricted T cells (5 x 104 per well) in sterile 96-well 
plates in RPMI 1640 culture medium lacking IL-2 (i.e., RPMI 1640 containing 10% iron-
supplemented bovine calf serum and penicillin/streptomycin) for 24 h at 37°C and 5% CO2. 
Culture supernatants were then withdrawn and tested for the indicated cytokines using a 
standard, commercially available ELISA and purified recombinant cytokines as standards. 
Anti-CD1d mAb blocking experiments were performed by coincubating the CD1d59 murine 
IgM mAb (Prof. S. Porcelli, Albert Einstein College of Medicine, New York, USA) or the 
MOPC-104E negative control IgM mAb (Sigma-Aldrich) with the APCs and T cells. The I-B4 
lectin from the plant Griffonia simplicifolia (Vector Laboratories; dissolved in 10 mM HEPES, 
0.15MNaCl, 0.08% NaN3, and 0.1mMCa2+) was co-incubated with the APCs and T cells at 
the indicated concentrations and compared with mock-treated (diluent buffer alone) APCs. 
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5.24.1.13. T cell responses to lipid Ags presented by plate-bound CD1d molecules  
CD1-restricted T cell clones were tested for responses to glycoplid antigens presented by 
plate-bound CD1d fusion proteins: the CD1d-Fc fusion protein or an isotype-matched 
negative control mAb was coated in a 10:1 ratio with an anti-LFA-1 mAb onto 96-well 
microtiter plates. Glycolipid antigens dissolved in DMSO or vehicle alone were diluted into 
PBS and incubated with the CD1d fusion protein or negative control mAb at 37°C for  
24–72 h. The plates were then thoroughly washed and CD1d-restricted T cell clones were 
added in RPMI 1640 culture medium, lacking IL-2. The plates were incubated for 24 h at 
37°C and 5% CO2, and the supernatants were then harvested and analyzed for cytokine 
content using a standard, commercially available ELISA. 
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α-GalCer has shown remarkable activity in terms of iNKT cell activation when bound with 
CD1d [102, 136-139, 144, 145, 180] and in doing so has become increasingly attractive as a 
prophylactic agent for the treatment of autoimmune diseases, such as T1D and SLE [139]. 
One of its modes of action includes inducing iNKT cells to produce beneficial TH2 cytokines, 
such as IL-4 [117]. In addition to cytokine stimulating properties, α-GalCer has been shown 
to stimulate iNKT cell expansion [163]; the diagnosis of  T1D has been associated with a 
reduced number of circulating iNKT cells [144, 180, 298], thus providing further evidence of 
the therapeutics potential of α-GalCer. 
 
Alongside the aforementioned effects of α-GalCer treatment, the potentially detrimental TH1 
cytokine IFN-γ is known to be released either at the same time, or immediately after TH2 
cytokines, and sometimes in far greater concentrations [128-130].  TH1 and TH2 cells, and 
the cytokines they produce, normally exist in an harmonious state [129, 131]. However, a 
disturbance in the equilibrium, and an increase in the pro-inflammatory cytokine IFN-γ, can 
lead to a breakdown of self-tolerance which in turn can trigger the development of an 
autoimmune disease [129, 131].  Destructive insulitis is paralled by predominant secretion of 
IFN-γ [140, 143] and treating NOD mice with anti-IFN-γ has been shown to delay the 
development of T1D [146, 148], both of which add to the mounting evidence that the over-
production of TH1 cytokines have a detrimental effect on the immune system. 
 
The fact that α-GalCer produces both TH2 and TH1 cytokines is less than ideal in the context 
of conditions, such as T1D and SLE.  In the hope of finding an antigen that could skew the 
immune system towards that of a predominantly TH2 response, analogues of α-GalCer were 
synthesised and tested for their biological activity. Overcoming several chemical hurdles, a 
library of analogues varying in the phytosphingosine base, N-acyl chain and sugar head 
group were synthesised.  
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Following on from the work of Miyamoto et al. [144] who found that a truncated sphingosine 
base preferentially induced the production of TH2 cytokines, analogues with base chains 
ranging from C18 (α-GalCer (44)) to C9, OCH9 (47) were synthesised. These analogues 
were tested for their ability to produce IL-4 and IFN-γ in direct comparison with α-GalCer, 
and although the ratio of IL-4: IFN-γ produced by OCH9 (47) was dramatically reduced 
compared with α-GalCer (44), OCH15 (45) and OCH12 (46), the overall concentration of 
cytokines produced was also reduced [218]. This could be rationalised from the observation 
that the shortened phytosphingosine chain does not fully occupy one of the channels in the 
protein structure, thus allowing a degree of flexibility and rotation in the positioning of the 
sugar head, which in turn affects the binding of the antigen:CD1d complex with the TCR. 
The hypothesis that a truncated phytosphingosine chain lengths also affect the binding time 
of the antigen:protein complex with the TCR can also be attributed to the skewed immune 
response; IL-4 is rapidly produced by iNKT cells, followed by a more sustained release of 
IFN-γ [272].  If an antigen binds for a shorter time with the TCR, the chances of IFN-γ being 
produced in concentrations as great as a stable hCD1d-antigen:TCR complex, are reduced. 
Experimentally, the affinity of an hCD1d:OCH9 complex with the iNKT cell TCR was shown 
to be greatly reduced, with a dissociation constant of 122µM compared with 1.6µM for α-
GalCer (44) [218]; a smaller dissociation constant is indicative of higher affinity between the 
two constituents.  
 
Despite its capacity to skew the immune system towards that of a TH2 response, OCH9 (47) 
is unable to stimulate iNKT cell expansion in a manner anywhere near α-GalCer (44) [218]. 
This could also be attributed to the decreased binding affinity between OCH9 (47) and the 
iNKT cell TCR, as iNKT cell proliferation is observed 24h after initial stimulation [117].  
 
The immunostimulatory activity of analogues, with varying sugar head groups, was also 
investigated through the course of this project. Motoki et al. [226] showed that the 
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lymphocytic proliferation activity of α-GalCer (44) was greater than that of α-GlcCer (50). 
The results from several experimental procedures mirrored the results gained by the Motoki 
group, and showed that α-GalCer (44) has greater lymphocytic proliferation activity than α-
GlcCer (50), but that α-L-FucCer (53) showed cell proliferation responses that were greater 
than the glucose analogue, but less efficient than the galactose analogue. This suggests 
that the positioning of the hydroxyl group at C4’ plays a pivotal role in determining the 
biological response of the analogues. Interestingly, the cytokine profiles of the three 
analogues also positions the response of α-L-FucCer (53) between that of α-GalCer (44) 
and α-GlcCer (50). The ratio of TH1: TH2 cytokine production by α-L-FucCer (53) is skewed 
toward that of a predominantly TH2 response.  
 
Research into variations in the N-acyl chain of α-GalCer in the context of GSLs and 
autoimmune diseases has been in the spotlight  over recent months [64, 98, 179, 180, 237, 
265-267]. Not only have a number of groups successfully incorporated fluorescent 
molecules into the N-acyl chain of α-GalCer [184, 185, 263], the length and saturation of the 
N-acyl chain of α-GalCer has been noted as having, in some cases, profound effects on the 
analogue’s biological activity.  In a manner similar to the conclusions regarding the truncated 
phytosphingosine base chain not fully occupying one of the CD1d protein tunnels, it has 
been speculated that alterations in the length and degree of unsaturation in an N-acyl chain 
also affect the analogue’s activity due to altered binding and stability. Moody et al. [269] 
demonstrated that the size of the N-acyl chain controls many aspects of an analogue’s 
interaction with CD1, such as the kinetics, sub-cellular localisation, efficiency of antigen 
loading into the groove and ultimately the presentation of the antigen. Yu et al. [266] showed 
that unsaturated analogues of α-GalCer are more biologically active than their fully saturated 
counterparts, with two cis orientated double-bonds being the most effective at skewing the 
immune response towards that of a TH2 response.  This was demonstrated by the IL-4/ IFN-
γ response of α-GalCer (44) compared with C20:2 (73) and C20:4 (71), which showed that 
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IL-4 production by C20:2 (73) was on a par with that of α-GalCer (44), with drastically 
reduced concentrations of IFN-γ being detected. Although C20:4 (71) also showed minimal 
IFN-γ production at both 2 and 20 hours, the concentration of IL-4 released by in vivo iNKT 
cells was reduced.  
 
The unsaturated analogue C20:2 (73) has also been shown to have a direct effect on 
delaying the development of T1D. NOD mice prone to the development of this autoimmune 
disease failed to present symptoms of the disease after treatment with C20:2 (73). This is in 
contrast to those treated with α-GalCer (44), which did not present with glucosuria as quickly 
as control animals, but showed a striking decrease in the number of animals without 
glucosuria after approximately 22 weeks.  
 
The theories behind the varying affects of unsaturated N-acyl analogues of α-GalCer, 
suggest that the orientation of the polar head-group, and thus recognition by the TCR, is not 
influenced by a change in the N-acyl chain structure. Unlike variations in the 
phytosphingosine chain which can lead to partial collapse of one of the CD1d protein 
tunnels, a truncated N-acyl chain influences changes in residues peripheral to the iNKT cell 
TCR [218], suggesting that the structure of the N-acyl chain affects binding of the analogue 
with CD1d, but not TCR recognition. The observed differences in the rates of dissociation of 
unsaturated and fully saturated N-acyl chain variants, shows that unsaturations increase the 
stability of the binding of α-GalCer analogues with CD1d proteins, and that the natural kink 
featured in C20:2 (73) (formed from the two cis orientationed double bonds) favours the 
tightly curved conformation required for binding within the N-acyl chain channel.  
 
Although these findings provide exciting insights into the elusive nature of CD1d-iNKT cell 
interactions, and add to the mounting knowledge of GSL antigens and the possibility of a 
‘super-antigen’, a definitive answer to the prevention of autoimmune diseases has by no 
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means been unearthed. These results encourage the development of novel α-GalCer 
analogues in the search for a compound that could hold therapeutic potential in the 
successful modulation of the immune system for prevention and treatment of autoimmune 
diseases.
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